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Deconvolution of charge envelopes shown in MS spectra to reveal monoisotopic 
masses of mAb species. 
3.8 Middle down analysis of Standard 1, replicate 2. A. Total Ion Chromatogram 
(TIC); B. MS spectra corresponding to each highlighted TIC peak; C. 
Deconvolution of charge envelopes shown in MS spectra to reveal monoisotopic 
masses of mAb species. 
3.9 Middle down analysis of Standard 1, replicate 3. A. Total Ion Chromatogram 
(TIC); B. MS spectra corresponding to each highlighted TIC peak; C. 
Deconvolution of charge envelopes shown in MS spectra to reveal monoisotopic 
masses of mAb species. 
3.10 Middle down analysis of Standard 2. A. Total Ion Chromatogram (TIC); B. MS 
spectra corresponding to each highlighted TIC peak; C. Deconvolution of charge 
envelopes shown in MS spectra to reveal monoisotopic masses of mAb species. 
3.11 Middle down analysis of Standard 3. A. Total Ion Chromatogram (TIC); B. MS 
spectra corresponding to each highlighted TIC peak; C. Deconvolution of charge 
envelopes shown in MS spectra to reveal monoisotopic masses of mAb species. 
3.12 Middle down analysis of anti-IL8 produced in culture maintained at 110% DO. A. 
Total Ion Chromatogram (TIC); B. MS spectra corresponding to each highlighted 
TIC peak; C. Deconvolution of charge envelopes shown in MS spectra to reveal 
monoisotopic masses of mAb species. 
3.13 Middle down analysis of anti-IL8 produced in culture maintained at 60% DO. A. 
Total Ion Chromatogram (TIC); B. MS spectra corresponding to each highlighted 
TIC peak; C. Deconvolution of charge envelopes shown in MS spectra to reveal 
monoisotopic masses of mAb species. 
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3.14 Middle down analysis of anti-IL8 produced using increased culture temperature 
of 39.5oC. A. Total Ion Chromatogram (TIC); B. MS spectra corresponding to each 
highlighted TIC peak; C. Deconvolution of charge envelopes shown in MS spectra 
to reveal monoisotopic masses of mAb species. 
3.15 Middle down analysis of anti-IL8 produced using increased culture temperature 
of 32.0oC. A. Total Ion Chromatogram (TIC); B. MS spectra corresponding to each 
highlighted TIC peak; C. Deconvolution of charge envelopes shown in MS spectra 
to reveal monoisotopic masses of mAb species. 
3.16 Middle down analysis of anti-IL8 produced in culture maintained at pH 7.2. A. 
Total Ion Chromatogram (TIC); B. MS spectra corresponding to each highlighted 
TIC peak; C. Deconvolution of charge envelopes shown in MS spectra to reveal 
monoisotopic masses of mAb species. 
3.17 Middle down analysis of anti-IL8 produced in culture maintained at pH 6.8. A. 
Total Ion Chromatogram (TIC); B. MS spectra corresponding to each highlighted 
TIC peak; C. Deconvolution of charge envelopes shown in MS spectra to reveal 
monoisotopic masses of mAb species. 
3.18 Base peak chromatogram corresponding to LC-MS peptide mapping analysis of 
tryptic peptides prepared from anti-IL8 mAb produced using 110% DO in culture 
media. 
3.19 Sequence coverage obtained following peptide mapping analysis of Standard 1 
sample, injection 1. A: Light chain peptides identified, B: Heavy chain peptides 
identified. Following LC-MS analysis of tryptic peptides, resultant data was 
searched using Biopharma Finder software for identification and visualisation of 
peptides.  Each peptide identified is signified by a coloured bar. Red bars 
represent peptides with a signal intensity of > 4.9 x 106; Yellow bars represent 
peptides with a signal intensity of > 1.4 x 105; Green bars represent peptides with 
a signal intensity of > 3.8 x 103. Each number shown within each bar equals to the 
retention time of that peptide. 
3.20 Anti-IL-8 IgG1 heavy and light chain protein sequence. Amino acid residues that 
were determined to have been modified following peptide mapping analysis are 
highlighted: deamidation residues are coloured green; oxidised residues are red; 
C-terminal truncated lysine is blue. CDR regions are underlined. 
4.1 Labelling of glycans using 2-aminobenzoic acid (2-AA). Glycans are labelled using 
a two-step reductive amination reaction, wherein the primary amide group of 2-
AA reacts with the aldehyde group of a glycan in a condensation reaction to form 
a Schiff’s base. The resulting imine group is then reduced using sodium 
cyanoborohydride to form a stable labeled glycans. 
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4.2 Optimisation of 2-AA labelling reaction time. Oligomannose N-glycans released 
from RNase B and complex sialylated N-glycans released from bovine fetuin were 
incubated with 0.37 M 2-AA containing 1 M sodium cyanoborohydride in 70:30 
DMSO acetic acid using a range of incubation times. The optimum incubation 
time determined was 5 hours at 65 oC. Above this time desialylation of sialylated 
N-glycans was observed. 
4.3 Evaluation of the purity of the 13C6 2-AA reagent. The graph shows the relative 
response of N-glycan samples labelled with the same concentration of the heavy 
or light 2-AA labelling reagent (dark blue) and relative response of samples 
labelled with light label and increased concentration of the heavy label to 
account for label purity (light blue); B. Evaluation of relative quantitation 
performance using stable isotope tagging. 
4.4 Annotated fluorescence and base peak intensity chromatograms for N-glycans 
released from polyclonal human serum IgG. The bar chart underneath the 
chromatograms depicts the mean light to heavy relative ratio as experimentally 
determined for the six technical replicates analyzed, y-error bars are also 
included at ± the standard deviation of the six technical replicates. 
4.5 Determination of glycosylation site occupancy. A. Representative base peak 
chromatogram obtained following LC-MSE analysis of tryptic peptides, B. 
Extracted ion chromatogram for EEQYDSTYR, C. MS spectrum corresponding to 
EEQYDSTYR, D. MS/MS spectrum for EEQYDSTYR showing identified b and y ions 
and amino acid sequence. 
4.6 Annotated fluorescence and base peak intensity chromatograms for N-glycans 
released from anti-IL8 IgG1. The bar chart underneath the chromatograms 
depicts the mean light to heavy relative ratio as experimentally determined for 
the five technical replicates analysed, y-error bars are also included at ± the 
standard deviation of the five technical replicates. 
5.1 Typical HDX-MS workflow. Proteins in solution at room temperature are diluted 
in excess deuterated solution and HDX is allowed to occur for a specified amount 
of time before the reaction is quenched in a low pH denaturation buffer. Protein 
sample is then injected into a pepsin column for low temperature digestion. 
Resultant peptides are separated using a fast separation gradient and detected 
via mass spectrometry. Finally the mass shift of analysed peptides due to 
deuterium uptake is determined and information regarding higher order 
structure of the protein may be deduced. 
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5.2 Deuterium uptake chart for FPPKPKDTLM (low temperature mAb - one MS 
spectrum from each time-point only is shown for brevity). Each IgG1 sample 
analysed was exposed to deuterated buffer for different lengths of time ranging 
from 0 to 240 minutes, before undergoing proteolysis and MS analysis. MS 
spectra corresponding to the same peptide (FPPKPKDTLM) determined in the 
same sample that had been exposed to deuterated buffer for various durations 
are shown. A characteristic mass shift is observed in the spectra following HDX 
corresponding to the increased peptide mass, resulting from the replacement of 
the peptide’s backbone amide hydrogen atoms with deuterium. 
5.3 Peptic peptides identified across all experiments for anti-IL8 IgG1 produced at 
standard conditions, 110% DO and 60% DO in mAb A. light chain and B. heavy 
chain. Each peptide is represented by a blue bar. 
5.4 Peptic peptides identified across all experiments for anti-IL8 IgG1 produced at 
standard conditions, pH 7.2 and pH 6.8 in mAb A. light chain and B. heavy chain. 
Each peptide is represented by a blue bar. 
5.5 Peptic peptides identified across all experiments for anti-IL8 IgG1 produced at 
standard conditions, 32.0oC and 39.5oC in mAb A. light chain and B. heavy chain. 
Each peptide is represented by a blue bar. 
5.6 Relative fractional uptake of deuterium for A. light chain and B. heavy chain anti-
IL8, produced under standard (85% DO), low DO (60% DO) and high DO (110% 
DO) bioprocess conditions. 
5.7 Relative fractional uptake of deuterium for A. light chain and B. heavy chain anti-
IL8, produced under standard (pH 7.0), low pH (pH 6.8) and high pH (pH 7.2) 
bioprocess conditions. 
5.8 Relative fractional uptake of deuterium for A. light chain and B. heavy chain anti-
IL8, produced under standard (37.0oC), low temperature (32.0oC) and high 
temperature (39.5oC) bioprocess conditions. 
5.9 Mirror plot showing the relative fractional uptake for mAb heavy chain from 
samples produced using standard and altered bioprocess conditions of pH 6.8. 
5.10 Mirror plot showing the relative fractional uptake for mAb light chain from 
samples produced using standard and altered bioprocess conditions of pH 6.8. 
5.11 Mirror plot showing the relative fractional uptake for mAb heavy chain from 
samples produced using standard and altered bioprocess conditions of pH 7.2. 
5.12 Mirror plot showing the relative fractional uptake for mAb light chain from 
samples produced using standard and altered bioprocess conditions of pH 7.2. 
5.13 Mirror plot showing the relative fractional uptake for mAb heavy chain from 
samples produced using standard and altered bioprocess conditions of 39.5oC. 
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5.14 Mirror plot showing the relative fractional uptake for mAb light chain from 
samples produced using standard and altered bioprocess conditions of 39.5oC. 
5.15 Mirror plot showing the relative fractional uptake for mAb heavy chain from 
samples produced using standard and altered bioprocess conditions of 32.0oC. 
5.16 Mirror plot showing the relative fractional uptake for mAb light chain from 
samples produced using standard and altered bioprocess conditions of 32.0oC. 
5.17 Mirror plot showing the relative fractional uptake for mAb heavy chain from 
samples produced using standard and altered bioprocess conditions of 110% DO.  
5.18 Mirror plot showing the relative fractional uptake for mAb light chain from 
samples produced using standard and altered bioprocess conditions of 110% DO. 
5.19 Mirror plot showing the relative fractional uptake for mAb heavy chain from 
samples produced using standard and altered bioprocess conditions of 60% DO. 
5.20 Mirror plot showing the relative fractional uptake for mAb light chain from 
samples produced using standard and altered bioprocess conditions of 60% DO. 
5.21 Difference index plots showing differences in deuterium uptake between 
standard mAb and A. high temperature mAb heavy chain, B. high temperature 
mAb light chain, C. low temperature mAb heavy chain and D. low temperature 
mAb light chain. 
5.22 Difference index plots showing differences in deuterium uptake between 
standard mAb and A. high temperature mAb heavy chain, B. high temperature 
mAb light chain, C. low temperature mAb heavy chain and D. low temperature 
mAb light chain. 
5.23 Difference index plots showing differences in deuterium uptake between 
standard mAb and A. high DO mAb heavy chain, B. high DO mAb light chain, C. 
low DO mAb heavy chain and D. low DO mAb light chain. 
5.24 Sensograms and residual plots from triplicate affinity analysis of FcRn binding to 
anti-IL8 IgG1 produced in cell culture maintained at 110% DO (A-C) and 60% DO 
(D-F). 
5.25 Sensograms and residual plots from triplicate affinity analysis of FcRn binding to 
anti-IL8 IgG1 produced in cell culture maintained at 39.5oC (A-C) and 32.0oC (D-F). 
5.26 Sensograms and residual plots from triplicate affinity analysis of FcRn binding to 
anti-IL8 IgG1 produced in cell culture maintained at pH 7.2 (A-C) and pH 6.8 (D-F). 
5.27 Sensograms and residual plots from triplicate affinity analysis of FcRn binding to 
anti-IL8 IgG1 produced in cell culture maintained at standard conditions: 
standard 1 (A-C), standard 2 (D-F). 
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5.28 Sensograms and residual plots from triplicate affinity analysis of FcRn binding to 
anti-IL8 IgG1 produced in cell culture maintained at standard conditions: 
standard 3 (A-C). 
5.29 Box-plot showing FcRn binding dissociation constants determined for anti-IL8 
IgG1 produced using different bioprocessing conditions of pH, DO and 
temperature (T). 
5.30 Resulting Sensograms and residual plots from triplicate affinity analysis of 
interleukin 8 binding to anti-IL8 IgG1 produced in cell culture maintained at 
39.5oC (A-C) and 32.0oC (D-F). 
5.31 Resulting Sensograms and residual plots from triplicate affinity analysis of 
interleukin 8 binding to anti-IL8 IgG1 produced in cell culture maintained at pH 
7.2 (A-C) and pH 6.8 (D-F). 
5.32 Resulting Sensograms and residual plots from triplicate affinity analysis of 
interleukin 8 binding to anti-IL8 IgG1 produced in cell culture maintained at 110% 
DO (A-C) and 60% DO (D-F). 
5.33 Resulting Sensograms and residual plots from triplicate affinity analysis of 
interleukin 8 binding to anti-IL8 IgG1 produced in cell culture maintained at 
standard conditions: standard 1 (A-C), standard 2 (D-F). 
5.34 Resulting Sensograms and residual plots from triplicate affinity analysis of 
interleukin 8 binding to anti-IL8 IgG1 produced in cell culture maintained at 
standard conditions: standard 3 (A-C). 
5.35 Box-plot showing interleukin-8 binding dissociation constants determined for 
anti-IL8 IgG1 produced using different bioprocessing conditions of pH, DO and 
temperature (T). 
6.1 Schematic of workflow for discovery proteomic analysis of HCPs in 
biotherapeutic protein samples. 
6.2 Extracted ion chromatogram displaying ion peaks for each of the standard 
peptides used for Hi3 quantitation. 
6.3 Venn diagram showing the distribution of HCPs identified in mAb samples eluted 
from Protein A resin using various buffers under study. A description of the 
protein entries shown in the Venn diagram may be found in Table 6.2.  
6.4 Chromatographic profiles obtained from (A) charge variant analysis and (B) SEC, 
both shown in expanded scale, for mAb1 samples purified from Protein A resin 
using acetate-, arginine-, citrate- and glycine-based buffers. Reference Table 6.4 
for numerical values obtained from these analyses. 
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6.5 Overlay of chromatgrams displaying N-glycan profiles of mAb1 processed from 
Protein A resin using elution buffers 100 mM sodium acetate, pH 3.5, 100 mM 
arginine, pH 3.5, 100 mM citrate, pH 3.5 and 100 mM glycine, pH 3.5. 
6.6 Graphic of anti-Interleukin 8 IgG1 (mAb1) structure. MAb1 peptides, which were 
identified in sample fractions also containing Calreticulin peptides, are 
highlighted in the heavy chain (blue) and light chain (green) portions of the 
structure. 
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Abstract 
Title:  Development and Application of Quantitative Liquid Chromatography – Mass 
Spectrometry Techniques to Facilitate Enhanced Bioprocessing of Therapeutic 
Proteins 
Candidate:   Amy Farrell 
 
Biopharmaceutical manufacturing is currently the principal growth sector within the 
pharmaceutical industry. Predominantly formed in mammalian cells, these therapeutic 
proteins exist as a spectrum of different isoforms and hence pose a unique set of challenges 
that must be addressed to ensure optimum product quality. To better understand whether the 
product really is the process, quantitative peptide centred multidimensional liquid 
chromatography tandem mass spectrometry (LC-MS) based proteomics studies were 
performed using a Chinese Hamster Ovary (CHO) cell line that expressed an anti-Interleukin-8 
IgG1 monoclonal antibody (mAb). Following serum free suspension batch culture under varied 
bioprocess conditions, quantitative proteomics was completed on the producer CHO cells to 
elucidate the cellular response to altered culture conditions of pH, temperature and dissolved 
oxygen. The developed platform was also applied for the analysis of naïve CHO K1 cells 
following their exposure to spent culture media from the various production runs. Complete 
characterisation of the expressed mAb was performed, using advanced LC-MS methods 
including high resolution middle down mass spectrometry; intact protein analysis of critical 
quality attributes, stable isotope based quantitative glycan analysis and hydrogen deuterium 
exchange mass spectrometry for structural comparability analysis. In addition data 
independent LC-MS quantitative proteomics of residual host cell protein impurities was also 
carried out to evaluate the effect of downstream processing on the quality of the final drug 
substance. Combined, the findings herein provide a holistic insight into the effect of various 
upstream and downstream parameters on the quality of therapeutic proteins and facilitate a 
greater understanding of the molecular mechanisms governing biopharmaceutical production 
systems, thereby creating a hypothesis for improved future cell line development using 
various engineering strategies.  
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1.0 
A Review of Analytical Technologies used 
for Quantitative CHO Cell Proteomics 
 
1.1 Introduction  
Chinese hamster ovary (CHO) cell lines are currently the dominant expression system for 
biotherapeutic proteins produced in mammalian cell lines and are utilised in the production of 
six of the top ten-selling biopharmaceutical products.[1] CHO cells lines are widely used due to 
their ability to facilitate correct protein folding and human-like post-translational 
modifications (e.g. glycosylation) of recombinant therapeutic  proteins. In addition, CHO cell 
lines are amenable to serum-free suspension cultivation and are readily adaptable to different 
media compositions, both critical features for protein production in large-scale bioreactors. 
Since regulatory approval for the first therapeutic protein, which was produced in a CHO cell 
line, was achieved, considerable efforts have been made to improve recombinant protein 
production. Initially the bulk of research was focused on increasing productivity and 
therapeutic protein quality by altering various bioprocessing parameters. More recently, 
advances in analytical instrumentation have enabled a deeper understanding of the cellular-
level mechanisms that effect protein production in these important cell lines. In particular 
developments in liquid chromatography (LC) and mass spectrometry (MS) have facilitated the 
emergence of ‘omics’ tools which have allowed us to gain a depth of understanding of CHO 
cell proteomes, the functional units of the cell, that previously had not been possible. 
Mass spectrometry coupled with technologies for sample preparation and separation, along 
with data analysis software for protein identification and quantitation, provide a powerful 
platform for analysis of proteomes from biologically relevant samples. Traditionally, CHO 
proteomics was driven by research using two-dimensional gel electrophoresis combined with 
mass spectrometry. The majority of these studies consisted of separation and isolation of 
proteins in gel ‘spots’ and ionisation and detection of peptides using matrix-assisted laser 
desorption ionisation – Time of flight (MALDI-ToF) mass spectrometry. More recently, major 
advances in gel-free peptide separation technologies, mass spectrometry and bioinformatics, 
augmented by the CHO genomic revolution have allowed LC-based proteomics to flourish. 
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Two-dimensional liquid chromatography coupled to mass spectrometry (2D-LC-MS) now 
routinely facilitates the identification of thousands of proteins from complex samples. 
Due to improvements in MS and bioinformatics, comprehensive characterisation and 
quantification of proteins within biologically relevant samples using quantitative proteomics is 
now achievable, enabling the classification of CHO cell proteins that play key roles in 
recombinant protein production, including those involved in growth, metabolism, protein 
processing, glycosylation and cell death.[2] Hence, knowledge gained through CHO cell 
proteomics have the potential to lead to further advances in therapeutic protein production in 
CHO cells, including improved media and bioprocess development,  advanced elimination of 
bioprocess impurities, characterisation of critical quality attributes and by identifying features 
that lead to desired phenotypes for biopharmaceutical production of therapeutic proteins. [3] 
In Chapter 1, analytical technologies that are currently applied for proteomic profiling of CHO 
cell line behaviour and characterisation of therapeutic proteins will be discussed. A particular 
focus is applied to LC-MS separation and detection strategies and related quantitative and 
bioinformatics tools. Subsequently, a review of the application of these techniques to better 
understand the CHO cell proteome will be outlined. 
 
1.2 Sample Preparation for Proteome Analysis 
Two typical proteomics approaches are used for analysis of large biomolecules by mass 
spectrometry; these are ‘Top-down’ and ‘Bottom-up’ approaches. In a bottom-up strategy, 
specific peptide bonds are cleaved to produce peptides composed typically of <20 amino acid 
residues, which are subsequently analysed using a mass spectrometer. Conversely, in a top-
down experiment, the complete undigested protein is analysed. In proteomics, the former 
approach is most frequently used as mass spectrometers are more efficient in deriving 
sequence information from peptides rather than whole proteins. [4]  
Traditionally, a bottom-up proteomic strategy consisted of ‘in-gel’ digestion, in which proteins 
were denatured and separated using sodium dodecyl sulphate – polyacrylamide gel 
electrophoresis (SDS-PAGE), followed by visualisation of proteins in a gel and excising of 
protein-containing gel plugs before reduction, alkylation, digestion and extraction from the gel 
matrix for MS analysis. [5] Alternatively ‘in-solution digestion’ was developed wherein direct 
solubilisation and denaturation of proteins in a digestion buffer was followed by disulphide 
reduction and alkylation of free sulfhydryl groups on cysteine residues before digestion with 
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an endoproteinase.  Both ‘in-gel’ and ‘in-solution’ sample preparation methods have various 
advantages and drawbacks, as outlined in Table 1.1. 
 
Table 1.1: Advantages and disadvantages associated with in-gel and in-solution digestion of 
proteomic samples. [6] 
 
 
In-gel 
digestion 
Advantages  Visual indication of relative abundance or proteins in a 
sample 
 Robustness against impurities interfering with 
digestion 
 Universal solubilisation of proteome using SDS 
Disadvantages  Proteins trapped in a gel may be inaccessible to digest 
reagent 
 Peptide recovery may be hampered by gel matrix 
 
 
In-
solution 
digestion 
Advantages  No detergents needed 
 Minimal sample handling 
 Rapid sample preparation 
 Easily automated 
 Reduced sample requirement 
Disadvantages  Digestion may be inhibited by interfering substances 
 Risk of incomplete solubilisation of proteome  
(e.g. membrane proteins) 
 
In order to overcome limitations associated with the sample preparation methods outlined, 
Mann and colleagues developed an alternative method for proteome sample preparation that 
reportedly combined the advantages of both ‘in-gel’ and ‘in-solution’ digestion approaches, 
known as filter-aided sample preparation (FASP). [7] Using FASP, solubilisation of proteins is 
achieved using SDS before application of the entire protein sample to a filtration device. The 
filtration device then serves as a vessel for detergent removal, buffer exchange, reduction and 
alkylation of proteins and finally protein digestion in solution. FASP therefore combines the 
solubilisation efficiency of in-gel digestion with the digestion efficiency of in-solution digestion 
methods.  
Several enzymes are available for protein digestion in bottom-up proteomics, however the 
most commonly used protease in proteomics is Trypsin. Trypsin has a well-defined specificity, 
hydrolysing only the peptide bonds in which a carbonyl group is followed by either arginine (R) 
or lysine (K) (except when R or K is N-linked to an aspartic acid residue). Due to the frequency 
of R and K residues within the proteome, Trypsin generates peptides with the preferred mass 
range for MS sequencing. [8] Additionally, tryptic peptides terminating in basic R and K 
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residues form prominent, easily detectable fragment ions. [9] In some instances, additional 
digestions are required for optimal proteomic sample preparation. The endoprotease Lys-C is 
often used prior to trypsin digestion producing larger peptide fragments than trypsinization. 
[10] Similarly, proteases such as Asp-N and Glu-C, may be used to produce peptides 
complementary to tryptic peptides for MS analysis. [4] 
 
1.3  Separation Technologies 
Two-dimensional gel electrophoresis (2-DE) has traditionally been the workhorse for 
proteomics, facilitating the separation of proteins based on differences in protein size and net 
charge at different pH values. Although 2-DE is renowned for its excellent resolving power, it 
has a number of limitations including poor reproducibility, co-migration of proteins, poor 
representation of low abundant, highly acidic or highly basic proteins and difficulty in 
automation. [11] To overcome low reproducibility in 2-DE, two-dimensional differential in-gel 
electrophoresis (2D-DIGE) was developed, allowing for differentially labelled samples to be 
separated and visualised on the same 2D gel. [12] However like 2-DE, 2D-DIGE is cumbersome 
and is limited by dynamic range for protein separation. Due to advances in ionisation 
techniques for mass spectrometry, liquid chromatography has emerged as a leading technique 
for proteomic separations over the last decade. Reversed phase (RP) chromatography, in 
which analytes are partitioned based on their interaction with a hydrophobic stationary phase 
while being carried in a polar hydrophilic mobile phase with increasing organic modifier 
content, is the most widely used gel-free chromatography method for proteomic sample 
preparation. [13] Like gel separation technologies, LC approaches often use a two dimensional 
(2D) separation strategy to ensure sufficient separation of peptides or proteins for detection.  
Use of orthogonal separation methods permits the resolution of peptides in highly complex 
samples on the basis of different physiochemical properties, thereby increasing overall peak 
capacity. [13] Frequently, orthogonal 2D-LC configurations consist of RP, [14] strong cation 
exchange (SCX), [15] strong anion exchange (SAX), [16] hydrophilic interactions 
chromatography (HILIC) [17] and other specific chemistries in the first dimension, coupled to 
RP-nano-LC in the second dimension. The use of nano-LC directly interfaced with MS was of 
great significance in regards to advances in proteomic analysis, as a reduction in internal 
diameter of analytical separation columns enabled increased separation efficiency, reduced 
solvent consumption, smaller sample requirements and ease of coupling to a mass 
spectrometer. [18] Furthermore, nano-LC systems incorporating split-less pumps ensure a 
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continuous flow required for electrospray ionisation (ESI) and hence are becoming a mainstay 
of proteomics research. [19] 
 
1.4 Detection by Mass Spectrometry 
MS detection has become a key enabler of in-depth proteomics over the last two decades, 
resulting from major advancements in mass spectrometry. A mass spectrometer measures the 
mass-to-charge (m/z) ratio of gas-phase ions, typically consisting of an ion source, for the 
production of gaseous ions from a sample; a minimum of one mass analyser, for separation of 
ions based on their m/z ratios and a detector to record ion data. The MS platform is 
completed by an inlet feature for introduction of sample into the ion source and a computer 
to process sample information and generate mass spectra. 
 
1.4.1 Ionisation of Biomolecules 
The application of MS to the analysis of biomolecules and emergence as an indispensable tool 
for protein analysis was facilitated by the development of ‘soft ionisation’ techniques, e.g. 
MALDI or ESI. Proteins and peptides are non-volatile, polar and thermally labile species that, 
for MS analysis, require an ionisation technique to transfer the analyte to gas phase without 
resulting in over fragmentation or extensive degradation of the biomolecule. [20] MALDI, 
classically used in combination with gel-separation strategies, is particularly applicable to top-
down analysis of high molecular weight proteins in simple sample mixtures as it 
predominantly generates singly-charged ions. However, MALDI-associated drawbacks include 
poor shot-to-shot reproducibility, potential signal suppression, limited detectable mass range 
and reliance on efficient sample preparation techniques. [20, 21] Due to recent analytical 
technological advances, LC-ESI-MS capabilities now far surpass those of gel-based MALDI-MS 
techniques. 
The concept of ESI, visualised in Figure 1.1-A, was developed by Fenn et al. in 1984 for the MS 
analysis of biological macromolecules. [22] During ESI, proteins or peptides in solution are 
pumped through a metal capillary maintained at a high voltage (2-6 kV) and nebulised at the 
tip of the capillary to produce a fine spray of charged droplets. The charged droplets strongly 
repel each other to form a conical shape known as a ‘Taylor cone’ and are quickly evaporated 
following the application of heat and a nebulising gas. [23] The reduction in droplet size results 
in a build-up of ions of one polarity on the surface of the drop and, at the point when the 
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forces of electrostatic repulsion are greater than the surface tension (i.e. the ‘Rayleigh limit’) 
the droplet explodes, culminating in the production of gas phase ions. The ions are then 
subsequently transferred into the mass spectrometer. [23, 24]  
 
 
Figure 1.1: A. Schematic diagram of electrospray ionisation process. [25] B. The relationship 
between ionisation efficiency and flow rate. ESI current is directly proportional to the square 
root of the flow rate (V) while the analyte mass flow (Mf) is directly proportional to V. Hence, 
the ionisation efficiency (i.e. the ratio of the ESI current and mass flow rate) is proportional to 
the inverse square root of V resulting in a dramatic improvement in ionisation efficiency at 
very low flow rates. [26, 27] 
 
ESI has a number of advantages rendering the technique particularly suitable for the analysis 
of biomolecules. Significantly, ESI is carried out at close to ambient temperatures, and hence 
thermally labile, polar molecules such as proteins and peptides may be ionised without 
decomposition. In addition as the ions are produced in solution, analytes with several 
ionisable sites may produce multiply-charged species, successfully extending the effective 
mass range of the instrument. [23] However, conventional ESI was greatly affected by 
fluctuation in flow rate and due to the size of the droplets emerging from the ESI capillary and 
requirement for nebulising gas, only a small portion of the sample is transferred into the mass 
analyser, as is shown in Figure 1.1-A. 
ESI-associated caveats were addressed by Wilm and Mann, when they first described their 
innovative nano-electrospray ion (nanoESI) source. [28] Wilm and Mann used glass capillaries 
pulled into sharp tips with a 1-2 μm spraying orifice to reduce the size of droplets formed at 
the tip of the capillary. Since droplets produced in the nanoESI source are relatively small and 
have high surface-to-volume ratios, a desolvation gas is not required for solvent evaporation. 
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[29] Additionally, the small droplet size has resulted in an increased tolerance of buffer salts 
and other impurities. Use of capillaries with a small spraying orifice also facilitated low flow 
rates (20 nL.min-1) resulting in increased ionisation efficiency as depicted in Figure 1.1-B. 
Furthermore, the use of low flow rates permits the positioning of the nanoESI capillary close to 
the MS inlet orifice, resulting in increased ion transmission in comparison to conventional ESI. 
Ultimately the use of a nano-scale ESI source resulted in a reportedly 100-fold improvement in 
ionisation efficiency enabling high sensitivity analysis while using low sample amounts.  
Initial use of nanoESI instrumentation involved placing sample into a needle and spraying the 
sample into the MS inlet. Although this resulted in an increase in overall ionisation efficiency, 
the absence of analytical separation made manipulation of the ion within the mass 
spectrometer difficult for MS/MS analysis. Fortuitously, the development of nanoESI coincided 
with progress in the miniaturisation of LC systems. The suitability of nanoESI for coupling to 
liquid separation techniques and the development of nano-LC pumps facilitating low flow 
rates have resulted in greatly advanced separation of peptide ion peaks and hence superior 
proteome coverage when coupled to mass spectrometers. Due to ease of automation and 
successful application to highly complex protein samples, integrated nano-LC-ESI-MS systems 
are now extensively applied in the field of proteomics research. 
 
1.4.2 Mass Analyser Configuration for Quantitative Proteomics and Product 
Characterisation 
As peptides typically have multiple charge states (z = 2, 3, 4), the ability of the mass analyser 
to resolve ions with minute differences in m/z is critical for accurate identification of protein 
and peptide species. Hence, many of the advancements in mass spectrometry in recent years 
have focused on increasing the resolving power of the mass analyser. Several mass analysers 
are available, including the first generation low resolution (<10,000) quadrupole, time-of-flight 
and ion trap mass analysers. However in recent years proteomics has been almost exclusively 
performed on high resolution hybrid instruments due to their capabilities for high mass 
accuracy, resolution, sensitivity and extended mass range. Table 1.2 depicts a number of 
available hybrid instruments, which usually incorporate two or more mass analysers. In these 
instruments ions from an ion source are focused and transmitted using a quadrupole or linear 
ion trap and separated and analysed using  a ToF, fourier transform ion cyclotron resonance 
(FT-ICR) or Orbitrap analyser, thereby combining the advantages of each individual mass 
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analyser. The power of these hybrid instruments is most notably reflected when operated in 
tandem MS mode, as will be discussed in section 1.4.3.  
Due to high resolution and broad mass range capabilities, in addition to more favourable start-
up costs in comparison to alternative high resolution instruments, the quadrupole time-of-
flight (QToF) mass spectrometer has been widely applied for the identification of CHO cell 
proteins. A QToF consists of a quadrupole, which serves to selectively transmit ions according 
to their mass to charge (m/z) ratios by varying the RF potential applied to four parallel poles, 
into a time-of-flight mass analyser. Ions are then directed towards a detector and measured 
according to the time taken to move through a field-free region between the inlet and the 
detector.  
High resolution instruments incorporating an Orbitrap mass analyser are capable of achieving 
the greatest resolving power when compared to other hybrid mass spectrometers. Pioneered 
by Makarov et al., the Orbitrap is an ion trap mass analyser composed of an outer barrel-like 
electrode encasing a co-axial spindle-like electrode, which traps ions in an orbital motion. An 
ion’s m/z ratio is measured from the frequency of harmonic oscillations undertaken by 
orbitally trapped ions along the axis of the electric field. [30] In-depth proteomics utilising 
Orbitrap-containing hybrid MS routinely lead to the identification of >4,000 proteins in a single 
MS analysis. [31] The concept of hybrid MS has been further expanded by the development of 
a tribrid MS incorporating three mass analysers (i.e. a quadrupole mass filter, an ultra-high 
field Orbitrap analyser and a dual pressure linear ion trap analyser (Table 1.2). This instrument 
has significantly improved capabilities for quantitative proteomics as will be discussed in 
Section 1.6. 
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Table 1.2: Common hybrid mass spectrometers used in proteomics. [32-35]  
Instrument 
Type 
Schematic of MS Typical Specifications 
QTof 
e.g. Waters 
Xevo G2 
QToF 
 
Resolution: 0.04 ∆m/z 
Mass accuracy: <1 ppm 
m/z range: 50-20,000 
 
QQQ 
e.g. Agilent 
6460  
Resolution: 0.4 ∆m/z 
Mass accuracy: 5 ppm 
m/z range: 10-3000 
Q-LIT  
e.g. AB 
SCIEX 
QTRAP 5500 
 
Resolution: 0.1 ∆m/z 
m/z range: 5-1250 
Q-Orbitrap 
e.g. Thermo 
Fisher 
Scientific Q 
Exactive 
 
Resolution: 0.001 ∆m/z 
Mass accuracy: <1 ppm 
m/z range: 50-4000 
LTQ-
Orbitrap 
e.g. Thermo 
Fisher 
Scientific 
Orbitrap 
Elite 
 
Resolution: 0.002 ∆m/z 
Mass accuracy: <1 ppm 
m/z range: 50-4000 
 
Q-LIT-
Orbitrap 
e.g. Thermo 
Fisher 
Scientific 
Orbitrap 
Fusion 
Lumos 
Tribrid 
 
Resolution: 0.0004 ∆m/z 
Mass accuracy: <1 ppm 
m/z range: 50-6000 
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1.4.3 Tandem Mass Spectrometry  
Identification of proteins following MS analysis was traditionally achieved using peptide mass 
fingerprinting, a technique whereby a peptide mass profile detected by MS analysis is 
compared with all predicted peptide digests in a database of known proteins, to identify the 
best possible protein match. [36] This method however is not suitable for the analysis of 
complex protein samples, as frequently common peptide sequences will exist across multiple 
proteins. The requirement for additional identification methods for analysis of protein 
mixtures led to the development of tandem MS; (MS/MS), facilitated by the construction of 
hybrid or tandem mass spectrometers combining two or more mass analysers (section 1.4.2). 
In MS/MS instrumentation, a single (precursor) ion is selected in the first mass analyser and 
subsequently fragmented to produce fragment (product) ions which are separated in the 
second mass analyser according to their mass. Resulting MS/MS spectra consist only of 
product ions from the selected precursor ion as displayed in Figure 1.2. The mass difference 
between peaks in the MS/MS spectrum may be correlated to the mass of an amino acid, 
hence the amino acid sequence of the peptide may be deduced.  
 
Figure 1.2: MS/MS spectrum generated from tryptic peptide AIDLIDEAASSIR from the E. coli 
protein chaperone ClpB (Hi3 E. coli standard peptides purchased from Waters (Dublin, 
Ireland)). Data was acquired using a Waters Xevo G2 QTof coupled to a Waters nanoAcquity 
UPLC system equipped with a nanoAcquity UPLC 2G-V/M Trap 5 µm symmetry C18, 180 µm x 
20 mm trapping column and a nanoAcquity UPLC 1.8 µm HSS T3, 75 µm x 200 mm analytical 
column.  
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Several methods exist for peptide fragmentation; however those most commonly used for 
proteomics are collision-induced dissociation (CID), electron transfer dissociation (ETD) and 
high energy collision dissociation (HCD). In CID, peptides are allowed to collide with gas 
molecules (typically helium, nitrogen or argon), resulting in vibrational excitement of the 
molecule and subsequent dissociation of the peptide backbone amide bonds located between 
carbonyl and amide groups. As depicted in Figure 1.3, resulting fragment ions are termed b-
ions if they retain the N-terminal part of the peptide or y-ions if they contain the C-terminal 
portion of the peptide. In addition a-ions may also be formed due to loss of a carbonyl group. 
[4, 37]  
 
Figure 1.3: Diagram of potential peptide fragmentation pattern following CID (b-, y- and a-
ions) and ETD (c-, z- and x-ions). 
 
Although widely applied for global proteomic analysis, CID is known to be unsuitable for 
analysis of many protein post translational modifications (PTMs) including phosphorylation 
and glycosylation. [38] CID proceeds via fragmentaion of the weakest bond on the peptide 
(usually between carbonyl and amide groups). However as PTMs tend to be labile, application 
of CID will result in cleavage of the PTM molecule from the peptide. [37] For phosphorylated 
peptides, resulting spectra will display a mass shift corresponding to loss of the PTM but will 
not confirm the peptide sequence. [39] Similarly for glycosylated peptides, the MS/MS 
spectrum will display characteristic oxonium ions, e.g. m/z 204 292, 366, and 657, yielding 
little or no sequence information. [40] 
In ETD, fragmentation is induced by converting positively charged peptides into radicals 
following transfer of electrons from chemical anions such as anthracene and fluoranthene. 
[41] Resulting peptide cation radicals are unstable and routinely undergo fragmentation 
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following dissociation of bonds between amide groups and α-carbons to produce 
characteristic c- and z-ions (Figure 1.3). [42] Due to the rapid nature of ETD, it is capable of 
retaining modifications and hence is ideal for the study of PTMs. [38] Furthermore, as ETD 
provides information on the location of PTMs, it is an important technique for advanced 
structural characterisation of proteins.  
CID is generally carried out using high energy beam instruments such as QToF and QQQ mass 
spectrometers for global proteomics, as peptides containing labile PTMs are less amenable to 
low energy, resonate excitation MS/MS analysis. [43] For this reason Makarov et al. developed 
HCD [44] for use alongside Orbitrap mass analysers to compete with high-beam instruments. 
In addition to achieving increased fragment ion efficiency when compared to other traditional 
trapping mass analysers, use of HCD results in an extended detection mass range for MS/MS 
fragments enabling MS/MS-based quantitation using stable isotopes (to be discussed in 
section 1.6). 
 
1.4.4 Data dependent versus Data independent Acquisition in Mass Spectrometry  
In mass spectrometry, peptide data is acquired in one of two general modes: data dependent 
acquisition (DDA) or data independent acquisition (DIA) mode. Traditionally DDA has been the 
gold standard for MS analysis. In DDA ionised peptides are analysed to generate a list of 
precursor masses then, depending on particular MS settings chosen (e.g. peak intensity), a 
certain number of precursor ions are selected for MS/MS fragmentation. Interpretation of 
resultant MS/MS spectra yields sequence information which may then be compared with a 
peptide database for protein identification. [45] As all fragment ions are detected and the 
precursor ion related to the fragments is known, an analyst may have confidence in the quality 
of peptide identifications from complex protein mixtures. However, since only a small number 
of precursor ions are selected in a defined period of time, DDA may display bias towards more 
abundant proteins in the sample being analysed. As peptides enzymatically derived from 
proteins will have varying ionisation efficiencies and proteins in a complex sample will have 
concentrations spanning a wide dynamic range (with the majority existing at concentrations at 
least two orders of magnitude lower than the most abundant protein), many of the low 
abundant proteins may not be identified. [46, 47] In order to combat this limitation, dynamic 
exclusion is often employed wherein previously selected precursor ions are excluded from 
subsequent ion selection for MS/MS fragmentation, thereby increasing proteome coverage in 
DDA analysis. [48] 
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The first DIA method was pioneered by Silva and co-workers, who described a MS acquisition 
method wherein no selection bias of precursor ions is used, later named MSE acquisition. [49, 
50] In MSE, the first mass analyser (shown as a quadrupole in Figure 1.4-A) transfers all 
precursor ions into a collision cell for fragmentation by CID. Collision energy applied is 
alternated between low and elevated energy, providing precursor (MS 1) and product (MS 2) 
ion spectra from every ion above the limit of detection of the instrument as low energy scans 
measure intact peptide ions while fragment ions are measured in high energy scans. [51] 
Bioinformatics software is then used to correlate fragment ions to their corresponding 
precursor ions based on retention time, mass accuracy and other physicochemical properties 
including fragment to precursor ratios and peptide fragmentation prediction. [52] 
 
 
Figure 1.4: A. Depiction of LC-MSE analysis on a QToF mass spectrometer.  All precursor ions 
are transferred into a collision cell for CID fragmentation using alternated low and elevated 
collision energy, providing precursor and product ion spectra from every ion above the limit of 
detection of the MS instrument. [53] B. Representation of DIA operating in SWATH mode, 
adapted from [54]. All precursor ions within successive precursor ion windows over the mass 
range of the experiment are transmitted into a collision cell for fragmentation by CID. 
 
During MSE, fragment ions peaks are aligned with the chromatographic profile of the precursor 
by determination of chromatographic peak characteristics such as apex peak retention time, 
start and end time of the peak and peak width at half maximum. [47] Therefore the success of 
the method is highly dependent on chromatographic proficiency. Despite improving the 
dynamic range for protein identification, limitations of MSE include its incompatibility with 
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some quantitative experiments, including those using isobaric tags (to be discussed in section 
1.6). 
Gillet et al. described an alternative strategy for DIA of proteome samples known as SWATH 
(sequential window acquisition of all theoretical spectra). [55] Similar to MSE, SWATH also 
involves the transmission of all precursor ions detected during the MS survey scan (MS 1), for 
fragmentation by CID. However, in SWATH mode the mass spectrometer repeatedly cycles 
through a set of precursor acquisition windows over the mass range 400-1200 m/z (i.e. 32 
successive 25 Da precursor isolation windows). As shown in Figure 1.4-B, during each cycle the 
mass spectrometer fragments all precursor ions in a specific mass range (e.g. 400-425 m/z, 
then 425-450 m/z etc.) and produces a MS/MS spectrum of all precursors in that isolation 
window. As the range of precursor ion windows is cycled throughout the entire 
chromatographic process, fragment ion spectra for all analytes in the specified mass range are 
also time-resolved. 
 
1.5 Bioinformatics  
Widespread use of MS in proteomics would not be possible without the availability of protein 
sequence databases and bioinformatics tools for protein identification and function 
assignment. Three main types of search engines for protein identification exist including de 
novo search engines (which derive peptide identifications based on peak patterns in MS/MS 
spectra without use of reference material, e.g. PEAKS [56]); spectral library search engines 
(that use a library of reference spectra to match MS/MS sample spectra, e.g. X!Hunter [57]) 
and sequence search engines. Various proprietary and non-proprietary sequence search 
engines are available for protein identification using different algorithms including SEQUEST 
[58], MASCOT [59], X!Tandem [60], Andromeda [61] and ProteinLynx Global Server [62]. Two 
main approaches for peptide sequencing using a search engine are shown in Figure 1.5. 
Probability-based matching is used in many of these (e.g. Mascot), where predicted peptide 
fragments are matched to experimentally observed fragment ion peaks. Alternatively, auto-
correlation may be used to determine the over-lap between an experimentally derived 
spectrum and a theoretical spectrum derived from each sequence in a reference database 
(e.g. SEQUEST). These tools often include the use of decoy databases to estimate false 
discovery rates for statistical validation of identification results.  
As the output of different mass spectrometers and alternative sequence search engines is 
produced in a variety of proprietary formats, the wide variety of data types produced can be 
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problematic for comparative analysis of results. In order to facilitate uniform, comparative 
analysis from a variety of instruments and processing tools, Keller et al. developed the Trans-
Proteomic Pipeline (TPP) which incorporates various bioinformatics tools and stores data in 
open XML format.  [63] Bioinformatics tools integrated into TPP include PeptideProphet, 
which validates peptides assigned to MS/MS spectra [64]; XPRESS, used for peptide and 
protein quantitation [65]; and ProteinProphet for validation of identified proteins. [66] 
 
 
Figure 1.5: Schematic of a data acquisition and database search workflow for proteomics. 
Experimental MS/MS spectra are matched against (A) predicted fragment ions or (B) 
theoretical MS/MS spectra from in-silico digested proteins, before reporting of best-matched 
peptides and related score. Adapted from [67]. 
 
Once proteins have been identified, it is common-place to use functional assignment 
bioinformatics tools to gain functional knowledge of entire protein systems composed of 
protein groups identified. Functional interpretation of identified proteins usually begins with 
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the association of a protein list with gene ontology (GO) terms that describe related biological 
processes, molecular functions and cellular components. Following GO term annotation, the 
abundance of specific GO terms, associated with an identified protein list, is compared with 
the natural abundance in the organism using a reference database. A probability value (p-
value) is then generated to show potential over-representation of a specific GO term in the 
test sample compared to the reference database [68]. More than 60 tools exist for GO-term 
enrichment, e.g. the database for annotation, visualisation and integrated discovery, DAVID 
[69, 70]. However care must be taken when choosing a tool for GO annotation as a wide 
discrepancy in reported GO-terms has been observed when using tools with different 
algorithms for annotation [71].  
Other resources useful for evaluating proteomic results in a biological context include 
interaction databases for pathway analysis e.g. KEGG [72] and Ingenuity pathway analysis 
(IPA). [73] Proteins that are directly involved or that contribute to regulation of a cellular 
reaction are contained in pathway databases, [68] which describe a series of cellular reactions 
that produce an observable biological effect. Using these comprehensive pathway databases, 
proteomic results may be scrutinised for involvement in biological processes. 
 
1.6 Quantitation  
Quantitative information regarding changes in protein expression levels, which may be 
provoked by pharmacological, environmental or genetic factors, is a key element in 
understanding disease mechanisms, productivity in bioprocessing and other biological 
processes. Several strategies for quantitative proteomics, each having specific strengths and 
limitations, have been described and may be categorised as either label-free or labelling 
methods.  
 
1.6.1  Label-free Quantitation 
Spectral counting and spectral indexing are label-free, relative quantitation strategies for 
determination of protein concentration by LC-MS/MS, wherein a protein abundance is 
estimated based on the number of tandem mass spectra obtained for each protein group in a 
mixture [74, 75]. Spectral counting methods are highly dependent on chromatographic 
separation reproducibility and require replication of experiments to ensure statistically 
significant results and hence may be limited by the availability of appropriate instrumentation. 
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In addition, the potential for detector saturation at high spectral counts and masking of low 
abundant proteins by high-abundance proteins may lead to erroneous quantitation results 
[76]. The demonstration of a linear correlation between ion concentration and ion current 
signal has led to the development of ion accounting based label-free quantitative proteomic 
methods. Silva et al. established a method for absolute quantitation of proteins by LC-MSE by 
demonstrating that for all proteins in a sample, the average MS signal for the three most 
intense tryptic peptides is constant per mole of protein, with a coefficient of variation of less 
than ± 10% [50]. Hence, using an internal standard of known quantitation, a universal signal 
response factor may be calculated and subsequently used to accurately determine the 
absolute quantitation for all proteins in a sample. This approach, known as ‘Hi3 quantitation’, 
is capable of accurately quantifying proteins across the entire dynamic range of the mass 
spectrometer in both simple and complex protein mixtures [77], albeit for data-independent 
MS analyses only. Label-free quantitative approaches are now commonly applied for clinical 
proteomics, wherein comparison of >102 samples are frequently required. However, excellent 
reproducibility of all experimental steps is essential for accurate and reliable quantification 
using label-free methods. [78] 
 
1.6.2  Labelled Quantitation 
Labelled quantitation approaches rely on the successful incorporation of a label into multiple 
protein samples and may be performed in either MS (comparing ion intensities of peptide 
peaks) or in MS/MS mode (utilising isobaric chemical labels). Quantitative proteomics 
measured in the MS 1 mode are most accurately achieved using stable isotopes for relative 
quantitation of identified proteins. Isotopic labelling is based on the assumption that two 
forms of a molecule, differing only as a result of a stable-isotope substitution, will behave 
identically in an MS experiment. Hence, the ratio of two sample peaks, separated by a 
characteristic mass shift equivalent to the difference in isotopic mass, directly indicates the 
relative concentration of a protein in comparative samples. In stable isotope labelling with 
amino acids in cell culture (SILAC), cells are grown in medium lacking an essential amino acid 
but supplemented with an isotopically labelled version of that amino acid, which is 
incorporated into the cell during culture. [79] Following MS analysis, the relative quantitation 
of proteins in differently labelled samples may be estimated. Initially, SILAC experiments were 
limited to samples prepared in cell culture as complete metabolic labelling of the proteome is 
required. However, since SILAC has proven to be an accurate and robust technique for 
quantifying proteomes, efforts have been made to extend this powerful technique to higher 
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organisms. SILAC model systems, which enable the determination of protein functions under 
complex in-vivo conditions, have been prepared by feeding lysine auxotrophic animals with a 
diet containing the natural or 13C6 (and/or 15N2)-substituted version of lysine. Reported SILAC 
model-systems currently available include mouse, [80] fruit fly [81] and zebra-fish. [82] 
Despite the applicability of available SILAC model systems, these can be costly and time-
consuming to prepare. Furthermore, it is unlikely that SILAC-modelling will be extended to 
human systems. However, Geiger and colleagues developed a novel ‘super-SILAC’ mix that 
facilitated the analysis of human tissue samples. [83] By mixing five SILAC-labelled cell lines 
with a human carcinoma tissue sample, hundreds of thousands of isotopically labelled 
peptides were incorporated as internal standards facilitating human tumour tissue proteome 
quantitation, hence broadening the scope of SILAC-based proteomics.  
In addition to metabolic-labelled strategies for MS-level quantitation, chemical labelling 
techniques e.g. stable isotope dimethyl labelling, have been applied for quantitative 
proteomics. Hsu and co-workers first introduced dimethyl-labelling as a quantitative 
proteomics technology, in which reductive amination using isotopomers of formaldehyde and 
cyanoborohydride results in highly selective dimethylation of primary amines. [84] A relative 
mass shift of 4 Da is observed for each derivatised site upon MS analysis in samples treated 
with formaldehyde and formaldehyde-D2, thereby facilitating relative quantitation of proteins 
in two sample populations. Later Boersema et al. built upon the dimethylation approach 
described by additionally labelling a third sample with 13C-formaldehyde-D2, facilitating the 
simultaneous analysis of three proteomic samples. [85] In both SILAC and dimethyl-labelling 
approaches the physicochemical properties of ions are conserved, therefore MS/MS sequence 
profiling and hence protein identification is not affected. However both methods were limited 
to three samples for comparative proteomics.  
Multiplexed relative quantitation of proteomes within a single MS experiment was first 
enabled by the development of isobaric tagging methods, e.g. iTRAQ and TMT. Isobaric tags 
for relative and absolute quantitation (iTRAQ) are a set of amine reactive isobaric labels that 
derivatise peptides in lysine side chains and at the N-terminus, hence labelling all peptides in a 
tryptic digest mixture. [86] Currently iTRAQ reagents are available for 4-plex and 8-plex 
experiments, composed of a reporter group, a balance group and an amine specific peptide 
reactive group. [86, 87] In MS 1, peptides labelled with iTRAQ reagents are indistinguishable 
(isobaric), however upon MS/MS fragmentation, signature ions (m/z 114 – 119 and m/z 121) 
are formed which when compared, allow for relative quantitation of all labelled sample 
peptides. [88] Similar to iTRAQ, tandem mass tags (TMT) are also a commercially available set 
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of isobaric chemical labels, developed by Thompson and co-workers. [89] TMT reagents, 
composed of a mass reporter group, a balance group, a cleavable linker and a peptide reactive 
group, were initially produced as duplex labels but are now available in 6-plex and 10-plex 
forms. [90] Recently, further extension of multiplexing capabilities have been reported, 
potentially enabling 16-plex reagents with 1 Da spacing between reporter ions, although these 
have yet to be commercialised. [91] A typical workflow for quantitative proteomics using TMT 
reagents is shown in Figure 1.6. 
 
A. 
 
B. 
 
Figure 1.6: A. Schematic of quantitative proteomic analysis workflow using 6-plex TMT 
reagents. Following sample preparation incorporating TMT reagents, samples are combined 
before analysis using LC-MS/MS. The ratio of peak heights for reporter fragment ions may 
then be used to determine the relative quantitation of peptides in the samples under 
comparison. B. Structure of 6-plex TMT reagents. 13C and 15N heavy isotopes are highlighted by 
red asterisks. [92]  
 
In addition to enabling multiplexing of samples in a single MS experiment, isobaric tagging 
methods provide potentially increased precision in quantitative proteomics as measurements 
are performed at the fragment mass spectra level (MS 2). [93] However, the number of 
labelling reagents that may be used within a single experiment are limited, hence the quantity 
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of samples that may be compared within a single experiment is also restricted (<10 
comparative samples). Furthermore, isobaric tagging methods may potentially be limited by 
ratio compression, i.e. distortion of peptide quantitation ratios due to interference in MS/MS 
spectra, from multiple precursors within a selected precursor isolation window. Ratio 
compression has been addressed by combining a narrower precursor isolation window with 
fragmentation at the LC peak apex, [94] by using a MS3 experiment on an LTQ Orbitrap mass 
spectrometer [95, 96] and alleviated using high-resolution sample fractionation. [97] 
Further improvements were made by McAllister and co-workers by isolating multiple fragment 
ions in the MS2 spectrum using isolation waveforms with multiple frequency notches (e.g. 
synchronous precursor selection (SPS)). Co-isolation and fragmentation of multiple MS2 
fragment ions resulted in a 10-fold increase in reporter ion signals thereby reducing reporter 
ion variance, enhancing the dynamic range of reporter ion quantitation and ultimately 
generating better-quality quantitative measurements. [98] The SPS-MS3 method was later 
applied for a quantitative phosphopeptide analysis incorporating 10-plex TMT labelling and 
analysed using a tribrid mass spectrometer (Thermo Fisher Scientific Orbitrap Fusion). An 
enhanced TMT reporter ion intensity and accuracy, with elimination of ratio distortion of 
reporter ions, was outlined. [99] 
Recently, a method for quantitative proteomics has been described that combines the multi-
plexing capability of isobaric tags with the accuracy of SILAC methods, termed neutron 
encoding (NeuCode) SILAC. [100] NeuCode SILAC exploits subtle mass differences in common 
stable isotopes caused by neutron-binding energy variation, effectively compressing isotopic 
information into very narrow m/z windows, which may be revealed when using ultra-high 
resolution mass spectrometers. Thus, NeuCode SILAC is capable of high levels of multiplexing 
(>10 samples) with high accuracy and broad dynamic range but is limited to mass 
spectrometers with very high resolving power (> 480,000).  
 
1.7 Proteomic Profiling of CHO Behaviour 
Reflecting their importance in the biopharmaceutical industry, numerous CHO proteomic 
studies have been undertaken to better understand these important expression systems. 
Proteomics has been used to directly identify and measure hundreds to thousands of proteins 
present in CHO cells that play key roles in recombinant protein production, including those 
involved in growth, protein processing, metabolism, glycosylation and cell death [2]. CHO cell 
proteomics can be broadly partitioned into a number of approaches, namely evaluation of 
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CHO cell proteomes following culture in conditions known to increase specific productivity 
(qP) or in response to other variations in bioprocessing conditions; profiling of CHO cells with 
desired phenotypes often following cellular engineering to achieve a desired phenotype; 
evaluation of secreted proteins and their effect on surrounding cells and to determine host 
cell protein (HCP) impurities that may be found in purified therapeutic drug substance. 
Proteomics can provide powerful insights into alterations in cell physiology following 
expression of an exogenous recombinant protein or variations in culture conditions, leading to 
further advancements in CHO cell production through possible genetic or environmental 
manipulations. As depicted in Table 1.3, many proteomic studies have been performed to 
determine differential protein expression following cell culture under qP-enhancing conditions 
compared to standard conditions. These studies aim to identify key regulatory proteins and 
pathways that may be used as targets for CHO cell engineering to further improve 
recombinant protein production. Table 1.3 also outlines CHO cell engineering strategies, which 
have been successfully applied to improve specific productivity in CHO cells. Proteomic 
approaches have been employed to assess the impact of down-regulation or over-expression 
of effector proteins used in CHO cell engineering, to enhance biopharmaceutical production 
[101].  
In addition to proteomic studies evaluating changes to protein regulation following culture in 
conditions that increase qP, numerous studies have been performed to determine molecular 
changes in response to altered feeding strategies. Metabolic shift through controlled nutrient 
feeding sustaining low glucose and glutamine concentrations reduces the production of toxic 
metabolites in cell culture and thereby results in higher viable cell concentrations without 
impacting qP [102, 103]. Pascoe et al. compared two different mAb-producing CHO cell lines 
with different lactate profiles under the same fed-batch culture conditions to determine 
changes in the CHO cell proteome linked to metabolism [104]. A substantial proportion of the 
differentially expressed proteins observed were found to be glycolytic enzymes, although 
structural proteins and proteins related to mAb production and protein processing were also 
observed. Notably, a proteomic investigation by Seow and co-workers showed how a feeding 
strategy, wherein low concentrations of glucose and glutamine were maintained, led to a 
reduction in metabolite production, altered expression of metabolic enzymes and changes to 
cellular metabolism. [103] This was further investigated by both Fan et al. and Wingens and 
co-workers who determined the effects of a metabolic shift from glucose surplus to glucose 
limitation on CHO cellular equipment. [105, 106] Wingens et al. found that changes in cellular 
machinery may be due to epigenetic effects, a conclusion also hinted at by Pascoe and co-
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workers who suggested that proteins expressed in cultures, displaying different metabolic 
profiles, may depend on how the nutrient limited conditions were generated. [104] A more in-
depth proteomics investigation of cellular responses to media glucose concentration was 
recently performed by Liu and colleagues using 2D-LC-MS/MS, resulting in the identification of 
potential cell engineering targets that may ultimately lead to increased qP along with 
prevention of apoptosis at standard glucose levels (5 g/L). [107] 
The vast majority of CHO proteomic studies have endeavoured to profile CHO proteomes of 
industrial relevant cell lines, [108, 109] (e.g. those exhibiting a high qP, [110, 111] an elevated 
growth rate phenotype [112]), or to comparatively evaluate various CHO cell lines including 
high and low recombinant protein producers. [113-115] Additionally research relating to 
bioprocessing strategies including proteomic profiling of CHO cells undergoing apoptosis 
during prolonged cultivation or following high passage cultivation have been performed. [116, 
117] However, following the publication of the first CHO genome sequenced by Xu et al., [118] 
Baycin-Hizal and colleagues, published the most significant CHO cell proteomics study of 
recent years, the first to be published reporting protein groups exclusively identified using a 
CHO cell genome thereby affording more accurate identification of proteins. [2] Cellular and 
secreted proteins were isolated by 2D LC and glycoproteins by solid phase extraction prior to 
LC-MS/MS analysis on an LTQ-Orbitrap Velos mass spectrometer, as depicted in Figure 1.7, 
yielding a total of 6,164 identified protein groups with a 4.2% false discovery rate. To further 
enhance knowledge of CHO cell physiology relevant to exogenous protein expression, the 
codon frequency of all experimentally detected CHO proteins was elucidated. This information 
facilitates the optimisation of codons for human proteins relevant to the codon frequency of 
CHO cells and may result in increased recombinant protein expression in CHO cell lines. 
Analysis of combined transcriptomic and proteomic data sets revealed an enrichment of a 
number of pathways, including apoptosis and protein processing, and also a reduction in 
proteins involved in glycosphingolipid and steroid hormone metabolism [2]. 
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Table 1.3:  Determination of proteome changes following culture under productivity-enhancing conditions and productivity-enhancing genetic 
interventions in CHO cells. 
Productivity-enhancing condition Therapeutic 
Product 
Cell line Analytical 
Technique 
Alterations in Proteome Reference 
Temperature shift  
(37oC to 30oC) 
SEAP CHO-K1 2DE Altered expression levels of unidentified proteins following 
temperature downshift. 
[119] 
Temperature shift  
(37oC to 31oC) 
- CHO-K1 2D-DIGE and 
MALDI-ToF-MS 
Differentially expressed protein involved in growth regulation, 
apoptosis, cap-independent translation and glycoprotein quality 
control. 
[120] 
Temperature shift  
(37oC to 33oC) 
EPO CHO-DUKX 2DE & MALDI-
ToF-MS 
Increased expression of proteins involved in protein folding and 
secretion, growth regulation and metabolism. Down regulation of 
proteins involved in some signalling pathways. 
[121] 
Temperature shift  
(37oC to 33oC) & 2mM NaBu  
IgG CHO-EcIn 2DE & nano-LC-
MS/MS 
Cellular secretory capacity-associated proteins differentially 
expressed. 
[122] 
3 mM Sodium butyrate hTPO CHO-DUKX-
B11 
2DE & MALDI-
ToF-MS & MS/MS 
Proteins associated with protein folding and secretion, growth 
regulation and metabolism differentially expressed. 
[123] 
1 mM Sodium butyrate IFN-γ CHO- IFN-γ 2DE & nano-LC-
MS/MS 
Differentially expressed proteins involved in protein metabolism and 
degradation, translation, apoptosis and fatty acid beta-oxidation. 
[124] 
0.5mM Sodium butyrate & 80 
µM zinc sulphate 
hGH CHO-K1 2D-DIGE and 
MALDI-Tof-MS 
Observed induction of proteins with metabolic and stress protection 
functions. 
[125] 
Hyperosmolarity   
(300 to 450 mOsm/kg) 
Antibody CHO-DG44 2-DE Up-regulation of glycotic enzymes, resulting in increased metabolic 
energy for mAb synthesis. Down-regulation of tubulin, reflecting a 
reduction in growth rate. 
[126] 
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Hyperosmolarity   
(310 to 510 mOsm/kg) 
Antibody CHO-DUKX-
B11 
2D-DIGE and 
MALDI-Tof-MS 
Protein involved in cellular metabolism, cellular architecture, protein 
folding, mRNA processing and protein secretion. 
[127] 
Hydrolysate addition - 5 g/L of 
soy hydrolysate, wheat gluten 
hydrolysate & yeastolate 
Antibody CHO-DG44 2-DE with nano-
LC-QToF-MS/MS 
Up-regulation of metabolism-associated, proliferation-related and 
cytoskeleton-associated proteins. Altered expression of several 
chaperone proteins. 
[128] 
Bcl-XL over-expression Humanised rh 
fusion protein 
CHO-DG44 In-solution 
digestion & nano 
LC-MS 
Differential expression of metabolism-associated, cytoskeleton- 
related and transcription-associated proteins and of proteins involved 
in cell cycle regulation, cell growth and glycolysis. 
[129] 
Bcl-XL over-expression - - iTRAQ labelling & 
2D-LC-MS 
Molecular chaperones, isomerases, cell growth markers and 
proliferation-associated and apoptosis-related proteins. 
[130] 
Bcl-XL over-expression & 3 mM 
NaBu 
EPO CHO-DUKX-
B11 
2D-DIGE and 
MALDI-Tof-MS 
Proteins related to apoptotic signalling pathways and proteins 
associated with cell survival, proliferation and repair of DNA damage. 
[131] 
Soluble PACEsol over-expression rh-human 
bone 
morphogeneti
c protein-2 
CHO-DUKX 2D-DIGE and 
MALDI-Tof-MS 
Proteins involved in protein folding, assembly and secretion, 
chaperone activity and protein translation. 
[132] 
MicroRNA-7 over-expression SEAP CHO-K1 Label-free nano-
LC-MS/MS 
Down-regulation of proteins relating to protein translation and RNA 
processing. Up-regulation of proteins involved in apoptosis and cell 
death 
[133] 
C-myc over-expression - CHO-K1 2DE & LC-MS/MS Up-regulation of proliferation-related and cytoskeleton-associated 
proteins and also in proteins involved in energy metabolism and 
protein biosynthesis. Down-regulation of proteins involved in cell to 
cell adhesion. 
[134] 
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Figure 1.7:  Schematic of the CHO proteome sample preparation and analysis approach 
utilised by Baycin-Hizal et al. Proteins were extracted from both cell lysates and spent media 
prior to in-gel separation and proteolysis or in-solution digestion and reversed phase-LC. 
Sample fractions were subsequently analysed by LC-MS/MS. In addition glycosylated peptides 
were analysed by solid phase extraction coupled to LC-MS/MS [2]. 
 
Subsequently, Meleady and co-workers generated a translated protein sequence for the CHO-
K1 cell line from cDNA sequence information published by Becker et al. [135]. This sequence, 
along with Swissprot data entries for Mus musculus and CHO-K1 (derived from the draft 
genome sequence published by Xu et al. [118]) were then used to identify proteins from CHO-
SEAP whole cell lysates. Meleady et al. demonstrated an improvement in MS-based proteomic 
identification, noting 282 additionally identified proteins following the use of CHO specific 
databases when compared to Mus musculus Swissprot database entries, despite the high 
homology between the two species. Importantly, the confidence of identification was 
heightened as both CHO-K1 databases yielded consistent and congruent results, despite being 
generated from different sources. [136] Evans and co-workers also endeavoured to generate a 
protein database for non-model species using expressed mRNA sequences for de novo 
derivation of proteomes. Their technique, proteomics informed by transcriptomics (PIT), was 
shown to identify >99% of distinct CHO proteins also identified by traditional analysis using 
cross-species protein sequencing. [137] 
Recently, the determination of host cell proteins (HCPs) in purified therapeutic protein sample 
has gained widespread interest in the biopharmaceutical community. HCP impurities, which 
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may be introduced into the harvest stream through cell lysis or secretion from host cells and 
are considered to be process-related impurities. [138, 139] Due to potential adverse clinical 
reactions in humans relating to HCPs, regulatory requirements necessitate their removal from 
therapeutic protein preparations to below detectable levels of highly sensitive analytical 
methods. [140] Although classically measured using immunosorbent assays, (e.g. enzyme-
linked immunosorbent assay (ELISA), [141]) which have been validated to provide a good 
quantitative estimation of the total HCP concentration, immunosorbent assays may under-
estimate weakly or non-immunoreactive proteins. [142] Proteomic techniques have been 
utilised to determine HCP profiles to further elucidate cellular processes occurring in CHO cells 
over the course of a production cycle. The vast advances in analytical technologies have now 
enabled a more in-depth understanding of the nature of individual HCPs that pass through 
downstream processing into final drug substances.  
Jin et al. used 2D-DIGE in a proteomic study to determine changes in HCP profiles following 
culture under altered upstream processing conditions. [142] Of the upstream processing 
parameters investigated including cell culture media, feeding strategy, cell viability at harvest 
and cell duration, cell viability was found to generate the most significant changes in HCP 
profile. This information could be used to implement upstream process analytical technologies 
to create more robust upstream process control, assist in the design of downstream 
purification processes and to ensure greater process consistency. A subsequent study by Tait 
and co-workers used 2-DE and LC-MS/MS to characterise HCP profiles in the supernatant of 
mAb-producing and null CHO cell lines, throughout different stages of cell culture. [139] A 
correlation between the day of harvest and high levels of HCPs present in the process 
supernatant was observed suggesting the majority of HCPs in the process stream resulted 
from the lysis of cells associated with viability loss. More recently, Doneanu et al. developed 
an online two-dimensional LC-MSE method for the analysis of HCPs in biotherapeutic proteins. 
[143] Using label-free ‘Hi3’ based quantitation, 33 HCPs with the lowest concentration of 16 
ppm, were identified from six IgG preparations. Similarly, Schenauer and co-workers also used 
2D-LC-MSE with label-free ‘Hi3’ quantitation for the identification and quantification of HCPs in 
therapeutic proteins. [144] The capability of the method to identify HCPs present at 13 ± 4 
ppm, with less than 2-fold quantitative error was demonstrated.  
During cell culture various types of proteins that can modify cell growth in culture, including 
ligands, receptors, waste products and endogenous growth factors, may be secreted by host 
cells [145, 146]. Accordingly, qualitative and quantitative information regarding secreted 
proteins at different stages of cell culture may aid bioprocess development. Recognising this 
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opportunity for improvement in bioprocessing operations, Kumar et al. used surface enhanced 
laser desorption ionisation (SELDI)-Tof MS to monitor secreted proteins in CHO culture media 
during different stages of the growth cycle [145]. Twenty-four proteins were observed to be 
differentially expressed over the course of the culture and were also found to accumulate in 
the process media over time. These secreted proteins represent potential targets for 
monitoring the removal of host cell proteins (HCPs) from the therapeutic protein product. 
Woolley and co-workers also evaluated the CHO secretome for possible identification of 
biomarkers, in this case to serve as an indication of stress and viability loss in CHO culture. 
[147] Also using SELDI-ToF, the intensity of a peak at 7.7 kDa corresponding to Galectin-1 was 
found to correlate with the degree of viability loss in triplicate cultures. 
Many secreted proteins serve as a mechanism to facilitate communication between cells in 
culture, with potential positive or negative outcomes. The identification of autocrine growth 
factors secreted by CHO cells has led to the generation of a protein-free basal media 
improving cell growth in culture. [148] However, following exposure to detrimental conditions 
cells may secrete proteins, such as cytokines, that may result in cytotoxicity and genomic 
instability in surrounding cells. This ‘bystander effect’ was investigated by Ahram et al. who 
initiated a proteomic study to investigate global changes in secreted proteins collected from 
conditioned CHO cell culture media samples subsequent to radiation exposure [146]. No 
evidence of changes in the type of proteins secreted was determined, possibly resulting from a 
weak response of CHO cells to low amounts of radiation. 
Despite many studies investigating the effect of qP enhancing culture conditions and cell 
engineering strategies on the quality and yield of therapeutic proteins, relatively few studies 
have examined how physicochemical properties of the recombinant therapeutic protein itself 
influence the CHO host cell. Sommeregger and colleagues demonstrated how distinct 
recombinant proteins evoke different proteomic responses within the host cell by performing 
label-free LC-MS/MS proteomic analysis of different CHO cells prepared from the same 
expression system but adapted to express different recombinant proteins. [149] 
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1.8 Future Perspectives 
Considerable progress in high-throughput proteomic analysis over the past decade has been 
fuelled to a large degree by continuous improvements in instrumentation. In particular, the 
advent of nano-scale separations, high-resolution tandem mass analysers and application of 
2D-LC-MS/MS has enabled the optimisation of proteomics. Further improvements in precursor 
ion resolution will be achievable with the emergence of new capabilities, e.g. ion mobility 
separation (IMS). When coupled to LC, IMS enables an additional dimension of precursor ion 
separation in the gas-phase, with the potential to increase proteome coverage by enhanced 
deconvolution of peptides occupying the same retention time and m/z space, for instance 
chimeric peptides. [150] Although the strengths of this technique have potentially not been 
fully realised, the extra dimension of separation is likely to be more-widely incorporated into 
future LC-MS configurations. Other emerging techniques for proteome analysis include protein 
structural characterisation technologies, e.g. hydrogen-deuterium exchange (HDX) mass 
spectrometry. HDX-MS is likely to provide product-quality information regarding protein 
dynamics, which when combined with functional annotation may potentially enable a more 
thorough understanding of protein systems. [151] One of the big challenges remaining in 
proteomics today centres on the processing of vast quantities of data generated using high 
resolution MS/MS. Improvements to overcome data analysis bottlenecks and ensure the 
quality of results achieved is likely to remain a focus for improved quantitative proteomics.  
 
1.9 Conclusions 
CHO cell expression systems are currently a significant area of research due to their 
widespread use in the production of therapeutic biomolecules. Although initial improvements 
in CHO bioprocessing centered on cell and bioprocess engineering strategies, more recent 
developments have been achieved through greater cellular-level understanding of these 
important production systems. Much of the knowledge gained has been achieved through in-
depth proteomic studies facilitated by key advancements in associated analytical technologies. 
Future progression in quantitative proteomics will undoubtedly arise from additional advances 
in instrumentation, data processing and quantitation technologies, allowing us to delve deeper 
into the proteome, leading to potential improvements in biologically significant areas of 
research including biopharmaceutical production and therapeutic protein characterisation. 
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1.10 Associated Publication and Author Contributions 
Published in part: Farrell, A., et al., Application of multi-omics techniques for bioprocess design 
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Literature review topic devised by Amy Farrell and Jonathan Bones; Literature review prepared 
by Amy Farrell and reviewed by Jonathan Bones; Related paper was written by Amy Farrell and 
reviewed by John J. Milne, Ian W Marison, Niaobh McLoughlin and Jonathan Bones. 
 
1.11 Aims of Thesis 
The goals of this work were to determine the impact of variation in the conditions used for 
bioprocessing of Chinese hamster ovary production cells on both the quality of the therapeutic 
monoclonal antibody product and on the production cells themselves. 
 
The specific aims of this thesis were: 
• To apply state-of-the-art quantitative proteomic techniques to determine potential changes 
to the proteome of monoclonal antibody producing CHO cells in response to the bioprocessing 
conditions used for cell culture; 
• To determine changes to CHO cells in culture in response to exposure to the secretome of 
adjacent cells when grown under conditions of altered bioprocessing; 
• To develop analytical platforms to extensively characterise differentially produced 
therapeutic monoclonal antibodies through application of analytical methods for 
determination of sequence-level modifications, variations in N-glycosylation profile and 
changes to the structure and function of the therapeutic biomolecules, thereby evaluating 
alterations in the safety, quality and efficacy of the mAb;  
• To develop an analytical platform to enable the identification of host cell proteins in 
therapeutic monoclonal antibody samples following downstream processing to enable 
optimisation of processing parameters for clearance of impurities from finished drug 
substances. 
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2.0 
Quantitative Proteomics Analysis of CHO 
Cells Following Culture under Altered 
Bioprocessing Conditions 
 
2.1 Introduction 
Chinese hamster ovary (CHO) cell lines are the primary expression system currently used in the 
biopharmaceutical industry and have been engineered to produce a wide range of 
recombinant therapeutic biomolecules, including those used to treat cancer, haemophilia, 
diabetes mellitus, inflammation-related conditions, neutropenia and metabolic disorders. [1] 
Anti-Interleukin 8 (anti-IL8), a therapeutic monoclonal antibody (mAb), has the potential for 
use in the treatment and diagnosis of metastatic melanoma and inflammatory disorders, e.g. 
adult respiratory distress syndrome, multiple organ failure and septic shock. [2, 3] Anti-IL8 
exerts its effect by binding to the cytokine interleukin 8 (IL8) thereby preventing the activity of 
IL8 in-vivo. IL8 has been shown to contribute to human melanoma advancement by 
functioning as a mitogenic and angiogenic factor, while IL8 concentration in serum was found 
to correlate with tumour load. [4-9] Additionally, IL8 is known to be involved in inflammatory 
responses, possibly due to induction of neutrophils [10] and is associated with adverse 
dermatological reactions in response to epidermal growth factor receptor inhibitors used in 
cancer treatment. [11] In this thesis, an anti-IL8 producing CHO DP-12 cell line is used to 
investigate the impact of altered bioprocessing on both an industrial relevant expression 
system and on the therapeutic product produced. Although the anti-IL8 IgG1 studied is not 
currently marketed as a therapeutic biomolecule it is similar to mAbs undergoing 
biopharmaceutical development for potential pharmacological indications. [12][13] 
Since the establishment of the biopharmaceutical industry, great strides have been made for 
optimisation of CHO cell bioprocessing. Continuous improvements of industrial bioprocesses 
and associated optimisation in bioreactor design and media formulation has resulted in 
considerable increases in product yields. [14] Many of the strategies to enhance bioprocessing 
have incorporated a reduction in temperature from 37oC to 30-32oC, [15-17] an increase in 
osmolarity, e.g. 300 to 450 mOSm.kg-1 [18] or a reduction in media pH. [17] Alternative 
approaches have included the addition of media supplements [19, 20] or the use of a 
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controlled feeding strategy. [21] These strategies have been shown to result in desirable 
outcomes with respect to bioprocessing, such as high cell viability, increased specific 
productivity and reduced accumulation of waste by-products. Cell engineering approaches 
have also been employed for the optimisation of specific productivity (qP), enhancing culture 
longevity and improving specific growth rate following CHO bioprocessing. By manipulation of 
genes involved in growth proliferation, [22] protein secretion, [23, 24] metabolic pathways 
[25] and apoptosis, [26-30] extended culture viability and increased qP have been achieved.  
Traditionally the majority of improvements to CHO bioprocessing have been realised by 
observing empirical responses to process changes. Despite two decades of CHO bioprocessing, 
there is still very poor comprehension of the cellular mechanisms that govern recombinant 
protein production in these important cell lines. Similarly little understanding exists regarding 
the impact of bioprocessing on the cellular machinery of the production cells. As proteins are 
the functional components of a cell, they have the potential to change cellular outputs. Hence, 
characterisation of the fundamental biological mechanisms of CHO cells in industrial cell 
culture may provide a foundation for further knowledge-driven improvements to 
manufacturing processes [31]. Increased understanding of the CHO proteome may lead to 
production of therapeutics that have guaranteed critical quality attributes and consequently 
reduced attrition rates often associated with biopharmaceutical production and process 
development.  
Recent technological achievements in analytical instrumentation have enabled profiling of the 
CHO proteome to a depth that was previously not possible. In particular advances in liquid 
chromatography and mass spectrometry have resulted in the identification of thousands of 
CHO proteins that play key roles in bioprocessing including those involved in cell growth, 
protein processing, glycosylation and metabolism. [32] Augmented by the publication of the 
CHO genome, [33] investigation of the cellular pathways involved in bioprocessing or 
pathways enhanced in CHO cells with desirable phenotypes is now achievable. As discussed in 
Chapter 1, use of high resolution hybrid mass spectrometers permit increasingly broad 
proteome coverage due to the high mass accuracy and resolving power of MS survey scan 
acquisition combined with fast, sensitive MS/MS analyses. State-of-the-art instruments 
incorporating a third mass analyser further enhance the dynamic range of detection 
achievable. By enabling synchronous precursor selection (SPS) prior to MS3 determination, 
inclusion of multiplexed quantitative strategies in proteomic experiments (e.g. use of tandem 
mass tag (TMT) reagents) has the ability to fully describe the dynamic processes that drive 
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recombinant protein production. In addition to comprehensively cataloguing proteins within a 
cell, use of LC-MS3 may provide insights into molecular interactions within the cell.  
In this chapter, a study is described wherein concurrent CHO DP-12 cell cultures, expressing 
anti-IL8, were initially prepared using standard bioprocessing conditions and later with altered 
bioprocessing conditions of pH, dissolved oxygen and temperature. Quantitative proteomics 
analysis of produced CHO cell lysate was performed using a two dimensional high pH low pH 
reversed phase nano liquid chromatography - mass spectrometry platform to facilitate 
comparison of the effects of individual culture characteristics on the CHO cell proteome. An 
Orbitrap Fusion Lumos tribrid mass spectrometer was employed enabling the identification 
and subsequent relative quantitation of, and hence, determination of altered protein 
expression in CHO DP-12 cells in response to the bioprocessing conditions utilised. Ingenuity 
pathway analysis (IPA) was subsequently applied for determination of enriched biological 
pathways within the differentially bioprocessed CHO cells. Furthermore, the method was also 
used to determine bystander responses resulting from changes to the secretome of CHO cells 
following bioprocessing under altered conditions. In this case naïve CHO K1 cultures were 
prepared and subsequently exposed to spent media from each of the CHO DP-12 cultures. 
Thus, by evaluating changes to naïve CHO K1 proteomes, a further layer of understanding 
regarding CHO bioprocessing could be achieved.  
 
2.2 Experimental 
2.2.1 Reagents and Consumables 
Sodium chloride (NaCl), sodium phosphate monobasic dihydrate (NaH2PO4 · 2H2O), sodium 
phosphate dibasic heptahydrate (Na2HPO4 · 7H2O), sodium hydroxide (NaOH), dithiothreitol 
(DTT),  iodoacetamide (IAA), acetonitrile, formic acid, triethylammonium bicarbonate (TEAB), 
ammonium hydroxide, L-arginine, phosphate buffered saline, Excell 325 PF CHO media, fetal 
bovine serum (FBS), methotrexate, recombinant human insulin, trypan blue, dimethyl-
sulfoxide, Dulbecco’s phosphate buffered saline (D-PBS), Tris buffer, hydrochloric acid, sodium 
dodecyl sulphate, urea, ammonium bicarbonate, trifluoroacetic acid (TFA), Bradford reagent, 
Bovine serum albumin (BSA), urea, Trizma-base and Amicon Ultra 0.5 mL centrifugal filters 
MWCO 10 kDa were purchased from Sigma Aldrich (Wicklow, Ireland). 0.1% formic acid in 
water (LC-MS Optima), acetonitrile, 0.1% formic acid (LC-MS Optima), 0.1% TFA in water (LC-
MS Optima), TMT sixplex isobaric mass tag reagents and penicillin-streptomycin were 
obtained from Fisher Scientific (Dublin, Ireland). Promega sequencing grade modified trypsin 
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was from MyBio Ltd. (Kilkenny, Ireland). L-glutamine and trypsin/EDTA solution were 
purchased from Biosciences Ltd. (Dublin, Ireland). 100% acetic acid (AnalaR NORMAPUR) was 
obtained from VWR (Dublin, Ireland).  
 
2.2.2 Cell Culture 
2.2.2.1 Aseptic Technique 
Cell culture work was carried out in a BioAir SafeMate 1.2 class II biological safety cabinet. 
Prior to use the laminar airflow cabinet was sterilised with UV light for one hour and 
thoroughly cleaned with 70% (v/v) ethanol. Subsequently, air in the laminar airflow cabinet 
was to allowed to circulate for a minimum of 15 minutes before cell culture commenced to 
ensure aseptic conditions were achieved. Any items placed in the cabinet were also swabbed 
with 70% (v/v) ethanol prior to entry into the cabinet. During use, one cell line only was 
introduced into the laminar airflow cabinet and upon completion of work with any given cell 
line, the laminar airflow cabinet was allowed to clear for at least 15 minutes before further 
use. This was to eliminate any possibility of cross-contamination between cell lines. The 
cabinets were cleaned weekly with Virkon and operation validated annually by a certified 
contractor. 
 
2.2.2.2 Adaption of CHO DP-12 to Serum-Free Media and Suspension Culture 
A Chinese hamster ovary cell line (CHO DP-12 clone#1934 [CHO DP-12, clone#1934 aIL8.92 NB 
28605/14] (ATCC® CRL-12445TM) producing recombinant human anti-IL-8 IgG1 antibody, was 
purchased from LGC standards (Middlesex, UK). Recommended culturing conditions for the 
CHO DP-12 cell line involved preparing adherent cell culture in DMEM, supplemented with 
10% fetal bovine serum (FBS), 200 nM methotrexate and 2 mg.L-1 recombinant human insulin 
in a T75 cm2 culture flask. As the CHO DP-12 cell line was purchased for use in proteomic 
studies, adaption of the cell line to grow in protein-free media was required to ensure no 
impact on proteomic results due to media components and also to facilitate simplified 
purification of the expressed mAb for subsequent product characterisation as described 
Chapters 3, 4 and 5. Initially, cells were grown adherently in supplier-recommended media 
formulation at 37 °C (5% CO2). Adaption to serum-free conditions was achieved by reducing 
the FBS concentration in the media to 5%, 2.5% and 1% over five passages. Once growing in 
1% FBS, the cells were transferred from a T75 cm2 flask to serum-free conditions in a 125 ml 
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Erlenmeyer shake flask. In an effort to ensure the growth medium was completely protein-
free, cells were subsequently further adapted to grow in a commercially available protein-free 
media recommended for CHO DP-12 cell cultures, namely ExcellTM 325 PF CHO. Adaption to 
protein-free media was accomplished by altering the composition of the culture medium from 
100:0, 75:25, 50:50, 25:75, 0:100 DMEM/ ExcellTM 325 PF CHO, over five passages. At each 
stage, the culture medium was supplemented with 10 mg.L-1 recombinant human insulin, 4 
mM L-glutamine, 200 nM methotrexate and 20,000 Units of Penicillin-Streptomycin. Finally, to 
ensure selection pressure for CHO DP-12 clones producing anti-IL-8 IgG1, the concentration of 
methotrexate was increased from 200 nM to 1 µM over two passages.  
 
2.2.2.3 Thawing of Cryopreserved Cell Banks and Cell Culture of Fully-Adapted CHO DP-12 
Cell Lines in Protein-Free, Suspension Culture 
CHO DP-12 cells, from a working cell bank stored at -196 °C, were rapidly thawed at 37 °C. 
Cells were re-constituted in 10 mL of pre-warmed complete media (ExcellTM 325 PF CHO, 10 
mg.L-1 recombinant human Insulin, 4 mM L-glutamine, 1 µM methotrexate and 20,000 Units of 
Penicillin-Streptomycin), before centrifugation at 800 rpm for five minutes. The resultant cell 
pellet was re-suspended in a 10 mL aliquot of fresh complete media, before cell counting using 
the trypan blue exclusion method and a haemocytometer. Cells were seeded at an initial 
viable cell density of 3 x 105 cells per mL of complete media in a 125 mL Erlenmeyer shake 
flask and were incubated at 37°C (5% CO2, 125 rpm). Passaging of cells was performed while 
cell cultures were in an exponential growth phase. 
 
2.2.2.4 Maintenance of the Cell Lines 
Cells for cryopreservation were harvested in the exponential phase of growth. Cell pellets 
were re-suspended in a suitable volume of ExcellTM 325 PF CHO supplemented with 10 mg.L-1 
recombinant human insulin, 4 mM L-glutamine and 5% DMSO and 1 mL aliquots of the 
suspension were placed in cryovials. Vials were then placed in a slow-freezing container at -
80oC to achieve cooling of cells at a rate of approximately -1oC per minute. After a period of 
five hours, vials were transferred to a Dewar containing liquid nitrogen for storage (-196°C). 
Cell lines were tested in-house for possible mycoplasma contamination using a Roche 
MycoTool mycoplasma real-time polymerase chain reaction kit with MagNa Pure LC2.0 and 
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the Roche LightCycler 480 instrumentation. No mycoplasma infection was determined in 
samples analysed. 
 
2.2.2.5 Cell Culture using Disposable Single Use Bioreactors 
All bioprocessing studies were performed using Sartorius Stedim Cultibag systems equipped 
with a 2L Optical Cultibag single use bioreactor. Bioreactors were placed on temperature 
controlled rocker stations and fitted with a gas line, dissolved oxygen and pH sensors and a 
base addition line. pH was initially set to pH 7.0 and maintained by the automated addition of 
sterile 1 M sodium hydroxide or by purging 0.22 µm sterile filtered CO2 gas into the head-
space of the disposable bioreactor. The rocker station angle was set to 7.0o. Gas flow was set 
to 0.3 L.min-1. The rocker also served as a heating element used to maintain the culture at the 
initial set-point of 37.0oC. Dissolved oxygen (DO) levels were maintained by purging a mixture 
of purified air and oxygen into the head-space of the bioreactor and also by altering the 
rocking speed of the disposable bioreactor (3 to 14 rocks per minute). 950 mL of media, 
composed of ExcellTM 325 PF CHO, 10 mg.L-1 recombinant human Insulin, 4 mM L-glutamine, 1 
µM methotrexate and 20,000 Units of Penicillin-Streptomycin, was added to each of three 
disposable bioreactors and were allowed to equilibrate to initial conditions of 37.0oC, pH 7.0 
and 85% DO overnight. Prior to inoculation with 50 mL of CHO DP-12 culture, pH readings 
were verified by removing an aliquot of media from the bioreactor and measuring the pH 
value using a calibrated pH electrode. CHO DP-12 cells were inoculated at a starting viable cell 
density of 3 x 105 cells.mL-1. Cell culture harvest was performed after 7 days of culture. Culture 
harvest was completed by transferring each culture into a sterile 1 L Duran bottle, before sub-
dividing the cultures into sterile falcon tubes and centrifuging at 125 x g for 5 minutes. Spent 
media was subsequently pipetted into fresh sterile falcon tubes. 50 mL aliquots of the spent 
media were retained for subsequent application to naïve CHO K1 cell cultures. The remaining 
spent media and all CHO DP-12 cell pellets were immediately placed at -80oC pending further 
analysis. 
 
2.2.2.6 Determination of Nutrient and Metabolite Concentration, Cell Count and Cell 
Viability 
A 5 mL aliquot of cell culture was removed from each of the bioreactors daily. Cell counting 
was performed using the trypan blue exclusion method and a haemocytometer. 1 mL of each 
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culture was centrifuged (5,000 x g, 10 minutes) to remove cellular material before 
measurement of IgG, L-glutamine, glucose, glutamate, ammonia and lactate concentration 
and also LDH activity in the clarified culture media using a Cedex Bioanalyser via photometric 
analysis. 
 
2.2.2.7 Culture of Naïve CHO K1 Cells 
A non-recombinant protein producing cell line (CHO K1 - ATCC® CCL-61TM) was purchased from 
LGC standards (Middlesex, UK). Initially grown in recommended F-12K media supplemented 
with 10% FBS and 4 mM L-glutamine, adaption to serum-free conditions was achieved by 
reducing the FBS concentration in the media to 5%, 2.5% and 1% over five passages. Once 
growing in 1% FBS, the cells were transferred from a T75 cm2 flask to serum-free conditions in 
a 125 ml Erlenmeyer shake flask. The CHO K1 cells were adapted to growth in commercial 
protein-free media by altering the composition of the culture medium from 100:0, 75:25, 
50:50, 25:75, 0:100 F-12K/ ExcellTM 325 PF CHO over five passages. For each bioprocess 
parameter studied, CHO K1 cultures were seeded in 12 x 125 mL Erlenmeyer culture flasks and 
allowed to grow for two days in Excell 325 PF medium supplemented with 10 mg.L-1 
recombinant human insulin, 4 mM L-glutamine, 200 nM methotrexate and 20,000 Units of 
Penicillin-Streptomycin. Once in the exponential growth phase spent media from each CHO 
DP-12 altered bioprocessing culture were applied to one of nine CHO K1 cultures. Three 
remaining CHO K1 cell cultures were maintained using the same media components but not 
exposed to spent media samples. The cells were exposed to the spent media for 24 hours 
before harvest via centrifugation (125 x g, 5 minutes). Cell pellets were immediately frozen at -
80oC pending further analysis.  
 
2.2.3 Proteomic Analysis of CHO Cells using High pH- Low pH 2D-LC-MS/MS  
2.2.3.1 CHO Proteome Sample Preparation 
Cell pellets were thawed on ice and rinsed with three 1 mL aliquots of PBS to ensure complete 
removal of culture medium. Freshly prepared 8M Urea in 100 mM Tris, pH 8.0 was added to 
reconstitute each cell pellet to an approximate final concentration of 1 x 107 cells.mL-1. 
Subsequently cells were homogenised via sonication for 30 seconds using a sonic 
dismembrator (Fisher Scientific) set to 20 V and centrifuged (16,000 x g, 10 minutes). 
Supernatant was placed in a fresh tube and assayed for protein content using a Bradford 
 Chapter 2 
50 
 
protein assay, wherein samples were diluted 50-fold with Bradford reagent and incubated for 
30 minutes at room temperature before recording the sample absorbance using a 
spectrophotometer at 595 nm. Sample concentration was calculated using a standard curve 
prepared from BSA standards of known concentration, diluted with Bradford reagent and 
inclubated concurrent to the CHO protein samples. Proteomic samples were prepared using 
the filter-aided sample preparation (FASP) method described previously. [34] Briefly, 100 µg of 
CHO cell lysate was added to a pre-rinsed 10 kDa MWCO filters and reduced with 5 mM DTT at 
25oC for 30 minutes, before alkylation with 15 mM IAA for 30 minutes at 20oC in darkness. 
Following buffer exchange into 100 mM TEAB, enzymatic digestion was performed overnight 
with trypsin at 37oC using a 1:50 (w/w, enzyme: protein) ratio. Subsequently sample peptides 
were retrieved from the filters by centrifugation before labelling with TMT-sixplex reagents as 
per manufacturer’s instructions. [35] 0.8 mg of each TMT labelling reagent dissolved in 41 µL 
of anhydrous acetonitrile was added to 100 µg of CHO tryptic peptides, before incubation for 
one hour at room temperature. The reaction was quenched by addition of 8 µL of 5% 
hydroxylamine prior to incubation for 15 minutes. Tryptic peptide samples from CHO DP-12 
and CHO K1 cultures were labelled as per the experimental design outlined in Tables 2.2 and 
2.3, respectively. Samples labelled with each set of TMT-sixplex labels were pooled into eight 
combined samples sets and reduced to dryness via vacuum centrifugation. 
 
2.2.3.2 First Dimensional Fractionation 
First dimensional separation of the peptide sample sets was carried out using high pH (pH 10) 
reversed-phase chromatography on a Waters Acquity H-Class UPLC instrument with UV 
detection. Separations were performed on an Acquity UPLC BEH 130 C18 1.7 µm 2.1 x 150 mm 
analytical column using a binary gradient of 10 mM ammonium formate in water, pH 10 (A) 
and 10 mM ammonium formate in 95% acetonitrile, pH 10 (B). Before separation analysis, 
samples were diluted to 500 µL with 0.1% formic acid and loaded onto the analytical column, 
using 3% B, over three injections. Sample separation was accomplished using gradient 
conditions as follows: 3% B initially for 2 minutes, increased to 10% B in 2 minutes with a 
further increase to 45% B over 33 minutes followed by a final increase to 100% B in two 
minutes with a two minute isocratic hold. Initial conditions were restored in one minute and 
held for an additional 10 minutes to ensure column re-equilibration. The column temperature 
was maintained at 40oC throughout and UV absorbance recorded at 214 nm. The flow rate was 
sustained at 200 µL.min-1. Sample eluate was collected at minute intervals over the course of 
the gradient and subsequently recombined to 10 sample fractions of equal concentration as 
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estimated based on the UV response. Finally sample fractions obtained for each sample set 
were reduced to dryness via vacuum centrifugation. 
 
2.2.3.3 Second Dimension nano-LC-MS Method Development 
All spectra were acquired on an Orbitrap Fusion Lumos (Thermo Fisher Scientific) coupled to a 
Dionex Ultimate® 3000 RSLCnano system. Peptides were separated on an Acclaim PepMap 
RSLC C18, 100 Å, 75µm x 50 cm, easy-spray column (Thermo Fisher Scientific) using a binary 
gradient of 0.1% (v/v) formic acid in water (C) and 0.1% (v/v) formic acid in acetonitrile (D). 
Gradient conditions were as follows: 5% D initially for 5 minutes, increased to 25% D in 85 
minutes with a further increase to 60% D over 20 minutes followed by a final increase to 90% 
D in 5 minutes with a 5 minute isocratic hold. Initial conditions were restored in one minute 
and held for an additional 29 minutes to ensure column re-equilibration. The column 
temperature was maintained at 40oC and the flow rate was 300 µL.min-1. Injection volume was 
1 µL, corresponding to 1 µg of labelled tryptic peptides. 
The mass spectrometer was operated in data dependent mode. Survey scans of peptide 
precursors were performed from 350 to 1500 m/z at 120,000 FWHM resolution (at 200 m/z) in 
the Orbitrap with a 4 x 105 ion count target and a maximum injection time of 50 ms. The 
instrument was set to run in top speed mode (considering only the most intense charge state 
for fragmentation) with 3 second cycles for the survey and the MS/MS scans. Following a 
survey scan, tandem MS was performed on the most intense precursors exhibiting a charge 
state from 2 to 7 and of greater than 5 x 103 intensity by isolation in the quadrupole using a 
mass filter width of 0.7 Th. Dynamic exclusion was set to each precursor for 60 seconds 
subsequent to acquisition ensuring a 10 ppm mass tolerance around the precursor and its 
isotopes. CID fragmentation was applied with 35% normalised collision energy and resulting 
fragments were detected using the turbo scan rate in the ion trap mass analyser. The AGC 
target for MS/MS was set to 104 and the maximum injection time limited to 50 ms. Precursor 
selection mass range was performed from 400 to 1200 m/z for MS2 and isobaric tag loss 
exclusion set for TMT. Synchronous precursor selection was enabled to include the top five 
fragment ions for the MS3 scan using an isolation window of 0.7 m/z. HCD fragmentation was 
applied with 65% collision energy to ensure maximal TMT reporter ion yield and resulting 
fragments were detected using the Orbitrap from 100 to 500 m/z at 30,000 FWHM resolution 
(at 200 m/z). The AGC target for MS/MS was set to 105 and the maximum injection time 
limited to 105 ms. 
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2.2.3.4 Bioinformatics 
Raw data was processed using Thermo Scientific™ Proteome Discoverer™ software version 
2.1.0.81. Proteome Discoverer™ software is a bioinformatics tool used to interpret Thermo 
Fisher Scientific mass spectrometry data acquired from complex biological samples. Proteome 
Discoverer™ software enables the identification and quantitation of proteins using various 
database search algorithms, e.g. Mascot and SEQUEST®, and supports multiple dissociation 
techniques, e.g. collision induced dissocation. MS2 spectra were searched with the SEQUEST® 
HT engine against the Cricetulus griseus, NCBI FASTA database 
(http://www.ncbi.nlm.nih.gov/assembly/GCF_000419365.1/, downloaded 12th August 2015) 
and also a CHO DG44 proteome database, translated from CHO DG44 transcriptome 
sequences, additionally annotated with mus musculus RefSeq notation. [36] Search 
parameters included an in silico tryptic digestion permitting ≤2 missed cleavages, fixed 
modifications including carbamidomethylation (+57.021 Da) of cysteine residues and TMT 
sixplex (+229.163 Da) of the N-terminus and K side chain and a variable modification set to 
oxidation of methionine residues (+15.9949 Da). Mass tolerances were set to 10 ppm for 
precursors and 0.6 Da for product ions. Peptide spectral matches (PSM) were validated using 
the Percolator® algorithm, based on q-values at a 1% FDR. For both the CHO DP-12 and CHO 
K1 studies, each set of 10 samples were grouped as fractions using Proteome Discoverer™ 
software and subsequent data merged to produce a single result file outlining all peptides and 
protein groups identified along with corresponding TMT reporter abundance values and 
sequence information. 
TMT reporter intensity values relating to peptides from each culture prepared under altered 
bioprocessing conditions were compared to corresponding TMT reporter abundances from 
peptides prepared under standard culture conditions. Log fold changes and p-values for the 
CHO DG44 proteome database-searched data were determined using InfernoRDN version 
1.1.5970.31895. [37] InfernoRDN is a statistical tool for quantitative analysis of ‘omics’ data 
sets and may be applied for normalisation of data, hypothesis testing, clustering and 
generation of heat-maps. Using InfernoRDN, peptide level abundance values corresponding to 
the TMT reporter ion for each peptide were log 2 transformed, median centered and grouped 
together according to their related protein group using the ‘ZRollup’ function. ANOVA analysis 
was performed at the protein level to determine related p-values and fold changes were 
calculated. Proteins with a p-value <0.05 and greater than 1.2 log fold change in the test 
samples compared to the control standard samples were listed as differentially regulated in 
the samples produced under altered bioprocessing conditions  
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Gene Ontology (GO) annotation terms of cell components were determined for identified 
proteins using the online tool, the database for annotation, visualisation and integrated 
discovery (DAVID) (http://david.abcc.ncifcrf.gov). [38, 39] DAVID is a bioinformatics tool that 
enables functional annotation of lists of genes or proteins to facilitate a better understanding 
of biological function relating to large protein data sets or list of genes. Mouse homologue 
RefSeq annotation correlating to identified CHO proteins, were used to determine the function 
of quantified CHO cell proteins in DAVID. Gene ontology terms, obtained using DAVID 
software, were visualised using REVIGO online software. REVIGO functions as a tool to 
summarise and interpret lists of GO terms through use of a clustering algorithm, which relies 
on semantic similarity measurements (http://revigo.irb.hr). [40]  Ingenuity Pathway Analysis 
(IPA) version 27216297 (QIAGEN, Redwood City, CA, USA) was utilised to map significantly 
differentially regulated proteins into biological networks and pathway maps. IPA is a tool for 
analysis, modelling and understanding of complex biological systems through provision of 
insights into potential relationships, mechanisms, functions and relevant molecular and 
protein pathways.   In this work, experimental data from human, mouse and rat were used for 
determination of protein pathways and networks in IPA, incorporating a significance threshold 
of p<0.01 and greater than 1.2 log fold change of test samples compared to the control 
standard samples. Biological functions for proteins statistically significant with a |Z score| ≥ 
1.0 for activation or repression were reported 
 
2.3 Results and Discussion. 
2.3.1 Experimental Design for Anti-IL8 Production under Altered Bioprocessing Conditions 
Since the realisation of CHO cells as recombinant protein expression systems for the 
biopharmaceutical industry, vast improvements in production strategies have resulted in high 
product titres and improved therapeutic protein quality in response to empirical 
improvements following measured changes to bioprocessing. In particular, changes to culture 
temperature, pH, dissolved oxygen, osmolarity and feeding strategies have been effective 
approaches used to halt apoptosis, stimulate protein secretion and alter cellular metabolism. 
[17, 41-44] Several studies have endeavoured to understand the cellular processes that effect 
change to protein secretion from CHO cells in response to some of the known productivity-
enhancing culture conditions. [36, 45-49] By investigating changes to the proteome of 
recombinant protein producing cells, various differentially regulated proteins have been 
identified which suggest potential pathways that may be in play when bioreactor settings have 
been optimised for protein production. However, advances in analytical technology, 
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supplemented by the recent sequencing of the Cricetulus griseus genome, have now enabled 
profiling of the CHO proteome at a depth that was previously not possible.  
A major aim of this work was to apply state of the art analytical technology to determine 
systematic responses of CHO cells to altered bioprocessing conditions. In this study multiple 
bioprocess production sequences were prepared to study the effects of pH, temperature and 
dissolved oxygen (DO) on the production of biotherapeutics as depicted in Figure 2.1. By 
preparing CHO cell cultures using disposable bioreactors commonly used in industrial settings 
a high level of process control could be achieved while closely mimicking a genuine production 
process. For each of the parameters under study, three concurrent cell cultures were 
prepared. Following inoculation of Sartorius Cultibag disposable bioreactors, batch culture of 
CHO DP-12 cells was performed at standard culture settings of 37.0oC, pH 7.0 and 85% DO. As 
the cell cultures began to enter the stationary phase of cell growth (equivalent to day 5 of cell 
culture), one parameter in two of the bioreactors was changed as shown in Table 2.1. The 
parameters selected reflect settings commonly used in bioprocessing, chosen to represent the 
outer limits of a design space used in biopharmaceutical production of CHO cell culture. Hence 
any changes that are identified may reflect tangible alterations in CHO cell proteomes that 
may occur in routine production in the biopharmaceutical industry. Cultures were allowed to 
proceed for 48 hours at altered bioprocessing conditions, at which stage the cultures were 
harvested (culture day 7) as outlined in Section 2.2.2.5. All cell cultures were harvested prior 
to entry into the logarithmic decline phase of cell growth, ensuring high viability at the time of 
culture harvest. In addition to production of CHO DP-12 batch culture, naïve CHO K1 cell 
cultures were also prepared concurrently. Following harvest of conditioned spent media from 
CHO DP-12 studies, aliquots of each of the spent media samples were applied to CHO K1 cell 
culture for approximately 24 hours before CHO K1 cell harvest. This step was performed to 
evaluate any potential changes to CHO cells in response to signalling factors in the secretome 
of production cells present due to the use of altered bioprocessing conditions. Additionally full 
characterisation of anti-IL8 expressed from CHO DP-12 cells during each of the studies 
described will be outlined in Chapters 3, 4 and 5. 
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Figure 2.1: Experimental design for the determination of changes to CHO cell proteome in 
response to altered bioprocessing. For each parameter studied (temperature, pH, dissolved 
oxygen (DO)), three concurrent cultures were prepared and maintained at standard culture 
conditions (37.0oC, pH 7.0, 85% DO) for the duration of th exponential growth phase. When 
cultures entered the stationary phase of cell growth (Day 5), one parameter was altered in two 
of the cultures as outlined in Table 2.1. Bioprocessing was continued for a further 2 days 
before harvesting of the cultures and separation of cells from spent cuture medium. An 
aliquot of media was then applied for culture or naïve CHO-K1 cells for a period of 24 hours. 
Anti-IL8 IgG1 was purified from the remaining media samples using Protien A affinity 
chromatography. 
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Table 2.1: Bioprocessing conditions used to prepare CHO DP-12 cell cultures in Sartorius 
Cultibag Disposable Bioreactors. 
Parameter 
Studied 
Bioreactor Settings applied for Stationary Phase Growth 
A B C 
Temperature High Temperature: 
39.5oC, pH 7.0,  
85% DO 
Standard 1: 
37.0oC, pH 7.0, 
85% DO 
Low Temperature: 
32.0oC, pH 7.0, 
85% DO 
pH High pH: 
37.0oC, pH 7.2, 
85% DO 
Standard 2: 
37.0oC, pH 7.0, 
85% DO 
Low pH: 
37.0oC, pH 6.8, 
85% DO 
Dissolved 
Oxygen 
High DO: 
37.0oC, pH 7.0, 
110% DO 
Standard 3: 
37.0oC, pH 7.0, 
85% DO 
Low DO: 
37.0oC, pH 7.0, 
60% DO 
 
 
 
2.3.2 Bioprocess Monitoring 
Throughout the duration of CHO DP-12 batch culture, aliquots of cell culture were sampled 
daily for determination of cell count, viability and concentration of nutrients and metabolites 
in each bioreactor; corresponding results are displayed in Figures 2.2 to 2.4. As the Figures 
show, high cell viability was maintained for the duration of batch culture (>85%). Viable cell 
count (cells.mL-1) and nutrient concentration profiles were found to follow expected trends 
based on published literature. The influence of temperature on growth rate, recombinant 
protein quality and expression, nutrient consumption and metabolite production in CHO cells 
has been intensively studied. [16, 42, 43, 50-52] As a consequence it is now widely accepted 
that a biphasic approach to setting culture temperature, incorporating initial culture at 37oC to 
increase cell density, followed by a reduction in culture temperature, results in inhibited 
growth rate, maintenance of high cell viability, reduced nutrient consumption, decreased 
metabolite production and ultimately enhanced specific productivity of recombinant proteins. 
Although there are some exceptions to these observations, [53] the current study was found 
to be in-line with general trends as following application of a temperature shift from 37.0oC to 
32.0oC, IgG concentration increased, glucose and glutamine consumption was reduced and 
ammonia and lactate production decreased. Additionally, the viable cell count did not change 
considerably when compared to an increase in viable cell count observed for cultures 
maintained at 37oC or increased to 39.5oC. Conversely, CHO DP-12 cells prepared at 39.5oC 
were found to have an elevation in nutrient consumption and metabolite production. These 
observations suggest the cellular machinery shifted towards cell growth rather than 
recombinant protein expression at elevated temperatures compared to reduced settings. 
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Cell growth, metabolism and recombinant protein production are known to be significantly 
influenced by culture pH, [17] however variations in the observed effects have been reported, 
including optimum growth at pH 7.6, [54] or conversely between pH 6.8 -7.0 [55] and between 
pH 7.0 - 7.2. [44] In this case the viable cell count for cultures maintained at pH 6.8 was found 
to be lower than that of cultures processed using higher pH settings. IgG concentration was 
increased following culture at pH 6.8 compared to pH 7.0-7.2, whilst a reduction in glucose 
and glutamine consumption and associated reduction in ammonia and lactate production 
were also observed. In correlation with reduced lactate concentration, lactate dehydrogenase 
(LDH) activity was also decreased at pH 6.8 when compared to pH 7.0 – 7.2. While distinct 
differences could be noted in viable cell count, IgG concentration and nutrient and metabolite 
profiles whilst altering pH and temperature settings, variation in DO content of culture media 
between 60 and 110% DO was not perceived to result in any distinct elevated or reduced 
trends for the analytes measured. This finding is in accordance with observations made by 
Trummer and co-workers, who found no significant impact to culture performance when DO 
levels were maintained between 30 and 90% of air saturation. [17]  
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Figure 2.2: Graphs showing cell viability and viable cell counts and also metabolite and nutrient concentrations recorded for CHO DP-12 cultures prepared to 
study the effects of culture temperature. All measurements were performed using a Cedex Bioanalyser via photometric analysis (n=1). 
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Figure 2.3: Graphs showing cell viability and viable cell counts and also metabolite and nutrient concentrations recorded for CHO DP-12 cultures prepared to 
study the effects of culture pH. All measurements were performed using a Cedex Bioanalyser via photometric analysis (n=1). 
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Figure 2.4: Graphs showing cell viability and viable cell counts and also metabolite and nutrient concentrations recorded for CHO DP-12 cultures prepared to 
study the effects of dissolved oxygen content of culture media. All measurements were performed using a Cedex Bioanalyser via photometric analysis (n=1).  
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2.3.3 Proteomic Method Performance 
The instrument set-up applied herein employs numerous separation and detection 
components to enable deep proteome identification and subsequent quantitation, which has 
recently become feasible due to the extensive capabilities of modern analytical 
instrumentation. In the first instance, sample complexity was reduced using off line basic pH 
reversed phase LC separation, which has proven to be successful for proteome sample 
separation when followed by orthogonal low pH reversed phase nano-LC. [32, 36] 
Subsequently, a mass spectrometer incorporating three mass analysers was used wherein 
ionised peptide precursors are selected during an MS1 survey scan in an Orbitrap for 
subsequent fragmentation in an ion trap mass analyser, before further fragmentation to 
cleave TMT reporter ions from corresponding peptides in the Orbitrap. Significantly the mass 
spectrometer, an Orbitrap Fusion Lumos (Thermo Fisher Scientific), is capable of performing 
synchronous precursor selection to co-isolate and co-fragment multiple MS2 fragment ions, 
which has been shown to significantly extend the dynamic range for reporter ion quantitation, 
hence increasing confidence in peptide quantitation when using multiplexing strategies with 
isobaric labelling reagents. [56] Thus, the analytical platform has the potential to not only 
permit global proteome identification but also to enable deep quantitative proteomics and, 
significantly, facilitate the study of enriched biological pathways that have been altered in 
response to different bioprocessing parameters applied during cell culture.  
 
2.3.3.1 Evaluation of Method Reproducibility  
Prior to application for analysis of CHO cell lysates from differentially produced cultures as 
outlined in Section 2.3.1, the reproducibility of the high pH low pH reversed phase nano-LC-
MS3 proteomic platform was evaluated. Technical replicate samples were prepared from a 
single CHO DP-12 cell lysate sample (Standard 1, Table 2.1). Following tryptic digestion, 
differential labelling using TMT-sixplex reagents and 2D-LC-MS3 analysis, resulting data was 
processed and abundance values obtained for TMT report ions corresponding to each 
identified protein group. Abundance values were then plotted to evaluate the performance of 
the proteomic platform. As displayed in Figure 2.5, exceptional correlation (R2>0.999) between 
different sample preparations was observed, demonstrating high performance consistency of 
the sample preparation and subsequent 2D-LC-MS3 analysis methods. 
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Figure 2.5: Scatter plots prepared from TMT abundance data for identified and quantified 
proteins from CHO DP-12 cell lysate, analysed using the 2D-LC-MS3 method, showing linear 
correlation between triplicate technical replicates prepared. 
 
 
2.3.3.2 Quantitative Proteomics Experimental Design and Platform Performance 
Having confirmed the reproducibility of the proteomic platform, samples were subsequently 
prepared from each of the CHO DP12 cultures as outline in Table 2.2. Each sample was 
prepared in duplicate and labelled in a manner which allowed for each condition (i.e. an 
elevated or reduced setting for each parameter) to be compared to a proteome sample from 
CHO DP-12 cells cultured in parallel using standard conditions. In addition, proteomic samples 
prepared from biological replicate cultures, produced under standard bioprocessing conditions 
during each study, were also included in the experimental design in order to establish 
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consistency of the proteomic platform from upstream bioprocessing of CHO cell cultures to 
the final data analysis steps of the proteomic platform. Using this approach for combination of 
differentially labelled samples, the method consistency could be evaluated by determining 
variation within each combined set of TMT-sixplex labelled samples and also between sets, 
e.g. by comparison of TMT6-127 abundance values corresponding to Standards 1 – 3 (Table 
2.2). Furthermore, duplicate samples prepared from altered bioprocessing conditions were 
included in different sample sets to add further confidence by ensuring results were not 
impacted by variations in instrument performance from day to day. As displayed in Figures 2.6 
and 2.7, high consistency in relative quantitation was demonstrated both within the same 2D-
LC-MS3 analysis (R2>0.98) and across different 2D-LC-MS3 analysis (R2>0.95). Figure 2.8 shows 
examples of first and second dimensional chromatograms acquired during 2D-LC-MS3 analysis, 
showing broad separation over the gradients applied as was typical of all samples analysed.  
 
Table 2.2: Experimental design for CHO DP-12 cultures prepared in Cultibag disposable 
bioreactors. CHO-DP12 culture conditions are outlined in more detail in Table 2.1. 
TMT 
label 
applied 
TMT6-126 TMT6-127 TMT6-128 TMT6-129 TMT6-130 TMT6-131 
Set A 
High Temp. 
Study: 
39.5oC 
Standard 
1 
Low Temp. 
Study: 
32.0oC 
Standard  
1 
Standard 
2 
Standard  
3 
Set B 
High pH 
Study: pH 
7.2 
Standard 
2 
Low pH 
Study: pH 
6.8 
High Temp. 
Study: 
39.5oC 
Standard 
1 
Low Temp. 
Study: 
32.0oC 
Set C 
High DO 
Study: 
110% DO 
Standard 
3 
Low DO 
Study: 60% 
DO 
High pH 
Study: pH 
7.2 
Standard 
2 
Low pH 
Study: pH 
6.8 
Set D 
Standard  
1 
Standard 
2 
Standard  
3 
High DO 
Study: 
110% DO 
Standard 
3 
Low DO 
Study: 60% 
DO 
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Figure 2.6: Scatter plots showing linear correlation between biological triplicate replicates prepared from different CHO DP-12 cell samples, cultured using 
identical bioprocess conditions, and subsequently TMT labelled and analysed as part of Set A or Set D (Table 2.2) using the 2D-LC-MS3 method described. 
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Figure 2.7: Scatter plots showing linear correlation between biological triplicate replicates prepared from different CHO DP-12 cell samples, cultured using 
identical bioprocess conditions, and subsequently TMT labelled and analysed using different 2D-LC-MS3 runs. 
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Figure 2.8: A. First dimensional chromatogram showing high pH reversed phase separation of 
sample peptides from Set D. B. Total ion chromatograms obtained during second-dimensional 
LC-MS3 analysis of Set D sample fractions.   
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A similar experimental approach was employed for proteomic analysis of naïve CHO K1 cells 
which were exposed to conditioned media samples, as displayed in Table 2.3. However, in this 
instance, only one set of biological replicates (to be analysed using the same 2D-LC-MS3 
analysis run) were generated. Three CHO K1 cultures that were prepared alongside cultures 
exposed to spent media were also analysed, these are described as Blank 1 to 3 in Table 2.3. 
The method performance was further confirmed by determining the correlation of abundance 
values obtained for reporter ions associated with protein groups identified and quantified in 
CHO K1 samples. Scatter plots were prepared using TMT ion abundances reported for 
untreated CHO K1 cultures revealing high correlation between quantified protein groups 
(Figure 2.9, R2> 0.99). Furthermore, samples cultured using spent media produced in CHO DP-
12 cultures prepared under standard conditions, also displayed high levels of correlation both 
within the same 2D-LC-MS3 analysis (Figure 10, R2> 0.99) and across different experiments 
(Figure 11, R2>0.95 ).  
 
Table 2.3: Experimental design for CHO K1 cultures treated with conditioned media obtained 
from CHO DP-12 cultures. Three untreated ‘blank’ CHO K1 cultures were also prepared. 
TMT label 
applied 
TMT6-126 TMT6-127 TMT6-128 TMT6-129 TMT6-130 TMT6-131 
Set E 
High Temp. 
Study: 
39.5oC 
Standard 
1 
Low 
Temp. 
Study: 
32.0oC 
Blank 1 Blank 2 Blank 3 
Set F 
High pH 
Study: pH 
7.2 
Standard 
2 
Low pH 
Study: pH 
6.8 
High Temp. 
Study: 
39.5oC 
Standard 
1 
Low 
Temp. 
Study: 
32.0oC 
Set G 
High DO 
Study: 
110% DO 
Standard 
3 
Low DO 
Study: 
60% DO 
High pH 
Study: pH 
7.2 
Standard 
2 
Low pH 
Study: pH 
6.8 
Set H 
Standard  
1 
Standard 
2 
Standard  
3 
High DO 
Study: 
110% DO 
Standard 
3 
Low DO 
Study: 
60% DO 
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Figure 2.9: Scatter plots showing linear correlation between biological triplicate replicates prepared from different CHO K1 cell samples, cultured without 
application of conditioned media samples, and subsequently TMT labelled and analysed using the 2D-LC-MS3 method described. 
 
Figure 2.10: Scatter plots showing linear correlation between biological triplicate replicates prepared from different CHO K1 cell samples, cultured using CHO 
DP-12 spent media produced under identical bioprocess conditions, and subsequently TMT labelled and analysed using the 2D-LC-MS3 method described. 
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Figure 2.11: Scatter plots showing linear correlation between biological triplicate replicates prepared from different CHO K1 cell samples cultured using CHO 
DP-12 spent media produced under identical bioprocess conditions, and subsequently analysed using the 2D-LC-MS3 method described. 
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2.3.3.3 Identification of CHO Cell Proteins 
In total 6,821 CHO DP-12 protein groups and 7,082 CHO K1 protein groups were identified and 
quantified across all proteomic analyses with <1% false discovery rate (FDR) and using a 
minimum of 2 peptides for protein identification. Within CHO DP-12 data sets the number of 
protein groups quantified ranged from 6,276 to 6,503, whilst the amount of protein groups 
measured within sets of CHO K1 proteomes ranged from 6,703 to 6,835. The majority of 
peptides identified had charges states of +2, +3 or +4, as is typical of tryptic peptides (Figure 
2.12). Broad sequence coverage was also achieved for the majority of protein groups 
quantified, >84% of proteins were identified using more than four peptides while >10% 
sequence coverage was achieved for over 83% of the protein groups determined for all sample 
sets (Figure 2.12). The CHO cell proteome coverage attained represents a significant extension 
to the number of CHO cell proteins that have been identified in previous CHO quantitative 
proteomics studies. Baycin-Hizal et al. identified 5,782 grouped proteins in the first proteomic 
analysis of CHO cells using the CHO genome exclusively, [32] however 48 first dimensional 
fractions were required for LC-MS/MS analysis, compared to ten used in this study, and a 
quantitative strategy was not incorporated into the method design. Quantitative proteomics 
of CHO cells was performed by Liu and co-workers used an mRNA CHO DG44 database for 
protein identification. [36] Using 22 fractions, separated over a 260 minute LC-MS/MS 
gradient, 4,986 CHO protein groups were identified; including 2,800 proteins quantified with a 
minimum of two peptides. In the current study, use of a tribrid mass spectrometer permits the 
use of a reduced first dimensional sample fractionation as the unmatched mass accuracy, 
resolution and detectable mass range capabilities of the instrument enables in-depth 
proteome coverage without extensive first dimensional fractionation. 
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Figure 2.12: 2D-LC-MS3 method performance. A. Charge state distribution of peptides used 
for identification of grouped proteins; B. Number of peptides identified for each CHO protein 
reported; C. Sequence coverage profile for all protein groups determined. 
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2.3.3.4  Gene Ontology Analysis 
In an effort to investigate if any bias exists in proteome coverage for proteins identified using 
the high pH low pH 2D-LC-MS3 method, the DAVID bioinformatics resource was used to 
determine gene ontology (GO) terms associated with the identified CHO DP-12 protein groups. 
[38, 39] Associated GO terms with <1% FDR were visualised using REVIGO and resultant 
interaction graphs representing enriched biological processes and molecular functions are 
shown in Figures 2.13 and 2.14, respectively, and a scatter plot showing related cellular 
compartments is displayed in Figure 2.15. 
 
 
Figure 2.13: Identified CHO DP-12 proteins were processed using DAVID for determination of  
potential associated biological functions. Enriched biological processes associated with 
proteins identified in CHO DP-12 cell lysate, identified using DAVID with p-values >0.05 and 
<1% FDR, were visualised using REVIGO. [38-40] The complexity of the graph and absence of 
clustering signifys the broad proteome coverage achieved. 
 
From the complexity of the graph showing biological processes related to protein groups 
identified and the absence of clustering of GO terms in this graph, it may be deduced that 
broad proteome coverage was achieved. Furthermore, all components of the cell, including 
nuclear, cytosolic and membrane compartments are well represented, as depicted in Figure 
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2.15. In terms of molecular function, a number of distinct clusters were observed (Figure 2.14), 
including RNA/DNA binding, ATPase and helicase activity, kinase and ligase activity and 
oxidoreductase activity, all of which are functions of growing cells. Hence it was deduced that 
wide proteome coverage was achieved using the optimised proteomic 2D-LC-MS3 platform. 
 
Figure 2.14: Identified CHO DP-12 proteins were processed using DAVID for determination of  
potential associated biological functions. Enriched molecular functions associated with 
proteins identified in CHO DP-12 cell lysate, identified using DAVID with results set to a 1% FDR 
and P-value > 0.05, were visualised using REVIGO. [38-40] A number of distinct clusters were 
observed, all of which were found to be functions of growing cells.  
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Figure 2.15: Identified CHO DP-12 proteins were processed using DAVID for determination of  
potential associated biological functions. Enriched cellular compartments associated with 
proteins identified in CHO DP-12 cell lysate, identified usign DAVID with results set to 1% FDR 
and P-vallue >0.05, are depicted. A description of a portion of the annotated cellular 
compartments are shown. Cellular compartments were visualised using REVIGO. [38-40] For 
each cellular compartment shown, the colour of the represenatative circle depicts Log 10 of 
the related p-value, as shown in the legend. 
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2.3.4 Quantitative CHO DP-12 Proteomics Following Altered Bioprocessing 
For each altered bioprocessing condition studied, peptide abundance data was compared to 
corresponding proteome samples produced from CHO cell lysate subsequent to culture under 
standard bioprocessing conditions. Using InfernoRDN fold changes and p-values were 
calculated and subsequently used to prepare volcano plots to investigate differential 
expression as shown in Figure 2.16. In order to evaluate differentially regulated proteins, a 
frequently selected threshold for significant change, within samples derived from the same 
cell line, of 1.2 fold change was utilised. [45, 47, 48, 57] As the overall number of proteins was 
so large, the individual protein data for all identified protein groups are not included in this 
thesis. Identified grouped proteins that were found to be differentially regulated are listed in 
Appendix 1. A range of 175 – 788 differentially regulated grouped proteins were determined in 
CHO DP-12 samples cultured under the altered bioprocessing conditions studied. Complete 
proteome data may be accessed on the National Institute of Bioprocessing Research and 
Training (NIBRT) server. 
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Figure 2.16: Volcano plots showing fold changes plotted against –Log10 of p-values calculated 
for CHO DP-12 proteins quantified. Significant proteins with fold changes >1.2 and p-value 
<0.05 are shown in black, green dots represent proteins with p-value >0.05 and >1.2 fold 
change; blue dots represent proteins with p value >0.05, <1.2 fold change; red dots signify 
proteins with p value <0.05, <1.2 fold change. 
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Significant proteins identified for each study were correlated with potential cellular pathways 
using Ingenuity pathway analysis (IPA) for determination of enriched or decreased pathways 
as a consequence of CHO DP-12 cell culture under conditions of altered bioprocessing. IPA 
uses information stored in a knowledgebase to generate cellular and molecular networks for 
identified proteins and uses a statistical algorithm to assign a significance score for the 
association (Z-score). [34] A higher score signifies greater statistical significance to support the 
correlation of those proteins in the network. For each study, the top three positively or 
negatively altered pathways having a |Z score| ≥ 1.0, and identified using a minimum of four 
proteins were determined and are reported in Table 2.4. The vast majority of potentially 
altered pathways determined across all samples were found to be involved in cellular 
signalling, e.g. PTEN signalling, NF-kappa-B signalling and 14-3-3-mediated signalling. 
Reflecting the high cell viability at the point of cell harvest, the majority of the cells were not 
found to have apoptotic activity. However, proteome samples generated from cells produced 
at pH 7.2 displayed down-regulation of prostaglandin G/H synthase 2 (PTGS2), which is 
involved in apoptosis resistance and up-regulation of tumour necrosis factor receptor 
superfamily member 3 (LTBR), an apoptotic promoter. These proteins may be related to a 
reduction in viability in cells cultured at pH 7.2 when compared to those maintained at pH 7.0. 
The CHO DP-12 cells produced at 60% DO were found to have increased signalling activity by 
Rho family GTPases, which are involved in a variety of cellular activities including actin 
cytoskeleton reorganisation and transcriptional regulation. Interestingly, NADPH oxidase 4 
(NOX4), which may function as an oxygen sensor, was found to be up-regulated. Potentially 
related to excess oxygen levels in the culture media, the oxidoreductase, superoxide 
dismutase (SOD1) was observed to be up-regulated (fold change = 1.609) in CHO DP-12 
proteome corresponding to cell culture at 110% DO. Unsurprisingly, a large number of heat 
shock proteins were up-regulated in CHO DP-12 cells produced at 39.5oC, including the DnaJ 
heat shock protein family members A1, C3, C8, C13, C16, C17 (DNAJA1, DNAJC3, DNAJC8, 
DNAJC13, DNAJC16, DNAJC17) and heat shock protein HSP 90-α (HSP90AA1). Conversely, heat 
shock protein HSP 90-β (HSP90AB1) was down-regulated (fold change = -1.217) in CHO cells 
produced at 32oC. 
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Table 2.4: Top up- or down-regulated pathways for CHO DP-12 cells cultured under various altered bioprocessing conditions, as determined using IPA. The top 
three pathways with an absolute z-score of >1.0 and identified using a minimum of 4 proteins are shown; gene names coloured green were found to be up-
regulated whereas those in red were identified as being down-regulated. 
 Sample Pathway Change to Pathway Z-Score Molecules 
Low pH 
mAb 
PTEN Signalling Up-regulated 2.333 CHUK, GSK3A, IKBKB, ILK, MAP2K1, PDGFRB, PDPK1, TGFBR1, TGFBR2 
NGF Signalling Down-regulated -2.121 CHUK, IKBKB, MAP2K1, PDPK1, PIK3C3, ROCK2, RPS6KA1, RPS6KA3, SMPD1 
EIF2 Signalling Down-regulated -2.000 eif2b5 eif2s1, eif2s3, eif3i, eif3l, eif4g2, map2k1, pdpk1, PIK3C3, RPS18, 
RPS21, RPS28 
FLT3 Signalling in hematopoietic progenitor 
cells  
Down-regulated -2.236 MAP2K1, PDPK1, PIK3C3, RPS6KA1, RPS6KA3 
High pH 
mAb 
NF-kB Signalling Up-regulated 1.342 FGFR1, LTBR, PIK3C3, TGFBR1, TGFBR2 
Stat3 pathway Up-regulated 1.000 FGFR1, MAP2K1, TGFBR1, TGFBR2 
Colorectal cancer metastasis Signalling Down-regulated -2.646 MAP2K1, MMP12, MMP19, MSH2, PIK3C3, PTGS2, TGFBR1, TGFBR2 
neutotrophin/TRK Signalling Down-regulated -2.000 MAP2K1, PDPK1, PIK3C3, RPS6KA1 
FLT3 Signalling in hematopoietic progenitor 
cells  
Down-regulated -2.000 MAP2K1, PDPK1, PIK3C3, RPS6KA1 
Low DO 
mAb 
Signalling by Rho Family GTPases Up-regulated 2.646 BAIAP2, CDC42EP1, EZR, GNA12, GNAQ, GNAS, NFKB2, NOX4, RAC1 
IL-1 Signalling Up-regulated 2.449 ADCY9, GNA12, GNAQ, GNAS, IL1RAP, NFKB2 
Colorectal cancer metastasis signalling Up-regulated 2.333 ADCY9, GNAS, IFNGR1, JAK1, MMP12, NFKB2, RAC1, STAT1, STAT3 
LXR/RXR Activation Down-regulated -2.236 CD36, CLU, CYP51A1, ECHS1, FASN, FDFT1, HADH, IL1RAP, LPL, NFKB2, PLTP 
PPARa/RXRa Activation Down-regulated -2.121 ACVR1, ADCY9, AIP, CD36, CHD5, FASN, GNAQ, GNAS, IL1RAP, LPL, MED12, 
NFKB2 
High DO 
mAb 
14-3-3-mediated Signalling Up-regulated 1.000 GSK3A, GSK3B, MAP2K1, PDCD6IP, YWHAG 
Cell cycle: G2/M DNA Damage Checkpoint 
Regulation 
Down-regulated -2.236 CUL1, PLK1, PTPMT1, TOP2A, TOP2B, YWHAG 
EIF2 Signalling Down-regulated -1.342 EIF2B5, EIF2S3, EIF3C, EIF3L, EIF3M, EIF4G2, GSK3B, MAP2K1, RPL11, RPL24, 
RPS15, RPS16 
NRF2-mediated oxidative stress Down-regulated -1.342 CBR1, CCT7, GSK3B, GSTM5, MAP2K1, SOD1, USP14, VCP 
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Low T. 
mAb 
PPARa/RXRa Activation Up-regulated 1.134 ACAA1, ACOX1, CD36, GNAS, HSP90AB1, IKBKB, IL1RAP, TGFB1 
LXR/RXR Activation Down-regulated -2.000 CD36, CLU, FDFT1, IL1RAP, SERPINF1 
PI3K/AKT Signalling Down-regulated -1.000 HSP90AB1, IKBKB, ILK, MCL1, OCRL 
High T. 
mAb 
NRF2-mediated oxidative stress response Up-regulated 1.667 AKR7A2, ATM, CLPP, DNAJA1, DNAJC3, DNAJC8, DNAJC13, DNAJC16, 
DNAJC17, ERP29, FTH1, GSTO1, GSTT2/GSTT2B, KEAP1, MAFG, PIK3R4, 
PRDX1, SQSTM1, STIP1, UBE2K 
PTEN Signalling Up-regulated 1.732 CSNK2B, IGF2R, IKBKB, ILK, INSR, ITGA5, OCRL, PDGFRA, PDGFRB, PTK2, 
RELA, TGFBR2 
PPaR Signalling Up-regulated 1.667 HSP90AA1, IKBKB, IL1RAP, IL1RL1, INSR, PDGFRA, PDGFRB, RELA, TRAF6 
IL-6 Signalling Down-regulated -3.317 ABCB1, ATM, CSNK2B, IKBKB, IL1RAP, IL1RL1, MCL1, PIK3R4, RELA, TRAF6, 
VEGFA 
Signalling by Rho Family GTPases Down-regulated -2.711 ACTR3, ARFIP2, ARHGEF2, ARHGEF6, ARPC1B, ATM, BAIAP2, CDC42EP1, 
CFL1, CLIP1, CYFIP1, GNA11, IQGAP1, ITGA5, MYL12A, PIK3R4, PTK2, RELA, 
RHOA, ROCK2, SEPT2, SEPT5, SEPT9, SEPT11, STMN1 
Thrombin Signalling Down-regulated -2.714 ARHGEF2, ARHGEF6, ATM, GNA11, IKBKB, MYL12A, PIK3R4, PTK2, RELA, 
RHOA, ROCK2, SRC 
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In addition to cellular pathways, individual proteins that were found to be significantly 
differentially altered across the different samples analysed, were also investigated. In this 
case, proteins determined to have an absolute Z-score > 2.0 were highlighted are shown in 
Table 2.5. A large proportion of differentially regulated proteins identified are thought to be 
involved in transcription and phosphorylation mechanisms associated with actively growing 
and protein producing cells, illustrating the activity of the cell undergoing normal processes 
during production. These observations reflect the results obtained while monitoring IgG and 
metabolite production and growth trends during CHO DP-12 bioprocessing as the cells were 
actively growing and expressing recombinant therapeutic proteins at the time of culture 
harvest. These findings indicate the ruggedness of the bioprocess in response to the induced 
pH, temperature and DO variations. However, the minor changes that were applied were not 
designed to induce stress, but rather to mimic an industrial process in an attempt to decipher 
what cellular-level changes have occurred and may occur in routine biopharmaceutical 
manufacture. Of the bioprocess parameters studied temperature shift is one of the most 
widely used methods in bioprocessing for induction of recombinant protein expression. [16, 
17, 41-44, 58] In this study differential expression on a cellular level appeared to be low for 
proteins that could be correlated with cellular pathways for CHO DP-12 cells produced at 
32.0oC when compared to those produced at 37.0oC. Despite the vastness of the dataset for 
quantitative proteomics, showing high reproducibility and incorporating high quantitation 
confidence due to the use of SPS-MS3, no obvious pathways that could be correlated with 
increased recombinant protein expression were determined. However, a number of caveats 
regarding data processing with IPA may be noted. Firstly, human, mouse and rat models were 
used for determination of protein pathways as no Chinese hamster model is available. 
Secondly, there were many proteins which were not assigned a Z-score and could not be 
correlated with pathways using IPA. Hence, it is possible that further data mining may yield 
additional information regarding the cellular activity of the CHO cells studied. 
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Table 2.5: Differentially regulated proteins identified in CHO DP-12 proteomes following 2D-
LC-MS3 and IPA analysis using an absolute Z-score > 2.0. 
Bioprocess 
Condition 
Upstream 
Regulator  
Molecule Type Predicted 
Activation 
State 
Activation 
z-score 
Low pH SSMAD4 Transcription regulator Inhibited  -2.224 
OLR1 Transmembrane receptor Inhibited  -2.000 
MGEA5 Deglycosylation enzyme Activated 2.673 
RIPK2 Kinase Activated 2.213 
ACOX1 Enzyme Activated 2.621 
LEP Growth factor Activated 2.372 
INSR Kinase Activated 2.164 
LGALS3 Involved in differentiation Activated 2.219 
MAPK1 Kinase Activated 3.208 
High pH RICTOR Subunit of mTORC2 Inhibited  -2.236 
SYVN1 Component of ER-associated 
degradation 
Activated 2.236 
Low DO Lh Complex (proliferation, transcription, 
apoptosis) 
Inhibited  -2.000 
PTEN phosphatase Inhibited  -2.415 
NUPR1 Transcription regulator Inhibited  -2.138 
NFE2L2 Transcription regulator Inhibited  -2.054 
APOE Transporter Inhibited  -2.423 
RB1 Transcription regulator Inhibited  -2.828 
RICTOR Subunit of mTORC2 Activated 3.162 
RABL6 cellular proliferation Activated 2.449 
ATP7B copper transport Activated 2.236 
CCND1 cell division Activated 2.200 
MTOR serine threonine protein kinase, up 
regulates protein synthesis 
Activated 2.236 
PTGER2 cell signalling, proliferation Activated 2.236 
CEBPB transcription factor Activated 2.359 
KDM5A transcription regulator Activated 2.449 
PLAU cellular response to fluid shear stress 
and glucose stimulus 
Activated 2.000 
CSF2 cytokine - kinase activity Activated 3.146 
MITF transcription factor  Activated 2.720 
MAP4K4 serine threonine protein kinase, 
response to environmental stress and 
cytokines  
Activated 2.132 
High DO NUPR1 Transcription regulator Inhibited  -2.668 
CD38 Enzyme Inhibited  -2.219 
CST5 Cysteine protease inhibitor Inhibited  -2.333 
EBF1 Transcription regulator Inhibited  -2.449 
IGF1R Transmembrane receptor Activated 2.138 
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ATP7B Transporter Activated 2.000 
CEBPB Transcription regulator Activated 2.547 
TFAM Transcription regulator Activated 2.000 
EIF4E Translation regulator Activated 2.200 
Esrra Transcription regulator Activated 2.000 
Low T. MYD88 Signalling innate immune response Inhibited  -2.000 
NFE2L2 Transcription regulator Inhibited  -2.158 
CST5 Cysteine protease inhibitor Inhibited  -3.000 
WT1 Transcription regulator Inhibited  -2.000 
High T. P38 MAPK Serine/threonine kinase Inhibited  -2.404 
MTORC1 Serine/threonine kinase Inhibited  -2.034 
PRKCD Kinase Inhibited  -2.000 
NR1H3 Ligand-dependent nuclear receptor Inhibited  -2.183 
SCAP Cholesterol/lipid metabolism Inhibited  -2.941 
IKBKB Kinase Inhibited  -2.029 
SP1 Transcription regulator Inhibited  -2.156 
NUPR1 Transcription regulator Inhibited  -2.746 
CD44 Enzyme Inhibited  -2.339 
SREBF1 Transcription regulator Inhibited  -3.423 
TNF Cytokine  Inhibited  -3.093 
KRAS Enzyme Inhibited  -2.464 
IL6R Transmembrane receptor Inhibited  -2.415 
SYVN1 Transporter Inhibited  -2.982 
CST5 Cysteine protease inhibitor Inhibited  -3.182 
EGR1 Transcription regulator Inhibited  -2.200 
TCF7L2 Transcription regulator Inhibited  -2.500 
SREBF2 Transcription regulator Inhibited  -2.184 
CTNNA1 Role in apoptosis, adhesion, growth, 
proliferation 
Activated 2.215 
26s 
Proteasome 
non-ATPase 
regulatory 
subunit 1 
Role in degradation in, expression in, 
binding, apoptosis 
Activated 2.236 
ESRI1 Complex (proliferation, transcription, 
apoptosis) 
Activated 2.345 
ACOX1 Enzyme Activated 2.043 
COL18A1 Endostatin Activated 2.219 
FLI1 Transcription regulator Activated 2.000 
INSIG1 Control of cholesterol synthesis Activated 2.567 
LEPR Transcription regulator Activated 2.137 
EIF4E Translation regulator Activated 2.132 
Esrra Transcription regulator Activated 2.630 
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2.3.5 Application of Quantitative Proteomics to Determine Bystander Response: Naïve 
CHO K1  
In addition to evaluating changes to proteomes of recombinant protein expressing CHO cells in 
response to altered bioprocessing conditions, a further study was performed wherein the 
media obtained from CHO DP-12 cell culture post-harvest was applied to non-producing CHO 
K1 cell culture. By identifying cellular-level variations in CHO K1 proteomes, an assessment 
regarding the impact of the secretome of production cells following altered bioprocessing may 
be made. For this study CHO K1 cell culture was prepared and treated with spent media, 
before proteomic analysis using the optimised 2D-nano-LC-MS3 platform and data processing 
methods as outlined in Section 2.2. InfernoRDN software was utilised for the determination of 
p-values and fold changes for CHO K1 proteins treated with media from altered bioprocessing 
CHO DP-12 cell cultures, compared to media used for culture under standard bioprocessing 
conditions. Significance thresholds for differentially regulated proteins were set to |fold 
change| > 1.2 and p-value < 0.05. Corresponding data, illustrated in volcano plots in Figure 
2.17, detail a high level of differentially regulated proteins in CHO K1 cells treated with media 
used to culture CHO DP-12 cells at 39.5oC (352 significant proteins) and at 110% DO (399 
significant proteins), compared to other samples (57 – 187 significant proteins determined). 
All differentially regulated CHO K1 protein groups identified are listed in Appendix 2. To 
evaluate potential cellular pathways that may be associated with differentially regulated 
proteins in all CHO K1 proteome samples investigated, data was processed using IPA. The top 
30 altered pathways determined following IPA analysis, with an absolute Z-score >1.0 and 
requiring a minimum of four proteins for pathway identification, are displayed in Figure 2.18. 
A high number of signalling pathways appear to have been activated in the CHO K1 cell 
cultures, in particular for the samples treated with media from high DO and high temperature 
culture studies. However, upon closer inspection it was noted that a number of up-regulated 
proteins are associated with multiple pathways. Proteins contributing to the Z-score of >10 
pathways identified are outlined in Table 2.6. 
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Figure 2.17: Volcano plots showing fold changes plotted against –Log10 of p-values calculated 
for CHO DP-12 proteins quantified. Significant proteins with fold changes >1.2 and p-value 
<0.05 are shown in blue, red dots represent proteins with p-value >0.05 and >1.2 fold change; 
green dots represent proteins with p value >0.05, <1.2 fold change; black dots signify proteins 
with p value <0.05, <1.2 fold change. 
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Figure 2.18: Heat map displaying the top canonical pathways identified for each CHO K1 
proteomic sample using IPA. Using IPA, differentially regulated proteins with p values <0.05 
and having >1.2 log fold change and associated with different known cellular pathways, were 
used to identify the top significantly differentially regulated pathways in each of the CHO K1 
samples following application of spent media from CHO DP-12 cells cultured under altered 
bioprocessing conditions. 
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Table 2.6: Individual protein (|Z-score|> 2.0) associated with >10 differentially regulated 
pathways observed following IPA analysis of CHO K1 proteomic data. 
Gene Protein Biological Activity 
NFKB1 Nuclear factor NF-kappa-B p 105 subunit Transcription factor, endpoint of signal 
transduction 
RRAS2 Ras-related protein R-Ras2 GTPase activity, intracellular protein 
transport 
GNAI2 Guanine nucleotide-binding protein G (i) 
subunit alpha-2 
Transmembrane signalling, GTP-
binding 
GNAQ Guanine nucleotide-binding protein G (q) 
subunit alpha 
Transmembrane signalling, GTP-
binding 
GNB2 Guanine nucleotide-binding protein 
G(1)/G(S)/G(T) subunit beta-2 
Transmembrane signalling, GTP-
binding 
GNB4 Guanine nucleotide-binding protein subunit 
beta-4 
Transmembrane signalling, GTP-
binding 
PPP2R2A Serine-threonine-protein phosphatase 2A 55 
kDa regulatory subunit B alpha 
Protein de-phosphorylation 
 
 
2.4 Conclusions and Future Work 
In this Chapter, a high pH low pH 2D LC-MS3 proteomic platform incorporating SPS-MS3 for 
identification and quantitation of TMT sixplex labelled proteomic samples was applied for 
determination of differentially regulated proteins and cellular pathways in CHO cells 
undergoing altered bioprocessing. The platform was found to be highly reproducible and 
capable of identification and quantitation of >6,200 protein groups with >1% FDR for all 
sample sets, ensuring high confidence in the data acquired. However, based on the pathways 
identified as having increased or decreased activity, it appears that proteomic analysis on its 
own may not provide enough of an insight into the molecular activities of these CHO cells. 
Many of the pathway changes observed were related to the activity of kinases, transcription 
factors whose activity may be modulated by phosphorylation. Despite determination of 
physical changes to their concentration, in the absence of phosphoproteome analysis an 
assumption must be made in regards to their activity. Thus to truly understand the cellular 
level activities of CHO cells producing recombinant therapeutics, a more global omics 
approach would be useful, in particular the addition of metabolomics and phosphoproteomics 
would be highly beneficial to gain a more in-depth understanding of these important 
production systems. Furthermore, augmentation of bioinformatics resources for CHO, in line 
with model systems such as human, mouse and rat, may enable more relevant biological 
findings to be made. Finally, in order to determine whether the product is the process, 
complementary characterisation of the therapeutic protein produced is required for a more 
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thorough assessment of the impact of altered bioprocessing on therapeutic protein 
production from CHO cell lines. 
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3.0  
Characterisation of Monoclonal Antibodies 
Following Production under Altered 
Bioprocessing Conditions 
 
3.1 Introduction 
Recombinant monoclonal antibodies (mAbs) are well-established pharmacological 
therapeutics featuring high specificity to target antigens, long serum half-life in humans and 
capabilities for the treatment of a wide range of ailments, such as inflammatory diseases and 
cancer. MAbs are large tetrameric glycoproteins, structurally composed of four polypeptide 
chains: two identical heavy chains (~50 kDa in size) and two identical light chains (~25 kDa in 
size), connected via disulfide bonds at their hinge region. Each mAb comprises of two variable 
antigen-binding fragments (Fab) and a crystallisable fragment (Fc), responsible for effector 
function via interaction with the Fcγ receptor family. [1] Inherently heterogeneous 
biomolecules, mAbs may undergo a broad range of both enzymatic and non-enzymatic 
modifications during biopharmaceutical production. [2] Protein modifications have the 
potential to alter the safety and efficacy profile of mAbs by impacting protein binding, 
reducing drug activity and giving rise to adverse toxicological and immunological responses in-
vivo. [3] Consequently, therapeutic protein characterisation is an essential component of drug 
development and manufacture, as outlined in the U.S. Food and Drug Administration’s 
initiatives including pharmaceutical cGMPs for the 21st century [4], process analytical 
technology (PAT) [5] and the International Conference on Harmonisation (ICH) tripartite 
guidelines on product development and quality.  [6, 7] Critical quality attributes (CQAs) that 
must be determined include protein identity (primary sequence), and frequently encountered 
host cell- and process-related modifications including deamidation, oxidation, N-terminal 
glutamine cyclization, C-terminal lysine truncation, glycosylation, isomerisation and 
incomplete disulfide bond formation. [8] Combinations of these modifications have been 
theorised to result in 108 potential mAb variants for each therapeutic mAb, [9] resulting in 
biomolecules with differences in size, charge, hydrophobicity, structure and potentially, 
therapeutic function. As no single analytical technique exists to determine all of these 
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attributes, a wide range of analytical technologies are required for the complete 
characterisation of therapeutic mAbs. 
Biophysical properties, including heterogeneity in size, net charge of the biomolecule and 
hydrophobic properties are most commonly determined using chromatographic techniques 
coupled with ultra-violet (UV) detection. Size exclusion chromatography (SEC-UV) is the most 
widely applied method for the determination of protein aggregation and formation of particles 
in response to structural, environmental and bioprocessing factors. [10] Concerns regarding 
the potential of protein aggregates to produce immunogenic reactions and alter the actual 
dosing concentration of drug substances, have led to interest in alternative methods for 
evaluating aggregation concentrations. [3] Hence complementary techniques, such as 
analytical ultracentrifugation (AUC) and hydrophobic interaction chromatography (HIC-UV) 
have been evaluated. HIC has shown promise for the determination of mAb isoforms including 
small aggregates (1- 10 µm), which are undetectable using SEC-UV. [11] Additionally, HIC has 
been applied for monitoring of modifications such as methionine or tryptophan oxidations, 
which result in a change in mAb hydrophobicity. [11] Ion exchange chromatography (IEX-UV), 
or more frequently, cation exchange chromatography (SCX-UV) using either a salt or pH 
separation gradient, is the gold standard for determination of the charge variant profile of 
therapeutic mAbs. [12] Different charge variants of mAbs may be formed as a result of a 
variety of modifications including C-terminal lysine processing of the mAb heavy chain, 
deamidation of asparagine or glutamine, cyclisation of N-terminal glutamic acid to form 
pyroglutamate and peptide bond cleavage. [2]  
Although chromatographic techniques are useful for the evaluation of potential changes to 
mAb sequence, they are not capable of identifying exact sequence changes, determining 
alterations to protein mass or of evaluating the relative concentration of mAb variants. High 
resolution mass spectrometry (MS) is a key technique for biotherapeutic characterisation, 
capable of providing sequence-level information that is crucial for the evaluation of 
therapeutic protein quality. Three general approaches are used for reversed-phase liquid 
chromatography-mass spectrometry, namely top-down, middle-down and peptide mapping 
strategies. Top-down approaches involve the analysis of intact mAb species and are capable of 
evaluating changes to protein mass caused by sequence modification and determination of 
post-translational modifications, e.g. glycosylation. However, top-down strategies frequently 
suffer from low sensitivity due to poor ionisation efficiencies of large biomolecules and low 
sequence coverage caused by poor fragmentation of peptide bonds in complex 
biotherapeutics. [13-15] Middle-down analysis of mAbs refers to the mass measurements of 
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mAb subunits following limited proteolysis to generate polypeptides that are more amenable 
to chromatographic separation and have higher MS ionisation efficiencies when compared to 
the large intact biomolecule (~150 kDa). Proteolytic enzymes Lys-C [16] and papain [17] have 
been applied for mAb subunit generation, however, the recently discover IdeS 
(immunoglobulin-degrading enzyme of Streptococcus pyrogenes) is fast becoming the go-to 
protease for middle-down analysis due to its simple, rapid and robust digestion procedure and 
high specificity, cleaving at the mAb hinge region between two glycine amino acid residues in 
IgG1. [18, 19] IdeS digestion is frequently followed by disulfide bond reduction to generate 
light chain (LC), scFc and Fd’ fragments as depicted in Figure 3.6. Middle down analysis may be 
applied for determination of changes to mAbs, wherein protein mass has been altered (e.g. 
from amino acid insertions or deletions or following sequence level modifications). 
Peptide mapping of mAbs is the most common approach for determination of protein amino 
acid sequence, [20] and generally involves initial protein denaturation using reagents such as 
guanidine-HCl, dithiothreitol or tris(2-carboxyethyl)phosphine (TCEP), followed by digestion 
with one or more proteases  (e.g. trypsin or Lys-C). [12] Resulting peptides may be analysed 
using LC-MS/MS, enabling the identification of sequence-level modifications that result in 
distinctive mass shifts upon data analysis (e.g. N-terminal pyroglutamate results in a mass 
reduction of 17 Da). [2] Recent advances in high resolution MS instrumentation have 
significantly increased the power of this technique by enabling the determination of small 
mass shifts corresponding to peptide modifications that may impact product quality, such as 
an increase in peptide mass of 0.984 Da corresponding to deamidation of an amino acid 
residue. [21] Using peptide mapping, the quantity of a modified peptide relative to the total 
amount of that peptide in a therapeutic protein sample may be deduced.  
In this Chapter, characterisation of anti-interleukin 8 IgG1 (anti-IL8) produced from CHO DP-12 
cells processed under altered conditions of temperature, pH or dissolved oxygen (DO), is 
described. Comparative analysis of anti-IL8 produced under altered conditions and anti-IL8 
produced using standard bioprocessing conditions, may reveal changes to the primary 
sequence of recombinant mAbs that could be attributed to the change in the bioprocess used 
for their production. Hence application of chromatographic and mass spectrometry techniques 
may enable a better understanding of the role of bioprocessing in achieving desired protein 
critical quality attributed essential for recombinant therapeutic protein safety, quality and 
efficacy. 
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3.2 Experimental 
3.2.1 Reagents and Consumables 
Phosphate buffered saline (PBS), dithiothreitol (DTT), iodoacetamide (IAA), ammonium 
bicarbonate (ABC), L-arginine, guanidine-hydrochloride, tris(2-carboxyethyl)phosphine (TCEP), 
Trizma-hydrochloride (Tris), sodium phosphate dibasic (Na2HPO4), sodium phosphate 
monobasic (NaH2PO4), sodium chloride (NaCl), ammonium sulphate ((NH4)2SO4) and Amicon 
Ultra centrifugal filter units 10 kDa MWCO were obtained from Sigma Aldrich (Wicklow, 
Ireland). Water (LC-MS Optima), water, 0.1% (v/v) formic acid (LC-MS Optima) and 
acetonitrile, 0.1% (v/v) formic acid (LC-MS Optima) were purchased from Fisher Scientific. CX-
1, pH gradient buffer A (pH 5.6), CX-1, pH gradient buffer B (pH 10.2), BCA assay kit and 0.45 
µm and 0.2 µm bottle top filter units were acquired from Thermo Fisher Scientific (Dublin, 
Ireland). Promega sequencing grade modified trypsin was from MyBio Ltd. (Kilkenny, Ireland). 
FabRICATOR (IdeS) was purchased from Genovis (Lund, Sweden). 
 
3.2.2 Purification of Anti-IL 8 from CHO DP12 
Anti-IL8 mAb was produced in Sartorius Cultibag disposable bioreactors as outlined in Chapter 
2, Section 2.2.2.5. Spent media from CHO DP-12 cell culture were retrieved from -80oC freezer 
and thawed before clarification of media samples by sequential filtration through 0.45 µm and 
0.2 µm syringe filters (VWR). Samples of clarified media were then passed through a HiTrap 
Protein A column (GE Healthcare) at a flow rate of 1 mL.min-1 and subsequently washed with 
PBS to ensure complete removal of all unretained material. Elution of anti-IL8 from the Protein 
A column was performed using 100 mM arginine, pH 3.5. The pH of eluate, collected in 
Amicon Ultra centrifugal filter units with a 10 kDa cut-off membrane (Sigma Aldrich), was 
neutralized using 0.5 M Tris buffer and buffer-exchanged into PBS (4,000 rpm for 20 min). An 
aliquot of the concentrated and buffer exchanged IgG1 sample was assayed for IgG content 
using a BCA protein assay. The remainder of the samples were divided into 100 µg portions 
and stored at -30oC pending further analysis. 
 
3.2.3 Size Exclusion Chromatography 
SEC-UV analysis was performed on a Vanquish Flex UHPLC (Thermo Scientific) using a diode 
array detector at 280 nm. The presence protein aggregates, monomers and fragment moieties 
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was determined using a MAbPacTM SEC-1, 5 µm, 300 Å, 4.0 x 300 mm analytical column 
(Thermo Scientific) under isocratic conditions of 50mM sodium phosphate buffer, 300 mM 
NaCl, pH 6.8 at 0.2 mL.min-1 for 25 minutes. The column temperature was 30oC. Triplicate 
analysis of 10 µg of each mAb sample was performed. Chromeleon version 7.2 software was 
used for data acquisition and analysis. 
 
3.2.4 Cation Exchange Chromatography 
Charge variant analysis of intact mAb was performed using a Vanquish Flex UHPLC using a 
diode array detector at 280 nm. pH gradient based separation on a MAbPacTM SCX-10 RS 
analytical column, 5 µm, 2.1 x 50 mm (Thermo Scientific) using CX-1 pH gradient buffer A, pH 
5.6 and CX-1 pH gradient buffer B, pH 10.2 (Thermo scientific). Elution of sample peaks was 
achieved using a linear gradient of 35 - 55% CX-1 pH gradient buffer B, pH 10.2 in 30 minutes. 
Column temperature was 25oC and flow rate was 0.5 mL.min-1. Chromeleon version 7.2 
software was used for data acquisition and analysis. 
 
3.2.5 Hydrophobic Interaction Chromatography 
HIC-UV analysis was performed on a Vanquish Flex UHPLC using a diode array detector at 280 
nm. To achieve sufficient separation of mAb species, two MabPacTM HIC-10, 5 µm, 4.6 x 100 
mm analytical columns (Thermo Scientific) were set up in sequence. Separation buffers used 
were 2 M ammonium sulphate, 100 mM sodium phosphate, pH 7.0 (A) and 100 mM sodium 
phosphate, pH 7.0 (B). Gradient conditions were as follows: 60% B for 2 minutes followed by 
an increase to 100% B over 38 minutes; solvent composition was maintained at 100% B for 5 
minutes before reduction to 60% B in 0.1 minute; column equilibration was achieved over 6 
minutes. Column temperature was maintained at 30oC. Flow rate was 1.0 mL.min-1. Triplicate 
analysis of 25 µg of each mAb sample was performed. Chromeleon version 7.2 software was 
used for data acquisition and analysis. 
 
3.2.6 Middle Down Analysis of IdeS-digested mAb 
One µL of the FacRICATOR enzymatic digestion solution (67 units IdeS µL-1 in Optima grade 
water) was combined with 50 µL of anti-IL8 in PBS (~100 µg) and incubated at 37°C for 2 hours 
at 500 rpm using an Eppendorf Thermomixer.  Reduction of disulphide bonds was achieved 
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with 4 M guanidine hydrochloride/ 50 mM TCEP for 45 minutes at 56oC. Following incubation, 
samples were reduced to dryness via vacuum centrifugation. Each sample was reconstituted in 
100 µL 0.1% formic acid in water. Middle down analyses were perfromed using a MabPacTM 
RP, 4 µm, 2.1 x 100 mm analytical column on a Vanquish UHPLC coupled to a Q Exactive HF 
mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Separation of mAb subunits 
was performed using a binary gradient of 0.1% (v/v) formic acid in water (C) and 0.1% (v/v) 
formic acid in acetonitrile (D). Gradient conditions were as follows: 25% D initially for one 
minute, increased to 32% D in 15 minutes with a further increase to 80% D in one minute with 
a one minute isocratic hold. Initial conditions were restored in 0.5 minutes and held for an 
additional 9.5 minutes to ensure column re-equilibration. The column temperature was 
maintained at 80oC throughout and flow rate was sustained at 250 µL.min-1. The mass 
spectrometer was operated in positive ion mode with MS scans ranging from 600 to 2400 m/z 
with a mass resolution of 240,000 at m/z 400. Briefly, MS instrumental paramters were set as 
follows: spray voltage was 3.8 kV sheath gas flow rate was 25 arbitrary units (AU), auxillary gas 
flow rate was 10 AU, spray current was 13 µA, capillary temperature was 320oC. Data was 
processed using Biopharma Finder version 1.0.76.10, using the Auto Xtract algorithm set to 
deconvolute spectra with a charge of 5 to 50 in the range 600 to 2000 m/z. Biopharma Finder 
software is an informatics platform used for the analysis of protein characterisation data 
acquired on Thermo Fisher Scientific mass spectrometers.  Biopharma Finder enables the 
confirmation of amino acid sequence, identification of the site and type of post translational 
modifications and facilitates the determintion of relative amounts of mAb peptide varients. 
 
3.2.7 Peptide Mapping 
Peptide sequence mapping of anti-IL-8 IgG1 samples was performed on a Vanquish UHPLC 
coupled to a Q Exactive Plus mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). 
Sample preparation was performed using the filter-aided sample preparation (FASP) method 
described previously. [22] 50 µg of mAb was diluted in 8 M urea in 100 mM Tris-HCl and added 
to a pre-rinsed 10 kDa MWCO filters. Samples were reduced with 5 mM DTT at 65oC for 30 
minutes, before alkylation with 15 mM IAA for 30 minutes at 20oC in darkness. Following 
buffer exchange into 50 mM ABC, enzymatic digestion was performed overnight with trypsin 
at 37oC using a 1:50 (w/w, enzyme: protein) ratio. Samples were eluted from the filters by 
centrifugation and subsequently reduced to dryness via vacuum centrifugation. 
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Tryptic peptides were reconstituted in 0.1% (v/v) formic acid in water and separated using an 
Acclaim 120 C18, 5µm, 2.1 x 250 mm analytical column (Thermo Fisher Scientific) with a binary 
gradient of 0.1% (v/v) formic acid in water (C) and 0.1% (v/v) formic acid in acetonitrile (D). 
Gradient conditions were as follows: 2% D increased to 30% D in 40 minutes with a further 
increase to 80% D over 3 minutes with a 3.5 minute isocratic hold. Initial conditions were 
restored in 0.5 minutes and held for an additional 18 minutes to ensure column re-
equilibration. The column temperature was maintained at 60oC throughout and flow rate was 
sustained at 250 µL.min-1. The mass spectrometer was operated in positive ion data 
dependent mode. Survey full-scan MS spectra (m/z 200-2000) were acquired in the Orbitrap 
with a mass resolution of 70,000 at m/z 400. The spray voltage was 3.5 kV. The top five most 
intense precursors were selected for MS2 fragmentation, using an isolation window of 2.0 m/z. 
Other MS parameters used included a capillary temperature of 320oC, sheath gas set to 20 AU 
and auxillary gas of 8 AU. Resultant data were processed using Biopharma Finder version 
1.0.76.10, using the following workflow parameters: mass accuracy = 5 ppm, maximum 
number of modifications per peptide = 1, protease = trypsin, specificity set to high, variable 
modifications: N-terminal pyro-glutamine, C-terminal lysine clipping, side chain 
carbamidomethylation and carboxymethylation, asparagine deamidation, glutamine 
deamidation and oxidation of methionine and tryptophan. Data was searched against a FASTA 
file composed of the anti-IL-8 IgG1 sequence taken from US Patent 6117980. [23]  
 
3.3 Results and Discussion 
Unlike small molecule chemical drug substances that may be produced showing consistent 
conformity between manufacturing batches, routine bioprocessing can result in the 
production of heterogeneous mAb products due to inherent difficulties in achieving 
consistency while producing large biomolecules from living cells. A huge number of potential 
mAb variants may be generated, as outlined in Figure 3.1 and may result in undesired negative 
effects on the safety, efficacy and stability profile of therapeutic biomolecules. However, using 
appropriate analytical techniques changes to the primary sequence of mAbs may be 
determined by evaluating differences in the mass, charge and hydrophobicity of proteins or 
peptides generated from those proteins. In this work, anti-IL8 IgG1 was produced under 
standard bioprocessing conditions and also in batch culture wherein one of the parameters 
studied was increased or decreased, thereby resulting in the acquisition of a range of mAb 
samples that may undergo comparability assessment to identify changes potentially attributed 
to the application of a particular bioprocess setting (Table 3.1). Various analytical techniques 
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were applied for characterisation and comparability assessment of the therapeutic mAb 
produced, including SEC-UV for determination of protein aggregation, SCX-UV for analysis of 
mAb charge variants and HIC-UV for evaluation of changes to the hydrophobicity of the mAb 
produced. Subsequently, existing modifications were further investigated using middle-down 
and peptide mapping strategies for sequence and domain-level characterisation of anti-IL8, 
produced under altered bioprocessing conditions. 
 
Table 3.1: Description of anti-IL8 samples for product characterisation analysis. 
mAb Sample Name Conditions used for batch culture of Anti-IL8 
Standard 1-3 mAb 37.0oC, pH 7.0, 85% DO 
High Temperature mAb 39.5oC, pH 7.0, 85% DO 
Low Temperature mAb 32.0oC, pH 7.0, 85% DO 
High pH mAb 37.0oC, pH 7.2, 85% DO 
Low pH mAb 37.0oC, pH 6.8, 85% DO 
High DO mAb 37.0oC, pH 7.0, 110% DO 
Low DO mAb 37.0oC, pH 7.0, 65% DO 
 
 
 
Figure 3.1: Schematic of a mAb, showing sites of potential sequence modifications denoted by 
symbols outlined in the corresponding legend. The number of modification sites for each half 
antibody multiplied by the number of possible variations at each site is shown in the 
parenthesis. Assuming variants on each side of the antibody are independent, each mAb has 
108 potential variations. [9] 
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 3.3.1 Intact Anti-IL8 Analysis  
Size exclusion chromatography (SEC) is frequently applied for the evaluation of protein 
aggregation due to its simplicity, low cost and low sample requirements. [24-26] 
Administration of protein aggregates have the potential to cause adverse immune responses 
in patients and hence levels of protein aggregation is a CQA that must be monitored in 
biotherapeutic proteins. [27] Cleavage of peptide bonds to produce smaller subunit fragments 
and/or subsequent erroneous re-formation of mAb tertiary structure and creation of dimers 
or trimers may be indicated by separation of non-monomeric species using SEC. [28] Other 
sequence-level modifications that may be highlighted using SEC include the oxidation of 
tryptophan residues, which reportedly result in the earlier elution of mAbs from SEC columns, 
attributed to a reduction in non-specific hydrophobic stationary phase interactions rather than 
a change in mAb size. [29] To determine changes to the aggregation profile of anti-IL8 in 
response to altered bioprocessing conditions, triplicate analysis of each of the samples 
produced were performed using the method outlined in Section 3.2.3. Following SEC analysis, 
chromatographic peaks were integrated to determine the % area of the monomer and 
aggregate peaks. Corresponding results are shown in Table 3.2. Size-related heterogeneity 
observed across all samples following SEC-UV analysis was found to be comparable, with levels 
of differentially sized species ranging from 0.18 – 0.34% of the entire mAb sample. From the 
results obtained using SEC analysis it may deduced that the levels of protein aggregation are 
not widely impacted by production within the range of bioprocessing parameters investigated. 
 
Table 3.2: Results from SEC-UV analysis of differentially produced mAb samples (n=3). 
 Replicate 1 Replicate 2 Replicate 3 
Sample % Area of 
Monomer 
% Area of 
Aggregate 
% Area of 
Monomer 
% Area of 
Aggregate 
% Area of 
Monomer 
% Area of 
Aggregate 
Standard 1 99.72 0.28 99.73 0.27 99.72 0.28 
Standard 2 99.75 0.25 99.75 0.25 99.74 0.26 
Standard 3 99.70 0.30 99.70 0.30 99.70 0.30 
High T mAb 99.68 0.32 99.67 0.33 99.66 0.34 
Low T mAb 99.72 0.28 99.72 0.28 99.73 0.27 
High DO mAb 99.69 0.31 99.70 0.30 99.70 0.30 
Low DO mAb 99.77 0.23 99.76 0.24 99.77 0.23 
High pH mAb 99.70 0.30 99.71 0.29 99.69 0.31 
Low pH mAb 99.82 0.18 99.80 0.20 99.78 0.22 
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Charge-related microheterogeneity of mAbs is frequently observed following bioprocessing 
due to both enzymatic processes and non-enzymatic degradation of therapeutic proteins. [30] 
Chemical modifications, such as deamidations and impart a negative charge onto mAbs 
thereby decreasing their isoelectric point (pI) and resulting in the formation of acidic mAb 
variants. [31, 32] Similarly, C-terminal cleavage of lysine residues results in the loss of 
positively charged amino acids on the mAb also creating acidic protein variants. [33] 
Conversely, the presence of one or more lysine amino acids or oxidation of mAb residues may 
result in an increase in mAb pI value and thus in the formation of basic mAb variants. [34, 35] 
To determine the charge variant profile of anti-IL8 IgG1 samples following production using 
different bioprocessing parameters, triplicate SCX-UV analysis of each mAb sample was 
performed enabling the separation of species according to differences in their pI. A number of 
distinct peaks, in addition to the main mAb peak, were observed in resulting chromatograms 
indicating the existence of greater than seven mAb variants within each sample, (Figures 3.2 
and 3.3). Chromatographic peaks were integrated manually and the area of each peak as a 
percentage of the total area was calculated (Table 3.3). Large disparities between the charge 
variant profiles for all of the samples were observed potentially relating to a variety of mAb 
modifications including asparagine deamidation, oxidation of methionine, tryptophan 
oxidation, glycation, sialylation and non-classical disulfide bond formation. [36] Two likely mAb 
variants include moieties incorporating either one or two C-terminal lysine residues, which are 
known to produce distinctive peaks eluting after the main mAb peak upon SCX analysis, such 
as those observed in the chromatograms shown in Figures 3.2 and 3.3. [37] Samples produced 
at pH 7.2 displayed higher levels of both acidic and basic variants, while samples produced at 
110% DO, pH 6.8 and 39.5oC resulted in an observed reduction in both acidic and basic 
variants when compared to mAb produced at standard conditions. In agreement with Zhang et 
al. [38] we determined a decrease in acidic variants and an increase in basic variant profile in 
mAb produced from batch culture maintained at 32.0oC when compared to mAb generated in 
culture at 37.0oC. 
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Table 3.3: Percentage area of peaks observed following SCX-UV analysis and manual 
integration of differentially produced anti-IL8; standard deviation between triplicate replicates 
is shown in the parenthesis. 
Sample Combined % area of 
peaks corresponding 
to acidic variants 
% Area of Main mAb 
peak 
Combined % area of 
peaks corresponding to 
basic variants 
Standard 1 6.82 (0.08) 76.25 (0.18) 16.68 (0.19) 
Standard 2 7.06 (0.14) 75.34 (0.27) 17.36 (0.10) 
Standard 3 6.66 (0.12) 76.58 (0.15) 16.70 (0.06) 
Low DO mAb 9.04 (0.21) 72.33 (0.13) 18.06 (0.42) 
High DO mAb 3.80 (0.18) 83.81 (0.21) 12.14 (0.05) 
Low pH mAb 3.41 (0.14) 85.88 (0.05) 10.47 (0.11) 
High pH mAb 9.12 (0.10) 64.10 (0.04) 26.53 (0.06) 
Low Temp. mAb 5.90 (0.14) 68.89 (0.18) 24.82 (0.42) 
High Temp. mAb 3.07 (0.09) 82.52 (0.34) 14.13 (0.13) 
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Figure 3.2: Chromatograms corresponding to triplicate SCX-UV analysis of A. anti-IL8 produced 
at 39.5oC, B. anti-IL8 produced at 32.0oC, C. anti-IL8 produced using 110% DO media content. 
Sample separation was performed using a MAbPac SCX-10 RS analytical column, 5 µm, 2.1 x 
50mm, on a Vanquish Flex UHPLC using a diode array detector at 280 nm. Data was acquired 
using Chromeleon version 7.2 software; peak areas were integrated manually. 
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Figure 3.3: Chromatograms corresponding to SCX-UV analysis (n=3) of A. anti-IL8 produced 
using 60% DO media content, B. mAb produced at pH 7.2, C. mAb produced at pH 6.8. Sample 
separation was performed using a MAbPac SCX-10 RS analytical column, 5 µm, 2.1 x 50mm, on 
a Vanquish Flex UHPLC using a diode array detector at 280 nm. Data was acquired using 
Chromeleon version 7.2 software; peak areas were integrated manually. 
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In addition to evaluating mAb microheterogeneity in terms of charge and size, separation of 
mAb variants according to their over-all hydrophobicity is now commonly applied for 
characterisation of therapeutic mAb products. Unlike reversed-phase chromatography, which 
also separates molecules based on hydrophobicity, HIC enables the elucidation of additional 
mAb characteristics as retention of biomolecules on the HIC column matrix is solely attributed 
to interaction with amino acid residues on the surface of the molecule and hence differences 
in HIC retention profile may allude to changes in mAb tertiary structure. [11]  Many common 
modifications may potentially alter mAb hydrophobicity, most notable oxidation of 
methionine or tryptophan, [39, 40] but also aspartic acid isomerization, formation of cyclic 
imide and domain misfolding. [11] To determine the hydrophobicity profile of anti-IL8 mAb in 
response to altered bioprocessing conditions of temperature, pH and DO, triplicate analysis of 
all produced mAb samples (Table 3.1) were performed using the method outlined in Section 
3.2.5. Resulting chromatograms produced for each of the mAb samples cultured under altered 
bioprocessing conditions are shown in Figures 3.4 and 3.5. Peaks were integrated to 
determine the percentage area of the main peak relative to all peaks in the chromatogram; 
corresponding data is shown in Table 3.4. The most notable changes were observed for anti-
IL8 produced at 110% DO and pH 6.8, both of which showed less heterogeneity in mAb 
hydrophobicity than mAb produced under standard conditions, and also for mAb produced at 
pH 7.2, as this sample was found to contain species with a wide range of hydrophobicities 
when compared to mAb generated from standard cell culture conditions. These differences 
may signify changes to the levels of amino acid oxidations or possible changes to mAb higher 
order structure. When combined with SEC analysis findings, it may be deduced that changes 
observed following HIC-UV analysis may not be attributed to variations in mAb 
aggregation/higher order structure profile thereby suggesting that the differences observed 
are a result of post translational modification of the primary sequence. 
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Table 3.4: Percentage area of main mAb peak observed following HIC-UV analysis of 
differentially produced anti-IL8 IgG1. Sample separation was performed using a MAbPac SEC-1 
analytical column, 5 µm, 4.0 x 300mm, on a Vanquish Flex UHPLC using a diode array detector 
at 280 nm. Data was acquired using Chromeleon version 7.2 software; peak areas were 
integrated manually. 
mAb sample analysed % Area of main peak 
Analysis 
1 
Analysis 
2 
Analysis 
3 
Average Standard 
deviation 
Standard 1 mAb 86.93 87.38 87.84 87.38 0.46 
Standard 2 mAb 85.42 85.78 85.35 85.52 0.23 
Standard 3 mAb 86.65 87.23 87.53 87.14 0.45 
Low DO mAb 86.38 85.45 86.02 85.95 0.47 
High DO mAb 92.97 91.69 93.68 92.78 1.01 
Low pH mAb 93.66 92.54 92.47 92.89 0.67 
High pH mAb 77.48 77.47 81.11 78.69 2.10 
Low Temp. mAb 86.10 84.61 84.76 85.16 0.82 
High Temp. mAb 90.55 89.82 89.25 89.87 0.65 
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Figure 3.4: Chromatograms corresponding to HIC-UV analysis (n=3) of A. anti-IL8 produced at 
39.5oC, B. anti-IL8 produced at 32.0oC, C. anti-IL8 produced using 110% DO media content. 
Sample separation was performed using a MAbPac SEC-1 analytical column, 5 µm, 4.0 x 
300mm, on a Vanquish Flex UHPLC using a diode array detector at 280 nm. Data was acquired 
using Chromeleon version 7.2 software; peak areas were integrated manually. 
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Figure 3.5: Chromatograms corresponding to HIC-UV analysis (n=3) of A. anti-IL8 produced 
using 60% DO media content, B. mAb produced at pH 7.2, C. mAb produced at pH 6.8. Sample 
separation was performed using a MAbPac SEC-1 analytical column, 5 µm, 4.0 x 300mm, on a 
Vanquish Flex UHPLC using a diode array detector at 280 nm. Data was acquired using 
Chromeleon version 7.2 software; peak areas were integrated manually. 
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3.3.2 Middle-down Analysis of IdeS Digested Anti-IL8 IgG1 
Despite the wide range of information regarding mAb heterogeneity that may be attained 
using HPLC-UV, mass spectrometry (MS) is required to provide essential information regarding 
mAb primary structure including amino acid sequence, protein mass and sequence-level 
modifications. Like top-down analysis of intact biomolecules, middle-down MS approaches 
enable the determination of protein mass and sequence modifications, by identification of 
differences in mass upon MS analyses. However, in contrast to top-down methodology, 
limited proteolysis of proteins incorporated into middle-down approaches results in the 
generation of polypeptides which are more suited to MS detection than intact biomolecules. 
To evaluate protein mass and domain-level changes to differentially produced anti-IL8 mAb 
under study (Table 3.1), antibody samples were digested using IdeS (FabRICATOR, Genovis), a 
cysteine protease with high specificity for the hinge region of IgG. [41, 42] IdeS cleaves IgG1 at 
the linkage between (ELL)G and G(PSVF) on the mAb heavy chain, as illustrated in Figure 3.6. 
[18] Following subsequent disulfide bond reduction, three polypeptide populations are 
formed: the intact light chain (LC), a heavy chain fragment containing the N-terminus (Fd’) and 
the remaining heavy chain portion containing the asparagine-293 N-glycosylation site and the 
C-terminus (scFc). In addition to determination of the exact mass for each of these subunits, 
MS analysis may also reveal potential modifications on each of these polypeptide fragments, 
e.g. different N-glycosylation moieties on scFC and various other enzymatic and non-
enzymatic modifications that produce distinctive mass shifts upon MS analysis. 
 
 
 
Figure 3.6: Limited proteolysis of IgG1 by IdeS (FabRICATOR). [43] FabRICATOR cleaves IgG1 
with high specificity at the hinge region between two glycine residues. Subsequent disulfide 
bond reduction results in the formation of three polypeptide populations of approximately 25 
kDa in size. 
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 Anti-IL8 IgG1 produced under standard and altered bioprocess conditions (Table 3.1) were 
prepared as described in Section 3.2.6. In an effort to evaluate method performance, standard 
1 mAb was prepared in triplicate and analysed in conjunction with the remaining mAb 
samples. Following MS acquisition, data was processed using the AutoExtract algorithm in 
BioPharma Finder (Thermo Fisher Scientific). Deconvolution of mass spectra obtained for each 
peak in the total ion chromatogram (TIC) acquired resulted in the generation of spectra 
corresponding to each of the mAb subunits produced following IdeS digestion. The mass of the 
polypeptide and related variants in each of the samples could then be deduced from the 
deconvoluted spectra. TIC traces, spectra showing charge envelope profiles corresponding to 
each peak and deconvoluted mass spectra for each sample analysis are shown in Figures 3.7 to 
3.17. As the figures show, interpretation of the deconvoluted mass spectra confirms the 
identity of three polypeptides corresponding to the mass of the LC, scFc and Fd’ mAb subunits. 
For each technical replicate, the difference in mass for each subunit identified was found to be 
< 2 ppm (0.99, 1.13 and 1.78 ppm, respectively for scFc, LC and Fd’ mAb subunits) showing 
good precision across all experimental analyses. Various other peaks were observed in the 
spectra confirming the existence of modified versions of these polypeptides. The 
monoisotopic mass of the scFc fragment (~25220 Da) corresponds to the theoretical mass of 
this subunit combined with the mass of FA2 (~1462.5 Da), the most abundant N-glycan moiety 
attached to humanised IgG1. Other variants that may be deduced from the deconvoluted 
spectra include scFc with N-glycan species including FA2G1 (~25383 Da), FA2G2 (~25545 Da), 
A2 (~25073 Da) and Man5 (~24991 Da). Due to the importance of glycosylation in modulating 
the structural stability and functional activity of mAbs, [44, 45] and because of the huge 
variation in potential N-glycans present on the mAb Fc region, the N-glycosylation profile of 
anti-IL8 is specifically investigated in more detail in Chapter 4. Modifications observed across 
all samples for the LC and Fd’ subunits were not as easily deduced, as common mass shifts, 
such as those outlined in Table 3.5 were not observed. For example, the peak of mass 
24000.888 Da observed in the deconvoluted mass spectrum corresponding to LC of Standard 2 
(Figure 3.10) was ~59.0 Da greater in mass than the main LC peak, possibly corresponding to 
multiple modifications on the same mAb fragment. Hence, for thorough evaluation of the 
exact modifications that are present on the mAb samples analysed peptide mapping analysis 
must be performed. However, as the reported masses for the most abundant peak in each of 
the deconvoluted mass spectra was not significantly changed across all samples analysed, it 
may be concluded that the application of different bioprocess parameters during batch culture 
of CHO DP-12 cells did not result in alterations to the primary sequence of the anti-IL8 IgG1 
produced.  
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Figure 3.7: Middle down analysis of Standard 1, replicate 1. A. Total Ion Chromatogram (TIC); B. MS spectra corresponding to each highlighted TIC peak; C. 
Deconvolution of charge envelopes shown in MS spectra to reveal monoisotopic masses of mAb species. 
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Figure 3.8: Middle down analysis of Standard 1, replicate 2. A. Total Ion Chromatogram (TIC); B. MS spectra corresponding to each highlighted TIC peak; C. 
Deconvolution of charge envelopes shown in MS spectra to reveal monoisotopic masses of mAb species. 
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Figure 3.9: Middle down analysis of Standard 1, replicate 3. A. Total Ion Chromatogram (TIC); B. MS spectra corresponding to each highlighted TIC peak; C. 
Deconvolution of charge envelopes shown in MS spectra to reveal monoisotopic masses of mAb species. 
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Figure 3.10: Middle down analysis of Standard 2. A. Total Ion Chromatogram (TIC); B. MS spectra corresponding to each highlighted TIC peak; C. Deconvolution 
of charge envelopes shown in MS spectra to reveal monoisotopic masses of mAb species. 
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Figure 3.11: Middle down analysis of Standard 3. A. Total Ion Chromatogram (TIC); B. MS spectra corresponding to each highlighted TIC peak; C. Deconvolution 
of charge envelopes shown in MS spectra to reveal monoisotopic masses of mAb species. 
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Figure 3.12: Middle down analysis of anti-IL8 produced in culture maintained at 110% DO. A. Total Ion Chromatogram (TIC); B. MS spectra corresponding to 
each highlighted TIC peak; C. Deconvolution of charge envelopes shown in MS spectra to reveal monoisotopic masses of mAb species.  
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Figure 3.13: Middle down analysis of anti-IL8 produced in culture maintained at 60% DO. A. Total Ion Chromatogram (TIC); B. MS spectra corresponding to 
each highlighted TIC peak; C. Deconvolution of charge envelopes shown in MS spectra to reveal monoisotopic masses of mAb species. 
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Figure 3.14: Middle down analysis of anti-IL8 produced using increased culture temperature of 39.5oC. A. Total Ion Chromatogram (TIC); B. MS spectra 
corresponding to each highlighted TIC peak; C. Deconvolution of charge envelopes shown in MS spectra to reveal monoisotopic masses of mAb species. 
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Figure 3.15: Middle down analysis of anti-IL8 produced using increased culture temperature of 32.0oC. A. Total Ion Chromatogram (TIC); B. MS spectra 
corresponding to each highlighted TIC peak; C. Deconvolution of charge envelopes shown in MS spectra to reveal monoisotopic masses of mAb species. 
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Figure 3.16: Middle down analysis of anti-IL8 produced in culture maintained at pH 7.2. A. Total Ion Chromatogram (TIC); B. MS spectra corresponding to each 
highlighted TIC peak; C. Deconvolution of charge envelopes shown in MS spectra to reveal monoisotopic masses of mAb species. 
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Figure 3.17: Middle down analysis of anti-IL8 produced in culture maintained at pH 6.8. A. Total Ion Chromatogram (TIC); B. MS spectra corresponding to each 
highlighted TIC peak; C. Deconvolution of charge envelopes shown in MS spectra to reveal monoisotopic masses of mAb species. 
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3.3.3 Peptide Mapping Analysis of Anti-IL8 Produced Under Altered Bioprocessing 
Conditions 
Peptide mapping analysis using liquid chromatography and mass spectrometry is a powerful 
strategy capable of simultaneously identifying and quantifying sequence variants, low 
abundance impurities and site-specific modifications of a protein primary sequence. [46] 
Frequently, peptide mapping involves protein denaturation, reduction of disulfide bonds, 
alkylation of cysteine resides and digestion with a protease to produce peptide fragments 
appropriate for MS detection. Subsequent data processing is generally facilitated by data 
analysis algorithms used to compare experimental data with a known protein sequence. In 
addition to identification of expected peptides based on comparison with the primary 
sequence, peptides found to have an increased or decreased mass may be correlated with 
having a known modification. Furthermore, the abundance of a modified peptide relative to 
the unmodified peptide may be deduced. This approach is especially useful for comparative 
analysis of protein samples, e.g. for analysis of biosimilars, evaluation of protein stability or 
when determining the impact of an upstream or downstream process change during protein 
manufacture.  
Here, peptide mapping analysis is used to determine the protein sequence of anti-IL8 IgG1 and 
to evaluate the incidence of protein modifications as a result of bioprocessing parameters 
used for CHO DP-12 culture during recombinant antibody expression. LC-MS analysis of tryptic 
peptides generated from each mAb sample was performed as outlined in Section 3.2.7, 
resulting in the acquisition of spectra showing excellent peak resolution as may be seen in 
Figure 3.18. Processing of MS data yielded 100% sequence coverage of all samples analysed 
(Figure 3.19). All of the data was searched against the light and heavy chain sequences for 
anti-IL8 (Figure 3.20) with potential variable modifications as outlined in Table 3.5.  
 
Table 3.5: Common modifications observed for monoclonal antibodies and applied for peptide 
mapping analysis of anti-IL8. [2, 21] 
Modification Monoisotopic Mass Shift 
(Da) 
Average Mass Shift 
(Da) 
C-terminal lysine clipping  -128.095 -128.174 
Glutamic acid to Pyroglutamate -17.027 -17.031 
Deamidation of asparagine or glutamine 0.984 0.985 
Oxidation of methionine or tryptophan 15.995 15.999 
Carbamidomethylation  57.021 57.051 
Carboxymethylation 58.005 58.036 
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Figure 3.18: Base peak chromatogram corresponding to LC-MS peptide mapping analysis of 
tryptic peptides prepared from anti-IL8  mAb produced using 110% DO in culture media.  
 
Identical modifications were observed on the heavy chain and light chain of each of the 
samples analysed. The amount of modified peptide relative to corresponding unmodified 
peptide was determined and is reported in Tables 3.6 and 3.7. The light chain of anti-IL8 has 
three potential oxidation sites, one methionine and two tryptophan residues, each of which 
displayed low levels of oxidation across all samples. Additionally, four of six asparagine 
residues showed varying levels of deamidation in the different mAb samples analysed. 
Deamidation of glutamine is known to be kinetically slower than that of asparagine and hence 
is not widely reported. [47] Correspondingly, despite the presence of a large number of 
glutamine amino acids in the anti-IL8 sequence, only one glutamine residue was found to be 
deamidated. Modification of the heavy chain primary sequence via oxidation of methionine 
and tryptophan and also deamination of asparagine amino acid was also observed. In addition, 
high concentrations of the modified form of the peptide corresponding to the C-terminal of 
the heavy chain (SLSLSPGK) were determined, indicating that the C-terminal lysine truncated 
version of the mAb is the most abundant form in all samples analysed. Surprisingly, 
modification of the N-terminal glutamine residue was not determined in any of the mAb 
samples as is commonly reported for humanised monoclonal antibodies. [48] However, N-
terminal cyclization of glutamine to pyro-glutamic acid is reportedly a slow process when 
proceeding non-enzymatically at neutral pH [49] and may be more noticeably present for mAb 
that is produced in cultures maintained for long periods or after pro-longed storage. [50]  
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Figure 3.19: Sequence coverage obtained following peptide mapping analysis of Standard 1 
sample, injection 1. A: Light chain peptides identified, B: Heavy chain peptides identified. 
Following LC-MS analysis of tryptic peptides, resultant data was searched using Biopharma 
Finder software for identification and visualisation of peptides.  Each peptide identified is 
signified by a coloured bar. Red bars represent peptides with a signal intensity of > 4.9 x 106; 
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Yellow bars represent peptides with a signal intensity of > 1.4 x 105; Green bars represent 
peptides with a signal intensity of > 3.8 x 103. Each number shown within each bar equals to 
the retention time of that peptide. 
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Table 3.6: Average percentage abundance values for light chain mAb modifications determined following peptide mapping analysis; standard deviation 
between replicate analyses is shown in the parenthesis (n=2). Values were determined following data analysis using Biopharma Finder software.  
Residue Modification Peptide Sequence Standard 
1 
Standard 
2 
Standard 
3 
High 
Temp. 
mAb 
Low 
Temp. 
mAb 
High DO 
mAb 
Low DO 
mAb 
High pH 
mAb 
Low pH 
mAb 
M4 Oxidation  DIQMTQSPSS LSASVGDR 1.05 
(0.03) 
1.09 
(0.04) 
1.21 
(0.02) 
1.16 
(0.05) 
1.71 
(0.02) 
1.24 
(0.03) 
1.11 (0.03) 1.12 
(0.02) 
1.18 
(0.00) 
W40 Oxidation  SSQSLVHGIGETYLHWYQQK PGK 0.04 
(0.00) 
0.03 
(0.00) 
0.04 
(0.01) 
0.05 
(0.00) 
0.05 
(0.00) 
0.06 
(0.01) 
0.04 (0.00) 0.04 
(0.00) 
0.04 
(0.00) 
W153 Oxidation  VQWK 0.06 
(0.00) 
0.05 
(0.00) 
0.07 
(0.00) 
0.06 
(0.00) 
0.09 
(0.03) 
0.08 
(0.02) 
0.07 (0.01) 0.06 
(0.01) 
0.07 
(0.00) 
N58 Deamidation  VSNR 0.76 
(0.04) 
0.86 
(0.02) 
0.64 
(0.04) 
0.71 
(0.09) 
0.36 
(0.01) 
0.75 
(0.04) 
0.74 (0.12) 0.73 
(0.05) 
0.70 
(0.00) 
N157 Deamidation  VDNALQSGNS QESVTEQDSK 0.77 
(0.06) 
0.74 
(0.03) 
0.78 
(0.06) 
0.79 
(0.06) 
0.62 
(0.04) 
0.71 
(0.00) 
0.82 (0.01) 0.76 
(0.09) 
0.74 
(0.00) 
Q160 Deamidation  VDNALQSGNSQESVTEQDSK 
DSTYSLSSTL TLSK 
4.10 
(0.04) 
4.25 
(0.17) 
3.67 
(0.03) 
4.85 
(0.38) 
2.65 
(0.35) 
3.73 
(0.02) 
4.09 (0.16) 4.09 
(0.24) 
4.08 
(0.00) 
N163 Deamidation  VDNALQSGNS QESVTEQDSK 4.03 
(0.14) 
3.99 
(0.01) 
3.91 
(0.01) 
4.53 
(0.09) 
3.07 
(0.43) 
4.05 
(0.22) 
4.11 (0.08) 4.05 
(0.02) 
3.74 
(0.00) 
N215 Deamidation  SFNR 0.26 
(0.00) 
0.30 
(0.01) 
0.26 
(0.01) 
0.30 
(0.01) 
0.27 
(0.00) 
0.26 
(0.02) 
0.27 (0.01) 0.26 
(0.01) 
0.25 
(0.00) 
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Table 3.7: Average percentage abundance values for heavy chain mAb modifications determined following peptide mapping analysis; standard deviation 
between replicate analyses is shown in the parenthesis (n=2). Values were determined following data analysis using Biopharma Finder software. 
Residue Modification Sequence Standard 
1 
Standard 
2 
Standard 
3 
High 
Temp. 
mAb 
Low 
Temp. 
mAb 
High DO 
mAb 
Low DO 
mAb 
High pH 
mAb 
Low pH 
mAb 
K452 Lysine 
Clipping 
SLSLSPGK 90.53 
(0.17) 
89.89 
(0.25) 
90.32 
(0.21) 
97.79 
(0.05) 
85.49 
(0.18) 
97.29 
(0.47) 
94.24 
(0.35) 
85.54 
(0.04) 
98.79 
(0.00) 
N55 Deamidation  GLEWVGYIDP SNGETTYNQK 38.80 
(0.48) 
39.75 
(0.01) 
36.57 
(0.05) 
38.33 
(0.25) 
37.31 
(0.63) 
39.24 
(0.26) 
38.50 
(0.97) 
39.11 
(0.29) 
38.89 
(0.00) 
N74 Deamidation  DNSKNTAYLQ MNSLR 8.74 
(0.04) 
9.34 
(0.39) 
8.90 
(0.81) 
9.18 
(0.35) 
3.63 
(0.05) 
8.22 
(0.25) 
8.91 
(0.15) 
8.63 
(0.40) 
9.51 
(0.00) 
N77 Deamidation  NTAYLQMNSL R 1.90 
(0.02) 
1.73 
(0.03) 
2.02 
(0.01) 
1.68 
(0.02) 
1.99 
(0.01) 
2.18 
(0.04) 
1.74 
(0.05) 
2.01 
(0.01) 
1.98 
(0.00) 
N84 Deamidation  NTAYLQMNSL R 6.03 
(0.01) 
5.48 
(0.06) 
6.05 
(0.05) 
5.04 
(0.13) 
7.19 
(0.10) 
6.52 
(0.01) 
5.57 
(0.24) 
6.51 
(0.03) 
6.52 
(0.00) 
N104 Deamidation  GDYRYNGDWFFDVWGQGTLV 
TVSSASTK 
88.05 
(0.65) 
91.74 
(0.10) 
68.75 
(3.53) 
89.53 
(1.70) 
30.42 
(7.24) 
61.95 
(5.46) 
91.92 
(1.47) 
79.00 
(1.36) 
69.62 
(0.00) 
N291 Deamidation  FNWYVDGVEV HNAK 4.05 
(0.14) 
3.97 
(0.07) 
3.94 
(0.01) 
3.91 
(0.09) 
4.05 
(0.05) 
4.27 
(0.10) 
3.96 
(0.02) 
4.17 
(0.06) 
4.06 
(0.00) 
N320 Deamidation  VVSVLTVLHQ DWLNGKEYK 73.77 
(0.17) 
69.61 
(0.35) 
75.01 
(0.15) 
69.16 
(0.67) 
66.44 
(0.16) 
72.19 
(0.11) 
68.01 
(0.05) 
71.00 
(0.55) 
74.74 
(0.00) 
N389 Deamidation  GFYPSDIAVE WESNGQPENN 
YK 
16.35 
(0.14) 
16.35 
(0.57) 
15.51 
(0.29) 
15.97 
(0.20 
13.91 
(0.22) 
15.34 
(0.33) 
15.67 
(0.18) 
15.95 
(0.36) 
14.53 
(0.00) 
M83 Oxidation  NTAYLQMNSL R 1.45 
(0.04) 
1.34 
(0.05) 
1.92 
(0.01) 
1.37 
(0.01) 
2.78 
(0.13) 
1.92 
(0.03) 
1.26 
(0.01) 
1.51 
(0.01) 
1.65 
(0.00) 
M257 Oxidation  DTLMISR 1.67 
(0.07) 
1.72 
(0.01) 
1.75 
(0.02) 
1.55 
(0.00) 
2.49 
(0.08) 
1.87 
(0.11) 
1.58 
(0.03) 
1.65 
(0.00) 
1.64 
(0.00) 
W282 Oxidation  FNWYVDGVEV HNAK 0.10 
(0.01) 
0.09 
(0.00) 
0.15 
(0.00) 
0.14 
(0.00) 
0.15 
(0.01) 
0.15 
(0.01) 
0.11 
(0.00) 
0.11 
(0.00) 
0.10 
(0.00) 
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In order to estimate potential changes to the concentrations of sequence-level modifications 
in response to the conditions used for mAb production, the percentage abundance of each of 
the modifications in samples produced under altered bioprocess conditions were compared to 
the levels of corresponding modifications in mAb samples produced using standard bioprocess 
conditions. For each of the modifications the ratio of the percentage abundance of that 
modification in the differentially produced mAb compared to the average percentage 
abundance of that modification found in the standard cultured-mAb samples was determined 
and is reported in Table 3.8. The mAb samples produced at pH 6.8, pH 7.2 and at 60% DO did 
not appear to have greatly altered levels of amino acid modifications for the heavy or light 
chain of anti-IL8. Deamidation of glutamine appeared to be increased in mAb produced at 
39.5oC but reduced at 32.0oC, suggesting a possible effect on the kinetics of glutamine 
deamidation due to culture temperature. An increase in the methionine and tryptophan 
oxidation levels in mAb produced at 110% compared to mAb produced at 85% was not 
reflected in the corresponding HIC or SCX traces possibly signifying the conformation of the 
modified residues is contained within the internal part of the mAb tertiary structure. The most 
pronounced change in sequence-level modifications were found to exist in mAb samples 
expressed in media maintained at 32oC, which showed comparatively low levels of 
deamidated peptides on the mAb light chain and on the N74 residue on the mAb heavy chain. 
Conversely, the levels of methionine and tryptophan oxidation were elevated on both the 
heavy and light chain sequences. Although the high levels of primary sequence oxidation 
observed for the mAb produced at low temperature may appear to correlate with the HIC and 
SCX data, showing both greater levels of basic and polar species, the same levels of oxidation 
were not observed for the mAb produced at pH 7.2, despite a similar charge and hydrophobic 
variant profile. Hence it is possible that there are additional factors at play that may influence 
the critical quality attributes of the mAb produced. 
Although sequence level modifications frequently are present on therapeutic proteins, the 
goal of product characterisation is to ensure that existing variants do not alter the safely, 
potency and efficacy profile of the drug substance. A modification to the primary sequence of 
a mAb may potentially impact the proteins CQAs if that modification occurs in one of the 
complementarity determining regions (CDR) of the antibody, which are responsible for target 
antigen binding and hence mAb therapeutic function. [51] Following peptide mapping analysis 
one modified amino acid residue, namely N55, which formed part of a CDR was identified. 
Although studies have revealed that deamidation of N55 may reduce ligand binding activity 
resulting in reduced mAb potency, [52] the levels of deamidation of N55 were not found to be 
relatively altered in the mAb samples determined. 
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Table 3.8: Ratio of light chain and heavy chain modifications determined in mAb produced under different bioprocessing conditions relative to average % 
abundance of each modification in mAb produced under standard conditions. 
 Residue Modification Sequence High DO 
mAb 
High pH 
mAb 
High Temp. 
mAb 
Low DO 
mAb 
Low pH 
mAb 
Low Temp. 
mAb 
Li
gh
t 
C
h
ai
n
 
N58 Deamidation  VSNR 1.00 0.97 0.95 0.98 0.94 0.48 
N157 Deamidation  VDNALQSGNSQESVTEQDSK 0.93 0.99 1.04 1.08 0.97 0.82 
Q160 Deamidation  VDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSK  0.93 1.02 1.21 1.02 1.02 0.66 
N163 Deamidation  VDNALQSGNSQESVTEQDSK 1.02 1.02 1.14 1.03 0.94 0.77 
N215 Deamidation  SFNR 0.95 0.96 1.10 1.01 0.91 1.02 
M4 Oxidation  DIQMTQSPSSLSASVGDR 1.10 1.00 1.04 0.99 1.06 1.52 
W40 Oxidation  SSQSLVHGIGETYLHWYQQKPGK 1.57 1.12 1.24 1.02 1.07 1.26 
W153 Oxidation  VQWK 1.34 1.07 1.01 1.16 1.13 1.60 
H
e
av
y 
C
h
ai
n
 
N55 Deamidation  GLEWVGYIDPSNGETTYNQK 1.02 1.02 1.00 1.00 1.01 0.97 
N74 Deamidation  DNSKNTAYLQMNSLR 0.91 0.96 1.02 0.99 1.06 0.40 
N77 Deamidation  NTAYLQMNSLR 1.16 1.07 0.89 0.92 1.05 1.06 
N84 Deamidation  NTAYLQMNSLR 1.11 1.11 0.86 0.95 1.11 1.23 
N291 Deamidation  FNWYVDGVEVHNAK 1.07 1.05 0.98 0.99 1.02 1.02 
N320 Deamidation  VVSVLTVLHQDWLNGKEYK 0.99 0.98 0.95 0.93 1.03 0.91 
N389 Deamidation  GFYPSDIAVEWESNGQPENNYK 0.95 0.99 0.99 0.98 0.90 0.87 
M83 Oxidation  NTAYLQMNSLR 1.22 0.96 0.87 0.80 1.05 1.77 
M257 Oxidation  DTLMISR 1.09 0.96 0.90 0.92 0.96 1.45 
W282 Oxidation  FNWYVDGVEVHNAK 1.27 0.94 1.23 0.94 0.90 1.30 
K452 Lysine clipping SLSLSPGK 1.08 0.95 1.08 1.04 1.09 0.95 
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Figure 3.20 Anti-IL-8 IgG1 heavy and light chain protein sequence. Amino acid residues that 
were determined to have been modified following peptide mapping analysis are highlighted: 
deamidation residues are coloured green; oxidised residues are red; C-terminal truncated 
lysine is blue. CDR regions are underlined. [23] 
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3.4  Conclusions 
Monoclonal antibodies are highly complex biomolecules, which have the potential to undergo 
a range of modifications resulting in extensive microheterogeneity for each mAb entity. Since 
the incidence of primary structure modification may be impacted by environmental factors, 
e.g. bioprocessing, wide-ranging characterisation of therapeutic protein samples are required. 
In this study, domain and sequence-level characterisation of differentially produced anti-IL8 
IgG1 was performed. Although SEC-UV and middle down MS analysis did not signify changes to 
the mass of protein samples analysed, application of SCX-UV and HIC-UV for intact protein 
analysis and also use of high resolution MS instrumentation for peptide mapping of the 
protein primary sequence, revealed differences in peptide-level modifications, protein variant 
charge and hydrophobicity. Interestingly, previously reported correlations between peptide 
level modifications, e.g. oxidation and deamidation, and changes to the hydrophobicity and 
charge characteristics of the IgG1 samples analysed were not clear-cut. These findings suggest 
that there is a fundamental need to further evaluate therapeutic mAbs, as improvements in 
chromatographic stationary phases and in high resolution MS analysis may reveal new 
features of therapeutic biomolecules that have not previously been determined. With the 
advent of increasing complex biotherapeutics, such as biosimilars, bispecific antibodies, 
antibody drug conjugates and other new drug therapies, it is now increasingly important to 
apply intuitive orthogonal analytical technologies to achieve a deeper understanding of 
therapeutic biomolecules at the sequence level. The results herein show, that in order to 
predict the safety, quality and efficacy of a therapeutic protein sample, a more holistic 
approach must be taken as prediction of potential protein properties based on sequence 
quality assessment may not be appropriate. Ultimately to fully characterise a proteins CQAs, a 
thorough evaluation of sequence and domain-level features, combined with structural and 
functional characterisation must be performed. 
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4.0  
Comparative Analysis of Monoclonal 
Antibody N-Glycosylation using Stable 
Isotope Tagging and UPLC-Fluorescence-MS 
 
4.1  Introduction 
Monoclonal antibody (mAb) N-glycosylation is a common post-translational modification, 
present on each mAb heavy chain at the highly conserved asparagine 297 residue in the CH2 
region of the Fc portion of mAbs. [1-3] In addition to preserving structural stability of the CH2 
domain, glycosylation has been shown to play a critical role in the effector function of mAbs, 
facilitating interaction with Fcγ receptors present on cells of the innate immune system. [4, 5] 
Hence N-glycans are important in modulating therapeutic mAb efficacy e.g. by facilitating 
antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and by 
extending serum half-life. [6, 7] As glycosylation is a critical quality attribute (CQA), 
quantitative structural characterisation of N-glycans present on antibody therapeutics is a 
regulatory requirement as outlined in ICH Q6B. [8] Characterisation of N-glycans is normally 
performed using liquid phase separation techniques with optical detection following 
enzymatic liberation of N-glycans from the antibody and derivatisation with a fluorophore to 
increase detection sensitivity. [9, 10] Despite recent advances in separation chemistries for 
oligosaccharides, peak area based quantitation remains a subjective and laborious process due 
to integration challenges for distorted peaks containing poorly or partially resolved N-glycans, 
or due to the presence of multiple glycans within a single chromatographic peak. [11] Such 
effects can result in either under reporting of a particular N-glycan or difficulties in the 
alignment of data for subsequent statistical evaluation. 
Relative or absolute quantitation, for the elucidation of protein differential expression, using 
stable isotope labelling technology has become widely used in proteomics. Methods employed 
include those in which a heavy analogue is either incorporated into the peptide metabolically, 
e.g. stable isotope labelling with amino acids in cell culture (SILAC), or via chemical 
derivatisation, e.g. stable isotope dimethylation of peptides. [12, 13] Quantitation is 
performed by determining the levels of ‘light’ and ‘heavy’ analyte pairs present following a 
single stage mass spectrometric analysis (MS1). Alternatively, isobaric tagging of analytes may 
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be performed, wherein analytes are derivatised with reagents bearing the same nominal mass. 
Using isobaric mass tags, quantitation is facilitated following the release of low mass reporter 
ions during tandem mass spectrometric analysis of the precursor ion. [14] Isobaric tagging 
offers the ability to multiplex higher numbers of experiments, however, problems with the 
associated quantitative performance have been reported in cases where multiple ions with 
mass to charge ratios (m/z) within the isolation window are selected and fragmented 
simultaneously. [15, 16] Application of stable isotope methods for quantitative glycomics has 
attracted attention with many published reports focusing upon heavy isotope incorporation 
during permethylation of oligosaccharides prior to MALDI-MS analysis. [17-19] This approach 
may be limited due to potential variance in light-heavy mass difference resulting from 
inconsistencies in the number of available methylation sites for isotope incorporation on the 
oligosaccharide. Recently, this limitation has been overcome by labelling of oligosaccharide 
samples for comparison with either 13CH3I or 12CH2DI, respectively, which introduces a mass 
difference of 2.922 mDa per methylation site. [20, 21] High resolution mass analysis using FT-
ICR or Orbitrap mass analysers are required to distinguish the resulting isotopic pair. Stable 
isotope incorporation using reductive amination has also been reported prior to MALDI-MS 
analysis using 13C6 or deuterated analogues of commonly used reagents for high sensitivity 
fluorescence detection. [22-29]  
In this Chapter, the development of a two-plex method for the quantitative analysis of N-
glycans present on a chimeric IgG1 monoclonal antibody is described, wherein released 
oligosaccharides are labeled with light (12C6) or heavy (13C6) 2-aminobenzoic acid (2-AA) prior to 
ultra-performance liquid chromatography (UPLC) with sequential fluorescence and accurate 
mass quadrupole time of flight (QToF) mass spectrometric detection. Optimisation and 
evaluation of the 12/13C6 2-AA tag was performed, which revealed a high level of technical 
precision determined using both N-glycan standards and oligosaccharides released from 
complex glycoproteins. The combination of isotopic labelling, UPLC separation and MS 
detection facilitated full quantitative evaluation and structural annotation of N-glycans 
present within the glycan pool under investigation. Minimisation of technical variation and 
operator subjectivity is achieved through multiplexing reference and analytical samples into a 
single LC-MS injection, demonstrating the suitability of the developed method for 
comparability analysis of N-glycosylation on therapeutic glycoproteins. 
 The developed method was applied for comparability assessment of different commercial lots 
of a chimeric IgG1 mAb. Comparison of different lots revealed notable differences in the levels 
of sialylated N-glycans and N-glycans bearing galactose α1-3 linked galactose (α-gal) epitopes. 
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Finally, considering the importance of N-glycosylation on the structural stability and effector 
function of therapeutic mAbs, the developed method was also applied to determine potential 
variations of the N-glycan profile on anti-Interleukin 8 (anti-IL8), a recombinant humanised 
IgG1, following production under varied culture conditions. Variation of bioprocessing 
conditions was found to results in changes to the glycoform profile, in particular changes to 
galactosylation in response to culture pH and changes to fucosylation levels following 
alterations in culture temperature.  
 
4.2  Experimental 
4.2.1  Reagents and Consumables 
Standard N-glycans (A2F, NA2F, Man5, NA2) and Peptide-N-glycosidase F (PNGase F) were 
purchased from Prozyme (San Leandro, CA). Bovine ribonuclease B (RNase B), Bovine fetuin, 
Human serum IgG, 12C6 2-aminobenzoic acid, 13C6 2-aminobenzoic acid, Dimethyl sulfoxide 
(DMSO), Acetic acid, Dithiothreitol (DTT), Iodoacetamide (IAA), and Formic acid were 
purchased from Sigma-Aldrich (Wicklow, Ireland). Sodium cyanoborohydride, Water, 0.1 % 
formic acid (LC-MS Optima), Acetonitrile, 0.1 % formic acid (LC-MS Optima) were purchased 
from Fisher Scientific, (Dublin, Ireland). Nanosep 10 kDa centrifugal devices were obtained 
from Pall (Port Washington, NY). Promega sequencing grade modified trypsin was from MyBio 
Ltd. (Kilkenny, Ireland). Different commercial lots of the chimeric IgG1 monoclonal antibody 
(mAb) for analysis were generously provided by San Cecilio University Hospital (Granada, 
Spain). 
 
4.2.2  Glycoprotein Deglycosylation 
100 μg aliquots of each standard glycoprotein (RNase B, bovine fetuin and human serum IgG), 
500 μg aliquots of commercial chimeric IgG1 and 250 μg aliquots of anti-IL8 IgG1 (produced in-
house using CHO DP12 cells and purified using Protein A affinity chromatography - Chapter 2, 
Section 2.2.2.5), were reduced with 1 mM DTT for 10 minutes at 65oC and alkylated by 
incubation with 5 mM IAA at room temperature in the dark for 30 minutes. N-glycans were 
enzymatically released by overnight (16 hour) incubation with 500 Units of PNGase F at 37 °C 
in 20 mM sodium bicarbonate buffer pH 7.0. The deglycosylation mixture was then 
centrifuged through a 10 kDa molecular weight cut-off (MWCO) to remove the protein. The 
filtrate containing the released glycans was reduced to dryness via vacuum centrifugation. 
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Once dry, the released glycans were treated with 50 μL of 1% v/v aqueous formic acid to 
ensure complete conversion to the reducing sugar form prior to derivatisation. 
 
4.2.3  Derivatisation of free glycans with 12C6 / 13C6 2-aminobenzoic acid  
Glycan samples were derivatised with either light or heavy 2-AA by reductive amination in the 
presence of sodium cyanoborohydride. 5 µL of a freshly prepared solution of 0.37M 12C6 2-AA 
or 13C6 2-AA containing 1 M NaCNBH3 prepared in DMSO/acetic acid (70:30), were added to 
the dried glycans and incubated for 5 hours at 65 °C. Following labelling the light and heavy 
samples were mixed together and prepared with 5 µL of purified water and 85 µL of 
acetonitrile. N-glycans were purified by HILIC chromatography using a Thermo Ultimate 3000 
RS UHPLC equipped with a BEH Glycan 2.1 x 50 mm, 1.7 µm analytical column (Waters). Briefly 
samples were introduced onto the column using a mobile phase composition of 32.5% 50 mM 
Ammonium formate, pH 4.5 and 67.5% acetonitrile. Following removal of excess fluorophore, 
the gradient composition was switched to 20% acetonitrile to enable elution of 2-AA 
derivatised N-glycans. Subsequently samples were dried via vacuum centrifugation. The 
cleaned N-glycans were re-suspended in 25 µL of purified water and stored at -40 °C pending 
analysis. 
 
4.2.4  Separation of 2AA-labeled glycans UPLC-FLR-MS   
Labeled N-glycans were separated using a Waters Acquity UPLC BEH Amide (1.0 x 150 mm, 1.7 
µm) column coupled to an Acquity UPLC equipped with online fluorescence detection (Waters 
Corporation, Milford, MA, USA). The fluorescence excitation and emission wavelength 
parameters were 350 and 425 nm, respectively. The flow rate was 0.150 mL.min-1 and column 
temperature was maintained at 60°C. A binary gradient of 50 mM ammonium formate, pH 4.4 
(A) and acetonitrile (B) was used as follows: 28% A for 1 min, 28-43% A for 30 minutes, 43-70 
% A for 1 minute, 70 % A for 3 min, 70-28% solvent A for 1 min and finally 28 % A for 4 
minutes. Samples were diluted in 75% acetonitrile prior to analysis and sample injection 
volume was 8 μL. The outlet of the chromatographic system was directly coupled to a Waters 
Xevo G2 QToF mass spectrometer (Milford, MA, USA) equipped with an electrospray ionisation 
interface. The instrument was operated in negative ion mode with a capillary voltage of 1.80 
kV. The ion source and nitrogen desolvation gas temperatures were set at 120°C and 400°C, 
respectively. The desolvation gas flow rate was 600 L/h. The cone voltage was maintained at 
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50 V. Full-scan MS data was acquired over the range of 450 to 2500 m/z. Data collection and 
processing was controlled using MassLynx version 4.1 (Waters Corporation, Milford, MA, USA). 
To avoid contamination of the instrument, the column flow was diverted to waste for the first 
1.2 minutes and after 32 minutes of the chromatographic run. 
 
4.2.5 Determination of Glycosylation Site Occupancy using LC-MSE 
Determination of glycosylation site occupancy was performed on a Waters Acquity UPLC 
instrument coupled to a Xevo G2 QToF mass spectrometer (Millford, MA, USA). 50 μg aliquots 
of commercial chimeric IgG1 were reduced with 5 mM DTT at 65oC for 15 minutes, before 
alkylation with 15 mM IAA for 30 minutes at 20oC in darkness. Following reduction and 
alkylation, enzymatic digestion was performed overnight with trypsin at 37oC using a 1:50 
(w/w, enzyme: protein) ratio. In addition, where required, commercial chimeric IgG1 tryptic 
digests were de-glycosylated by incubation with 500 Units of PNGase F. Tryptic peptides were 
subsequently separated using a BEH 130 C18 2.1 x 150 mm analytical column (Waters) with a 
binary gradient of 0.1% formic acid in water (C) and 0.1% formic acid in acetonitrile (D). 
Gradient conditions were as follows: 2% D initially for 2 minutes, increased to 10% D in 3 
minutes with a further increase to 35% D over 40 minutes followed by a final increase to 90% 
D in two minutes with a two minute isocratic hold. Initial conditions were restored in one 
minute and held for an additional 10 minutes to ensure column re-equilibration. The column 
temperature was maintained at 40oC throughout and flow rate was sustained at 200 µL.min-1. 
The mass spectrometer was operated in positive ion data independent mode with one second 
sequential low and high energy scans in the range of 50 to 2,000 Da. The spray voltage was 3 
kV. A collision energy ramp from 20 to 45 V was used for the high energy function. Leucine 
enkephalin (m/z 556.2771, z=1) was used as lock mass solution, recorded at 30 second 
intervals. Resultant data were processed using ProteinLynx Global Server (PLGS) version 3.0.1, 
using the following workflow parameters: automatic peptide and fragment tolerances with 
lockmass correction of all doubly charged masses, minimum number of fragment ion matches 
per peptide = 3, minimum number of fragment ion matches per protein = 7, minimum number 
of unique peptides per protein = 2, primary digest reagent trypsin, with maximum number of 
one missed cleavage, fixed modification: carbamidomethyl C, variable modifications: oxidation 
M and deamidation N, Q, false discovery rate maintained at 1% FDR. Data was searched 
against a fasta file composed of the known sequence for the chimeric IgG1. 
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4.3  Results and Discussion 
Quantitative structural analysis of N-glycans present on therapeutic glycoproteins is required 
by regulatory agencies for new drug applications and to demonstrate correlation between 
different manufacture batches, biosimilars or following changes to a bioprocess. Despite 
advances in separation chemistries for glycosylation profiling, the presence of multiple glycan 
structures in a single peak or peak distortion as a result of partial or poor resolution of closely 
eluting oligosaccharide structures, can affect relative peak area based quantitation. Although 
LC-MS analysis of N-glycans may overcome these challenges, potential differences with 
ionisation efficiencies or instrument response factors may lead to distorted results. These 
issues may be circumvented using stable isotope tagging methods as comparative samples are 
combined following labelling and analysed in a single LC-MS injection. Hence, technical 
variation of the measurement is minimized and comparability assessment based upon the 
relative ratio of the light and heavy peaks for each glycan present may be facilitated. In this 
Chapter, the development and application of a two-plex stable isotope labelling strategy for 
the comparability assessment of N-glycans present on commercial chimeric IgG1 using 12/13C6 
2-AA labelling prior to hydrophilic interaction UPLC with sequential fluorescence and accurate 
mass QToF-MS detection is described. Application of the method for the determination of lot-
to-lot consistency of the N-glycans present on the chimeric IgG1 and to evaluate changes to 
the N-glycan profile on anti-IL8 IgG1 following culture under varied bioprocessing conditions is 
described. 
 
4.3.1  Optimisation and Evaluation of 12/13C6 2-AA Performance  
Initial investigations focused upon the optimisation of the 2-AA conjugation reaction to ensure 
complete N-glycan derivatisation. Glycans are labelled using a two-step reductive amination 
reaction, wherein the primary amide group of 2-AA reacts with the aldehyde group of a glycan 
in a condensation reaction to form a Schiff’s base. The resulting imine group is then reduced 
using sodium cyanoborohydride to form a stable labeled glycans, as shown in Figure 4.1.  
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Figure 4.1: Labelling of glycans using 2-aminobenzoic acid (2-AA). Glycans are labelled using a 
two-step reductive amination reaction, wherein the primary amide group of 2-AA reacts with 
the aldehyde group of a glycan in a condensation reaction to form a Schiff’s base. The resulting 
imine group is then reduced using sodium cyanoborohydride to form a stable labeled glycans.    
 
Hydrophilic interaction UPLC with sequential fluorescence and MS detection was employed to 
facilitate the detection of the fluorescent oligosaccharide 2-AA conjugate and also any 
underivatised N-glycans present following the derivatisation reaction. Reaction time was 
systematically optimised using a combination of oligomannose N-glycans release from RNase B 
and complex sialylated N-glycans released from bovine fetuin to ensure complete 
derivatisation whilst maintaining oligosaccharide integrity. Figure 4.2 shows the determined 
conjugation efficiency following incubation for various reaction times. From this data it was 
determined that the optimum incubation time for labelling was 5 hours at 65oC in 0.37 M 2-AA 
containing 1 M sodium cyanoborohydride in 70:30 DMSO acetic acid. 
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Figure 4.2: Optimisation of 2-AA labelling reaction time. Oligomannose N-glycans released 
from RNase B and complex sialylated N-glycans released from bovine fetuin were incubated 
with 0.37 M 2-AA containing 1 M sodium cyanoborohydride in 70:30 DMSO acetic acid using a 
range of incubation times. The optimum incubation time determined was 5 hours at 65 oC. 
Above this time desialylation of sialylated N-glycans was observed. 
 
Following optimisation of the N-glycan derivatisation conditions, the quantitative response of 
the 12/13C6 2-AA analogues was then determined using N-glycan standards labeled and mixed in 
a 1:1 light: heavy molar ratio. Quantitation of the resulting LC-MS, i.e. the ratio of the sum of 
the extracted mass chromatogram peak areas generated using the combination of the 12C6 
isotopes relative to the 13C6 isotopic data for the [M-2H]2- pseudomolecular ion, [25] did not 
provide the expected 1:1 ratio. To investigate the root cause of this observation the purity of 
the 12C6 2-AA and the 13C6 2-AA reagents was evaluated using reversed phase liquid 
chromatography with UV and MS detection which revealed the presence of an impurity in the 
13C6 2-AA reagent (~33%). This impurity exhibited low solubility in 70:30 DMSO/acetic acid and 
did not react with the N-glycans to form a conjugated product. Correction for the purity of the 
13C6 2-AA reagent facilitated the experimental achievement of the expected 1:1 ratio for 
equimolar concentrations of N-glycan standards labeled with the light and heavy reagents 
(Figure 4.3-A). 
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Figure 4.3: A. Evaluation of the purity of the 13C6 2-AA reagent. The graph shows the relative 
response of N-glycan samples labelled with the same concentration of the heavy or light 2-AA 
labelling reagent (dark blue) and relative response of samples labelled with light label and 
increased concentration of the heavy label to account for label purity (light blue); B. Evaluation 
of relative quantitation performance using stable isotope tagging.  
 
In order to evaluate quantitation performance, a variety of labelled N-glycan standards were 
prepared (bi-antennary N-glycans with and without core fucose, antennary galactose and sialic 
acid residues) to assess linearity and accuracy of the quantitative response. The molar ratios of 
the light and heavy labelled N-glycan standards were mixed in theoretical ratios of 1:1, 2:1, 5:1 
and 10:1. Quantitation was performed by determining the ratio of the sum of the extracted 
mass chromatogram peak areas generated using the combination of the 12C6 isotopes relative 
to the 13C6 isotopic data for the [M−2H]2− pseudomolecular ion. Evaluation of the experimental 
data revealed close agreement of the experimental ratios with the theoretically mixed values. 
As shown in Figure 4.3-B, translation of the data into linearity plots resulted in correlation 
coefficients for fitted least squares regression trend lines of R2 > 0.99 for all glycan standards 
tested indicating excellent linear quantitative performance of the 12/13C6 2-AA reagents. 
Quantitative precision of the 12/13C6 2-AA labelling method was next established using IgG N-
glycans released from polyclonal IgG that was extracted from healthy human control serum 
using Protein A affinity chromatography. Normalisation was performed based upon the total 
amount of IgG taken for each deglycosylation (250 μg). Six technical replicate pairs were 
prepared with an expected light heavy ratio of 1:1 for all N-glycans. Each technical replicate 
was analysed using hydrophilic interaction UPLC-fluorescence-MS, the mean and standard 
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deviation of the six technical replicates was determined, resulting data is depicted in Figure 
4.4.  
 
 
Figure 4.4: Annotated fluorescence and base peak intensity chromatograms for N-glycans 
released from polyclonal human serum IgG. The bar chart underneath the chromatograms 
depicts the mean light to heavy relative ratio as experimentally determined for the six 
technical replicates analyzed, y-error bars are also included at ± the standard deviation of the 
six technical replicates. 
 
Annotation of the N-glycans present in each chromatographic peak was based upon the 
oligosaccharide composition as derived from the m/z value, expression of the retention time 
as a glucose unit value, comparison with an in-house database and MS/MS analysis for 
structural confirmation where required. Excellent precision was established for the six 
replicate analysis of the light heavy pairs with the expected 1:1 light-heavy ratio obtained and 
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with an average percentage error of ~5% across all N-glycans annotated, (range 2-9%), 
demonstrating the excellent precision of the described approach. 
 
4.3.2  Comparability Assessment of Different Lots of a Commercial mAb using 12/13C6 2-AA 
N-Glycan UPLC-Fluorescence-MS  
The developed two-plex 12/13C6 2-AA labelling hydrophilic interaction UPLC-fluorescence-MS 
approach was applied to investigate the consistency of N-glycans present on two different 
commercial lots of a chimeric IgG1 mAb. To ensure validity of the generated data, the 
experimental design focused upon triplicate analysis of technical replicates (lot 1 versus lot 1, 
lot 2 versus lot 2 and finally, lot 1 versus lot 2), with each comparison normalised based upon 
the amount of mAb taken for deglycosylation (500 μg). Twenty four structures were annotated 
and relative quantitation was inferred from the light to heavy ratios for each oligosaccharide 
present. Resulting data is displayed in Table 4.1, which lists the mean light-heavy ratio for each 
N-glycan and the standard deviation of the triplicate measurement (displayed in parenthesis). 
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Table 4.1: Relative light to heavy ratios determined for the analysis of the individual lots of 
mAb analysed as indicated in the table header. 
Glycan Structure Ratio  
(12C6) Lot 1:  
(13C6) Lot 1 
Ratio 
(12C6) Lot 2:   
(13C6) Lot 2 
Ratio 
(12C6) Lot 1:  
(13C6) Lot 2 
A1 0.96 (0.02) 1.03 (0.04) 0.92 (0.03) 
FA1 1.00 (0.01) 0.98 (0.08) 1.00 (0.03) 
A2 0.95 (0.01) 1.03 (0.06) 0.82 (0.06) 
M4A1 0.97 (0.04) 0.95 (0.07) 1.00 (0.04) 
FA2 0.99 (0.02) 0.99 (0.08) 0.81 (0.02) 
M5 0.96 (0.04) 0.97 (0.08) 0.88 (0.06) 
FA1G1 0.97 (0.01) 1.00 (0.04) 0.80 (0.01) 
M5A1/M4A1G1 0.96 (0.01) 1.02 (0.06) 1.00 (0.07) 
FA2G1 [6] 0.98 (0.01) 0.98 (0.06) 0.59 (0.07) 
FA2G1 [3] 1.00 (0.01) 0.96 (0.06) 0.69 (0.02) 
FM5A1/FM4A1G1 0.99 (0.00) 0.98 (0.05) 0.99 (0.01) 
FA1G1Gal1 0.95 (0.02) 0.97 (0.09) 0.64 (0.01) 
M5A1G1/M4A1G1Gal1 0.96 (0.02) 1.02 (0.13) 0.75 (0.05) 
FA2G2 0.94 (0.04) 1.00 (0.05) 0.44 (0.03) 
FM5A1G1 0.99 (0.06) 1.02 (0.09) 0.72 (0.04) 
FA1G1Sg1 1.03 (0.03) 1.01 (0.08) 0.72 (0.03) 
FA2G1Sg1 1.02 (0.01) 1.05 (0.11) 0.54 (0.01) 
FA2G2Gal1 0.95 (0.08) 0.94 (0.13) 0.39 (0.01) 
FA2G1Sg1 1.02 (0.06) 0.97 (0.16) 0.63 (0.08) 
FM4A1G1Sg1 1.04 (0.02) 0.98 (0.10) 0.66 (0.02) 
FA2G2Sg1 0.96 (0.02) 0.99 (0.06) 0.41 (0.02) 
M5A1G1Sg1 0.94 (0.02) 0.96 (0.10) 0.65 (0.04) 
FM5A1G1Sg1 0.99 (0.03) 0.98 (0.09) 0.66 (0.02) 
FA2G2Sg1Gal1 0.99 (0.01) 1.02 (0.04) 0.41 (0.02) 
 
 As seen from Table 5.1, the replicate analysis of individual lots (lot 1 versus lot 1 and lot 2 
versus lot 2) indicated excellent and precise quantitative performance of the developed 
platform, with ratios near unity, as expected, for each N-glycan annotated. Interestingly, when 
the two lots were compared against each other distinct differences in the levels of certain 
glycans present were easily identified. The relative ratios of the majority of high mannose and 
hybrid oligosaccharides present on both lots were highly comparable with relative light heavy 
ratios of unity observed for many of these structures. Notably, the relative light heavy ratios 
for the complex biantennary glycans, particularly sialylated glycans and those containing a 
galactose α1-3 linked galactose residue, showed a dramatic difference between the two lots. 
Glycosylation site occupancy was also determined using LC-MSE (Figure 4.5) by subjecting 
aliquots of both lots of mAb to trypsin (Sequence coverage: Lot 1; 69.9% light chain, 66.0% 
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heavy chain, Lot 2; 66.2% light chain, 56.2% heavy chain) and PNGase F followed by trypsin 
(Sequence coverage: Lot 1; 50.9% light chain, 52.0% heavy chain, Lot 2; 44.4% light chain, 
39.1% heavy chain). The relative peak area of the unoccupied glycopeptide (EEQYNSTYR) and 
the deamidated glycopeptide (EEQYDSTYR) generated following enzymatic deglycosylation 
were evaluated, enabling N-glycosylation site occupancy of 99.92 and 99.90% to be 
determined for lot 1 and lot 2, respectively. The reason for the difference in N-glycosylation 
between the two commercial lots is unclear but may be process related, for example, cellular 
age at time of harvest has been previously demonstrated to exhibit a similar effect of the 
glycosylation of an IgG4 mAb produced in CHO. [30] Process manufacturing changes have also 
been shown to be detectable through the analysis of different lots of drug product. [31] It is 
acknowledged that many more drug product lots would need to be analysed to deduce such a 
conclusion; however, the presented two-plex 12/13C6 2-AA labelling method represents a simple 
and eloquent solution for glycosylation comparability analysis, capable of detecting substantial 
differences between products as demonstrated due to the minimisation of technical variability 
and operator subjectivity from the analysis. 
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Figure 4.5: Determination of glycosylation site occupancy. A. Representative base peak 
chromatogram obtained following LC-MSE analysis of tryptic peptides, B. Extracted ion 
chromatogram for EEQYDSTYR, C. MS spectrum corresponding to EEQYDSTYR, D. MS/MS 
spectrum for EEQYDSTYR showing identified b and y ions and amino acid sequence. 
 
4.3.3  Comparability Assessment of Anti-IL8 IgG1 N-glycan Profile in Response to 
Conditions of Altered Bioprocessing Using 12/13C6 2-AA N-Glycan UPLC-Fluorescence-
MS  
Glycosylation is a CQA of therapeutic proteins, which can modulate the efficacy of mAbs in-
vivo, hence an ability to achieve a consistent glycoform profile is desired in biopharmaceutical 
production. In recent times, regulatory agencies including the U.S. Food and Drug 
Administration (FDA) have suggested a quality by design (QbD) approach to biopharmaceutical 
manufacture, wherein quality is designed into a drug product through greater understanding 
of the processes that are used in their manufacture. [32] In the QbD paradigm, a product is 
produced using process parameters that are maintained within a ‘design space’, in which the 
CQA’s of a drug product are consistently achieved. In this section the developed 12/13C6 2-AA N-
Glycan UPLC-Fluorescence-MS platform was applied to evaluate changes to the N-
glycosylation profile of a mAb that has been produced under bioprocessing conditions that 
were altered but maintained within typical limits of  a design-space for upstream 
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bioprocessing. Anti-IL8 was produced in CHO DP-12 cells that were prepared in cultures 
maintained at various pH, temperature and dissolved oxygen (DO) settings as described in 
Chapter 2, Section 2.2. N-glycans released from Protein A-purified mAb produced in each of 
these cultures were prepared as described in section 4.2.  
Method performance of the 12/13C6 2-AA N-Glycan UPLC-Fluorescence-MS platform was 
confirmed using mAb N-glycans released from anti-IL8 that had been secreted from CHO DP12 
cells cultured using standard conditions (pH 7.0, 85% DO, 37oC). Normalisation was performed 
based upon the total amount of IgG used for each deglycosylation (250 µg). Five technical 
replicate pairs were prepared with an expected light heavy ratio of 1:1 for all N-glycans. Each 
technical replicate was analysed using hydrophilic interaction UPLC-fluorescence-MS and the 
mean and standard deviation of the five technical replicates was determined (data shown in 
Figure 4.6). Composition of N-glycans present in each chromatographic peak was derived from 
the m/z value, expression of the retention time as a glucose unit value and comparison with 
an in-house database. Acceptable accuracy and precision was established for the five replicate 
analyses with the expected 1:1 light-heavy ratio obtained for all N-glycans annotated with the 
exception of one species, namely MAN5. MAN5 was present at levels that were too low to 
facilitate accurate quantitation and hence this species will not be considered for quantitation 
when reporting N-glycan species present in anti-IL8 IgG1 samples. The remaining annotated N-
glycan species were found to have an average percentage error of <3% (range 1-8%) 
confirming excellent method performance. 
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Figure 4.6: Annotated fluorescence and base peak intensity chromatograms for N-glycans 
released from anti-IL8 IgG1. The bar chart underneath the chromatograms depicts the mean 
light to heavy relative ratio as experimentally determined for the five technical replicates 
analysed, y-error bars are also included at ± the standard deviation of the five technical 
replicates. 
 
For each set of anti-IL8 mAb produced, three replicate preparations of the mAb were prepared 
and labelled using 13C6 2-AA. Each of these was combined with the equivalent amount of mAb 
produced under standard bioprocessing conditions, labelled using 12C6 2-AA. The pooled N-
glycan samples were then analysed using UPLC-Fluorescence-MS as described in section 4.2.4. 
Ten oligosaccharises were annotated and relative quantitation was inferred from the heavy to 
light ratios for each N-glycan structure present. The mean heavy-light ratio for each N-glycan, 
and the standard deviation of the triplicate measurement (displayed in the parenthesis), are 
presented in Table 4.2. 
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Distinct differences in the N-glycoform profile of anti-IL8 were observed following production 
in a range of bioprocessing conditions. The most obvious trend in glycoform profile changes 
were observed for those mAbs that were cultured with increased or decreased pH settings. 
Anti-IL8 produced in culture maintained at pH 7.2 was found to contain higher levels of 
galactosylation compared to cultures maintained at pH 7.0, whereas a shift towards decreased 
galactosylation of glycan chains was observed at pH 6.8. Both cell culture at 39.5oC and also at 
110% DO resulted in higher proportions of afucosylated species. 
Changes to the levels of therapeutic protein N-glycans in response to bioprocessing conditions 
has been a focus of several studies, most notably for erythropoietin (EPO) producing cell lines 
due to potential effect on serum half-life of EPO. [2] In this study, the greatest proportion of 
sialylated N-glycans were observed on anti-IL8 mAb produced at pH 7.2 when compared to 
those secreted at pH 7.0, whereas a reduction in sialylated species was observed for mAb 
samples produced at a higher temperature (39.5oC) or at higher DO levels (110%). Trummer et 
al. [33] found the highest concentration of sialylated species at pH 7.0, on CHO-produced 
homodimeric fusion protein Epo-Fc, compared to those produced at higher and lower pH 
settings. A reduction in sialic acid content of the glycoform profile for EPO under conditions of 
both reduced temperature (30-35oC) and high dissolved oxygen (70-100%) were also noted. 
Conversely, Yoon et al. [34] detected a decrease in sialic acid content as pH was increased in 
EPO-producing CHO cultures.  
As trends in glycoprofile changes observed herein, and changes in glycan profiles in response 
to variations in bioprocess conditions reported in the literature do not correlate, it may be 
suggested that the effects of alterations of various bioprocess parameters are cell line or 
product dependent rather than exclusively bioprocess dependent. Hence, incorporation of 
QbD into a final drug product may require a more holistic understanding of the effects of 
culture process, cell type and the therapeutic protein itself, along with a greater 
understanding of metabolic pathways to gain physiological insights. 
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Table 4.2: Relative light to heavy ratios determined for the analysis of anti-IL8 IgG1. N-glycan 
species released from IgG1 cultured under standard conditions with one parameter varied, as 
outline in the table header information, were labelled using 12C6 2-AA, while those from 
cultures maintained at standard conditions (37oC, 85% DO, pH7.0) were labelled using 13C6 2-
AA.  
Glycan 
Structure 
m/z Altered Bioprocessing Condition 
High T. 
mAb 
(39.5oC) 
Low T. 
mAb 
(32.0oC) 
High pH 
mAb 
(pH 7.2) 
Low pH 
mAb 
(pH 6.8) 
(pH 6.8) 
High DO 
mAb 
(110%) 
Low DO 
mAb 
(65%) 
A1 616.230 1.09 
(0.09) 
0.90 
(0.11) 
0.98 
(0.04) 
0.84 
(0.02) 
1.15 
(0.07) 
1.01 
(0.11) 
FA1 689.259 0.82 
(0.05) 
1.03 
(0.05) 
0.96 
(0.01) 
0.78 
(0.01) 
0.89 
(0.01) 
1.05 
(0.02) 
FA1G1 770.285 0.97 
(0.10) 
0.95 
(0.02) 
1.16 
(0.04) 
0.95 
(0.03) 
0.91 
(0.07) 
0.92 
(0.15) 
A2 717.770 1.17 
(0.12) 
0.93 
(0.05) 
0.91 
(0.02) 
0.84 
(0.03) 
1.21 
(0.03) 
1.17 
(0.15) 
FA2 790.799 0.89 
(0.04) 
1.12 
(0.06) 
0.87 
(0.00) 
0.86 
(0.01) 
0.96 
(0.03) 
1.16 
(0.04) 
A2G1 798.796 1.07 
(0.04) 
0.87 
(0.09) 
1.11 
(0.12) 
1.00 
(0.02) 
1.18 
(0.05) 
0.82 
(0.06) 
FA2G1 871.825 0.99 
(0.05) 
1.08 
(0.06) 
1.09 
(0.01) 
0.99 
(0.01) 
0.95 
(0.03) 
1.06 
(0.03) 
FA2G1' 871.825 0.96 
(0.06) 
1.03 
(0.03) 
1.13 
(0.05) 
0.98 
(0.04) 
1.00 
(0.05) 
1.04 
(0.04) 
FA2G2 952.851 1.18 
(0.06) 
1.02 
(0.03) 
1.26 
(0.02) 
1.07 
(0.04) 
0.92 
(0.02) 
1.01 
(0.04) 
FA2G2S1 1098.392 0.83 
(0.05) 
1.07 
(0.17) 
1.35 
(0.04) 
1.09 
(0.06) 
0.84 
(0.07) 
1.09 
(0.01) 
 
 
4.4  Conclusions 
The development and application of a two-plex method for comparative glycomics of N-
glycosylation present on mAbs, based upon the differential labelling of samples for 
comparison with either ‘light’ 12C6 2-AA or ‘heavy’ 13C6 2-AA prior to hydrophilic interaction 
UPLC with sequential fluorescence and accurate mass QToF-MS detection, is described. 
Optimisation of 2-AA conjugation was investigated followed by an evaluation of the 
quantitative performance of the 12/13C6 2-AA labeled N-glycans. The method was found to be 
linear, evaluated using reference N-glycan standards, and precise with expected light heavy 
relative ratios of approximately unity determined for six technical replicate analyses of the N-
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glycans present on polyclonal serum IgG. Application of the method for lot-to-lot 
comparability analysis of a commercial chimeric IgG1 mAb revealed alterations in the levels of 
certain glycans, in particular sialylated bi-antennary glycans and glycans bearing galactose α1-
3 linked galactose residues between the two drug product lots. Additionally a comparability 
assessment of anti-IL8 IgG1 N-glycan profile in response to conditions of altered bioprocessing 
using the developed platform revealed changes to the glycoform profile of anti-IL8, notably for 
galactose-containing N-glycans produced in cultures at pH 7.2 and afucosylated species 
produced in cultures maintained at 110% DO.  
The presented method is ideally suited for comparability analyses due to the minimisation of 
technical variation and operator subjectivity from the analysis, combined with the ability to 
perform full quantitative structural characterisation of all oligosaccharides, including isomeric 
species, present in the glycan pool. The method builds on widely used and understood 
chemistry and concepts but adds an additional dimension through the application of the stable 
isotope labelling based quantitation. The described platform can be readily employed for 
physiochemical demonstration of molecular comparability following process or manufacturing 
changes, or for the assessment of similarity between innovator and biosimilar candidate 
molecules. 
 
4.5 Associated Publication and Author Contributions  
Published in part: Millán Martín, S., et al., Comparative analysis of monoclonal antibody N-
glycosylation using stable isotope labelling and UPLC-fluorescence-MS. Analyst, 2015, 140(5): 
1442-7.  
Research study devised by Amy Farrell, Silvia Millán Martín and Jonathan Bones; Research 
performed by Amy Farrell, Silvia Millán Martín and Cedric Delporte; Natalia Navas Iglesias 
provided commercial samples; Data and related paper were reviewed by Jonathan Bones and 
Niaobh McLoughlin.  
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5.0  
Structural and Functional Characterisation 
of Monoclonal Antibodies Following 
Production under Altered Bioprocessing 
Conditions 
 
5.1 Introduction 
Therapeutic monoclonal antibodies (mAbs) are large, complex macromolecules, consisting of 
thousands of atoms intricately connected to form unique three-dimensional structures. 
Conformation of protein higher order structure may have a profound effect on the mAb 
function as conformational changes have the potential to alter the accessibility of binding sites 
to cellular or antigen targets. Protein structure is maintained by various interactions, including 
hydrogen bonds and electrostatic forces, which impart significant structural flexibility enabling 
dynamic motion in solution. [1] Sequence-level protein modifications may interrupt the 
interactions that are critical to protein structure and, hence, may affect the functional activity 
of mAbs in-vivo. In particular, changes to mAb higher order structure may alter the 
accessibility of the Fc binding site, responsible for non-antigen binding activity and in vivo half-
life, or similarly may modify the complementarity-determining regions (CDRs) leading to a 
reduction in antigen binding affinity, ultimately affecting potency and therapeutic efficacy of 
mAbs. Consequently, in addition to primary sequence characterisation, elucidation of the 
structure and structure-function relationship for a protein should be determined during 
product or bioprocess development, when evaluating biosimilar therapeutic proteins or 
following changes to a bioprocess. [2] Regulatory agencies recommend for comparability 
purposes, that an attempt should be made to determine the higher order structure of a 
protein. Alternatively if structural characterisation is not possible, changes to a protein tertiary 
structure should be assessed by determining the biological activity of the therapeutic drug 
substance. [3] 
Numerous techniques are available for structural characterisation of proteins, including the 
well-established nuclear magnetic resonance (NMR) spectroscopy [4, 5] and X-ray 
crystallography. [6] Although widely applied, practical limitations exist for the application of 
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NMR to intact protein characterisation, including difficult spectral annotation attributed to the 
large molecule size and a requirement for isotopic labelling. [7] X-ray crystallography 
applications may be limited due to the necessity for generation of antibody crystals and also 
resulting from reservations regarding the impact of complex sample preparation buffers on 
the protein under analysis. [8] Other biophysical characterisation techniques are available, 
including analytical ultracentrifugation (AUC), size exclusion chromatography (SEC), 
differential scanning calorimetry and circular dichroism. [8] However these methods only 
provide limited data and are incapable of providing information regarding the location of a 
change on a protein molecule or of identifying subtle alterations to a protein’s higher order 
structure. Hydrogen deuterium exchange mass spectrometry (HDX-MS) has become an 
increasingly popular alternative technique for determination of protein structure. Backbone 
amide hydrogen’s located at the surface of the protein or involved in weak hydrogen bonds 
exchange rapidly with deuterium when place in a deuterated solvent, whereas those 
contained within the interior of the protein structure or forming stabilising hydrogen bonds 
exchange at a much slower rate. [9] Following HDX, the labelling reaction may be quenched 
using a low pH denaturation buffer and the protein digested by means of an acid-resistant 
protease (e.g. pepsin). Analysis of resulting peptides is performed using a rapid liquid 
chromatography separation method followed by mass spectrometry detection for evaluation 
of deuterium uptake and hence determination of protein tertiary structure. A typical HDX-MS 
workflow is illustrated in Figure 5.1.  
Analysis of chemical composition (amino acid sequence) and higher order structure may 
provide extensive information regarding potential changes to a therapeutic mAb, e.g. in 
response to bioprocess changes or for biosimilar comparability. However, to fully characterise 
a mAb the functional capabilities of the protein must also be assessed. Antibody therapeutics 
may be classified as having two general mechanisms of action. Therapeutic mAbs may exert 
their effect by binding directly to their cellular target (e.g. cell surface tumour antigens), 
thereby enabling immune mediated effects to take place. Alternatively, mAbs may be directed 
against soluble molecules (e.g. cytokines) and function by binding to and inhibiting the action 
of the target molecule. [10] In this work, a humanised anti-interleukin 8 (anti-IL8) IgG1 was 
produced from CHO DP-12 culture. Anti-IL8 IgG1 functions in humans by binding to the 
cytokine interleukin-8 forming a complex which may be recognised by the immune system 
thereby facilitating clearance from the body. Hence, for anti-IL8 IgG1 to produce a 
pharmacological effect, the antibody must be allowed to circulate for a sufficient period of 
time in human serum. Fortuitously, the success of IgG1 mAbs as drug therapies may in part be 
attributed to a long serum half-life in humans as a result of their ability to bind to the neonatal 
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Fc receptor (FcRn), a soluble receptor expressed by cells of endothelial, epithelial and myeloid 
lineages. [11, 12] Binding of IgG1 to FcRn is exquisitely pH dependent: FcRn forms a complex 
with IgG1 at acidic pH (<pH 6.5) protecting mAbs from degradation inside the endosomal 
compartment and facilitating recycling of the mAb to the cell surface, where upon the FcRn-
IgG1 complex dissociates at neutral pH (or higher). [13] Many new drug therapies, e.g. 
antibody drug conjugates and Fc-fusion proteins, have been engineered to exploit the high 
binding specificity of FcRn-IgG1 and hence, create a long serum half-life. [14, 15]  
FcRn-IgG binding has also been widely applied for the evaluation of IgG antibody 
pharmacokinetics in drug development, to estimate the serum half-life of new drug products 
and for comparability assessment of mAbs following process changes. [16, 17]  Different 
analytical strategies exist for the determination of IgG binding and function, including cell-
based assays or ligand binding assays. As a general rule-of-thumb, mAbs that function by 
binding to cellular targets are usually assessed using cell based assays while those that interact 
with soluble receptors are determined using a technique based on ligand binding wherein 
ligand interaction is normally the first step in protein-induced cellular response. [18] Since 
anti-IL8 IgG1 functions by binding to soluble interleukin-8, and is circulated in the body as a 
result of binding to soluble FcRn receptors, determination of ligand binding is an appropriate 
strategy to investigate its functional activity. Surface plasmon resonance (SPR) biosensor 
binding assays are widely applied for the determination of mAb functional activity. In SPR, 
changes in reflected polarised light are measured following binding of analytes to ligands 
embedded in a dextran matrix on the surface of a gold plated sensor chip. [19] Using SPR the 
rate of association and dissociation of an antigen to a mAb and also their binding affinity may 
be assessed. Thus, structural alterations to a therapeutic protein impacting antigen binding, 
which transpire following environmental changes, degradation or exist between biosimilar 
products, may be identified by measuring the binding affinity or binding rates of the 
therapeutic protein. 
In this chapter, potential changes to the structural conformation and the function of anti-IL8 
mAb produced from CHO DP-12 cells under conditions of altered bioprocessing, as outlined in 
Chapter 2 (pH, temperature, dissolved oxygen (DO)), are investigated. HDX-MSE is applied to 
identify which regions, if any, of the mAb higher order structure are potentially altered as a 
result of variations in bioprocessing parameters. In addition SPR-based binding assays are 
applied to determine potential changes to serum half-life caused by culture under different 
conditions by evaluating the binding affinity of FcRn to differentially cultured mAbs. 
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Additionally, by determining the binding dynamics of anti-IL8 IgG1 to interleukin 8, possible 
changes to the function of anti-IL8 mAbs are evaluated. 
 
5.2  Experimental 
5.2.1 Reagents and Consumables 
Deuterium oxide (D2O), Deuterium chloride (DCl), Potassium phosphate dibasic, Potassium 
phosphate monobasic, Tris(2-carboxyethyl)phosphine (TCEP), Guanidine hydrochloride, 
Hydrochloric acid, [Glu1]-Fibrinopeptide B, Monosodium phosphate monohydrate, 
Tris(hydroxymethyl)-aminomethane (Tris), Sodium chloride (NaCl), Acetonitrile, Formic acid 
and Methanol were obtained from Sigma Aldrich (Wicklow, Ireland). Sodium iodide and 
Leucine enkephalin were received from Waters (Dublin, Ireland). Water, 0.1% formic acid (LC-
MS Optima), Acetonitrile, 0.1% formic acid (LC-MS Optima), and Water, 0.1% TFA (LC-MS 
Optima) were obtained from Fisher Scientific (Dublin, Ireland). Recombinant human CXCL8/IL-
8 protein and Recombinant human FcRn protein were purchased from R&D systems 
(Minnesota, USA). Biacore series S sensor chip CM5, Biacore series S Protein A sensor chip, 10 
mM sodium acetate, pH 5.0, Glycine-hydrochloride, HBS-EP+ buffer and amine coupling 
reagents (1-ethyl-3-(3-dimethylaminopropyl)carbodimide hydrochloride (EDC), N-
hydroxysuccinimide (NHS) and 1.0 M ethanolamine-HCL pH 8.5) were obtained from GE 
Healthcare (Dublin, Ireland). 
 
5.2.2 Hydrogen-Deuterium Exchange Mass Spectrometry 
Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS) was performed using a 
nanoAcquity UPLC M-class system with a LEAP HDX automation manager coupled to a Waters 
Synapt G2 HDMS QToF. The HDX-MS platform was equipped with an Enzymate BEH pepsin 
column, 2.1 x 30 mm (Waters), an Acquity UPLC BEH C18 1.7 µm VanGuard Pre-Column, 2.1 x 
5 mm (Waters) and an Acquity UPLC BEH C18 1.7 µm, 1.0 x 100 mm analytical column 
(Waters). Purified anti-IL8 IgG1 produced under conditions of altered bioprocessing (Section 
2.2.2.5) and later purified and quantified (Section 3.2.2) were diluted to a concentration of 5 
mg. mL-1 in 10 mM potassium phosphate, pH 7.0. For each labelling time point, 4.8 µL of anti-
IL8 IgG1 was diluted with 20-fold 10 mM potassium phosphate in D2O, pH 6.6 at room 
temperature and incubated for a pre-defined time (20 s, 1 min, 2 min, 10 min, 30 min, 1 hr, 2 
hr, 4 hr). Following incubation, the reaction was quenched by the addition of 50 mM 
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potassium phosphate, 2 M guanidine-HCl, 200 mM TCEP, pH 2.30 before on-line pepsin 
digestion. The digestion temperature was set to 20oC. All subsequent chromatographic 
separations were performed in a cooling chamber maintained at 0.0 ± 0.1oC to prevent back 
exchange of deuterium. To minimise carry-over between each sample preparation, a blank 
injection and a pepsin column wash, using 1.5 M guanidine-HCl, 4% acetonitrile, 0.8% formic 
acid, 200 mM TCEP, pH 2.5, were performed. 
Eluting peptides were loaded via trapping column for 3 minutes at 200 µL.min-1, using an 
isocratic gradient of 0.1% (v/v) formic acid in water (A) and 0.1% (v/v) formic acid in 
acetonitrile (B). Peptides were subsequently directly sampled onto a C18 analytical column and 
separated using the following gradient conditions: 5% to 35% B in 6 minutes, followed by a 
further increase to 95% B over 1 minute and a 3 minute isocratic hold. Subsequently the 
column was washed three times by decreasing mobile phase composition to 5% B in 1 minute 
followed by increase to 95% B. Initial conditions were restored in one minute and held for an 
additional 2 minutes to ensure column re-equilibration. The flow rate was 40 µL.min-1. Eluate 
from the chromatographic system was sampled directly into a Synapt G2 HDMS QTof mass 
spectrometer (Millford, MA, USA) via an electrospray ion source. The mass spectrometer was 
operated in positive ion data independent resolution mode with 0.3 second sequential low 
and high energy scans in the range of 50 to 2,000 Da. The spray voltage was 3 kV. A collision 
energy ramp from 15 to 35 V was used for the high energy function. Glu-fibrinopeptide (m/z 
785.8426, z=2) was used as lockmass solution, recorded at 30 second intervals. Non-
deuterated control experiments were also carried out to identify all peptides produced during 
enzymatic digestion. 
Following analysis unlabelled samples were processed using ProteinLynx Global Server 
software (PLGS, version 3.0.1) for identification of sample peptides. Workflow parameters 
used include automatic peptide and fragment tolerances with lockmass correction of all 
doubly charged masses, minimum number of fragment ion matches per peptide = 2, minimum 
number of fragment ion matches per protein = 5, minimum number of unique peptides per 
protein = 1, primary digest reagent trypsin, with maximum number of one missed cleavage, 
fixed modification: carbamidomethyl C, variable modifications: oxidation M, deamidation N 
and deamidation Q, false discovery rate maintained at 1% FDR. Data was searched against a 
fasta file composed of known mAb sequence described in US patent 6117980 A. [20] All HDX-
MS data were processed using DynamX® HDX data analysis software version 3.0.0 (Waters) 
with additional manual verification of the raw spectra. DynamX® is a software tool designed to 
automate visualisation and sorting of data acquired using a Waters HDX-MS platform. The 
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following settings were used for filtering of the data: minimum intensity of 1000, minimum 
sequence length of 6, maximum sequence length of 30, file threshold = 3 and retention time 
RSD of 5%. Deuterium uptake for each peptide was calculated by subtracting the centroid of 
the isotopic distribution for non-labelled peptide ions from the centroid of the isotopic 
distribution for peptide ions for each deuterated sample. A minimum sequence coverage of 
70% and average redundancy of <5 was required for all data. HDX comparability profiles were 
plotted using an algorithm developed by Houde et al. incorporated into DynamX software. [1] 
 
5.2.3 Surface Plasmon Resonance 
All SPR experiments were carried out on a Biacore T100 instrument (GE Healthcare, Uppsala, 
Sweden) using Biacore T100 Control Software version 2.0.4. Processing of acquired data was 
perfumed using Biacore Evaluation software version 2.0.4. 
 
5.2.3.1 Determination of FcRn-Anti-IL8 Binding Affinity 
Standard amine coupling was performed to immobilise FcRn on to the surface of a Series S 
CM5 chip. Briefly, the dextran surface of two flow cells was activated by injecting a 1:1 
solution of EDC/NHS for 420 s at 10 µL.min-1. FcRn molecules were diluted to 2.5 µg.mL-1 in 10 
mM sodium acetate, pH 5.0 and injected at a flow rate of 5 µL.min-1 (onto the test flow cell 
only) until the target response level of 500 RU was reached. Subsequently, the surface of both 
flow cells was blocked by injecting 1 M ethanolamine pH 8.5 for 420 s at 10 µL.min-1. The 
running buffer, 50 mM sodium phosphate/150 mM NaCl, pH 6.0, was allowed to flow at a rate 
of 30 µL.min-1. For each anti-IL8 sample studied, a range of concentrations of the mAb were 
prepared in triplicate in running buffer (0, 10, 25, 50, 100, 150 and 200 µg.mL-1) and injected at 
25oC using a multi-cycle approach. Regeneration of the immobilised FcRn surface was achieved 
following each mAb sample introduction using 100 mM Tris/200 mM NaCl, pH 8.0, injected for 
60 seconds at 30 µL.min-1. For each analysis, the response was calculated at a position 4 
seconds before the injection stop, with a 5 second window. A steady state affinity fit model 
was applied for determination of the dissociation constant. 
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5.2.3.2 Evaluation of Anti-IL8 – Interleukin 8 Binding Kinetics 
A Series S Protein A chip was utilised for the determination of changes to the binding kinetics 
of anti-IL8 IgG1 to the cytokine interleukin-8 using a single-cycle kinetics procedure. Before 
use the Protein A chip was primed with HBS-EP+ running buffer and conditioned via triplicate 
injection of 10 mM glycine, pH 1.5 for 60 seconds using a flow rate of 30 µL.min-1. For each 
analysis, a 10 µg.mL-1 solution of mAb was passed over the active sample flow cell for 30 s at 5 
µL.min-1 to enable capture of the protein on the protein A chip surface. Interleukin 8, prepared 
at a range of concentrations (0.625, 1.25, 2.5, 5 and 10 nM), was then injected in order of 
increasing concentration over reference and active flow cell using five 150 s injections at 30 
µL.min-1, applying a single cycle kinetics approach. [21] Following the final interleukin-8 
injection, a 1200 s dissociation time was applied. Regeneration of the chip surface was 
achieved using a 30 s injection of 10 mM glycine, pH 1.5 at 30 µL.min-1.  Data was referenced 
by subtraction of the response from the reference flow cell before kinetic fit analysis was 
performed via Biacore Evaluation software using a 1:1 binding fit model.  
 
5.3 Results and Discussion 
5.3.1 HDX-MS 
Hydrogen/deuterium exchange-mass spectrometry (HDX-MS) is a useful method for structural 
characterisation of therapeutic mAbs, as it may potentially generate information regarding 
locations of conformation differences and conformational dynamics of proteins in solution. [1, 
22-27] By monitoring the HDX of a protein’s backbone amide hydrogen for deuterium as a 
function of time, information regarding the protein structure and conformation in solution 
may be deduced. HDX-MS poses a number of significant analytical challenges. Firstly, due to 
the labile nature of the deuterium label, a quenching step must be incorporated into the 
analytical workflow to ensure no back-exchange of deuterium occurs. Frequently, the HDX 
reaction is quenched via a reduction in solution temperature and pH (<pH 3) as other methods 
such as use of organic solvents may be incompatible with biomolecules or with subsequent 
analytical steps. [28-30] Secondly, protein digestion must be performed under quench 
conditions; hence a protease that exhibits activity at low temperature and in low pH 
conditions is required. Pepsin fulfils these criteria, while additionally enabling automation of 
HDX-MS experiments as it is commercially available immobilised on analytical columns. 
However, sequence coverage obtained following MS analyses of peptic digests can be 
suboptimal depending on conditions used (e.g. temperature, exposure time, enzyme-protein 
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ratio) and most importantly on the protein itself. [31] Unlike other frequently used proteases 
for sample preparation prior to MS analyses (e.g. Trypsin, Lys-C, Asp-N) pepsin does not cleave 
with high specificity. [31, 32] Although pepsin tends to cleave after bulky hydrophobic amino 
acid residues (e.g. phenylalanine), the digestion pattern of pepsin is reportedly most 
influenced by the molten globule conformation of a protein in acidic conditions. [31] Various 
approaches to improving sequence coverage achievable have been reported, including the use 
of denaturants (e.g. guanidine hydrochloride) and reducing agents (e.g. TCEP), and increasing 
back pressure to facilitate enhanced digestion efficiency. [30, 33] In this study, HDX-MS was 
employed for the comparative structural evaluation of anti-IL8 IgG1 following production using 
a variety of bioprocessing conditions frequently used in therapeutic Chinese hamster ovary 
(CHO) cell culture (described in Chapter 2). Conformational changes in protein therapeutics 
are reportedly triggered by a variety of factors including chemical modification, thermal or pH 
denaturation and mutation caused by disparities in bioprocessing and may occur with or 
without a change in primary structure. [9] Hence, by determination of protein high order 
structure for each anti-IL8 IgG1 sample produced, potential changes to mAb tertiary structure 
caused by alterations in bioprocessing may be deduced. For each mAb sample analysed, 
triplicate HDX samples were prepared for each time-point, digested and separated using a 
short chromatographic gradient before undergoing MSE analysis, as described in Section 5.2.2. 
Data generated was subsequently analysed for determination of changes to the mass of 
peptides in samples exposed to deuterated buffer for increasing periods of time. Peptides 
found to have exchanged deuterium in place of hydrogen atoms produced a MS spectrum 
showing distinctive mass shifts corresponding to the levels of deuterium incorporated into 
each peptide, as shown in Figure 5.2. 
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Figure 5.1: Typical HDX-MS workflow, adapted from [30]. Proteins in solution at room 
temperature are diluted in excess deuterated solution and HDX is allowed to occur for a 
specified amount of time before the reaction is quenched in a low pH denaturation buffer. 
Protein sample is then injected into a pepsin column for low temperature digestion. Resultant 
peptides are separated using a fast separation gradient and detected via mass spectrometry. 
Finally the mass shift of analysed peptides due to deuterium uptake is determined and 
information regarding higher order structure of the protein may be deduced. 
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Figure 5.2: Deuterium uptake chart for FPPKPKDTLM (low temperature mAb - one MS 
spectrum from each time-point only is shown for brevity). Each IgG1 sample analysed was 
exposed to deuterated buffer for different lengths of time ranging from 0 to 240 minutes, 
before undergoing proteolysis and MS analysis. MS spectra corresponding to the same peptide 
(FPPKPKDTLM) determined in the same sample that had been exposed to deuterated buffer 
for various durations are shown. A characteristic mass shift is observed in the spectra 
following HDX corresponding to the increased peptide mass, resulting from the replacement 
of the peptide’s backbone amide hydrogen atoms with deuterium. 
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Initial experiments resulted in poor mAb digestion efficiencies for samples analysed (~65% 
sequence coverage for mAb light chain, ~70% sequence coverage for mAb heavy chain). To 
ensure as broad coverage as possible for the mAb samples studied, optimisation of the 
experimental platform was achieved by increasing the TCEP concentration of the quench 
buffer from 50 M to 200 M, increasing the digestion temperature from 15oC to 20oC and by 
placing a BEH C18, 1.7 µm, 2.1 x 50 mm analytical column on the UPLC waste line for the 
purposes of increasing back-pressure to the pepsin column. Following these modifications the 
sequence coverage achievable was increased to >72% for mAb light chain and >83% for mAb 
heavy chain. Similar peptides were generated across all experiments, showing reproducible 
peptic digestion profiles for anti-IL8 IgG1 within different sample preparations; sequence 
coverage maps displaying peptides produced are shown in Figures 5.3 to 5.5. In each 
experiment, a minimum of 147 peptic peptides were unambiguously identified with a 
maximum redundancy of 4.12, representing a minimum of 72.6% of the total light chain and 
81.2% of the total heavy chain amino acid sequence for anti-IL8 IgG1.  
 
 
Figure 5.3: Peptic peptides identified across all experiments for anti-IL8 IgG1 produced at 
standard conditions, 110% DO and 60% DO in mAb A. light chain and B. heavy chain. Each 
peptide is represented by a blue bar. 
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Figure 5.4: Peptic peptides identified across all experiments for anti-IL8 IgG1 produced at 
standard conditions, pH 7.2 and pH 6.8 in mAb A. light chain and B. heavy chain. Each peptide 
is represented by a blue bar. 
 
Figure 5.5: Peptic peptides identified across all experiments for anti-IL8 IgG1 produced at 
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standard conditions, 32.0oC and 39.5oC in mAb A. light chain and B. heavy chain. Each peptide 
is represented by a blue bar. 
 
The relative fractional uptake of deuterium for peptides produced from mAb cultures from 
each study (i.e. DO, pH and temperature study cultures) at each time-point was determined by 
comparison of the centroid mass from peptides produced at each time-point to the mass of 
un-deuterated peptide ions. To evaluate deuterium incorporation in different parts of the mAb 
structure, heat maps and mirror plots showing the relative fractional uptake of deuterium for 
a particular peptide as a function of time were generated. Figures 5.6 to 5.8 show 
corresponding heat-maps for each study. Peptides that are enclosed within the protein 
structure and therefore, not exposed to deuterium do not undergo HDX and, hence, do not 
exhibit an increase in relative fractional uptake for deuterium over-time. Conversely peptides 
on the outer part of the mAb higher order structure readily exchange their backbone amide 
hydrogen atoms for deuterium and thus display a high deuterium fractional uptake relative to 
un-deuterated samples. Finally, peptides that are partially exposed to the deuterated buffer 
undergo a slower rate of HDX and hence produce a relative fractional uptake profile wherein 
the uptake of deuterium is observed to increase as a function of time. Heat maps 
corresponding to anti-IL8 produced in each study clearly visualise the regions of the mAb that 
are encased within the protein structure as these show poor uptake of deuterium overall the 
time-points analysed, appearing as green in the heat maps, whereas portions of IgG1 that 
comprise the outer part of the structure readily incorporate deuterium across the time-points 
and are displayed in red. Portions of mAb that are partially enclosed within the mAb higher 
order structure display increased deuterium uptake over time, displayed as changing colour 
over time according to the scale shown in the corresponding figures. 
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Figure 5.6: Relative fractional uptake of deuterium for A. light chain and B. heavy chain anti-
IL8, produced under standard (85% DO), low DO (60% DO) and high DO (110% DO) bioprocess 
conditions. 
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Figure 5.7: Relative fractional uptake of deuterium for A. light chain and B. heavy chain anti-
IL8, produced under standard (pH 7.0), low pH (pH 6.8) and high pH (pH 7.2) bioprocess 
conditions. 
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Figure 5.8: Relative fractional uptake of deuterium for A. light chain and B. heavy chain anti-
IL8, produced under standard (37.0oC), low temperature (32.0oC) and high temperature 
(39.5oC) bioprocess conditions. 
Figures 5.9 to 5.14 show mirror plots depicting the average relative fractional uptake for heavy 
or light chain mAb from each condition compared to standard mAb that was produced during 
the same production run. In all mirror plots the horizontal axis denotes each peptide, shown 
as differentially coloured dots each colour representing the duration of HDX as shown in the 
accompanying legend, sorted in ascending order from the N-terminus to the C-terminus for 
each mAb chain. Distance from the mid-point represents increased deuterium uptake, 
described as the ratio of the mass of the deuterated peptide relative to the mass of the 
corresponding un-deuterated sample. The grey area depicts the standard deviation for relative 
fractional uptake for each peptide across all time-points. 
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Figure 5.9: Mirror plot showing the relative fractional uptake for mAb heavy chain from 
samples produced using standard and altered bioprocess conditions of pH 6.8. 
 
Figure 5.10: Mirror plot showing the relative fractional uptake for mAb light chain from 
samples produced using standard and altered bioprocess conditions of pH 6.8. 
 
Figure 5.11: Mirror plot showing the relative fractional uptake for mAb heavy chain from 
samples produced using standard and altered bioprocess conditions of pH 7.2. 
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Figure 5.12: Mirror plot showing the relative fractional uptake for mAb light chain from 
samples produced using standard and altered bioprocess conditions of pH 7.2. 
 
Figure 5.13: Mirror plot showing the relative fractional uptake for mAb heavy chain from 
samples produced using standard and altered bioprocess conditions of 39.5oC. 
 
Figure 5.14: Mirror plot showing the relative fractional uptake for mAb light chain from 
samples produced using standard and altered bioprocess conditions of 39.5oC. 
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Figure 5.15: Mirror plot showing the relative fractional uptake for mAb heavy chain from 
samples produced using standard and altered bioprocess conditions of 32.0oC. 
 
Figure 5.16: Mirror plot showing the relative fractional uptake for mAb light chain from 
samples produced using standard and altered bioprocess conditions of 32.0oC. 
 
Figure 5.17: Mirror plot showing the relative fractional uptake for mAb heavy chain from 
samples produced using standard and altered bioprocess conditions of 110% DO.  
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Figure 5.18: Mirror plot showing the relative fractional uptake for mAb light chain from 
samples produced using standard and altered bioprocess conditions of 110% DO. 
 
Figure 5.19: Mirror plot showing the relative fractional uptake for mAb heavy chain from 
samples produced using standard and altered bioprocess conditions of 60% DO. 
Figure 5.20: Mirror plot showing the relative fractional uptake for mAb light chain from 
samples produced using standard and altered bioprocess conditions of 60% DO. 
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Finally, to determine whether the relative fractional uptake of each peptide was changed 
between mAb produced at standard conditions and mAb produced under conditions of altered 
bioprocessing, the difference in deuterium incorporation for peptides in comparative samples 
were determined and used to prepare difference index plots as shown in Figures 5.21 to 5.23. 
The differential value for each peptide (shown along x-axis) for each HDX reaction was 
calculated by subtracting the deuterium uptake value of the altered bioprocessing sample 
from that of the mAb produced under standard bioprocess conditions. The summed difference 
for all HDX time-points for all peptides are signified by the vertical grey bars in each difference 
index plot. Criteria for determining statistically significant HDX differences between the 
peptides from altered bioprocessing and standard mAb samples were evaluated as described 
previously. [25] The standard deviation (SD) of summed difference values for each peptide 
across different experiments was determined and averaged; 3 × average SD was set as the 
difference limit for significance determination. As the average SD of summed difference values 
for each peptide was calculated to be 0.37 Da, the limit outside of which difference values 
were deemed to be significant was set as ±1.1 Da (represented by dashed lines in Figures 5.21 
to 5.23). Positive difference index values signify increased HDX in anti-IL8 IgG1 samples 
produced under altered bioprocessing conditions compared to samples produced under 
standard conditions, while negative values represent decreased relative HDX for altered mAb 
samples. For each of the samples determined no distinct regions were found to be significantly 
changed in mAb produced under altered bioprocessing conditions compared to mAb produced 
at standard conditions. However, a number of individual peptides, detailed in Table 5.1, 
displayed alterations in deuterium uptake which were found to be different based on the 
significance criteria applied. Three of the seven peptides identified as having altered 
conformation within the mAb higher order structure, across all experiments, were found to 
incorporate amino acids previously determined to contain sequence-level modifications 
(Chapter 3). However, those regions of the mAb that were found to contain both alterations to 
the the mAb structure and also a primary sequence modification were identified solely on the 
light chain of anti-IL8 IgG1 samples produced under low temperature conditions of 32.0oC. 
Interestingly, three peptides determined for mAb heavy chain for anti-IL8 IgG1 produced at 
32.0oC displayed altered deuterium uptake but were not correlated with having sequence-
level modifications. However, the low temperature mAb sample was found to exhibit the 
greatest changes to levels of modified amino acids when compared to other samples analysed. 
Thus, it is possible that changes in protein conformation, may not necessarily result from 
changes to protein primary sequence at the site of conformational change, but may be an 
outcome of modifications to adjacent or spatially close sequence-level modifications.  
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Table 5.1: Peptides displaying altered deuterium uptake compared to standard mAb samples 
analysed and related peptide modifications identified. 
Sample mAb  
Chain 
Peptide Position Peptide 
Modification 
Low T mAb Light HWYQQKPGKAPKLLI H39-I53 Oxidation W40 
High pH mAb Light AKVQWKVDNALQSGNSQE A149-E166 Oxidation W153, 
Deamidation N157, 
Deamidation Q160, 
Deamidation Q163 
High DO mAb Heavy  VQSGGGLVQPGGS V5-S17 n/a 
Low DO mAb Heavy  TLSRDNSKNTAY T69-Y80 Deamidation N74, 
Deamidation N77 
Low T mAb Heavy  VSWNSGALTSGVHTFPAVL V161-L179 n/a 
Low T mAb Heavy  NSGALTSGVHTFPAVL N164-L179 n/a 
Low T mAb Heavy  TVDKSRWQQGNVFSCSVM T416-M433 n/a 
 
It has been been widely reported that changes to a the higher order structure of a therapeutic 
protein have the potential to alter the safety, potency and efficiacy characteristics of that 
protein by reducing or inhibiting accessibility to mAb binding sites. [23, 25, 26, 34] Hence for 
IgG1, sequence or structural modificiations of CDRs or the highly conserved CH3 domain, 
responsible for FcRn binding, may have a profound effect on the physiological activities of 
therapeutic mAbs. Changes in the primary sequence or higher order structure may allude to 
alterations in the physiological activity of a therapeutic mAb, however, to confidently assess 
the impact of these CQAs to protein activity determination of the functional activity must be 
performed.  
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Figure 5.21: Difference index plots showing differences in deuterium uptake between 
standard mAb and A. high temperature mAb heavy chain, B. high temperature mAb light 
chain, C. low temperature mAb heavy chain and D. low temperature mAb light chain. 
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Figure 5.22: Difference index plots showing differences in deuterium uptake between 
standard mAb and A. high temperature mAb heavy chain, B. high temperature mAb light 
chain, C. low temperature mAb heavy chain and D. low temperature mAb light chain. 
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Figure 5.23: Difference index plots showing differences in deuterium uptake between 
standard mAb and A. high DO mAb heavy chain, B. high DO mAb light chain, C. low DO mAb 
heavy chain and D. low DO mAb light chain. 
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5.3.2 SPR Analysis Using Biacore 
Surface plasmon resonance (SPR) enables the elucidation of alterations in the binding 
capabilities of proteins by measuring the affinity, or rate of association and dissociation, of a 
protein to a target antigen which has been immobilised onto a gold-plated sensor chip. 
Conversely, a protein may be captured onto a surface and the rate of an antigen binding to the 
protein determined. By measuring changes in reflected polarised light following protein-
antigen binding, changes to binding characteristics may be assessed. Anti-IL8 IgG1 is 
pharmacologically active due to its ability to bind to interleukin-8 facilitating its removal from 
the body, and to bind to the neonatal Fc receptor, ensuring extended serum half-life in 
humans. Both of these features were evaluated to assess changes to the functional 
characteristics of anti-IL8 IgG1 following production under conditions of altered bioprocessing. 
 
5.3.2.1 Determination of FcRn-Anti-IL8 IgG1 Binding for Anti-IL8 IgG1 Produced Using 
Altered Bioprocessing 
FcRn is a heterodimeric protein consisting of a major histocompatibility complex class 1-like 
protein and a β2-microglobulin subunit. [13, 16] It is expressed by endothelial, epithelial and 
myeloid cells, which internalise serum constituents including mAbs from the blood stream by 
pinocytosis. [13] FcRn binds with high affinity to the Fc domain of IgG1 at the highly conserved 
CH2-CH3 region in a strictly pH dependent manner, resulting in a 2:1 stoichiometry. [11, 16, 35] 
The pH dependent nature of the interaction enables the FcRn-mediated protection of IgG1 
from intracellular degradation by binding to the receptor within the acidic endosomal 
environment. Subsequently, FcRn facilitates the recycling of IgG to the cell surface and release 
into the blood stream for re-circulation. As FcRn is strongly correlated with serum half-life of 
IgG1 in-vivo, it is frequently used during drug development for in-vitro assessment of the 
pharmacokinetic capabilities of therapeutic mAbs. [12] Additionally, lab-based evaluation of 
the effects of primary sequence modifications on IgG-FcRn binding affinities have been 
studied, e.g. charge heterogeneity was found to have little or no effect on IgG1-FcRn binding, 
[36] whereas methionine oxidation in mAb CH2-CH3 regions significantly reduced IgG1-FcRn 
binding. [34, 37] In the current study, determination of FcRn binding affinity to anti-IL8 IgG1 is 
used to assess changes to the functional capabilities of mAb that has been produced under 
conditions of altered pH, temperature and DO. Using multi-cycle affinity SPR analysis, FcRn 
was immobilised onto a Biacore CM5 chip before passing over different concentrations of anti-
IL8 IgG1. The affinity constants (KD) for each triplicate analysis of the IgG1-FcRn binding 
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interaction were determined and are reported in Table 5.2. Increasing KD values signify low 
affinity and hence weak binding interactions. Corresponding sensograms and steady state fit 
graphs for triplicate analysis of mAb samples produced under standard and altered 
bioprocessing conditions are shown in Figures 5.24 to 5.28. 
 
Table 5.2: Dissociation constants determined following SPR binding affinity analysis of anti-IL8 
IgG1 and FcRn. 
 Anti-IL8 sample Analysis 1 - KD (nM) Analysis 2 - KD (nM) Analysis 3 - KD (nM) 
Low DO mAb  697.6 736.2 677.9 
High DO mAb 742.2 728.4 687.7 
Low pH mAb  675.2 704.2 665.7 
High pH mAb  695.1 703.0 725.0 
Low T mAb  819.1 807.0 858.2 
High T mAb  739.7 718.2 712.8 
Standard 1 694.8 675.0 756.1 
Standard 2 691.8 699.5 680.8 
Standard 3 686.2 738.0 698.0 
 
A box-plot depicting the binding affinity values determined for each IgG1 sample analysed is 
displayed in Figure 5.29. A distinct difference in the binding affinity for anti-IL8 IgG1 produced 
at 32.0oC compared to mAb expressed in CHO DP-12 culture using all other parameters 
investigated was observed. It is possible that a correlation between the reduction in FcRn 
binding affinity and heavy chain conformational changes for mAb produced at 32.0oC may 
exist. Furthermore, primary sequence modifications determined for mAb produced at 32.0oC 
may also play a role in the reduced FcRn affinity for this IgG1 sample. Anti-IL8 IgG1 produced 
at 32.0oC was determined to have a higher proportion of oxidised methionine-257 when 
compared to other mAb samples analysed (Chapter 3). This would appear to correlate with the 
findings of Bertolotti-Ciarlet et al. and Pan and colleagues, who associated a reduction in FcRn 
binding affinity with methionine oxidation on mAb heavy chain. [37, 38]  
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Figure 5.24: Sensograms and residual plots from triplicate affinity analysis of FcRn binding to 
anti-IL8 IgG1 produced in cell culture maintained at 110% DO (A-C) and 60% DO (D-F). 
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Figure 5.25: Sensograms and residual plots from triplicate affinity analysis of FcRn binding to 
anti-IL8 IgG1 produced in cell culture maintained at 39.5oC (A-C) and 32.0oC (D-F).
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Figure 5.26: Sensograms and residual plots from triplicate affinity analysis of FcRn binding to 
anti-IL8 IgG1 produced in cell culture maintained at pH 7.2 (A-C) and pH 6.8 (D-F). 
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Figure 5.27: Sensograms and residual plots from triplicate affinity analysis of FcRn binding to 
anti-IL8 IgG1 produced in cell culture maintained at standard conditions: standard 1 (A-C), 
standard 2 (D-F). 
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Figure 5.28: Sensograms and residual plots from triplicate affinity analysis of FcRn binding to 
anti-IL8 IgG1 produced in cell culture maintained at standard conditions: standard 3 (A-C). 
 
 
Figure 5.29: Box-plot showing FcRn binding dissociation constants determined for anti-IL8 IgG1 
produced using different bioprocessing conditions of pH, DO and temperature (T). 
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5.3.2.2 Determination of Binding Kinetics for Interleukin-8 and Anti-IL8 IgG1 Produced Using 
Altered Bioprocessing Conditions 
Having assessed the binding affinity to its cellular receptor FcRn, changes to the binding 
affinity of anti-IL8 IgG1 following production under altered bioprocess conditions to the target 
antigen interleukin-8 were assessed. In this instance a single-cycle SPR analysis approach was 
used, wherein the anti-IL8 samples under study were captured onto a Protein a SPR chip 
before the introduction of interleukin-8 for determination of binding affinity. Affinity 
constants determined following single-cycle SPR analysis of anti-IL8 IgG1 and interleukin-8 
binding kinetics are displayed in Table 5.3. Corresponding sensograms and residual plots for 
each analysis are shown in Figures 5.30 to 5.34. Finally, box-plots depicting the data displayed 
in Table 5.3 are presented in Figure 5.35. The box plot shows a slight decrease in the binding 
affinity of anti-IL8 IgG1 produced in culture maintained at 110% DO. It is possible that this 
change in binding affinity may be related to a change in the conformation of the mAb heavy 
chain adjacent to the CDR1 region, observed for the anti-IL8 sample produced at 110% DO. An 
observed increase in the proportion of oxidised tryptophan-40 residues, located close to the 
CDR1 and CDR2 regions of the light chain for this sample, may also potentially have 
contributed to the altered binding affinity of anti-IL8 IgG1 to interleukin-8. 
 
Table 5.3: Affinity constants obtained following single-cycle SPR analysis of anti-IL8 IgG1 and 
interleukin-8 binding kinetics. 
 Anti-IL8 sample Analysis 1 - KD (nM) Analysis 2 - KD (nM) Analysis 3 - KD (nM) 
Low DO mAb  18.0 19.4 17.9 
High DO mAb 27.3 28.7 25.4 
Low pH mAb  17.2 17.5 17.6 
High pH mAb 21.1 20.4 18.7 
Low T mAb  19.5 22.4 20.8 
High T mAb 18.2 18.0 16.5 
Standard 1 21.5 21.8 20.3 
Standard 2 22.4 23.4 22.5 
Standard 3 22.2 22.8 21.0 
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Figure 5.30: Resulting Sensograms and residual plots from triplicate affinity analysis of 
interleukin 8 binding to anti-IL8 IgG1 produced in cell culture maintained at 39.5oC (A-C) and 
32.0oC (D-F). 
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Figure 5.31: Resulting Sensograms and residual plots from triplicate affinity analysis of 
interleukin 8 binding to anti-IL8 IgG1 produced in cell culture maintained at pH 7.2 (A-C) and 
pH 6.8 (D-F). 
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Figure 5.32: Resulting Sensograms and residual plots from triplicate affinity analysis of 
interleukin 8 binding to anti-IL8 IgG1 produced in cell culture maintained at 110% DO (A-C) and 
60% DO (D-F).  
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Figure 5.33: Resulting Sensograms and residual plots from triplicate affinity analysis of 
interleukin 8 binding to anti-IL8 IgG1 produced in cell culture maintained at standard 
conditions: standard 1 (A-C), standard 2 (D-F). 
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Figure 5.34: Resulting Sensograms and residual plots from triplicate affinity analysis of 
interleukin 8 binding to anti-IL8 IgG1 produced in cell culture maintained at standard 
conditions: standard 3 (A-C). 
 
 
Figure 5.35: Box-plot showing interleukin-8 binding dissociation constants determined for anti-
IL8 IgG1 produced using different bioprocessing conditions of pH, DO and temperature (T). 
Chapter 5 
198 
 
5.4 Conclusions  
In this Chapter, the effect of altering bioprocess conditions of pH, temperature and DO on the 
structure and function of therapeutic anti-IL8 IgG1 was evaluated. HDX-MS was used for in-
depth structural characterisation of the biomolecule revealing conformational changes to 
some portions of anti-IL8 IgG1 in response to expression in CHO DP-12 culture maintained 
under different bioprocess parameters, namely 32.0oC, pH 7.2, 60% DO and 110% DO. Almost 
half of these observed structural modifications could be aligned with sequence level 
modifications determined previously. Although structural changes at both primary sequence 
level and to the higher order structure may indicate potential variations in therapeutic mAb 
function, to fully characterise the potential effects of altered bioprocessing on the quality of 
the mAb, a functional assessment using SPR analysis was also performed. Following SPR 
analysis to determine mAb binding to FcRn, the cellular receptor responsible for re-circulation 
of mAb in the body and hence serum half-life of mAbs, variations in the binding affinities of 
FcRn and mAb produced at 32.0oC were determined. These results indicate a possible 
reduction in serum half-life for anti-IL8 IgG1 produced at 32.0oC and may be potentially related 
to conformational changes and primary sequence changes observed for this mAb sample. 
Additional SPR analysis to assess the binding characteristics of anti-IL8 IgG1 produced using 
different bioprocessing conditions to the target antigen interleukin-8 revealed an observed 
change in binding affinity for mAb produced using 110% DO content of culture media. Despite 
scope for improvement, in particular for HDX digestion efficiency, these two techniques 
epitomise powerful analytical tools that may be applied for comparability assessment of 
biosimilars or to determine changes to function, efficacy and safety of protein 
biopharmaceuticals in response to changes in production. Furthermore, the combined results 
highlight the need for multiple analytical strategies to fully evaluate changes to recombinant 
protein products in response to manufacture changes.  
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6.0  
Identification and Quantitation of 
Bioprocess-related Host Cell Protein 
Impurities following Downstream 
Processing of Therapeutic Monoclonal 
Antibodies 
 
6.1 Introduction 
Monoclonal antibodies (mAbs), the largest class of recombinant biotherapeutic proteins 
currently marketed, are secreted from host cells during fermentation and subsequently 
purified using an optimised downstream processing (DSP) platform. Host cell proteins (HCPs) 
may be co-purified with therapeutic mAbs and hence are considered as a major class of 
bioprocess-related impurities and categorised as a critical quality attribute in the International 
Conference on Harmonisation (ICH) guideline Q11 - Development and manufacture of drug 
substances. [1] Due to their potential impact on drug product safety, including their potential 
to cause adverse events or antigenic effects in patients, it is a regulatory requirement to 
remove these impurities from therapeutic mAb products to below detectable levels when 
measured using highly sensitive analytical methods. [2][3] As HCPs have a diverse range of 
immunological and physiochemical properties, downstream processing (DSP) of mAbs requires 
multiple orthogonal purification steps, often comprised of Protein A affinity capture followed 
by additional chromatographic polishing. [4, 5] Protein A chromatography is capable of 
removing >98% of HCPs directly from the product stream and hence has become a standard 
component of downstream processing platforms for monoclonal antibodies and Fc fusion 
proteins. HCPs that are not removed via Protein A affinity chromatography have been shown 
to be retained due to their interaction with bound mAb rather than association with the 
Protein A resin itself. [6] The concentration and composition of HCPs in the harvest stream has 
been shown to be dependent on the host cell line and culturing process, cell viability at the 
time of harvest, the choice of downstream processing techniques and on the sequence of mAb 
under production. [4, 7-11] Considerable work has been undertaken to develop robust and 
sensitive analytical methods for HCP detection and quantitation due to the importance in 
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detecting HCPs during process development, biopharmaceutical production and in the final 
drug product. 
The HCP content of in-process and final mAb drug product samples are typically quantified 
using anti-HCP enzyme-linked immuno-sorbent assays (ELISA). However, as the generation of 
antibodies used for ELISA is dependent on the immune response of the species used for anti-
HCP antibody generation, HCPs that do not provoke an immune response or that produce a 
low immune response may not be detected. [9] Nevertheless, anti-HCP ELISA is highly 
sensitive (1-100 ppm) and is recommended by regulatory agencies for quantitation of total 
HCP content within in-process samples and in final drug product. [12] While quantitative 
information of the total HCP content provided by ELISA analysis is currently acceptable for lot-
release, it does not provide any information on the profile or properties of HCPs, which may 
be used for process design improvement. Hence methods that facilitate identification of 
individual HCPs have gained prominence in recent years, most notable those incorporating 
mass spectrometry-based detection. Two dimensional gel electrophoresis (2-DE) with 
subsequent mass spectrometry-based protein identification has been used to determine HCPs 
present in products produced by different CHO cell lines.[6, 13-15] While more recently, LC-
MS techniques have been applied to evaluate the clearance of HCPs from the process stream 
following various downstream processing steps. [16-18] 
Quantitative proteomic approaches involving liquid chromatography coupled to mass 
spectrometry (LC-MS) operated in the data dependent acquisition (DDA) mode are widely 
used for detection of proteins in complex biological mixtures. However, as mAb concentration 
in biopharmaceutical samples are typically more than three orders of magnitude greater than 
HCP species, low intensity HCP peptides are not selected for fragmentation by DDA due to the 
intensity bias of the mAb peptides. Consequently, data independent acquisition (DIA) modes, 
such as multiplexed data acquisition (MSE), have proven to be more suitable for the detection 
and quantitation of low abundance HCPs. [3, 19-22] The use of multidimensional 
chromatographic separation methods, in conjunction with MSE detection allows for the 
analysis of a broad dynamic range of proteins [23] and when combined with label free Hi3 
quantitation, [24] LC-MSE represents a powerful approach for the quantitative analysis of 
HCPs. [19] Unlike alternative proteomic methods for HCP analysis that require the 
incorporation of a HCP enrichment step, [3, 25, 26] the 2D-LC-MSE method has the added 
advantage of enabling the analysis of HCPs in the presence of the biotherapeutic protein 
product.  
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In this study, we applied an offline 2D-LC-MSE proteomic platform with Hi3 quantitation to 
evaluate the suitability of four different elution buffers for the removal of HCPs from mAb 
samples following Protein A purification. In the first dimension a high pH reversed-phase HPLC 
method was used to generate a peptide map. Collected fractions were subsequently further 
separated using low pH reversed-phase nano-LC with hyphenated MS detection operated in 
the data independent MSE mode. The effect of elution buffer choice on the quality of the 
therapeutic protein was evaluated by determination of critical quality attributes (CQAs) 
including aggregation profile, charge variant analysis and N-glycosylation analysis. In addition, 
the developed proteomic platform was used to investigate the impact of the time of cell 
culture harvest on the HCP repertoire of a therapeutic protein following Protein A purification. 
Subsequently, the incorporation of additional DSP procedures to compliment Protein A 
purification in removing HCPs from the product stream was evaluated.  
 
6.2  Experimental 
6.2.1  Reagents and Consumables 
Dithiothreitol (DTT),  Iodoacetamide (IAA), Acetonitrile, Formic acid, Triethylammonium 
bicarbonate (TAB), Ammonium hydroxide, Sodium acetate, Trisodium citrate dehydrate, L-
arginine, Phosphate buffered saline, [Glu1]-Fibrinopeptide B, Trifluoroacetic acid (TFA), Sodium 
hydroxide (NaOH), Acetone, Acetic acid, Trichloroacetic acid (TCA), Ammonium Bicarbonate, 
Sodium chloride (NaCl), dimethyl sulfoxide (DMSO), 2-aminobenzamide (2-AB), Sodium 
Cyanoborohydride, Phosphate Buffered Saline (PBS), Sodium phosphate monobasic dihydrate 
(NaH2PO4 · 2H2O) and Sodium phosphate dibasic heptahydrate (Na2HPO4 · 7H2O) were 
purchased from Sigma Aldrich and were ACS reagent grade or better (Wicklow, Ireland).  
Water, 0.1 % formic acid (LC-MS Optima), Acetonitrile, 0.1 % formic acid (LC-MS Optima) and 
Water, 0.1 % TFA (LC-MS Optima) were obtained from Fisher Scientific (Dublin, Ireland).  pH 
gradient buffers CX-1, pH gradient buffer A (pH 5.6) and CX-1, pH gradient buffer B (pH 10.2) 
were acquired from Thermo Scientific. Promega sequencing grade modified trypsin was from 
MyBio Ltd. (Kilkenny, Ireland). New England Biolabs Glycerol Free PNGase F, (exoglycosidase 
enzymes) were purchased from Brennan and Co. (Dublin, Ireland). Glycine was obtained from 
USB Corporation (Ohio, USA). A BioRad QuickStartTM Bradford Protein Assay Kit with Bovine γ-
globulin standard sets was acquired from Fannin Ltd. (Dublin, Ireland). A CHO HCP ELISA kit 
was purchased from Cygnus Technologies (North Carolina, USA). 100% Acetic acid (AnalaR 
NORMAPUR) was from VWR (Dublin, Ireland). RapiGest SF surfactant and Hi3 E. coli standard 
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peptides were purchased from Waters (Dublin, Ireland). New Objectives Silica Tip Pico Tip 
emitters were obtained from Aquilant scientific UK Ltd. (Hampshire, UK).  
 
6.2.2  Cell Culture 
A Chinese hamster ovary cell line (CHO DP-12 clone#1934 [CHO DP-12, clone#1934 aIL8.92 NB 
28605/14] (ATCC® CRL-12445TM) producing recombinant human anti-interleukin 8 IgG1 
antibody, mAb1, was purchased from LGC standards (Middlesex, UK) and adapted to grow in 
serum-free suspension culture. CHO DP-12 cells were grown in 200 mL (shake flask, 125 rpm) 
of Excell 325 PF CHO serum-free cell culture medium (Sigma Aldrich) supplemented with 10 
mg.L-1 recombinant human Insulin (Sigma Aldrich), 1 µM Methotrexate (Sigma Aldrich), 4 mM 
L-glutamine (Biosciences) and 20,000 Units of Penicillin-Streptomycin (Fisher Scientific) at 
37 °C (5% CO2). Viability and viable cell density were measured using the trypan blue exclusion 
method and a haemocytometer. Culture supernatant was obtained by centrifuging the cell 
suspension (4000 rpm, 5 minutes) and was stored at -30oC pending further analysis. 
 
6.2.3  IgG Purification 
6.2.3.1 Protein A Affinity Chromatography 
Aliquots of cell culture supernatant were clarified prior to Protein A purification by sequential 
filtration through 0.45 µm and 0.2 µm syringe filters (VWR). Samples were then purified via 
Protein A chromatography using a 1 mL HiTrap Protein A column (GE Healthcare). Samples of 
clarified media were passed through the Protein A column at a flow rate of 1 mL.min-1 and 
subsequently washed with PBS to ensure complete removal of all un-retained material. Elution 
of mAb1 from the Protein A column was performed using one of four buffers, namely 100 mM 
sodium acetate, pH 3.5; 100 mM glycine, pH 3.5; 100 mM citrate, pH 3.5 or 100 mM arginine, 
pH 3.5. The pH of eluate, collected in Amicon Ultra centrifugal filter units with a 10 kDa cut-off 
membrane (Sigma Aldrich), was neutralized using 0.5 M Tris and buffer-exchanged into PBS 
(4,000 rpm for 20 min). An aliquot of the concentrated and buffer exchanged mAb1 sample 
was assayed for IgG content using the Bradford assay, wherein samples were diluted 50-fold 
with Bradford reagent and incubated for 30 minutes at room temperature before recording 
the sample absorbance using a spectrophotometer at 595 nm. Sample concentration was 
calculated using a standard curve prepared from BSA standards of known concentration 
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prepared at the same time The remainder of the samples were stored at -30oC pending further 
analysis. 
 
6.2.3.2 Multimodal Chromatography Purification via CaptoTM Adhere ImpRes 
Following Protein A purification, 2 mg of mAb1 was further purified using a multimodal strong 
anion exchange resin, CaptoTM adhere ImpRes (GE Healthcare), operating in flow-through 
mode. Following sample application, the column was washed with PBS until mAb1 had fully 
eluted from the column. Adsorbed material was eluted using 100 mM acetic acid, pH 3.0. The 
flow-through mAb1 was collected in Amicon Ultra 10 kDa centrifugal filter units (Sigma 
Aldrich) and centrifuged (4,000 rpm for 20 min). An aliquot of mAb1 sample was assayed for 
IgG content using the Bradford assay. The remainder of the sample was stored at -30oC 
pending further analysis.  
 
6.2.4  High pH- Low pH 2D-LC-MSE Analysis of HCPs 
1 mg of mAb was denatured with 0.1% (w/v) Rapigest, reduced with 5 mM DTT for 60 minutes 
at 20oC, alkylated with 15 mM IAA for 30 minutes at 20oC in darkness and enzymatically 
digested overnight (37 oC) with trypsin using a 1:50 (w/w, enzyme: protein) ratio. Following 
digestion the Rapigest surfactant was hydrolysed by the addition of an equal volume of 1% 
(v/v) formic acid in 10% acetonitrile. Samples were incubated for 10 minutes at 20oC and 
centrifuged (10 minutes, 16,000 x g) for removal of the insoluble constituent of the hydrolysed 
Rapigest. The supernatant was reduced to dryness via vacuum centrifugation. 
Dried peptides were reconstituted in 500 µL of 0.1% formic acid and analysed using a Waters 
2695 Alliance HPLC instrument with UV detection for first dimension separation. Peptide 
separations were performed on a Waters XBridge BEH 130 C18 3.5 µm 2.1 x 150 mm analytical 
column using a binary gradient of 20 mM ammonium formate in water, pH 10 (A) and 20 mM 
ammonium formate in 90% acetonitrile, pH 10 (B). Gradient conditions were as follows: 3% B 
initially for 2 minutes, increased to 10% B in 2 minutes with a further increase to 45% B over 
33 minutes followed by a final increase to 100% B in two minutes with a two minute isocratic 
hold. Initial conditions were restored in one minute and held for an additional 10 minutes to 
ensure column re-equilibration. The column temperature was maintained at 40oC and the flow 
rate was 200 µL.min-1. Sample fractions were collected at minute intervals over the course of 
the gradient and subsequently recombined to 20 samples in such a way as to ensure that 
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resulting samples contained peptides with a range of hydrophobicity and a similar peptide 
concentration, estimated based on UV absorbance at 214 nm. Resulting samples were reduced 
to dryness via vacuum centrifugation. 
A Waters nanoAcquityTM UPLC® instrument equipped with a nanoAcquity UPLC 2G-V/M Trap 5 
µm symmetry C18, 180 µm x 20 mm trapping column and a nanoAcquity UPLC 1.8 µm HSS T3, 
75 µm x 200 mm analytical column was used for the second dimension low pH LC-MS 
separation of peptides. Prior to loading, peptide samples were reconstituted in 1.6 µL 0.1% FA 
and 6.4 µL of 1 pmol.µL-1 Hi3 E. coli standard peptides and loaded onto the trapping column at 
a flow rate of 10 µL.min-1 using 0.1% (v/v) formic acid in water (C) and 0.1% (v/v) formic acid in 
acetonitrile (D). Trapping conditions were maintained at 99.9% C for 5 minutes. Subsequent 
analytical separation of peptides was achieved using the following gradient conditions:  3% D 
initially for 2 minutes, increased to 6% D in 2 minutes with a further increase to 25% D over 88 
minutes followed by a final increase to 85% B in two minutes with a two minute isocratic hold. 
Initial conditions were restored in 11 minutes and held for an additional 15 minutes to ensure 
column re-equilibration. The column temperature was maintained at 30oC throughout and the 
flow rate at 0.3 µL.min-1. Injection volume was 2.5 µL. 
Eluate from the chromatographic system was sampled directly into a Synapt G2 HDMS QTof 
mass spectrometer (Millford, MA, USA) via a NanoLockSprayTM dual electrospray ion source 
equipped with a nanoflow sprayer using 10 ± 1 µm PicoTip emitters. The mass spectrometer 
was operated in positive ion data independent mode with one second sequential low and high 
energy scans in the range of 50 to 2,000 Da. The spray voltage was 3 kV. A collision energy 
ramp from 20 to 45 V was used for the high energy function. Glu-fibrinopeptide (m/z 
785.8426, z=2) was used as lockmass solution, recorded at 30 second intervals. 
Resultant data were processed using ProteinLynx Global Server (PLGS) version 3.0.1. for 
identification and quantitation of HCPs, using the following workflow parameters: automatic 
peptide and fragment tolerances with lockmass correction of all doubly charged masses, 
minimum number of fragment ion matches per peptide = 3, minimum number of fragment ion 
matches per protein = 7, minimum number of unique peptides per protein = 2, primary digest 
reagent trypsin, with maximum number of one missed cleavage, fixed modification: 
carbamidomethyl C, variable modifications: oxidation M and deamidation N, Q, false discovery 
rate maintained at 1% FDR. Data was searched against the Cricetulus griseus, NCBI FASTA 
database (http://www.ncbi.nlm.nih.gov/assembly/GCF_000419365.1/, downloaded 12th June 
2015), appended with Hi3 standard protein sequence (E. coli chaperone protein ClpB) and the 
known mAb sequence. Processing parameters were optimized using Waters PLGS Threshold 
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Inspector software version 2.0. Processed data for each sample fraction were combined using 
the ‘Merge data’ function in PLGS. A minimum of two unique peptides was required for 
protein identification. Three unique peptides were necessary for Hi3 quantitation of individual 
proteins. For each identified protein, PLGS software reported absolute quantitation in terms of 
femtomoles and nanograms of protein in each sample. Given that one milligram of mAb was 
prepared; it was possible to determine the amount of each HCP expressed in nanograms per 
milligram of mAb, i.e. ppm of HCP in mAb sample. 
 
6.2.5 Intact Protein Analysis of mAb Critical Quality Attributes 
MAb critical quality attributes (CQAs) including aggregation profile and charge variant analysis 
were determined using a Waters Acquity H-Class Bio UPLC instrument with UV detection at 
280 nm.  The presence of protein aggregates and higher order structures was determined via 
size exclusion chromatography, SEC-UV, using an Acquity UPLC BEH200 SEC 1.7 µm, 2.1 x 150 
mm (Waters) column under isocratic conditions of 100 mM sodium phosphate buffer, 150 mM 
NaCl, pH 6.8 at 0.3 mL.min-1. Charge variant analysis of intact mAb was performed using a pH 
gradient based separation on a MAbPac SCX-10 RS analytical column, 5 µm, 2.1 x 50 mm 
(Thermo Scientific) using CX-1 pH gradient buffer A, pH 5.6 and CX-1 pH gradient buffer B, pH 
10.2 (Thermo scientific). Elution of sample peaks was achieved using a linear gradient of 37 - 
55% CX-1 pH gradient buffer B, pH 10.2 in 10 minutes.  
 
6.2.6  Glycan Analysis 
50 µg of Protein A purified mAb1 was prepared in 50 mM ammonium bicarbonate, reduced 
with 1 mM DTT for 10 minutes at 65oC and alkylated by incubation with 5 mM IAA at room 
temperature in the dark for 30 minutes. N-glycans were enzymatically released by overnight 
(16 hour) incubation with 500 Units of PNGase F. Following digestion, the mAb was removed 
from solution using ice cold ethanol precipitation. The liquid phase containing the glycans was 
reduced to dryness via vacuum centrifugation. Released glycans were then fluorescently 
derivatised via reductive amination using 5 µL of 0.37 M 2-aminobenzamide (2AB) and 0.95 M 
sodium cyanoborohydride in 30% v/v acetic acid in DMSO at 65oC for two hours. Upon 
completion of the labelling reaction, 10 µL of water and 85 µL of acetonitrile were added to 
the sample. Excess fluorophore was removed by HILIC chromatography using a Thermo 
Ultimate 3000 RS HPLC equipped with an Acquity BEH Glycan analytical column, 1.7 µm, 2.1 x 
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50 mm (Waters). Purified N-glycans were collected and reduced to dryness by vacuum 
centrifugation. 2AB-derivatised N-glycan samples were subsequently reconstituted in 50 µL of 
80% acetonitrile and analysed using a Waters Acquity I-Class UPLC instrument with 
fluorescence detection. Separations were performed using a BEH Glycan, 1.7 µm, 2.1 x 100 
mm analytical column using a gradient of 50 mM ammonium formate, pH 4.5 and acetonitrile, 
70 to 53% acetonitrile at 0.561 mL.min-1 in 15.5 minutes. Column temperature was maintained 
at 40oC. Excitation and emission wavelengths for fluorescence detection were λex = 330 nm 
and λem = 420 nm. Exoglycosidase digestion of N-glycans was performed using an adaption of 
the method described by Royle and co-workers. [27]  
 
6.2.7  Anti-Host Cell Protein ELISA 
HCPs were quantified by ELISA using a CHO HCP ELISA kit (Cygnus technologies) according to 
the high sensitivity protocol recommended by the manufacturer.  Optical density was 
measured using a Perkin Elmer Victor X3 Multi-label plate reader at 450 nm. 
 
6.3 Results and Discussion 
6.3.1 Analytical Platform Performance 
 
Figure 6.1: Schematic of workflow for discovery proteomic analysis of HCPs in biotherapeutic 
protein samples.  
 
A standard schematic of the workflow used for processing of HCP samples is shown in Figure 
6.1. To determine the performance of the proteomic platform, cell culture media containing 
mAb1, HCPs and other contaminants was harvested and processed using Protein A affinity 
chromatography. In total 1 mg of mAb1 was reduced, alkylated and digested with trypsin 
before undergoing offline 2D high pH/low pH reversed phase separation. Unlike previous 
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studies which utilised online 2D-LC-MSE for the analysis of HCPs in biopharmaceutical samples, 
[19, 28] the use of offline high pH separation in the first dimension allows for the generation 
of a high performance peptide map at pH 10. As will be discussed later in this Section, the 
formation of a peptide separation map permits the subsequent investigation of potential sites 
of interaction between HCPs and individual mAb peptides. Following high pH fractionation, the 
sample fractions were combined such that approximately the same amount of peptides was 
contained in each of 20 samples for low pH nano-LC-MSE analysis. As previously noted the use 
of the data independent MSE approach allows us to investigate the HCPs attached to the 
actual therapeutic protein itself, by enabling a broad dynamic range for protein detection and 
by eliminating any selection bias for ions as is characteristic of data dependent MS acquisition 
modes. Due to the complexity of the method, incorporating multi-dimensional separation and 
long run times, the precision of the proteomic method was evaluated in terms of repeatability, 
based on the response of Hi3 standard peptides added to each of the prepared samples. 
Following MS analysis, the peak heights of five Hi3 standard peptides in extracted ion 
chromatograms for each of 20 second dimensional LC-MSE injections across three 
experiments, shown in Figure 6.2, were evaluated using the ANOVA statistical test. Using 
ANOVA it was determined that at 95% confidence level, no significant difference (P-value > 
0.05) in the peak heights of the Hi3 standards was determined across multiple experiments. 
Actual P-values from ANOVA analysis of standard peptide ion peak height in different samples 
and experiments are displayed in Table 6.1. The Hi3 quantitation method was used to ensure 
stringency with the resultant proteomic data, wherein a minimum requirement of three 
unique identified peptides per protein was needed for quantitation. In addition to ensuring 
the accurate quantitation of proteins, previously proven by Silva et al.[24], the necessity for a 
minimum of three unique peptides also ensures specificity of protein identifications. 
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Figure 6.2: Extracted ion chromatogram displaying ion peaks for each of the standard peptides 
used for Hi3 quantitation. 
Table 6.1: Resulting P-values from ANOVA determination of peak heights for each standard 
peptide ion in extracted ion chromatograms analysed. 
Hi3 Standard Peptide 
Sequence 
Average Molecular 
Weight 
m/z P-value 
NNPVLIGEPGVGK 1293.4863 647.38 0.13770 
LPQVEGTGGDVQPSQDLVR 1995.1776 998.54 0.12817 
VIGQNEAVDAVSNAIR 1655.8292 828.47 0.07979 
VTDAEIAEVLAR 1286.4484 643.88 0.55885 
AIDLIDEAASSIR 1373.5266 687.39 0.14309 
 
 
6.3.2 Evaluation of Protein A Elution Buffers on mAb HCP Load 
DSP of mAbs generally involves the use of Protein A affinity chromatography in the first stage 
of the purification process, wherein the mAb is retained and washed at neutral pH and 
subsequently eluted from the Protein A resin by exposure to low pH (2.8-4.0) elution buffers. 
A variety of elution buffers for Protein A purification are frequently used in industry including 
acetate, arginine, citrate and glycine based buffers. [29, 30] The choice of elution buffer and 
also pH and volume of elution buffer form a large portion of DSP development. [31]  
To determine the criticality of the Protein A elution buffer for elimination of HCPs from the 
product stream, the developed proteomic platform was applied to evaluate the effect of 
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different Protein A elution buffers commonly used in DSP on the resulting mAb HCP load. 
Suspension batch culture of CHO DP12 cells expressing a human anti-interleukin 8 IgG1 
antibody, mAb1, was prepared using batch culture as described in Section 6.2.2. Following 
entry into the stationary phase of cell growth, the culture was harvested and subsequently 
divided into four equal volumes of spent media, which were individually filtered and purified 
using HiTrap Protein A affinity chromatography in accordance with the procedure outlined in 
Section 6.2.3.1. For each of the four samples, mAb1 was eluted from the Protein A resin using 
one of the following buffers: 100 mM sodium acetate, pH 3.5; 100 mM arginine, pH 3.5; 100 
mM citrate, pH 3.5 or 100 mM glycine, pH 3.5. Following buffer exchange into PBS, the 
samples were assayed for protein content and analysed for HCP concentration using high 
pH/low pH reversed phase 2D-LC-MSE method described previously. HCPs that were found to 
have co-purified with mAb1 following Protein A chromatography are depicted in Figure 6.3. 
The description and quantity of the HCPs identified in each of the samples is outlined in Table 
6.2.  
 
Figure 6.3: Venn diagram showing the distribution of HCPs identified in mAb samples eluted 
from Protein A resin using various buffers under study. A description of the protein entries 
shown in the Venn diagram may be found in Table 6.2.  
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Table 6.2: Summary of identified HCPs and related concentrations in combined sample sets processed from Protein A resin with different elution buffers. 
List of HCPs identified with >2 unique peptides Concentration of HCP in combined 
sample sets (ppm - ng/mg) 
PLGS protein 
score Range 
Protein 
average 
mass 
(kDa) 
Protein 
Sequence 
Coverage Range 
(%) 
Number 
of 
Peptides 
Identified 
Protein 
Entry 
Protein Description 100 mM 
Acetate 
100 mM 
Arginine 
100 mM 
Citrate 
100 mM 
Glycine 
CH10 10 kDa heat shock protein 
mitochondrial 
ND ND ND * 542.0 11.032 23.53 2 
RL20 60S ribosomal protein L30 ND 44.1 * ND 780.6 - 2090.1 12.955 20.80 - 26.09 2 – 3 
GRP78 78 kDa glucose-regulated protein 73.7 126.3 205.6 ND 419.3 - 503.4 72.550 11.93 - 14.53 7 – 12 
ACTC Actin alpha cardiac muscle 1 * ND ND ND 307.7 42.361 14.59 2 
ACTB Actin cytoplasmic 1 * ND ND 113.7 470.9 - 569.6 42.080 20.27 - 36.27 2 – 11 
ACTG Actin cytoplasmic 2 19.5 ND ND ND 627.4 33.391 17.69 7 
ANXA2 Annexin A2 * ND ND 232.6 396.4 - 771.0 38.946 9.73 - 25.37 2 – 5 
ANXA5 Annexin A5 95.1 ND ND * 346.7 - 536.4 36.122 10.28 - 19.31 2 – 6 
SLPI Antileukoproteinase 1088.3 819.4 3727.5 4528.7 2531.1 - 21214.76 16.745 30.56 - 59.72 4 – 10 
ACTBL Beta-actin-like protein 2 153.0 ND ND ND 257.1 37.484 15.57 5 
CALR Calreticulin 208.1 ND 360.8 380.5 819.7 - 1882.2 48.414 30.46 - 37.41  8 – 13 
CATB Cathepsin B 99.4 ND * 261.1 479.2 - 2732.9 38.417 10.03 - 40.12 2 – 8 
CATD Cathepsin D ND ND ND 951.6 285.7 44.567 7.60 8 
CCL2 C-C motif chemokine 2 ND * * ND 635.6 - 703.7 16.201 5.59 2 
CLUS Clusterin 445.9 ND ND ND 535 52.385 20.58 12 
CXCL3 C-X-C motif chemokine 3 72.7 ND ND * 2258.0 - 3765.8 11.264 40.59 2 - 5  
DLDH Dihydrolipoyl dehydrogenase 
mitochondrial 
* ND ND ND 342.5 54.702 5.89 2 
FIBB Fibrinogen beta chain * ND ND ND 335.0 54.893 3.55 2 
G3PT Glyceraldehyde-3-phosphate 
dehydrogenase 
* ND ND ND 407.4 35.976 6.91 2 
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H12 Histone H1.2 ND ND ND 82 1212.3 21.285 17.92 5 
H13 Histone H1.3 * ND ND ND 1196.2 20.512 17.87 2 
H2B1F Histone H2B type 1-F/J/L ND ND * ND 2297.5 11.158 27.45 2 
H3 Histone H3 ND ND * ND 951.4 24.371 11.93 2 
H4 Histone H4 ND ND * 86.3 782.6 - 1301.0 8.983 24.69 - 37.04 2 – 3 
MFGM Lactadherin ND 207.1 419.6 ND 2639.8 - 3598.1 48.284 43.56 - 52.22 9 – 15 
MMP19 Matrix metalloproteinase-19 * ND 210.0 449.8 462.7 - 584.3 59.170 12.57 - 20.38 2 – 8 
TIMP2 Metalloproteinase inhibitor 2 358.7 298.0 346.9 1583.4 507.5 - 2285.2 27.486 17.62 - 52.46 6 – 9 
PHOCN MOB-like protein phocein isoformX2 627.4 ND ND * 540.8 - 2205.8 32.759 20.28 - 25.17 2 – 8 
NELFE Negative elongation factor E ND ND * ND 755.8 42.788 26.26 2 
NID1 Nidogen-1 3357.9 * ND 2516 308.9 - 744.5 135.143 14.19 - 25.91 2 – 26 
YBOX1 Nuclease-sensitive element-binding 
protein 1 
318.6 ND ND ND 565.7 32.776 31.03 8 
PPIB Peptidyl-prolyl cis-trans isomerase B ND * 85.3 ND 619.8 - 1464.6 23.692 21.76 - 22.22 2 – 6 
PRDX1 Peroxiredoxin-1 * ND ND * 210.0 - 653.6 22.548 9.17 - 16.08 2 
PCOC1 Procollagen C-endopeptidase 
enhancer 
98.8 ND ND 1210 222.8 - 1109.1 51.131 16.45 - 33.55 7 – 11 
PRC2B Proline-rich protein 2-like 1940.1 ND * ND 1310.9 - 1512.2 52.585 62.63 - 63.93 2 - 52 
BROMI Protein Broad minded isoform X3 ND * ND * 374.5 - 415.7 146.423 4.77 - 5.16 2 
S1046 Protein S100-A6 1.4 ND ND ND 1187.4 10.108 61.80 6 
PLBL2 Putative phospholipase B-like 2 * ND ND ND 313.2 65.940 9.40 2 
RCN1 Reticulocalbin-1 * ND ND ND 741.6 19.539 55.76 2 
HTRA1 Serine Protease HTRA1 247.6 781.0 1247.9 2119.5 592.1.2 - 1530.7 48.697 24.94 - 38.98 7 - 13 
 Total concentration  
(ppm - ng HCP/mg IgG) 
9206.2 2275.9 6603.6 14515.2     
 
HCPs identified using a minimum of 2 peptides are denoted by the symbol ‘*’, while undetected HCPs are represented by ‘ND’. 
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A total of 40 individual HCPs were identified across the four samples. The highest overall HCP 
concentration was quantified in the mAb1 sample eluted from Protein A resin with a glycine-
based buffer. This is in agreement with total HCP concentration values obtained following 
sample determination using HCP ELISA, namely 169.36 ppm, 139.21 ppm, 156.45 ppm and 
216.12 ppm for mAb1 processed using acetate-, arginine-, citrate- and glycine-based buffers 
respectively. Although the actual HCP concentration values recovered using ELISA was less 
than those quantified using the 2D-LC-MSE method, the quantified total concentration for 
sample purified using a glycine-based buffer was notably higher for both methods. Deviations 
between results obtained for HCP concentration using ELISA and 2D-LC-MSE methods were 
investigated using CHOPPI, a web based tool for determination of immunogenicity potential of 
CHO proteins. [32] Using CHOPPI, many of the HCPs identified and quantified in mAb samples 
purified with the different buffer systems outlined, were predicted to be immunologically inert 
(immunogenicity score < -20), as shown in Table 6.3. Therefore many of the HCPs identified 
potentially will not illicit an immune response during the generation of antibodies used for 
anti-HCP ELISA. Hence anti-HCP ELISA may underestimate the total concentration of HCPs in a 
mAb samples.  
In the remaining samples eluted from Protein A resin using acetate, arginine and citrate-based 
buffers, the total HCP concentrations determined were 9206.2, 2275.9, and 6603.6 ppm, 
respectively. The most abundant HCPs quantified were proline rich protein 2, nidogen-1, 
antileukoproteinase, metalloproteinase inhibitor 2, and serine protease HTRA1, the latter 
three contaminants being common to all four samples. Several of the HCPs identified, 
including the most abundant HCPs outlined, were in agreement with those identified in other 
studies investigating HCP content of biotherapeutic mAb samples produced in CHO cells. [4, 
16, 19, 33, 34] Interestingly, some of the HCPs identified in the mAb1 samples processed using 
the different Protein A elution buffers investigated are those that are known to impact DSP 
and the quality of therapeutic protein products, e.g. purative phospholipase B-like 2 and 
various histones. Purative phospholipase B-like 2 has been shown to catalyse the breakdown 
of Polysorbate 20, a non-ionic surfactant frequently used in biopharmaceutical formulation to 
prevent protein aggregation and denaturation. [35, 36] Histones are the primary component 
of Chromatin, which bind Protein A via their nucleosomal histone components thereby 
inhibiting access of mAb to Protein A, reducing the binding capacity of Protein A and ultimately 
decreasing the overall yield of therapeutic mAbs. [37]  
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Table 6.3: Whole protein immunogenicity score reported by the CHOPPI web tool for 
assessment of immunogenicity risk from HCPs in CHO-based protein production. Proteins with 
an immunogenicity score of > 20 are considered to be a high risk for immunogenicity, while 
proteins with a score < -20 are reportedly immunologically inert.  
Protein Entry Protein Description CHOPPI Immunogenicity 
Score 
YBOX1 Nuclease-sensitive element-binding protein 1 -65.86 
RCN1 Reticulocalbin-1 -57.94 
PRDX1 Peroxiredoxin-1 -51.76 
GRP78 78 kDa glucose-regulated protein -48.51 
G3PT Glyceraldehyde-3-phosphate dehydrogenase -39.89 
H13 Histone H1.3 -39.18 
CALR Calreticulin -37.79 
ACTB Actin cytoplasmic 1 -34.19 
CATB Cathepsin B -32.6 
NID1 Nidogen-1 -32.42 
ACTC Actin alpha cardiac muscle 1 -32.34 
H12 Histone H1.2 -28.81 
PCOC1 Procollagen C-endopeptidase enhancer -28.49 
ACTBL Beta-actin-like protein 2 -26.78 
TIMP2 Metalloproteinase inhibitor 2 -25.28 
FIBB Fibrinogen beta chain -24.24 
DLDH Dihydrolipoyl dehydrogenase mitochondrial -22.06 
PPIB Peptidyl-prolyl cis-trans isomerase B -13.65 
HTRA1 Serine Protease HTRA1 -13.02 
CATD Cathepsin D -11.36 
ACTG Actin cytoplasmic 2 -9.36 
MFGM Lactadherin -9.16 
CH10 10 kDa heat shock protein mitochondrial -7.1 
CLUS Clusterin -3.55 
MMP19 Matrix metalloproteinase-19 -2.49 
SLPI Antileukoproteinase 0.01 
PHOCN MOB-like protein phocein isoform X2 4.44 
H2B1F Histone H2B type 1-F/J/L 6.77 
H4 Histone H4 7.67 
NELFE Negative elongation factor E 10.59 
ANXA2 Annexin A2 14.87 
CCL2 C-C motif chemokine 2 18.31 
H3 Histone H3 25.79 
PLBL2 Putative phospholipase B-like 2 32.89 
S1046 Protein S100-A6 52.84 
ANXA5 Annexin A5 52.91 
RL20 60S ribosomal protein L30 57.41 
CXCL3 C-X-C motif chemokine 3 91.84 
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ICH guideline Q5E outlines a requirement to ensure that any alterations in a bioprocess should 
not have an adverse impact on the safety, quality and efficacy of a therapeutic drug product. 
[38] In addition to examining the impact of Protein A elution buffer selection on the HCP load 
of the mAb product, additional CQAs were also examined, including protein aggregation 
profile, N-glycosylation analysis, charge variants and levels of oxidation and deamidation of 
the mAb product. 
Charge variant analysis and determination of protein aggregation were performed as 
described in Section 6.2.5 and resulting chromatographic profiles are shown in Figure 6.4. 
Comparable aggregation profiles were observed for all samples. In agreement with previous 
studies, which have shown IgG1 to be resistant to low pH aggregation, [29] the results herein 
demonstrate low concentration of protein aggregation following Protein A purification with 
each of the buffer systems under evaluation. The SEC and charge variant analysis results are 
presented in Table 6.4. For both charge variant analysis and SEC, the mAb1 sample purified 
from Protein A using citrate buffer was found to contain the highest concentration of variants 
and aggregation although these values were to not found to be statistically significantly higher 
than those purified with alternative elution buffers.  
 
 
Figure 6.4: Chromatographic profiles obtained from (A) charge variant analysis and (B) SEC, 
both shown in expanded scale, for mAb1 samples purified from Protein A resin using acetate-, 
arginine-, citrate- and glycine-based buffers. Reference Table 6.4 for numerical values 
obtained from these analyses. 
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Table 6.4: Analytical results from charge variant and size exclusion analysis of intact mAb1. 
Buffer under 
evaluation 
Charge variant analysis Size exclusion analysis 
% acidic 
variants 
% main % basic 
variants 
% 
aggregates 
% 
monomer 
% 
fragment 
100 mM sodium 
acetate, pH3.5 
2.75 ± 
0.23 
87.61 ± 
0.14 
9.64 ± 
0.94 
0.10 ± 
0.94 
99.87 ± 
0.12 
0.03 ± 
10.57 
100 mM 
arginine, pH3.5 
2.14 
±1.64 
88.72 ± 
0.14 
9.14 
±0.59 
0.10 ± 
3.08 
99.87 ± 
0.06 
0.03 ± 
15.59 
100 mM citrate, 
pH3.5 
3.43 ± 
1.36 
87.21 ± 
0.21 
9.37 ± 
0.26 
0.19 ± 
0.95 
99.76 ± 
0.10 
0.05 ± 
13.74 
100 mM glycine, 
pH3.5 
1.94 ± 
2.15 
88.76 ± 
0.22 
9.30 ± 
0.57 
0.12 ± 
3.24 
99.84 ± 
0.05 
0.04 ± 
3.49 
 
 
Analysis of N-glycans present on mAb1 samples eluted from Protein A resin with the different 
buffer systems was also performed as per Section 6.2.6; resulting chromatograms are shown 
in Figure 6.5. Peaks corresponding to the N-glycans released from the mAb1 samples were 
integrated and compared based on relative percentage areas. Differences in the levels of 
certain N-glycans identified using a panel of exoglycosidase digestions were found to be those 
bearing terminal galactose residues, Figure 6.5, between the mAbs eluted using the different 
buffers. Although galactosylation has not been correlated with adverse events in patients 
treated with biotherapeutic mAb products, it may impact mAb effector functions [39] and 
hence these results suggest, for this particular mAb, the use of glycine-based buffers in DSP 
may have an effect on product efficacy. 
Levels of deamidation and oxidation on the mAb peptide identified following LC-MSE analysis 
of Protein A purified mAb1 samples eluted with the four aforementioned buffer systems were 
also examined. A total of 13, 10, 10 and 9 modified peptides were identified in mAb1 samples 
processed using acetate-, arginine- citrate- and glycine-based buffers, respectively, eight of 
which were common to all samples (data not shown).  
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Figure 6.5: Overlay of chromatgrams displaying N-glycan profiles of mAb1 processed from 
Protein A resin using elution buffers 100 mM sodium acetate, pH 3.5, 100 mM arginine, pH 
3.5, 100 mM citrate, pH 3.5 and 100 mM glycine, pH 3.5.  
 
As each of the mAb1 samples purified using Protein A resin were produced using the same cell 
culture, resulting data from HCP analysis and determination of CQAs should in theory be 
identical across all samples. As the difference in Protein A elution buffer remained the single 
variable in DSP of the mAbs, any disparity in HCP profile or quality attributes of the mAb could 
be associated with the choice of the Protein A elution buffer. The glycine elution buffer 
resulted in the highest overall concentration of HCPs and also revealed a negative impact on 
mAb CQAs relative to the other buffers investigated. The greatest number of individual HCPs 
identified and the highest number of modified mAb1 peptides were found in mAb1 purified 
using an acetate buffer. Samples purified using the arginine buffer were found to contain 
fewer individual HCP species and a considerably lower overall concentration of HCPs when 
compared to othe purified mAb1 samples. Arginine buffers have recently attracted increased 
interest for the elution of mAbs from Protein A resins due to their ability to suppress protein-
protein interactions and protein-surface interactions [40] resulting in desirable characteristics 
including enhancement of virus inactivation. [41] The arginine-based elution buffer was used 
for all subsequent Protein A purifications of mAb1 in this study. 
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As offline high performance peptide maps were generated while fractionating the mAb1 
samples, the possibility of relating the carriage of HCP through DSP to specific portions of the 
mAb itself was investigated. Calreticulin, a HCP identified in multiple samples, was selected for 
further investigation to determine possible interactions with mAb1. Calreticulin was identified 
and quantified in a single fraction of three of the mAb samples analysed using 2D-LC-MSE. 
MAb1 peptides also contained within these fractions were noted and are highlighted in Figure 
6.6. As the Figure shows, the peptides contained within the fractions are not confined to one 
particular portion of the mAb, inhibiting any potential correlation of interaction of Calreticulin 
with a specific mAb sequence region. Grand average of hydropathy (GRAVY) score for each of 
the mAb1 and HCP peptides was also evaluated resulting in no significant enrichment of 
GRAVY scores suggesting that the retention of HCPs is not hydrophobicity based (data not 
shown). 
 
Figure 6.6: Graphic of anti-Interleukin 8 IgG1 (mAb1) structure. MAb1 peptides, which were 
identified in sample fractions also containing Calreticulin peptides, are highlighted in the heavy 
chain (blue) and light chain (green) portions of the structure. [42] 
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6.3.3 Evaluation of Impact of Harvest Time on HCP Repertoire 
Cell culture duration and cell viability are interrelated factors that may have a significant effect 
on the composition and quantity of HCPs in biotherapeutic products. [9, 14, 15, 34] To 
investigate the impact of cell culture harvest time, the developed 2D-LC-MSE proteomic 
platform was applied in a temporal manner to determine changes in the HCP repertoire of 
purified mAb samples, following harvest at different stages of cell culture. Replicate cell 
cultures producing mAb1 were prepared concurrently and batch cultured under identical 
conditions for five days. On day five, having reached the stationary phase of cell growth, the 
first culture was harvested. The second cell culture was continued for a further two days, until 
such a time as the culture had reached the end of the stationary phase of cell growth and at 
which time the viability of the cells had begun to decrease. Resultant mAb1 samples were 
analysed for HCP content using the high pH low pH 2D-LC-MSE method described in Section 
6.2.4. Identified and quantified HCPs in the mAb1 samples are outlined in Table 6.5.  
HCPs identified at the onset of stationary phase samples are predominantly secreted proteins 
while the majority (>70%) of HCPs identified in the end of stationary phase samples are 
characterised as intracellular proteins. [43] In addition, the mAb1 samples, from culture 
harvested at the beginning of the stationary phase were found to contain lower levels of HCPs 
when compared to mAb harvested at the end of the stationary phase. The increased instances 
of intracellular proteins in mAb1 samples harvested at the end of the stationary phase may be 
attributed to a loss in viability of cell culture (98.5% to 90.8%) likely resulting from lysis or 
rupture of cells rather than secretion of protein material from within the cell. 
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Table 6.5: Host cell proteins identified and quantified in Protein A purified mAb1 samples 
harvested at different stages of cell culture growth. 
Protein 
Entry 
Protein Description Cellular Location Cell Culture Harvest time 
HCP 
concentration 
(ppm) - Start 
of stationary 
phase 
HCP 
concentration 
(ppm) - End of 
stationary 
phase 
GRP78 78 kDa glucose-
regulated protein 
Cytoplasm, 
Endoplasmic 
reticulum 
ND 329.6 
ACTB Actin (cytoplasmic 1) Cytoplasm ND 83.5 
ATL4 ADAMTS-like protein 4 Secreted *  
SLPI Antileukoproteinase Secreted * 25.9 
ABCG3 ATP-binding cassette 
sub-family G member 3 
Cell membrane ND * 
DHX8 ATP-dependent RNA 
helicase DHX8  
Nucleus, cytoplasm ND * 
CALR Calreticulin Endoplasmic 
reticulum 
ND * 
CLUS Clusterin Secreted, nucleus, 
cytoplasm 
* 288.6 
G3P Glyceraldehyde-3-
phosphate 
dehydrogenase 
Cytoplasm, nucleus ND 67.7 
H2AX Histone H2AX Nucleus, chromosome ND * 
MFGM Lactadherin Secreted 21.3 ND 
MMP19 Matrix 
metalloproteinase-19 
Secreted 43.5 * 
TIMP2 Metalloproteinase 
inhibitor 2 
Secreted ND * 
NID1 Nidogen-1 Secreted 1189.7 772.3 
PRDX1 Peroxiredoxin-1 Cytoplasm, nucleus 559.8 343.2 
PAIRB Plasminogen activator 
inhibitor 1 RNA-binding 
protein 
Cytoplasm, nucleus * ND 
PCOC1 Procollagen C-
endopeptidase 
enhancer 
Secreted * ND 
HTRA1 Serine Protease HTRA1 Secreted, cytoplasm ND 111.2 
TPA Tissue-type 
plasminogen activator 
Secreted, cytoplasm * ND 
Total HCP concentration (ppm - ng of HCP/ mg of mAb) 1814 2022 
 
HCPs identified using a minimum of 2 peptides are denoted by the symbol ‘*’, while 
undetected HCPs are represented by ‘ND’. 
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6.3.4 Evaluation of Additional Downstream Processing Steps 
Purification of mAbs requires multiple complimentary DSP steps to remove HCPs and other 
contaminants with potentially wide ranging physicochemical and physiological properties. As 
previously discussed, the first step usually involves the use of Protein A resin to extract mAbs 
from the harvest stream. Subsequently, the product undergoes one or two additional 
chromatography polishing steps to guarantee a highly pure product. These additional steps are 
aimed at reducing HCPs, host cell DNA, low molecular weight clipped species, high molecular 
weight aggregates and also leached Protein A resin, to acceptable levels. [31] Common 
polishing steps include cation exchange chromatography, anion exchange chromatography, 
hydrophobic interaction chromatography or a combination of multiple chromatographic resin 
interactions known as mixed mode chromatography. The choice of chromatography mode 
depends on the properties of the host expression system and the biotherapeutic protein, the 
impurities that require clearance and difficulty involved in impurity removal. [44] As common 
DSP unit operations for mAbs dictate the use of subsequent chromatographic steps to 
compliment Protein A purification, the effect of integrating a multi-modal chromatography 
step on the profile and concentration of HCPs in a purified mAb sample was evaluated. A 
mixed mode strong anion exchange resin with hydrophobic properties, Capto Adhere 
ImpResTM (GE Healthcare), was incorporated as a second DSP step to evaluate the capability of 
this additional DSP step for removal of HCP impurities. Capto Adhere ImpResTM resin contains 
a quaternary ammonium group for anion exchange mediated retention of negatively charged 
sample components such as host cell DNA, an aromatic functionality and small alkyl chain that 
may facilitate retention of sample components through hydrophobic interactions. [5]  
To evaluate the effect of the additional multi-modal step, an aliquot of mAb1-containing 
culture harvest was purified using Protein A chromatography. Subsequently, a portion of the 
purified mAb1 was further processed using mixed-mode Capto Adhere ImpResTM 
chromatography conducted in flow-through mode as outlined in Section 6.2.3.2. Comparative 
analysis of both samples was then performed by 2D-LC-MSE. HCPs identified and quantified in 
samples taken before and after the multi-modal chromatography step are shown in Table 6.6.  
Unsurprisingly, the addition of the second purification step resulted in a dramatic reduction in 
HCP profile concentration. A singular HCP, namely Histone H2AX, was found to be present in 
the Capto Adhere ImpResTM-purified mAb1 sample but not at levels that could facilitate 
quantitation. 
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 Table 6.6: Host cell protein profile of mAb1 samples taken before and after mixed-mode 
chromatographic polishing using Capto Adhere ImpResTM. 
 
Protein 
Entry 
 
Protein Description 
Concentration of HCP in combined sample 
sets (ppm - ng/mg) 
Following Protein 
A purification 
Following Protein A 
and Capto adhere 
ImpRes purification 
GRP78 78 kDa glucose-regulated protein 329.6 ND 
ACTB Actin (cytoplasmic 1) 83.5 ND 
SLPI Antileukoproteinase 25.9 ND 
ABCG3 ATP-binding cassette sub-family G 
member 3 
* ND 
DHX8 ATP-dependent RNA helicase DHX8  * ND 
CALR Calreticulin * ND 
CLUS Clusterin 288.6 ND 
G3P Glyceraldehyde-3-phosphate 
dehydrogenase 
67.7 ND 
H2AX Histone H2AX * * 
MMP19 Matrix metalloproteinase-19 * ND 
TIMP2 Metalloproteinase inhibitor 2 * ND 
NID1 Nidogen-1 772.3 ND 
PRDX1 Peroxiredoxin-1 343.2 ND 
HTRA1 Serine Protease HTRA1 111.2 ND 
Total HCP concentration (ppm - ng of HCP/ mg 
of mAb) 
2022 ND 
 
HCPs identified using a minimum of 2 peptides are denoted by the symbol ‘*’, while 
undetected HCPs are represented by ‘ND’. 
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6.4 Conclusions 
A high pH/low pH reversed phase nano-2D-LC-MSE method with Hi3 quantitation for the 
determination of HCPs in purified mAb samples is described. The use of off-line high pH 
fractionation facilitates a more thorough investigation of potential interactions that may have 
resulted in the carriage of HCPs through Protein A purification during DSP. No specific 
correlations of HCPs with regions of the mAb were identified; however, presented data 
suggests that the interaction of HCPs with mAb was not hydrophobicity based. The choice of 
Protein A elution buffer was demonstrated to exhibit a potential impact on the HCP repertoire 
of purified mAb samples. A link between the time of culture harvest and the abundance of 
HCPs present following a Protein A affinity capture step was verified, and is thought to result 
from a loss of cell viability in samples harvested at a later stage of cell culture. Inclusion of 
additional DSP demonstrated how complementary polishing successfully removed HCPs in the 
process stream to very low levels. Taken together these results show the importance in 
optimising components of downstream processing including choice of buffers used for 
purification and viability or age of cell culture at the time of harvest. This data shows how 
mass spectrometry methods are capable of providing a wealth of information that provides 
valuable insights for DSP. Compared to ELISA, mass-spectrometry-based methods may provide 
a more comprehensive characterisation of HCPs, not only facilitating a more efficient removal 
strategy for DSP, but also allowing for a more rational assessment of potential safety risks 
posed by individual HCPs. 
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7.0  
Overall Conclusions and Future Research 
Direction 
 
7.1 Overall Conclusions 
CHO cells are important expression systems currently used in the biopharmaceutical industry 
for the production of a wide range of therapeutic proteins and thus represent a significant 
area of interest for biopharmaceutical research. Although specific production of biomolecules 
in CHO cells has previously been optimised using cell and bioprocess engineering strategies, 
current and future advances in analytical instrumentation are theorised to contribute to 
increased cellular-level understanding of CHO cells and ultimately result in improvements in 
biotherapeutic production and product quality. The goals of this work were to apply state-of-
the-art analytical techniques to gain a greater understanding of recombinant protein 
producing CHO cells during routine bioprocessing. By preparing concurrent identical CHO DP-
12 cell cultures, in highly controlled bioreactor systems, and altering one bioprocessing 
parameter, e.g. pH, temperature or dissolved oxygen, potential changes to the CHO cell 
proteomes in response to that particular condition could be identified. Subsequently, through 
application of spent media to naïve CHO cells, a further goal to evaluate the effects of CHO 
secretome during bioprocessing could be assessed. In addition to evaluation of CHO cells, 
extensive product characterisation techniques were developed and applied for determination 
of the impact of altered bioprocessing on the therapeutic protein produced. Furthermore, 
since the presence of host cell protein (HCP) impurities in therapeutic drug products has the 
potential to cause adverse events in patients, a final goal was to develop an analytical method 
that could identify HCP impurities in purified drug product.  
Chapter 2 focused on the development and application of a state-of-the-art quantitative 
proteomics platform, incorporating two dimensional high pH-low pH reversed phase nano 
liquid chromatography mass spectrometry with SPS-MS3 detection of TMT-sixplex labelled 
proteome samples, to facilitate comparison of the effects of individual culture characteristics 
on a CHO cell proteome. In addition to profiling the changes to a recombinant monoclonal 
antibody producing CHO cell line, caused by alterations in bioprocessing parameters typically 
applied during biopharmaceutical production, the platform was also applied for the evaluation 
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of the bystander response of CHO cells in culture, to the secretome of production cells 
maintained at different bioprocess conditions. The developed proteomic platform displayed 
excellent performance capabilities, enabling the identification and relative quantitation of 
thousands of proteins with relatively low first dimensional pre-fractionation. Application of the 
method for the evaluation of CHO DP-12 cells producing anti-interleukin 8 IgG1 enabled the 
realisation of a snapshot into CHO production cells responding to altered bioprocessing, 
illustrating the robustness of the bioprocess in terms of the effect on recombinant protein 
expressing CHO cells. Observation of increased activity for proteins involved in signalling 
pathways for both CHO production cells, and also for naïve CHO cells in response to CHO 
secretome, signified a high level of activity within the cells relating to normal growth but also 
highlighted the benefit of investigating the cell as a whole, i.e. to use a multi-omics approach 
incorporating phosphoproteomics, metabolomics and product characterisation, to obtain a full 
picture of the molecular level manifestations within the cell in response to the altered 
bioprocessing conditions applied. 
The proteomics study was complemented by sequence level characterisation of recombinant 
anti-interleukin 8 IgG1 produced during CHO DP-12 culture maintained under different 
bioprocessing settings. This work, described in Chapter 3, involved the determination of the 
size, hydrophobicity and charge variant profile of mAb samples via evaluation of intact mAb 
species using various chromatographic approaches. Although miniscule changes to the size 
profile were observed, variations in the hydrophobicity and charge of some mAb samples were 
determined.  High resolution mass spectrometry analysis was applied for the evaluation of 
protein mass following limited proteolysis to produce mAb subunits more amenable to mass 
spectrometry detection. Changes to the mass of the most abundant mAb species were not 
observed, however mAb heterogeneity was illustrated by the existence of low levels of species 
with variations in polypeptide mass, potentially corresponding to differently N-glycan moieties 
and sequence-level modifications. Protein heterogeneity was further investigated by high 
resolution LC-MS analysis of tryptic peptides for identification of modifications to mAb primary 
sequence. Varying levels of modified species were observed for various samples, most notably 
for anti-IL8 IgG1 produced at 32.0oC. 
Due to the importance of mAb N-glycosylation in regards to the therapeutic function of mAbs 
in-vivo, variations in the N-glycosylation profile of anti-IL 8 IgG1 were investigated in Chapter 
4. A twoplex method for comparative glycomics of N-glycans present on IgG1 was developed, 
based upon the differential labelling of samples for comparison with either ‘light’ 12C6 2-AA or 
‘heavy’ 13C6 2-AA prior to hydrophilic interaction UPLC with sequential fluorescence and 
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accurate mass QToF-MS detection. Application of the developed method for the relative 
quantitation of N-glycans attached to mAbs produced under altered bioprocessing conditions 
revealed changes to the levels of some N-glycan species, in particular those attached to anti-IL 
8 IgG1 produced at pH 7.2 and 110% dissolved oxygen. 
The purpose of product characterisation is to estimate potential changes to the therapeutic 
function and safety of a drug substance, hence to thoroughly evaluate the effect of altered 
bioprocessing on the therapeutic protein produced, characterisation of the changes to the 
structure and function of the IgG was performed. In Chapter 5, a developed HDX-MS platform 
for the determination of conformation changes to therapeutic mAbs was described. 
Identification of changes to the uptake of deuterium by backbone amide hydrogen atoms of 
differentially produced anti-IL8 IgG1 as a function of time via MSE detection of peptic peptides 
produced form samples following HDX, a number of conformational changes were detected in 
mAbs produced under altered conditions of 32.0oC, pH 7.2, 60% DO and 110%DO. Subsequent 
surface plasmon resonance analysis of anti-IL8 samples revealed changes to the binding 
affinity of mAb produced at 32.0oC for FcRn, the mAb cellular receptor, indicating a potential 
alteration in the serum half-life of anti-IL8 IgG1 resulting from low temperature production. 
Further surface plasmon resonance analysis to determine changes in the binding affinity of 
anti-IL8 to its target antigen interleukin 8 signified a negative impact on the therapeutic 
efficacy of mAbs produced using culture media with a dissolved oxygen concentration of 
110%.  
Finally, in addition to assessing the impact of upstream bioprocessing on therapeutic 
biomolecules, the identification and quantitation of bioprocess-related host cell protein 
impurities following downstream processing is described in Chapter 6. In this case a high pH 
low pH reversed phase nano-liquid chromatography mass spectrometry platform was 
developed and applied to evaluate different features of downstream processing including the 
choice of buffer used during Protein A purification, influence of multiple downstream 
processing steps and the effect of harvest time on the profile of HCPs detected. The developed 
platform may be of significance for product and process development as unlike many other 
methods described in the literature for HCP analysis, the method described is capable of 
identification of low levels of HCP impurities without the requirement for extraction or pre-
concentration, which may artificially alter the actual HCP profile of therapeutic mAbs. Thus 
improvements to downstream processing may be made by targeting of HCPs identified using 
the platform described. 
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7.2 Future Research Direction 
The following areas have been identified as potential avenues for future research: 
 The developed high performance analytical platform, capable of quantitative 
proteomic analysis of thousands of proteins within a cellular sample, highlighted the 
ruggedness of the bioprocess used for CHO DP-12 culture. However, application of the 
platform to other molecules could be more informative, in particular for 
manufacturing processes wherein product critical quality attributes are difficult to 
control. This method could potentially form a key component of process optimisation 
and application of quality by design during product development. 
  Proteomic analysis of CHO DP-12 cells and naïve CHO K1 cells revealed significant 
differential regulation of signalling pathways within the cell. Application of a 
combination of other omics strategies may provide an enhanced view of the molecular 
events within the cells. Specifically use of metabolomics, for determination of cellular 
outputs and phosphoproteomics, to evaluate whether variations in protein regulation 
observed in this study are attributed to differential signalling or differential 
expression, would be beneficial. Should additional markers be identified, a potential 
for cellular engineering for phenotype modification may arise, now possible using 
technologies such as CRISPR-Cas9. 
 The advanced mass spectrometry-based analytical platforms developed for product 
characterisation were applied exclusively to monoclonal antibody samples, however 
as these methods use high resolution accurate mass technology, they may be used for 
the characterisation of any molecular entity. Application of the developed methods to 
new therapeutic entities, such as Fc fusion proteins, bispecific antibodies and antibody 
drug conjugates may be of particular interest. However, despite providing crucial 
information, the methods described were based on middle-down and bottom-up 
approaches to product characterisation. An ability to acquire high resolution mass 
spectrometric data of intact biomolecules could provide additional information 
regarding the causes of observed structural, functional or primary sequence 
modifications, i.e. to determine if a specific structural modification is a result of a 
sequence-level modification or vice versa. 
 The HCP platform developed, based on MSE, was highly conservative due to criteria 
required for Hi3 quantitation (>3 identified peptides for each protein). Future work to 
advance the platform further using either an improvement in the informatics platform 
to remove any potential bias for spectral intensity or a transformation of the platform 
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to higher resolution accurate mass platforms e.g. parallel reaction monitoring using an 
Orbitrap mass analyser, where accurate quantitation could be acquired based solely 
on the precursor may enable further confidence in the data acquired.  
 The HCP analysis platform could enable the development of targeted analytical 
methods that may be used in a Quality Control laboratory to facilitate process 
monitoring and process improvements thereby potentially reducing high product 
attrition rates often associated with biopharmaceutical production. Skyline, a software 
application for building multiple reaction monitoring (MRM) quantitiative MS methods 
(https://skyline.gs.washington.edu), may enable the utilisation of data (generated 
using the HCP platform described in Chapter 6) for design of targeted MRM methods. 
These methods may then be further optimised using a triple-Quadrupole MS 
instrument, e.g. Agilent 6460. 
 HDX is capable of providing useful information regarding protein higher order 
structure, however it is based on the reaction of amide hydrogen atoms only, thus 
facilitating tertiary structure determination only. If this method was complemented by 
the application of biophysical technology e.g. light scattering, fast photochemical 
oxidation of proteins (FPOP) or other spectroscopy-based methods, a deeper level of 
structural characterisation could be achieved.  
 Despite some degree of resolution between intact protein species using available 
technologies, e.g. hydrophobic interaction and ion exchange chromatography, poor 
resolution attributable to low diffusion coefficients is observed. Scope for 
improvement exists for chromatographic methods available for intact protein analysis, 
in particular to enable efficient mass spectrometry analysis of intact protein species. 
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Supplementary Data 
Appendix A 
CHO DP-12 Proteins determined to be significantly differentially regulated in CHO DP-12 
cultures prepared at altered Bioprocessing conditions when compared to CHO DP-12 cells 
cultured under standard Bioprocessing conditions. Proteomic samples were analysed using 
2D-LC-MS3 and data analysed using Thermo Fisher Scientific Proteome Discoverer version 
2.1.0.81 and InfernoRDN version 1.1.5970.31895. 
 
Table 1-A: Differentially regulated CHO DP-12 proteins determined in samples corresponding 
to culture using an increased bioprocessing temperature of 39.5oC. 
RefSeq 
Annotation 
Description Fold 
Change 
p-
value 
NM_001081242 talin 2 1.944 0.018 
NM_144857 cDNA sequence BC011248 1.895 0.002 
NM_010480 predicted gene 5511; heat shock protein 90, alpha (cytosolic), 
class A member 1 
1.853 0.015 
NM_133726 suppression of tumorigenicity 13 1.835 0.011 
NP_001162071 guanine nucleotide binding protein-like 3 (nucleolar)-like 1.814 0.003 
NM_027852 retinoic acid receptor responder (tazarotene induced) 2 1.794 0.029 
NM_010729 lysyl oxidase-like 1 1.789 0.009 
NM_010893 neuraminidase 1 1.782 0.000 
NP_001135450 TPX2, microtubule-associated protein homolog  1.780 0.007 
NM_011933 2-4-dienoyl-Coenzyme A reductase 2, peroxisomal 1.768 0.009 
NM_001001491 tropomyosin 4; predicted gene 7809 1.764 0.006 
NM_001082961 small nuclear ribonucleoprotein N; SNRPN upstream reading 
frame; predicted gene 5802; similar to SNRPN upstream reading 
frame protein 
1.762 0.011 
NM_021895 actinin alpha 4 1.760 0.025 
NM_145392 BCL2-associated athanogene 2 1.759 0.010 
NM_144937 ubiquitin specific peptidase 3 1.737 0.007 
NM_145150 protein regulator of cytokinesis 1 1.733 0.021 
NM_024223 cysteine rich protein 2 1.731 0.001 
NM_016906 Sec61 alpha 1 subunit (S. cerevisiae) 1.730 0.001 
NM_019772 predicted gene 9169; RIKEN cDNA 1110004F10 gene 1.730 0.001 
NM_009297 suppressor of Ty 6 homolog  1.730 0.027 
NM_009048 RalBP1 associated Eps domain containing protein 1.730 0.001 
NM_001001491 tropomyosin 4; predicted gene 7809 1.729 0.001 
NM_054043 Musashi homolog 2 (Drosophila) 1.729 0.002 
NM_011175 Legumain 1.729 0.012 
NM_025591 RIKEN cDNA 2010309E21 gene; similar to CG5323-PA 1.727 0.003 
NM_025364 predicted gene 6563; SAP domain containing ribonucleoprotein 1.723 0.023 
NM_024428 dpy-30 homolog (C. elegans); predicted gene 2059; similar to 
RIKEN cDNA 2810410M20 gene 
1.723 0.005 
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NM_008972 predicted gene 12504; predicted gene 9800; predicted gene 
4617; predicted gene 6625; predicted gene 7614; similar to 
prothymosin alpha; prothymosin alpha; predicted gene 9009 
1.723 0.006 
NM_028871 predicted gene 6159; heterogeneous nuclear ribonucleoprotein R 1.722 0.009 
NM_026842 ubiquilin 1 1.719 0.007 
NM_011070 prefoldin 2 1.719 0.043 
NM_012021 peroxiredoxin 5 1.719 0.031 
NM_013897 translocase of inner mitochondrial membrane 8 homolog b 
(yeast) 
1.719 0.008 
NM_008866 lysophospholipase 1 1.717 0.005 
NM_026572 predicted gene 3672; similar to Glycine cleavage system H 
protein, mitochondrial precursor; glycine cleavage system 
protein H (aminomethyl carrier) 
1.716 0.009 
NM_026623 nudix (nucleoside diphosphate linked moiety X)-type motif 21 1.715 0.004 
NM_008683 neural precursor cell expressed, developmentally down-
regulated gene 8 
1.714 0.011 
NM_130889 acidic (leucine-rich) nuclear phosphoprotein 32 family, member 
B 
1.713 0.011 
NM_016786 ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast) 1.713 0.011 
NM_133716 stromal membrane-associated GTPase-activating protein 2 1.709 0.005 
NM_007466 apoptosis inhibitor 5 1.706 0.002 
NM_144897 apolipoprotein A-I binding protein 1.706 0.017 
NP_001136216 RIKEN cDNA 2610110G12 gene 1.706 0.003 
NM_026020 similar to LOC665931 protein; ribosomal protein, large P2; 
predicted gene 7852; WD repeat domain 89 
1.705 0.016 
NM_025657 leucine rich repeat containing 57 1.705 0.043 
NM_011801 craniofacial development protein 1 1.703 0.017 
NM_172262 amine oxidase, flavin containing 1 1.703 0.014 
NM_008520 latent transforming growth factor beta binding protein 3 1.700 0.018 
NM_026988 Parathymosin 1.698 0.005 
NM_008638 methylenetetrahydrofolate dehydrogenase (NAD+ dependent), 
methenyltetrahydrofolate cyclohydrolase 
1.698 0.018 
NM_010023 dodecenoyl-Coenzyme A delta isomerase (3,2 trans-enoyl-
Coenyme A isomerase) 
1.693 0.005 
NM_133934 ISY1 splicing factor homolog (S. cerevisiae) 1.693 0.012 
NM_198937 hematological and neurological expressed 1-like 1.692 0.023 
NM_080419 immunoglobulin superfamily, member 8 1.692 0.001 
NM_023397 RIKEN cDNA 1810034K20 gene 1.692 0.023 
NM_011418 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily b, member 1 
1.692 0.023 
NM_025337 aldo-keto reductase family 7 1.691 0.015 
NM_010479 heat shock protein 1B; heat shock protein 1A 1.691 0.007 
NM_010361 glutathione S-transferase, theta 2 1.691 0.024 
NM_011623 topoisomerase (DNA) II alpha 1.688 0.000 
NM_133795 tetratricopeptide repeat domain 1 1.686 0.002 
NM_029752 Bri3 binding protein 1.685 0.010 
NM_010398 histocompatibility 2, T region locus 23; similar to RT1 class Ib, 
locus H2-Q-like, grc region 
1.685 0.003 
NM_026280 matrix-remodelling associated 7 1.683 0.013 
NM_028871 predicted gene 6159; heterogeneous nuclear ribonucleoprotein 
R 
1.683 0.017 
NM_176968 5'-nucleotidase domain containing 1 1.682 0.018 
NM_172572 rhomboid 5 homolog 2 (Drosophila) 1.682 0.011 
NM_011752 zinc finger protein 259 1.682 0.041 
NP_001157185 predicted gene 9755; Tu translation elongation factor, 1.681 0.002 
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mitochondrial 
NM_053104 RNA binding motif protein 9 1.680 0.021 
NM_023232 diablo homolog (Drosophila) 1.680 0.008 
NM_019641 stathmin 1; predicted gene 11223; predicted gene 6393 1.677 0.021 
NM_025299 thioredoxin-like 4A 1.677 0.003 
NM_001029844 vaccinia related kinase 1 1.676 0.016 
NM_029250 ethanolamine kinase 1 1.676 0.010 
NP_001157583 nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 1 
1.675 0.006 
NM_012047 bromodomain containing 7 1.675 0.010 
NM_028870 clathrin, light polypeptide (Lcb) 1.674 0.032 
NM_153552 THO complex 1 1.674 0.003 
NM_001168382 PHD finger protein 14 1.674 0.001 
NM_027296 tRNA nucleotidyl transferase, CCA-adding, 1 1.674 0.012 
NM_023735 ARP3 actin-related protein 3 homolog (yeast) 1.674 0.001 
NM_145955 RIKEN cDNA 1110007A13 gene 1.673 0.000 
NM_021315 nucleolar complex associated 3 homolog (S. cerevisiae) 1.673 0.027 
NM_021604 Agrin 1.671 0.008 
NM_008234 helicase, lymphoid specific 1.668 0.013 
NM_008408 STT3, subunit of the oligosaccharyltransferase complex 1.667 0.004 
NM_198645 coiled-coil domain containing 58 1.666 0.038 
NM_145588 kinesin family member 22 1.666 0.038 
NM_133783 prostaglandin E synthase 2 1.665 0.005 
NM_025315 mediator complex subunit 21 1.665 0.026 
NM_015774 ERO1-like (S. cerevisiae) 1.664 0.019 
NM_026522 chitinase domain containing 1 1.664 0.029 
NM_028312 coiled-coil domain containing 12; predicted gene 8518 1.663 0.030 
NM_145620 RRP9, small subunit (SSU) processome component, homolog 
(yeast) 
1.663 0.004 
NM_020584 telomeric repeat binding factor 2, interacting protein 1.663 0.027 
NM_026195 5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase; similar to 5-
aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase 
1.663 0.011 
NM_021895 actinin alpha 4 1.662 0.003 
NM_010948 nuclear distribution gene C homolog (Aspergillus), pseudogene 1; 
nuclear distribution gene C homolog (Aspergillus) 
1.662 0.001 
NM_013902 FK506 binding protein 3 1.662 0.006 
NM_011768 zinc finger protein X-linked; similar to zinc finger protein 1.661 0.033 
NM_146154 protein phosphatase 1, regulatory (inhibitor) subunit 8 1.659 0.035 
NM_008251 predicted gene 11663; predicted gene 2992; predicted gene 
7862; high mobility group nucleosomal binding domain 1; similar 
to high mobility group nucleosomal binding domain 1 
1.659 0.003 
NM_009408 topoisomerase (DNA) I 1.657 0.004 
NM_009346 TEA domain family member 1 1.656 0.010 
NM_029802 ADP-ribosylation factor interacting protein 2 1.656 0.006 
NM_013716 Ras-GTPase-activating protein SH3-domain binding protein 1 1.656 0.008 
NM_016784 pleiotropic regulator 1, PRL1 homolog (Arabidopsis) 1.656 0.035 
NM_145414 NOL1/NOP2/Sun domain family, member 5 1.656 0.022 
NM_007971 enhancer of zeste homolog 2 (Drosophila) 1.656 0.004 
NM_026487 ATPase family, AAA domain containing 1 1.655 0.017 
NM_017477 coatomer protein complex, subunit gamma 1.654 0.003 
NM_025776 RNA binding motif protein 22 1.654 0.038 
NM_026602 breast carcinoma amplified sequence 2 1.649 0.010 
NM_029293 phosphohistidine phosphatase 1 1.648 0.048 
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NM_016844 similar to 40S ribosomal protein S28; predicted gene 10443; 
predicted gene 12943; predicted gene 13192; similar to 
ribosomal protein S28; predicted gene 10263; predicted gene 
3511; ribosomal protein S28 
1.648 0.033 
NM_019673 actin-like 6A 1.648 0.024 
NM_026040 serum response factor binding protein 1; similar to SRF-
dependent transcription regulation associated protein 
1.647 0.003 
NM_001013616 tripartite motif-containing 6; similar to Tripartite motif protein 6 1.646 0.046 
NM_001033273 RIKEN cDNA 5031439G07 gene 1.646 0.049 
NM_008012 aldo-keto reductase family 1, member B8 1.646 0.001 
NM_026631 NHP2 ribonucleoprotein homolog (yeast) 1.646 0.002 
NM_008249 transcription factor B2, mitochondrial; predicted gene 1818 1.645 0.005 
NM_028767 forkhead box P4 1.645 0.020 
NM_010756 similar to mafG; v-maf musculoaponeurotic fibrosarcoma 
oncogene family, protein G (avian) 
1.644 0.034 
NM_148930 RNA binding motif protein 5 1.644 0.040 
NM_015816 LSM4 homolog, U6 small nuclear RNA associated (S. cerevisiae) 1.643 0.031 
NM_138599 translocase of outer mitochondrial membrane 70 homolog A  1.642 0.005 
NM_153516 BCL2-like 13 (apoptosis facilitator) 1.640 0.038 
NM_028597 THO complex 3 1.639 0.017 
NM_026120 RIKEN cDNA 2410127L17 gene; predicted gene 7622 1.638 0.021 
NM_008907 predicted gene 9234; peptidylprolyl isomerase A 1.638 0.001 
NM_030109 splicing factor 3b, subunit 2 1.638 0.007 
NM_026063 hypothetical protein LOC675054; RIKEN cDNA 2900010M23 gene 1.635 0.023 
NM_021433 syntaxin 6 1.635 0.044 
NM_026023 NudC domain containing 2 1.635 0.002 
NM_023215 predicted gene 6365; RIKEN cDNA 2500003M10 gene 1.633 0.032 
NM_008854 protein kinase, cAMP dependent, catalytic, alpha 1.633 0.039 
NM_016737 stress-induced phosphoprotein 1 1.632 0.027 
NM_010917 similar to Nidogen precursor (Entactin); nidogen 1; similar to 
Nid1 protein 
1.632 0.004 
NM_009786 calcyclin binding protein 1.632 0.004 
NM_026422 mitochondrial ribosome recycling factor; similar to mitochondrial 
ribosome recycling factor; predicted gene 6374 
1.631 0.047 
NP_085112 histone cluster 1, H1a 1.628 0.020 
NM_138747 NOP2 nucleolar protein homolog (yeast) 1.628 0.023 
NM_133815 lamin B receptor 1.627 0.008 
NM_133757 phosphatidylglycerophosphate synthase 1 1.627 0.004 
NM_011958 origin recognition complex, subunit 4-like (S. cerevisiae) 1.626 0.007 
NM_022023 glia maturation factor, beta 1.626 0.044 
NM_172400 DnaJ (Hsp40) homolog, subfamily C, member 8; predicted gene 
4928 
1.626 0.008 
NM_008881 plexin A1 1.626 0.007 
NM_011034 peroxiredoxin 1; predicted gene 7204 1.626 0.046 
NM_030721 acyl-Coenzyme A oxidase 3, pristanoyl 1.625 0.004 
NM_001044751 Corticosteroid 11-beta-dehydrogenase isozyme 1 1.624 0.010 
NM_025351 coiled-coil-helix-coiled-coil-helix domain containing 6 1.623 0.010 
NM_008704 similar to Nucleoside diphosphate kinase A (NDK A) (NDP kinase 
A) (Tumor metastatic process-associated protein) (Metastasis 
inhibition factor NM23) (NDPK-A) (nm23-M1); non-metastatic 
cells 1, protein (NM23A) expressed in 
1.623 0.007 
NP_083939 predicted gene 11675; eukaryotic translation elongation factor 1 
delta (guanine nucleotide exchange protein) 
1.623 0.010 
NM_053179 N-acetylneuraminic acid synthase (sialic acid synthase) 1.620 0.013 
NM_010931 ubiquitin-like, containing PHD and RING finger domains, 1; 1.619 0.016 
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predicted gene 5648; similar to nuclear zinc finger protein Np95 
NM_025814 serpine1 mRNA binding protein 1 1.618 0.003 
NP_001258827 Peroxisomal acyl-coenzyme A oxidase 1 1.618 0.001 
NM_007624 predicted gene 6917; similar to chromobox homolog 3; predicted 
gene 5792; predicted gene 7469; predicted gene 6901; predicted 
gene 7721; predicted gene 5196; complement component 7; 
chromobox homolog 3 (Drosophila HP1 gamma) 
1.617 0.030 
NM_020506 exportin 4 1.611 0.010 
NM_027478 RIKEN cDNA 5730494N06 gene; predicted gene 7368 1.611 0.015 
NM_011306 retinoid X receptor beta 1.611 0.045 
NP_951062 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 1.611 0.017 
NM_023479 elaC homolog 2 (E. coli) 1.610 0.005 
NM_001177658 39S ribosomal protein L15, mitochondrial 1.609 0.001 
NM_027226 forty-two-three domain containing 1 1.609 0.019 
NM_027219 CDC42 effector protein (Rho GTPase binding) 1 1.609 0.026 
NM_011750 splicing factor 1 1.608 0.042 
NM_027044 prefoldin 5 1.608 0.041 
NM_019796 synaptotagmin binding, cytoplasmic RNA interacting protein 1.607 0.007 
XP_619909 predicted gene 5449; small nuclear ribonucleoprotein D2; 
predicted gene 5848; predicted gene 10120 
1.607 0.013 
NM_018888 ubiquinol-cytochrome c reductase complex chaperone, CBP3 
homolog (yeast) 
1.605 0.002 
NM_022988 Ngg1 interacting factor 3-like 1 (S. pombe) 1.604 0.003 
NM_025994 similar to EF hand domain containing 2; EF hand domain 
containing 2 
1.604 0.038 
NM_207176 testis derived transcript 1.601 0.030 
NM_021336 small nuclear ribonucleoprotein polypeptide A' 1.601 0.008 
NM_019813 drebrin 1 1.600 0.001 
NM_134122 nurim (nuclear envelope membrane protein) 1.599 0.018 
NP_598452 poly-U binding splicing factor 60 1.599 0.023 
NM_011327 sterol carrier protein 2, liver 1.598 0.003 
NM_001093753 splicing factor, arginine/serine-rich 11 1.597 0.000 
NM_175465 SEC14 and spectrin domains 1; predicted gene 9165 1.595 0.014 
NM_146036 AHA1, activator of heat shock protein ATPase homolog 1 (yeast) 1.593 0.001 
NM_008991 ATP-binding cassette, sub-family D (ALD), member 3 1.592 0.002 
NM_019537 proteasome (prosome, macropain) assembly chaperone 1 1.592 0.036 
NM_054081 similar to metastasis-associated protein; metastasis associated 1; 
similar to MTA1 
1.591 0.011 
NM_001037756 breast cancer metastasis-suppressor 1-like 1.589 0.015 
NM_010219 FK506 binding protein 4 1.588 0.001 
NM_008305 perlecan (heparan sulfate proteoglycan 2) 1.587 0.003 
NM_172288 nucleoporin 133 1.586 0.009 
NM_144930 expressed sequence AU018778 1.585 0.015 
NM_023402 Myosin regulatory light chain 12B 1.585 0.003 
NM_018868 NOP58 ribonucleoprotein homolog (yeast) 1.582 0.030 
NM_021559 zinc finger protein 191 1.581 0.040 
NM_053183 predicted gene 8228; DEAD (Asp-Glu-Ala-Asp) box polypeptide 
50 
1.580 0.001 
NM_025292 RIKEN cDNA 1810020G14 gene; synaptojanin 2 binding protein; 
predicted gene 4116 
1.579 0.028 
NM_026503 RIKEN cDNA 1110058L19 gene 1.579 0.002 
NP_033898 Basigin 1.576 0.022 
NM_139236 nucleolar protein family 6 (RNA-associated) 1.576 0.049 
NM_025281 Ly1 antibody reactive clone 1.574 0.050 
NM_025375 Williams Beuren syndrome chromosome region 22 1.571 0.044 
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NM_145556 predicted gene 13886; TAR DNA binding protein 1.570 0.008 
NM_009881 chromodomain protein, Y chromosome-like; predicted gene 
7584 
1.569 0.022 
NM_152807 coiled-coil domain containing 137 1.568 0.027 
NM_013559 heat shock 105kDa/110kDa protein 1 1.564 0.007 
NM_020027 HLA-B associated transcript 2 1.561 0.010 
NM_134080 filamin, beta 1.560 0.007 
NM_025996 translocase of outer mitochondrial membrane 34 1.559 0.011 
NM_153571 HscB iron-sulfur cluster co-chaperone homolog (E. coli) 1.559 0.012 
NM_021465 stromal antigen 2 1.557 0.036 
NM_025349 predicted gene 13182; LSM7 homolog, U6 small nuclear RNA 
associated (S. cerevisiae); predicted gene 10146 
1.554 0.020 
NM_026532 similar to Chain A, D92n,D94n Double Point Mutant Of Human 
Nuclear Transport Factor 2 (Ntf2); predicted gene 10349; 
predicted gene 4682; nuclear transport factor 2; similar to 
nuclear transport factor 2; predicted gene 9386; predicted gene 
10333 
1.552 0.006 
NM_053089 NMDA receptor-regulated gene 1 1.551 0.007 
NM_009295 syntaxin binding protein 1 1.550 0.012 
NM_001081196 heterogeneous nuclear ribonucleoprotein U-like 2 1.549 0.011 
NM_001033270 solute carrier family 4, sodium bicarbonate cotransporter, 
member 7 
1.549 0.007 
NM_010324 similar to Aspartate aminotransferase, cytoplasmic 
(Transaminase A) (Glutamate oxaloacetate transaminase 1); 
glutamate oxaloacetate transaminase 1, soluble 
1.548 0.015 
NM_007951 predicted gene 6941; predicted gene 10131; enhancer of 
rudimentary homolog (Drosophila) 
1.546 0.007 
NM_026483 M-phase phosphoprotein 10 (U3 small nucleolar 
ribonucleoprotein) 
1.545 0.033 
NM_010015 defender against cell death 1 1.544 0.046 
NM_013492 similar to clusterin; clusterin 1.543 0.014 
NM_029688 sulfiredoxin 1 homolog (S. cerevisiae) 1.543 0.040 
NM_025507 SNW domain containing 1 1.543 0.009 
NM_008722 predicted gene 6477; predicted gene 9118; nucleophosmin 1; 
similar to Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) 
(Numatrin) (Nucleolar protein NO38); predicted gene 7289; 
predicted gene 5611 
1.542 0.036 
NM_001081071 lysocardiolipin acyltransferase 1 1.542 0.011 
NM_023731 coiled-coil domain containing 86 1.541 0.015 
NM_133933 ribophorin I 1.539 0.002 
NM_145417 arginyl aminopeptidase (aminopeptidase B) 1.535 0.025 
NM_078478 growth hormone inducible transmembrane protein 1.534 0.046 
NM_015824 origin recognition complex, subunit 3-like (S. cerevisiae) 1.530 0.026 
NM_144885 cDNA sequence BC005624; predicted gene 5904 1.530 0.013 
NM_010579 eukaryotic translation initiation factor 6 1.528 0.020 
NM_008549 mannosidase 2, alpha 1 1.525 0.018 
NM_010368 glucuronidase, beta 1.525 0.020 
NM_021714 WW domain binding protein 11 1.524 0.033 
NM_001078167 splicing factor, arginine/serine-rich 1 (ASF/SF2); similar to 
splicing factor, arginine/serine-rich 1 (splicing factor 2, alternate 
splicing factor) 
1.523 0.029 
NM_019648 methionine aminopeptidase 2 1.523 0.023 
NM_144861 regulation of nuclear pre-mRNA domain containing 1A 1.521 0.033 
NM_023140 predicted gene 12669; glutaredoxin 3 1.520 0.030 
NM_009278 Sjogren syndrome antigen B 1.518 0.013 
Appendix A 
 
- 7 - 
 
NM_029157 splicing factor 3a, subunit 3 1.517 0.009 
NM_007453 similar to Peroxiredoxin-6 (Antioxidant protein 2) (1-Cys 
peroxiredoxin) (1-Cys PRX) (Acidic calcium-independent 
phospholipase A2) (aiPLA2) (Non-selenium glutathione 
peroxidase) (NSGPx); peroxiredoxin 6 
1.517 0.005 
NM_016777 nuclear autoantigenic sperm protein (histone-binding); similar to 
nuclear autoantigenic sperm protein; NASP 
1.516 0.043 
NM_024448 RAB12, member RAS oncogene family 1.516 0.001 
NM_133976 IMP3, U3 small nucleolar ribonucleoprotein, homolog (yeast); 
RIKEN cDNA 4933427G23 gene 
1.515 0.013 
NP_001029080 mediator complex subunit 22 1.513 0.041 
NM_172666 alkylglycerone phosphate synthase 1.512 0.001 
NM_026780 SYF2 homolog, RNA splicing factor (S. cerevisiae) 1.512 0.018 
NM_009981 phosphate cytidylyltransferase 1, choline, alpha isoform 1.510 0.039 
NP_001095925 amyloid beta (A4) precursor-like protein 2 1.510 0.003 
NM_023130 RIKEN cDNA C130057N11 gene; hnRNP-associated with lethal 
yellow 
1.509 0.005 
NM_010911 nitrogen fixation gene 1 (S. cerevisiae); similar to Nitrogen 
fixation gene 1 (S. cerevisiae) 
1.508 0.011 
NM_026742 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 
assembly factor 4 
1.507 0.016 
NM_007512 ATPase inhibitory factor 1 1.507 0.043 
NP_001158082 sphingomyelin phosphodiesterase 4 1.506 0.033 
NM_009033 RNA binding motif protein, X chromosome retrogene 1.505 0.033 
NM_178647 CGG triplet repeat binding protein 1 1.503 0.002 
NM_021512 nucleoporin 160 1.503 0.006 
NM_001103165 poly(rC) binding protein 2 1.503 0.042 
NM_001081164 OTU domain containing 4 1.501 0.012 
NM_016884 heterogeneous nuclear ribonucleoprotein C 1.499 0.035 
NM_198090 predicted gene 7498; hypothetical protein LOC635773; predicted 
gene 9242; predicted gene 6793; predicted gene 14730; 
predicted gene 7551; predicted gene 14398; predicted gene 
6528; predicted gene 6641; hypothetical protein LOC630507; 
predicted gene 5550;  
1.494 0.008 
NM_133780 similar to nuclear pore complex-associated intranuclear coiled-
coil protein TPR; translocated promoter region 
1.493 0.012 
NM_173763 cysteine conjugate-beta lyase 2 1.489 0.011 
NP_904359 phospholipase A2, group XIIA 1.489 0.040 
NM_010447 heterogeneous nuclear ribonucleoprotein A1-like 2; similar to 
heterogeneous nuclear ribonucleoprotein A1; predicted gene 
13418; predicted gene 5461; predicted gene 8652; predicted 
gene 5643; similar to Heterogeneous nuclear ribonucleoprotein 
A1 (Helix-des 
1.489 0.001 
NM_194342 unc-84 homolog B (C. elegans) 1.488 0.037 
NM_134138 proteasome (prosome, macropain) assembly chaperone 2; 
similar to Clast3 protein 
1.485 0.014 
NM_198326 NSFL1 (p97) cofactor (p47) 1.483 0.006 
NM_031165 similar to heat shock protein 8; heat shock protein 8 1.479 0.021 
NM_019816 apoptosis antagonizing transcription factor 1.475 0.045 
NM_001013374 lectin, mannose-binding 2-like 1.475 0.018 
NM_028599 WD repeat domain 75 1.474 0.015 
NM_017374 similar to protein phosphatase 2a, catalytic subunit, beta 
isoform; protein phosphatase 2 (formerly 2A), catalytic subunit, 
beta isoform 
1.473 0.012 
NM_001024806 CCAAT/enhancer binding protein zeta 1.473 0.045 
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NM_026276 aminoadipate-semialdehyde dehydrogenase-
phosphopantetheinyl transferase; hypothetical protein 
LOC100044211 
1.470 0.013 
NM_133242 RNA binding motif protein 39 1.469 0.014 
NM_008618 malate dehydrogenase 1, NAD (soluble) 1.468 0.034 
NM_016776 MYB binding protein (P160) 1a 1.468 0.015 
NM_145415 expressed sequence AA408296 1.467 0.002 
NM_001127346 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 
assembly factor 2 
1.466 0.026 
NM_001033297 predicted gene 561 1.464 0.004 
NM_175639 WD repeat domain 43; RIKEN cDNA 2610029G23 gene; 
hypothetical protein LOC674157 
1.463 0.004 
NM_001081028 signal-induced proliferation-associated 1 like 3 1.463 0.018 
NM_138607 family with sequence similarity 50, member A 1.462 0.048 
NM_080560 ubiquitin-conjugating enzyme E2N; similar to ubiquitin-
conjugating enzyme E2 UbcH-ben; similar to ubiquitin-
conjugating enzyme E2N; predicted gene 5943 
1.462 0.025 
NM_009634 adenylosuccinate lyase 1.462 0.012 
NM_053186 cyclin M3 1.461 0.049 
NM_027091 predicted gene 4353; nucleoporin 35 1.460 0.001 
NM_009025 RAS p21 protein activator 3 1.458 0.025 
NM_009798 capping protein (actin filament) muscle Z-line, beta 1.456 0.016 
NM_019562 ubiquitin carboxyl-terminal esterase L5 1.456 0.021 
NM_001163300 scaffold attachment factor B 1.456 0.016 
NM_010752 mitotic arrest deficient 1-like 1 1.455 0.028 
NM_134255 ELOVL family member 5, elongation of long chain fatty acids 
(yeast) 
1.455 0.001 
NM_007690 chromodomain helicase DNA binding protein 1 1.453 0.002 
NM_010613 KH-type splicing regulatory protein 1.453 0.003 
NM_026673 similar to Novel transmembrane domain containing protein; 
apolipoprotein O 
1.453 0.041 
NM_009089 polymerase (RNA) II (DNA directed) polypeptide A 1.451 0.036 
NM_009825 serine (or cysteine) peptidase inhibitor, clade H, member 1 1.450 0.029 
NM_024434 leucine aminopeptidase 3 1.448 0.010 
NM_001002929 nucleoporin 85 1.447 0.011 
NM_008828 phosphoglycerate kinase 1; predicted gene, EG668435 1.446 0.022 
NM_025820 Crn, crooked neck-like 1 (Drosophila) 1.446 0.020 
NM_026041 ribosomal RNA processing 15 homolog (S. cerevisiae) 1.444 0.014 
NM_008774 poly(A) binding protein, cytoplasmic 1 1.443 0.021 
NM_026270 AKT1 substrate 1 (proline-rich) 1.440 0.019 
NM_178918 UTP15, U3 small nucleolar ribonucleoprotein, homolog (yeast) 1.440 0.013 
NM_133928 coiled-coil-helix-coiled-coil-helix domain containing 4 1.439 0.016 
NM_024166 coiled-coil-helix-coiled-coil-helix domain containing 2; predicted 
gene 13202; similar to coiled-coil-helix-coiled-coil-helix domain 
containing 2; predicted gene 12350 
1.438 0.024 
NM_001001932 early endosome antigen 1 1.435 0.013 
NM_019869 RNA binding motif protein 14 1.433 0.024 
NM_008669 N-acetyl galactosaminidase, alpha 1.431 0.047 
NP_033778 A kinase (PRKA) anchor protein 1 1.428 0.034 
NM_145431 notchless homolog 1 (Drosophila) 1.428 0.010 
NM_030743 ring finger protein 114 1.428 0.000 
NM_007626 chromobox homolog 5 (Drosophila HP1a) 1.427 0.001 
NM_033526 ubiquilin 4 1.427 0.005 
NM_026075 SFRS12-interacting protein 1 1.425 0.046 
NM_023374 succinate dehydrogenase complex, subunit B, iron sulfur (Ip); 1.423 0.048 
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similar to succinate dehydrogenase Ip subunit 
NM_026305 predicted gene 11401; similar to transcription elongation factor 
B (SIII), polypeptide 2; predicted gene 8971; transcription 
elongation factor B (SIII), polypeptide 2 
1.422 0.007 
NM_007801 cathepsin H 1.421 0.021 
NM_016891 protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 
65), alpha isoform 
1.420 0.022 
NM_017393 caseinolytic peptidase, ATP-dependent, proteolytic subunit 
homolog (E. coli) 
1.420 0.023 
NM_025700 phosphoglucomutase 1 1.419 0.001 
NM_029631 abhydrolase domain containing 14b 1.419 0.023 
NM_008292 hydroxysteroid (17-beta) dehydrogenase 4 1.418 0.039 
NP_001092280 peptidyl-tRNA hydrolase 2 1.417 0.027 
NM_139139 DnaJ (Hsp40) homolog, subfamily C, member 17; predicted gene 
6257 
1.416 0.030 
NM_023153 CWC15 homolog (S. cerevisiae) 1.416 0.005 
NM_145706 nucleoporin 43 1.415 0.013 
NM_010568 insulin receptor 1.414 0.044 
NM_145627 RNA binding motif protein 10; predicted gene 12799 1.410 0.030 
NM_011431 elongation factor Tu GTP binding domain containing 2 1.409 0.011 
NM_001111279 WD repeat and FYVE domain containing 1 1.408 0.002 
NM_009383 Tia1 cytotoxic granule-associated RNA binding protein-like 1 1.404 0.011 
NM_172410 similar to nucleoporin 93; nucleoporin 93 1.403 0.008 
NM_019758 mitochondrial carrier homolog 2 (C. elegans); predicted gene, 
100039384; predicted gene, 100039506 
1.401 0.024 
NM_028766 transmembrane protein 43 1.397 0.029 
NM_025374 glyoxalase 1 1.395 0.019 
NM_177420 similar to Phosphoserine aminotransferase 1; phosphoserine 
aminotransferase 1 
1.395 0.028 
NM_001045523 bromo adjacent homology domain containing 1 1.392 0.045 
NM_001033268 family with sequence similarity 120, member A 1.390 0.002 
NM_178216 histone cluster 2, H3b; histone cluster 1, H3f; histone cluster 1, 
H3e; histone cluster 2, H3c1; histone cluster 1, H3d; histone 
cluster 1, H3c; histone cluster 1, H3b; histone cluster 2, H3c2; 
histone cluster 2, H2aa1; histone cluster 2, H2aa2 
1.388 0.033 
NM_025616 translocase of inner mitochondrial membrane 50 homolog 
(yeast) 
1.387 0.046 
NM_010722 lamin B2 1.386 0.045 
NM_001005419 2-aminoethanethiol (cysteamine) dioxygenase 1.385 0.026 
NM_145575 caldesmon 1 1.382 0.014 
NM_026439 coiled-coil domain containing 80 1.382 0.008 
NM_011508 predicted gene 5265; similar to suppressor of initiator codon 
mutations, related sequence 1; predicted gene 4017; predicted 
gene 6913; predicted gene 7688; predicted gene 6535; predicted 
gene 6900; predicted gene 5471; predicted gene 7845; predicted 
gene  
1.380 0.021 
NM_001013375 UTP18, small subunit (SSU) processome component, homolog 
(yeast) 
1.378 0.001 
NM_008388 eukaryotic translation initiation factor 3, subunit E 1.372 0.009 
NM_172532 aldhehyde dehydrogenase family 5, subfamily A1 1.371 0.042 
NM_027250 RIKEN cDNA 2010305A19 gene 1.369 0.026 
NM_016692 inner centromere protein 1.364 0.012 
NM_026438 pyrophosphatase (inorganic) 1 1.363 0.002 
NM_010322 glyceronephosphate O-acyltransferase 1.361 0.047 
NM_019765 CAP-GLY domain containing linker protein 1 1.359 0.032 
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NM_144804 DEP domain containing 7 1.358 0.018 
NM_028112 SEH1-like (S. cerevisiae 1.357 0.023 
NP_733486 RNA binding motif protein 12 1.357 0.000 
NM_138659 pre-mRNA processing factor 8 1.356 0.007 
NM_177253 cleavage stimulation factor, 3' pre-RNA, subunit 3 1.355 0.018 
NM_183017 tubulin tyrosine ligase-like family, member 12 1.354 0.005 
NM_025860 predicted gene 16433; similar to DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 18; predicted gene 9214; predicted gene 8173; 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 
1.352 0.021 
NM_019553 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 1.345 0.014 
NM_011814 fragile X mental retardation, autosomal homolog 2 1.344 0.016 
NM_028381 coiled-coil domain containing 94 1.343 0.030 
NM_026077 RIKEN cDNA 3110040N11 gene 1.342 0.038 
NM_023733 carnitine O-octanoyltransferase 1.342 0.021 
NM_026318 RIKEN cDNA 2310003F16 gene 1.341 0.038 
NP_001106817 similar to Transcriptional repressor p66 alpha (GATA zinc finger 
domain-containing protein 2A); GATA zinc finger domain 
containing 2A 
1.340 0.046 
NM_009672 acidic (leucine-rich) nuclear phosphoprotein 32 family, member 
A 
1.338 0.027 
NM_001080948 La ribonucleoprotein domain family, member 4; predicted gene 
14373; predicted gene 8177 
1.337 0.044 
NM_025482 tumor protein D52-like 2 1.336 0.014 
NM_027513 nucleoporin 205 1.335 0.014 
NM_025430 mitochondrial ribosomal protein L35 1.334 0.012 
NM_178707 zinc finger protein 592 1.334 0.020 
NM_001161816 predicted gene 15455 1.333 0.005 
NM_026313 RIKEN cDNA 3300001P08 gene 1.330 0.003 
NM_183020 ataxin 2-like 1.328 0.028 
NM_001081056 exportin, tRNA (nuclear export receptor for tRNAs) 1.328 0.029 
NM_009668 bridging integrator 1 1.328 0.004 
NM_023142 actin related protein 2/3 complex, subunit 1B 1.326 0.035 
NM_009975 casein kinase 2, beta polypeptide 1.325 0.032 
NM_028372 metallo-beta-lactamase domain containing 2 1.325 0.039 
NM_026452 coenzyme Q9 homolog (yeast) 1.324 0.044 
NM_009009 RAD21 homolog (S. pombe) 1.324 0.017 
NM_172404 cysteine conjugate-beta lyase 1 1.321 0.012 
NM_026578 GAR1 ribonucleoprotein homolog (yeast) 1.319 0.024 
NM_009471 uridine monophosphate synthetase 1.317 0.042 
NM_178625 transmembrane protein 209 1.317 0.003 
NM_001171147 yes-associated protein 1 1.316 0.033 
NM_016764 peroxiredoxin 4 1.316 0.021 
NM_010726 phytanoyl-CoA hydroxylase 1.314 0.019 
NM_007991 similar to Fibrillarin; fibrillarin 1.314 0.029 
NM_010123 eukaryotic translation initiation factor 3, subunit A 1.314 0.006 
NM_001164671 predicted gene 15542; predicted gene 7816; similar to DnaJ-like 
protein; predicted gene 6335; DnaJ (Hsp40) homolog, subfamily 
A, member 1, pseudogene; DnaJ (Hsp40) homolog, subfamily A, 
member 1 
1.313 0.040 
NM_133885 oxysterol binding protein-like 9 1.302 0.048 
NM_134077 RNA binding motif protein 26 1.301 0.010 
NM_026768 mitochondrial ribosomal protein S18A 1.299 0.030 
NM_013511 erythrocyte protein band 4.1-like 2 1.296 0.024 
NM_009456 predicted gene 7423; predicted gene 5858; predicted gene 6562; 
similar to ubiquitin-conjugating enzyme UbcH7; predicted gene 
1.293 0.026 
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3076; ubiquitin-conjugating enzyme E2L 3; predicted gene 
15267; predicted gene 9057; predicted gene 10705; predicted 
gene 10145 
NM_177214 small nuclear ribonucleoprotein 200 (U5) 1.290 0.020 
NM_009938 coatomer protein complex subunit alpha 1.289 0.036 
NM_172924 RIKEN cDNA C230081A13 gene 1.275 0.012 
NM_001017429 cytochrome c oxidase, subunit XVII assembly protein homolog 
(yeast) 
1.274 0.028 
NM_133953 splicing factor 3b, subunit 3 1.273 0.018 
NM_153126 N-acetyltransferase 10 1.268 0.033 
NM_009536 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, epsilon polypeptide 
1.262 0.010 
NM_001045529 microrchidia 3 1.261 0.025 
NM_016926 squamous cell carcinoma antigen recognized by T-cells 3 1.255 0.026 
NM_007687 cofilin 1, non-muscle; similar to Cofilin-1 (Cofilin, non-muscle 
isoform); predicted gene 6180 
1.252 0.004 
NM_026129 endoplasmic reticulum protein 29 1.251 0.010 
NM_001077529 predicted gene 7730; non-metastatic cells 2, protein (NM23B) 
expressed in; predicted gene 5566; predicted gene 5425; similar 
to Nucleoside diphosphate kinase B (NDK B) (NDP kinase B) (P18) 
1.250 0.008 
NM_001033300 guanine monphosphate synthetase; predicted gene 7282 1.249 0.006 
NM_009082 similar to ribosomal protein; predicted gene 6344; predicted 
gene 11449; predicted gene 13841; predicted gene 8210; 
hypothetical protein LOC675793; ribosomal protein L29; 
predicted gene 12704; predicted gene 7252; predicted gene 
8965; predicted gene 13213 
1.245 0.032 
NM_021299 adenylate kinase 3 1.243 0.039 
NP_001268984 Probable ATP-dependent RNA helicase DDX46 1.240 0.008 
NM_144560 growth arrest-specific 2 like 1 1.236 0.046 
NM_016805 heterogeneous nuclear ribonucleoprotein U 1.235 0.002 
NM_010135 enabled homolog (Drosophila) 1.228 0.039 
NM_183392 nucleoporin 54 1.227 0.023 
NP_001157089 threonyl-tRNA synthetase 2, mitochondrial (putative) 1.213 0.017 
NM_028044 similar to calponin 3, acidic; predicted gene 4815; calponin 3, 
acidic 
1.211 0.021 
NM_001024205 nuclear fragile X mental retardation protein interacting protein 2 1.210 0.009 
NM_019489 peptidylprolyl isomerase E (cyclophilin E) 1.209 0.006 
NM_145610 peter pan homolog (Drosophila) 1.206 0.008 
NM_134010 nucleoporin 107 1.203 0.014 
NM_023764 toll interacting protein -1.203 0.016 
NM_009424 TNF receptor-associated factor 6 -1.205 0.001 
NM_025691 signal recognition particle 72 -1.208 0.048 
NM_175546 WD repeat and FYVE domain-containing protein 2 -1.211 0.041 
NM_175313 RIKEN cDNA A130022J15 gene -1.213 0.002 
NM_012001 COP9 (constitutive photomorphogenic) homolog, subunit 4 
(Arabidopsis thaliana) 
-1.217 0.021 
NM_175244 HECT domain containing 3 -1.217 0.027 
NM_181594 enhancer of mRNA decapping 4 -1.218 0.048 
NM_009418 tripeptidyl peptidase II -1.219 0.020 
NM_029746 component of oligomeric golgi complex 2 -1.229 0.024 
NM_011370 cytoplasmic FMR1 interacting protein 1 -1.231 0.035 
NM_181413 ankyrin repeat and SAM domain containing 1 -1.231 0.004 
NM_133913 RIKEN cDNA 2010209O12 gene -1.232 0.023 
NP_001185841 Rho guanine nucleotide exchange factor 2 -1.236 0.025 
NM_007381 acyl-Coenzyme A dehydrogenase, long-chain -1.249 0.003 
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NM_027185 differentially expressed in FDCP 6 -1.250 0.003 
NM_138749 plexin B2 -1.250 0.033 
NM_175145 transmembrane protein 127 -1.251 0.007 
NM_146001 huntingtin interacting protein 1 -1.253 0.004 
NM_172338 DnaJ (Hsp40) homolog, subfamily C, member 16 -1.254 0.029 
NM_019760 serine incorporator 1 -1.255 0.020 
NM_133717 RAB43, member RAS oncogene family -1.257 0.039 
NM_007438 aldolase A, fructose-bisphosphate; predicted gene 8767; 
predicted gene 7556 
-1.258 0.012 
NM_024465 abhydrolase domain containing 12 -1.258 0.048 
NM_021420 serine/threonine kinase 4 -1.262 0.018 
NM_012042 cullin 1 -1.268 0.007 
NM_008564 minichromosome maintenance deficient 2 mitotin (S. cerevisiae) -1.268 0.007 
NM_178645 bleomycin hydrolase -1.270 0.000 
NM_008929 DnaJ (Hsp40) homolog, subfamily C, member 3 -1.270 0.011 
NM_001136075 numb gene homolog (Drosophila) -1.270 0.016 
NM_011130 polymerase (DNA directed), beta -1.275 0.001 
NM_201226 leucine rich repeat containing 47; similar to leucine rich repeat 
containing 47 
-1.275 0.014 
NM_010301 guanine nucleotide binding protein, alpha 11 -1.276 0.021 
NM_001113413 ring finger protein 13 -1.278 0.010 
NM_019826 isovaleryl coenzyme A dehydrogenase -1.279 0.038 
NM_033477 DNA segment, Chr 17, human D6S53E -1.286 0.005 
NM_030035 golgi autoantigen, golgin subfamily b, macrogolgin 1 -1.287 0.018 
NM_001034085 protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 
65), beta isoform 
-1.287 0.020 
NM_026061 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8 -1.293 0.019 
NM_009103 ribonucleotide reductase M1 -1.294 0.011 
NP_001153189 septin 2 -1.294 0.023 
NM_008184 glutathione S-transferase, mu 6 -1.296 0.039 
NM_009680 adaptor-related protein complex 3, beta 1 subunit -1.297 0.040 
NM_025835 propionyl Coenzyme A carboxylase, beta polypeptide -1.297 0.044 
NM_184053 calumenin -1.298 0.005 
NM_007598 CAP, adenylate cyclase-associated protein 1 (yeast) -1.298 0.022 
NM_024267 importin 4 -1.314 0.015 
NM_001163026 DnaJ (Hsp40) homolog, subfamily C, member 13 -1.315 0.012 
NM_028782 lon peptidase 1, mitochondrial -1.325 0.023 
NM_016802 ras homolog gene family, member A; similar to aplysia ras-
related homolog A2; predicted gene 12844 
-1.327 0.037 
NM_027707 Nipped-B homolog (Drosophila) -1.328 0.005 
NM_008136 guanine nucleotide binding protein-like 1 -1.329 0.011 
NM_025429 serine (or cysteine) peptidase inhibitor, clade B, member 1a -1.333 0.030 
NM_009812 caspase 8 -1.335 0.023 
NP_035932 caseinolytic peptidase X (E.coli) -1.337 0.028 
NM_007861 dihydrolipoamide dehydrogenase -1.338 0.015 
NM_009072 Rho-associated coiled-coil containing protein kinase 2 -1.341 0.010 
NM_178589 tumor necrosis factor receptor superfamily, member 21 -1.342 0.048 
NM_007754 carboxypeptidase D; similar to carboxypeptidase D -1.343 0.026 
NM_011706 transient receptor potential cation channel, subfamily V, 
member 2 
-1.343 0.043 
NM_001077411 glucosidase, beta, acid -1.348 0.026 
NM_027270 exocyst complex component 1 -1.349 0.028 
NM_023525 carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, 
and dihydroorotase 
-1.350 0.001 
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NM_010163 exostoses (multiple) 2 -1.355 0.028 
NM_007399 a disintegrin and metallopeptidase domain 10 -1.362 0.005 
NM_008293 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid 
delta-isomerase 1 
-1.363 0.013 
NM_007499 ataxia telangiectasia mutated homolog (human) -1.366 0.036 
NM_134100 major facilitator superfamily domain containing 5 -1.366 0.014 
NM_001081309 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 4, 
p150 
-1.368 0.011 
NM_080287 engulfment and cell motility 2, ced-12 homolog (C. elegans) -1.371 0.015 
NM_011874 proteasome (prosome, macropain) 26S subunit, ATPase, 4 -1.376 0.008 
NM_007999 flap structure specific endonuclease 1 -1.379 0.029 
NM_009373 transglutaminase 2, C polypeptide -1.379 0.004 
NM_027357 proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 -1.381 0.000 
NM_008947 similar to peptidase (prosome, macropain) 26S subunit, ATPase 
1; protease (prosome, macropain) 26S subunit, ATPase 1 
-1.384 0.014 
NM_178029 SET domain containing 1A -1.385 0.014 
NM_213614 similar to CDCrel-1AI; septin 5 -1.387 0.015 
NP_001185796 Dynactin subunit 1 -1.390 0.027 
NM_001013371 deltex 3-like (Drosophila) -1.395 0.026 
NM_007908 eukaryotic elongation factor-2 kinase -1.397 0.035 
NM_172767 von Willebrand factor A domain containing 5A -1.397 0.026 
NM_011602 talin 1 -1.400 0.009 
NM_198249 RIKEN cDNA E130112L23 gene -1.400 0.023 
NM_153592 ER lipid raft associated 2 -1.400 0.000 
NP_001005331 eukaryotic translation initiation factor 4, gamma 1 -1.401 0.007 
NM_011875 proteasome (prosome, macropain) 26S subunit, non-ATPase, 13 -1.403 0.006 
NM_133794 glutaminyl-tRNA synthetase -1.404 0.025 
NM_013657 sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3C 
-1.405 0.009 
NM_023644 methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) -1.406 0.006 
NM_030262 protein O-fucosyltransferase 2 -1.407 0.001 
NM_144941 microtubule-associated protein 7 domain containing 1 -1.409 0.001 
NM_130862 brain-specific angiogenesis inhibitor 1-associated protein 2 -1.410 0.006 
NM_010620 kinesin family member 15 -1.411 0.022 
NM_172827 leucyl/cystinyl aminopeptidase -1.414 0.045 
NM_153569 cyclin G associated kinase -1.415 0.024 
NM_025692 ubiquitin-like modifier activating enzyme 5 -1.415 0.032 
NM_008565 minichromosome maintenance deficient 4 homolog (S. 
cerevisiae) 
-1.415 0.022 
NM_010763 mannosidase, alpha, class 1A, member 2 -1.416 0.035 
NM_011723 xanthine dehydrogenase -1.418 0.026 
NM_133995 ureidopropionase, beta -1.418 0.025 
NM_008788 procollagen C-endopeptidase enhancer protein -1.420 0.038 
NM_080638 major vault protein -1.420 0.018 
NM_008149 glycerol-3-phosphate acyltransferase, mitochondrial -1.422 0.034 
NM_009795 calpain, small subunit 1 -1.422 0.048 
NM_028662 solute carrier family 35, member B2 -1.423 0.032 
NM_020332 progressive ankylosis -1.426 0.034 
NM_181395 peroxidasin homolog (Drosophila) -1.428 0.001 
NM_011787 autocrine motility factor receptor -1.429 0.016 
NM_026079 inhibitor of kappa light polypeptide enhancer in B-cells, kinase 
complex-associated protein 
-1.430 0.001 
NM_026644 1-acylglycerol-3-phosphate O-acyltransferase 4 (lysophosphatidic 
acid acyltransferase, delta) 
-1.430 0.037 
NM_010941 NAD(P) dependent steroid dehydrogenase-like -1.432 0.007 
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NM_030253 poly (ADP-ribose) polymerase family, member 9 -1.432 0.008 
NM_008984 protein tyrosine phosphatase, receptor type, M -1.434 0.035 
NM_053110 glycoprotein (transmembrane) nmb -1.435 0.026 
NM_011312 S100 calcium binding protein A5 -1.442 0.009 
NM_008448 kinesin family member 5B -1.445 0.003 
NM_009212 immunoglobulin mu binding protein 2 -1.446 0.044 
NM_053262 hydroxysteroid (17-beta) dehydrogenase 11 -1.449 0.044 
NM_001160330 molybdenum cofactor synthesis 3 -1.452 0.000 
NM_008481 laminin, alpha 2 -1.456 0.022 
NM_021429 HCLS1 binding protein 3 -1.456 0.005 
NM_001033167 solute carrier family 22, member 23 -1.456 0.048 
NM_026545 proteasome (prosome, macropain) 26S subunit, non-ATPase, 8 -1.460 0.027 
NM_019519 Rab geranylgeranyl transferase, a subunit -1.462 0.041 
NM_133907 ubiquitin protein ligase E3C -1.467 0.031 
NM_139144 O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-acetylglucosaminyl 
transferase) 
-1.469 0.030 
NM_023420 collagen, type IV, alpha 3 (Goodpasture antigen) binding protein -1.472 0.029 
NM_008364 interleukin 1 receptor accessory protein -1.476 0.025 
NM_175193 golgi integral membrane protein 4 -1.477 0.041 
NM_030238 dynein cytoplasmic 1 heavy chain 1 -1.477 0.011 
NM_013700 ubiquitin specific peptidase 5 (isopeptidase T) -1.483 0.025 
NM_013796 N-acetylglucosamine-1-phosphodiester alpha-N-
acetylglucosaminidase 
-1.484 0.035 
NM_008328 similar to Interferon-activatable protein 203 (Ifi-203) (Interferon-
inducible protein p203); similar to interferon activated gene 203; 
interferon activated gene 203 
-1.484 0.009 
NM_008566 minichromosome maintenance deficient 5, cell division cycle 46 
(S. cerevisiae) 
-1.487 0.038 
NM_198007 activating signal cointegrator 1 complex subunit 3 -1.488 0.002 
NM_173443 valosin containing protein (p97)/p47 complex interacting protein 
1 
-1.495 0.034 
NM_010708 lectin, galactose binding, soluble 9 -1.495 0.026 
NM_011696 predicted gene 7591; voltage-dependent anion channel 3 -1.498 0.015 
NM_177876 vacuolar protein sorting 37B (yeast) -1.500 0.029 
NM_009045 v-rel reticuloendotheliosis viral oncogene homolog A (avian) -1.506 0.024 
NM_001080968 golgi autoantigen, golgin subfamily a, 2 -1.507 0.028 
NM_029572 endoplasmic reticulum protein 44 -1.512 0.014 
NM_008255 3-hydroxy-3-methylglutaryl-Coenzyme A reductase -1.514 0.049 
NM_133224 ATPase type 13A1 -1.516 0.008 
NP_001020566 Rous sarcoma oncogene -1.517 0.015 
NM_172769 sterol-C5-desaturase (fungal ERG3, delta-5-desaturase) homolog 
(S. cerevisae) 
-1.517 0.010 
NM_026171 nuclear VCP-like -1.517 0.010 
NM_198163 RAB35, member RAS oncogene family -1.518 0.013 
NM_183106 tetratricopeptide repeat domain 17 -1.518 0.023 
NM_010562 integrin linked kinase; predicted gene 6263 -1.518 0.048 
NM_013472 annexin A6 -1.519 0.001 
NM_001081193 LEM domain containing 3 -1.519 0.006 
NM_028264 transmembrane protein 55A -1.520 0.006 
NM_013495 carnitine palmitoyltransferase 1a, liver -1.520 0.049 
NM_001163126 component of oligomeric golgi complex 5 -1.522 0.024 
NM_001081252 UDP-glucose ceramide glucosyltransferase-like 2 -1.522 0.013 
NP_001240821 Anion exchange protein 2 -1.522 0.048 
NM_013528 glutamine fructose-6-phosphate transaminase 1 -1.523 0.002 
Appendix A 
 
- 15 - 
 
NM_027677 G protein-coupled receptor 39 -1.523 0.002 
NM_007842 DEAH (Asp-Glu-Ala-His) box polypeptide 9 -1.524 0.026 
NM_028817 acyl-CoA synthetase long-chain family member 3 -1.526 0.034 
NM_177215 oculocerebrorenal syndrome of Lowe -1.527 0.003 
NM_027127 glutathione peroxidase 8 (putative) -1.527 0.036 
NM_009112 S100 calcium binding protein A10 (calpactin) -1.527 0.036 
NM_011026 purinergic receptor P2X, ligand-gated ion channel 4 -1.528 0.048 
NM_009755 bone morphogenetic protein 1 -1.528 0.012 
NM_172381 expressed sequence AI314180 -1.530 0.031 
NM_001013380 dynein, cytoplasmic 1 light intermediate chain 2 -1.532 0.020 
NM_008684 neogenin -1.533 0.008 
NM_008562 similar to myeloid cell leukemia sequence 1; myeloid cell 
leukemia sequence 1 
-1.534 0.011 
NM_008512 low density lipoprotein receptor-related protein 1 -1.534 0.027 
NM_025816 Tax1 (human T-cell leukemia virus type I) binding protein 1 -1.536 0.035 
NM_027815 RIKEN cDNA 9030624J02 gene -1.536 0.009 
NM_144792 sphingomyelin synthase 1 -1.538 0.044 
NM_010261 Rab acceptor 1 (prenylated) -1.539 0.000 
NM_011018 sequestosome 1 -1.541 0.039 
NM_133838 EH-domain containing 4 -1.541 0.006 
NM_010515 insulin-like growth factor 2 receptor -1.543 0.001 
NM_025551 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 -1.544 0.018 
NM_013795 predicted gene 10221; predicted gene 4602; predicted gene 
9391; ATP synthase, H+ transporting, mitochondrial FO complex, 
subunit G2, pseudogene; predicted gene 11477; predicted gene 
9712; ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit g; 
-1.546 0.000 
NM_145543 chloride channel CLIC-like 1 -1.546 0.001 
NM_009794 calpain 2 -1.548 0.011 
NM_008826 phosphofructokinase, liver, B-type -1.550 0.027 
NM_025550 proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 -1.552 0.036 
NM_008482 laminin B1 subunit 1 -1.552 0.000 
NM_022009 flightless I homolog (Drosophila); similar to cytoskeletal actin-
modulating protein 
-1.553 0.003 
NM_001146268 platelet derived growth factor receptor, beta polypeptide -1.554 0.015 
NM_145558 predicted gene 13910; similar to Hydroxyacyl-Coenzyme A 
dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-
Coenzyme A hydratase (trifunctional protein), beta subunit; 
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme 
A thiolase/enoyl-Coenzyme A hyd 
-1.555 0.044 
NM_025586 similar to ribosomal protein L15; predicted gene 8420; predicted 
gene 6937; predicted gene 4581; predicted gene 5613; predicted 
gene 7287; predicted gene, 674243; predicted gene 4607; 
predicted gene 10224; predicted gene 8037; predicted gene 
4294; predict 
-1.557 0.044 
NM_021557 retinol dehydrogenase 11 -1.558 0.000 
NM_027992 transmembrane protein 106B -1.558 0.032 
NM_026610 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 4; 
predicted gene 3873; predicted gene 3244 
-1.560 0.028 
NM_145506 erythrocyte protein band 4.1-like 5 -1.560 0.013 
NM_009149 golgi apparatus protein 1 -1.561 0.025 
NM_134083 regulator of chromosome condensation (RCC1) and BTB (POZ) 
domain containing protein 2 
-1.562 0.014 
NM_024436 RAB22A, member RAS oncogene family -1.563 0.003 
NM_010890 neural precursor cell expressed, developmentally down- -1.564 0.002 
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regulated 4 
NM_176860 ubiquitin associated and SH3 domain containing, B -1.564 0.037 
NM_007988 fatty acid synthase -1.565 0.000 
NM_030013 cytochrome P450, family 20, subfamily A, polypeptide 1 -1.566 0.015 
NM_007508 ATPase, H+ transporting, lysosomal V1 subunit A -1.569 0.010 
NM_024226 reticulon 4 -1.569 0.011 
NM_010875 neural cell adhesion molecule 1 -1.572 0.002 
NM_020586 HERPUD family member 2 -1.572 0.002 
NM_173013 microtubule-associated protein 1S -1.573 0.007 
NM_011313 S100 calcium binding protein A6 (calcyclin) -1.575 0.043 
NM_178772 arylacetamide deacetylase-like 1 -1.575 0.031 
NM_011704 vanin 1 -1.577 0.002 
NM_001045489 milk fat globule-EGF factor 8 protein -1.577 0.020 
NM_152801 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 -1.578 0.021 
NM_009842 CD151 antigen -1.579 0.029 
NM_007509 ATPase, H+ transporting, lysosomal V1 subunit B2 -1.579 0.006 
NM_012002 COP9 (constitutive photomorphogenic) homolog, subunit 6 
(Arabidopsis thaliana) 
-1.579 0.026 
NM_010546 inhibitor of kappaB kinase beta -1.580 0.019 
NM_080445 similar to UDP-Gal:betaGal beta 1,3-galactosyltransferase, 
polypeptide 6; UDP-Gal:betaGal beta 1,3-galactosyltransferase, 
polypeptide 6 
-1.582 0.016 
NM_008898 P450 (cytochrome) oxidoreductase -1.582 0.008 
NM_019703 phosphofructokinase, platelet -1.583 0.004 
NM_009530 alpha thalassemia/mental retardation syndrome X-linked 
homolog (human) 
-1.583 0.001 
NM_016721 IQ motif containing GTPase activating protein 1 -1.584 0.002 
NM_009371 transforming growth factor, beta receptor II -1.585 0.002 
NM_011311 hippocampus abundant transcript-like 1; S100 calcium binding 
protein A4 
-1.586 0.007 
NM_009933 collagen, type VI, alpha 1 -1.586 0.013 
NM_178376 Ras-related GTP binding A -1.591 0.025 
NM_175229 serine/arginine repetitive matrix 2; similar to Serine/arginine 
repetitive matrix protein 2; similar to retinitis pigmentosa 
GTPase regulator 
-1.592 0.012 
NM_027410 tectonin beta-propeller repeat containing 1 -1.592 0.011 
XM_001475417 similar to cytochrome c oxidase, subunit Vb; predicted gene 
11273; cytochrome c oxidase, subunit Vb 
-1.592 0.022 
NM_138579 TRIO and F-actin binding protein -1.592 0.002 
NM_145138 NIMA (never in mitosis gene a)-related expressed kinase 9 -1.593 0.018 
NM_008948 proteasome (prosome, macropain) 26S subunit, ATPase 3 -1.595 0.005 
NM_011504 syntaxin binding protein 3A -1.596 0.017 
NM_025515 similar to Coiled-coil domain containing 90B; coiled-coil domain 
containing 90B 
-1.596 0.031 
NM_001081066 DENN/MADD domain containing 3 -1.598 0.006 
NM_183162 cDNA sequence BC006779 -1.598 0.039 
NM_009465 AXL receptor tyrosine kinase -1.599 0.003 
NM_009481 ubiquitin specific peptidase 9, X chromosome -1.601 0.006 
NM_008133 glutamate dehydrogenase 1; predicted gene 5902 -1.602 0.002 
NM_008325 iduronidase, alpha-L- -1.603 0.008 
NM_008451 kinesin light chain 2 -1.604 0.014 
NM_010046 diacylglycerol O-acyltransferase 1 -1.605 0.036 
NM_175126 zinc finger, CCHC domain containing 3 -1.606 0.043 
NM_023220 RIKEN cDNA 2010106G01 gene -1.607 0.012 
NM_028248 transmembrane protein 87B -1.608 0.022 
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NM_021607 nicastrin -1.608 0.047 
NM_022563 discoidin domain receptor family, member 2 -1.610 0.020 
NM_145925 pituitary tumor-transforming 1 interacting protein -1.612 0.003 
NM_144922 heterogeneous nuclear ribonucleoprotein U-like 1 -1.613 0.002 
NM_019811 acyl-CoA synthetase short-chain family member 2 -1.613 0.039 
NM_033320 glucuronyl C5-epimerase -1.613 0.037 
NM_178070 vacuolar protein sorting 33B (yeast) -1.614 0.006 
NM_029005 mixed lineage kinase domain-like -1.614 0.004 
NM_007502 ATPase, Na+/K+ transporting, beta 3 polypeptide -1.615 0.016 
NM_172935 amidohydrolase domain containing 2 -1.618 0.030 
NM_010577 integrin alpha 5 (fibronectin receptor alpha) -1.619 0.025 
NM_011989 solute carrier family 27 (fatty acid transporter), member 4 -1.621 0.035 
NM_013587 low density lipoprotein receptor-related protein associated 
protein 1 
-1.623 0.001 
NM_133348 acyl-CoA thioesterase 7 -1.623 0.001 
NM_009269 serine palmitoyltransferase, long chain base subunit 1 -1.626 0.008 
NM_016709 AU RNA binding protein/enoyl-coenzyme A hydratase -1.627 0.001 
NM_001033284 cDNA sequence BC026585 -1.627 0.006 
NM_010362 glutathione S-transferase omega 1 -1.630 0.033 
NM_029091 kinesin light chain 4 -1.630 0.005 
NM_019861 cathepsin F -1.633 0.013 
NM_009294 syntaxin 4A (placental) -1.633 0.006 
NM_175438 aldehyde dehydrogenase 4 family, member A1 -1.633 0.001 
NM_011654 predicted gene 3756; tubulin, alpha 1B; predicted gene 5620; 
similar to alpha-tubulin isotype M-alpha-2; predicted gene 
14150; predicted gene 3226 
-1.635 0.000 
NM_144825 TAO kinase 1 -1.637 0.009 
NM_016679 kelch-like ECH-associated protein 1 -1.639 0.049 
NM_139272 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 2 
-1.640 0.032 
NM_207298 cerebral endothelial cell adhesion molecule -1.641 0.005 
NM_010684 lysosomal-associated membrane protein 1 -1.642 0.048 
NM_198105 family with sequence similarity 120, member C -1.643 0.009 
NM_172380 KTEL (Lys-Tyr-Glu-Leu) containing 1 -1.644 0.009 
NM_010233 fibronectin 1 -1.645 0.025 
NM_001004156 pleckstrin homology domain containing, family G (with RhoGef 
domain) member 5 
-1.646 0.048 
NM_001025250 vascular endothelial growth factor A -1.646 0.050 
NM_054097 phosphatidylinositol-5-phosphate 4-kinase, type II, gamma -1.647 0.006 
NM_139307 vasorin -1.647 0.012 
NM_007530 B-cell receptor-associated protein 29 -1.648 0.007 
NM_019802 gamma-glutamyl carboxylase -1.649 0.031 
NM_053181 pyridoxal-dependent decarboxylase domain containing 1 -1.649 0.038 
NM_026719 LMBR1 domain containing 1 -1.650 0.001 
NM_172687 coenzyme Q3 homolog, methyltransferase (yeast) -1.650 0.041 
NM_024281 ribosome binding protein 1 -1.654 0.008 
NM_001083316 platelet derived growth factor receptor, alpha polypeptide -1.655 0.001 
NM_172557 RUN and FYVE domain containing 1 -1.656 0.027 
NM_017380 septin 9 -1.658 0.000 
NM_030210 acetoacetyl-CoA synthetase -1.658 0.031 
NM_015742 myosin IXb -1.659 0.004 
NM_017472 sorting nexin 3 -1.660 0.038 
NM_001009818 septin 11 -1.662 0.040 
NM_153774 importin 9 -1.663 0.010 
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NM_153125 SEC16 homolog A (S. cerevisiae) -1.664 0.017 
NM_026698 transmembrane protein 129 -1.665 0.028 
NM_011170 prion protein -1.666 0.006 
NM_029841 RIKEN cDNA 2510039O18 gene; similar to RIKEN cDNA 
2510039O18 gene 
-1.666 0.022 
NM_011076 ATP-binding cassette, sub-family B (MDR/TAP), member 1A -1.666 0.022 
NM_010117 rhomboid family 1 (Drosophila) -1.669 0.036 
NM_177304 ectonucleotide pyrophosphatase/phosphodiesterase 6 -1.670 0.003 
NM_146121 RAB GTPase activating protein 1 -1.670 0.008 
NP_001240839 Protein Nat8f7 -1.671 0.021 
NP_001070732 adaptor protein complex AP-2, alpha 1 subunit -1.671 0.022 
NM_026228 solute carrier family 39 (metal ion transporter), member 8 -1.672 0.002 
NM_133826 ATPase, H+ transporting, lysosomal V1 subunit H -1.674 0.012 
NM_001033293 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 -1.676 0.003 
NM_001033202 ubiquitin specific peptidase 30 -1.677 0.006 
NM_145619 poly (ADP-ribose) polymerase family, member 3 -1.678 0.008 
NM_001081306 protein tyrosine phosphatase, receptor type Z, polypeptide 1 -1.678 0.021 
NM_194334 TBC1 domain family, member 2B -1.678 0.017 
NM_144878 flavin containing monooxygenase 4 -1.679 0.016 
NM_010239 ferritin heavy chain 1 -1.680 0.008 
NM_153800 Rho GTPase activating protein 22 -1.682 0.009 
NM_011400 solute carrier family 2 (facilitated glucose transporter), member 
1 
-1.683 0.002 
NM_026677 RAB13, member RAS oncogene family -1.683 0.002 
NM_053014 1-acylglycerol-3-phosphate O-acyltransferase 3 -1.684 0.002 
NM_028428 fucosyltransferase 11 -1.684 0.033 
NM_021534 peroxisomal membrane protein 4 -1.685 0.026 
NM_009288 serine/threonine kinase 10 -1.687 0.004 
NM_010049 dihydrofolate reductase -1.691 0.003 
NM_145960 mitochondrial translational release factor 1 -1.692 0.010 
NM_172570 tripartite motif-containing 47 -1.693 0.024 
NM_024436 RAB22A, member RAS oncogene family -1.697 0.003 
NM_133921 nuclear transcription factor, X-box binding-like 1 -1.697 0.012 
NM_029884 heparan-alpha-glucosaminide N-acetyltransferase -1.698 0.003 
NM_175121 solute carrier family 38, member 2 -1.702 0.011 
NM_145540 integrator complex subunit 3 -1.708 0.004 
NM_001033534 layilin -1.708 0.016 
NM_007653 CD63 antigen -1.711 0.017 
NP_001116240 leucine rich repeat containing 8D -1.712 0.006 
NM_008980 protein tyrosine phosphatase, receptor type, A -1.712 0.003 
NM_008175 granulin -1.713 0.015 
NP_062718 Nuclear receptor coactivator 4 -1.713 0.005 
NM_013792 alpha-N-acetylglucosaminidase (Sanfilippo disease IIIB) -1.715 0.026 
NM_027379 fatty acyl CoA reductase 1 -1.716 0.001 
NM_080555 phosphatidic acid phosphatase type 2B -1.725 0.001 
NM_153198 high mobility group box transcription factor 1 -1.725 0.004 
NM_026825 leucine rich repeat containing 16A -1.727 0.013 
NM_008608 matrix metallopeptidase 14 (membrane-inserted) -1.730 0.005 
NM_022018 family with sequence similarity 129, member A -1.735 0.003 
NM_007387 acid phosphatase 2, lysosomal -1.738 0.009 
NM_011577 transforming growth factor, beta 1 -1.739 0.007 
NM_007874 receptor accessory protein 5 -1.741 0.040 
NP_001258788 Beta-adducin -1.744 0.012 
NM_007643 CD36 antigen -1.752 0.004 
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NM_010106 predicted gene 5869; predicted gene 7161; predicted gene 7105; 
predicted gene 5822; similar to eukaryotic translation elongation 
factor 1 alpha 1; predicted gene 6192; predicted gene 6392; 
predicted gene 6767; predicted gene 6170; predicted gene 6548; 
pre 
-1.754 0.005 
NM_010441 predicted gene 7996; high mobility group AT-hook 2 -1.755 0.005 
NM_010212 four and a half LIM domains 2 -1.757 0.007 
NM_029600 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 -1.758 0.003 
NM_031871 GH3 domain containing -1.768 0.003 
NM_178337 tubulin-specific chaperone E -1.770 0.000 
NP_034873 interleukin 1 receptor-like 1 -1.772 0.010 
NM_030201 heat shock protein 70 family, member 13 -1.784 0.027 
NM_007982 PTK2 protein tyrosine kinase 2 -1.797 0.002 
NM_028431 peptidase (mitochondrial processing) beta -1.803 0.017 
NM_172456 endo/exonuclease (5'-3'), endonuclease G-like -1.818 0.005 
NM_013477 ATPase, H+ transporting, lysosomal V0 subunit D1 -1.822 0.002 
 
Table 1-B: Differentially regulated CHO DP-12 proteins determined in samples corresponding to 
culture using a reduced bioprocessing temperature of 32.0oC 
RefSeq 
Annotation 
Description Fold 
Change 
P-
Value 
NM_011638 transferrin receptor 1.792 0.025 
NM_008881 plexin A1 1.782 0.005 
NM_023130 RIKEN cDNA C130057N11 gene; hnRNP-associated with lethal 
yellow 
1.728 0.002 
NP_001103445 synaptopodin 1.713 0.009 
NM_146090 zinc binding alcohol dehydrogenase, domain containing 2 1.701 0.017 
NM_011170 prion protein 1.697 0.007 
NM_028870 clathrin, light polypeptide (Lcb) 1.692 0.028 
NM_026159 retinol saturase (all trans retinol 13,14 reductase) 1.691 0.023 
NM_021895 actinin alpha 4 1.680 0.042 
NM_008558 similar to Myn protein; Max protein 1.680 0.026 
NM_026041 ribosomal RNA processing 15 homolog (S. cerevisiae) 1.679 0.010 
NM_025788 nucleus accumbens associated 1, BEN and BTB (POZ) domain 
containing 
1.675 0.002 
NM_130862 brain-specific angiogenesis inhibitor 1-associated protein 2 1.673 0.001 
NM_011544 transcription factor 12 1.670 0.026 
NM_001163662 nucleobindin 1 1.665 0.047 
NM_019772 predicted gene 9169; RIKEN cDNA 1110004F10 gene; similar to 
small acidic protein 
1.662 0.033 
NM_026277 NIN1/RPN12 binding protein 1 homolog (S. cerevisiae) 1.661 0.000 
NM_175126 zinc finger, CCHC domain containing 3 1.660 0.042 
NM_009264 small proline-rich protein 1A 1.658 0.043 
NM_026623 nudix (nucleoside diphosphate linked moiety X)-type motif 21 1.656 0.002 
NM_016844 similar to 40S ribosomal protein S28; predicted gene 10443; 
predicted gene 12943; predicted gene 13192; similar to ribosomal 
protein S28; predicted gene 10263; predicted gene 3511; 
ribosomal protein S28 
1.654 0.018 
NM_172943 similar to AlkB, alkylation repair homolog 5 (E. coli); alkB, 
alkylation repair homolog 5 (E. coli) 
1.654 0.022 
NM_009032 RNA binding motif protein 4 1.653 0.038 
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NM_008980 protein tyrosine phosphatase, receptor type, A 1.649 0.031 
NM_023731 coiled-coil domain containing 86 1.644 0.008 
NM_026732 mitochondrial ribosomal protein L14 1.633 0.037 
NM_133887 syntaxin 12 1.624 0.015 
NM_019813 drebrin 1 1.610 0.003 
NM_021895 actinin alpha 4 1.610 0.010 
NM_027044 prefoldin 5 1.602 0.040 
NM_001033284 cDNA sequence BC026585 1.600 0.000 
NM_183020 ataxin 2-like 1.594 0.003 
NM_011197 prostaglandin F2 receptor negative regulator 1.591 0.022 
NM_008562 similar to myeloid cell leukemia sequence 1; myeloid cell leukemia 
sequence 1 
1.590 0.002 
NM_080555 phosphatidic acid phosphatase type 2B 1.587 0.001 
NM_033526 ubiquilin 4 1.583 0.029 
NM_016690 heterogeneous nuclear ribonucleoprotein D-like 1.580 0.042 
NM_021557 retinol dehydrogenase 11 1.576 0.004 
NM_010213 four and a half LIM domains 3 1.572 0.018 
NM_021336 small nuclear ribonucleoprotein polypeptide A' 1.571 0.039 
NM_024166 coiled-coil-helix-coiled-coil-helix domain containing 2; predicted 
gene 13202; similar to coiled-coil-helix-coiled-coil-helix domain 
containing 2; predicted gene 12350 
1.569 0.047 
NM_008972 predicted gene 12504; predicted gene 9800; predicted gene 4617; 
predicted gene 6625; predicted gene 7614; similar to prothymosin 
alpha; prothymosin alpha; predicted gene 9009 
1.568 0.018 
NM_025587 predicted gene 5963; ribosomal protein S21 1.568 0.050 
NM_020506 exportin 4 1.561 0.024 
NM_010875 neural cell adhesion molecule 1 1.560 0.012 
NM_011312 S100 calcium binding protein A5 1.560 0.021 
NM_025682 paraspeckle protein 1 1.554 0.006 
NM_025315 mediator complex subunit 21 1.552 0.008 
NM_016786 ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast) 1.552 0.029 
NM_026677 RAB13, member RAS oncogene family 1.552 0.034 
NM_025430 mitochondrial ribosomal protein L35 1.550 0.009 
NP_001129553 structure specific recognition protein 1 1.550 0.022 
NM_001171147 yes-associated protein 1 1.547 0.041 
NM_153787 BCL2-associated transcription factor 1 1.546 0.006 
NM_026538 DEAD (Asp-Glu-Ala-Asp) box polypeptide 56 1.546 0.015 
NM_172769 sterol-C5-desaturase (fungal ERG3, delta-5-desaturase) homolog 
(S. cerevisae) 
1.541 0.017 
NM_144560 growth arrest-specific 2 like 1 1.539 0.016 
NM_001024205 nuclear fragile X mental retardation protein interacting protein 2 1.534 0.013 
NM_009643 AHNAK nucleoprotein (desmoyokin) 1.521 0.001 
NM_144930 expressed sequence AU018778 1.520 0.005 
NM_008155 glucose phosphate isomerase 1 1.517 0.013 
NM_016696 glypican 1 1.512 0.022 
NM_007705 cold inducible RNA binding protein 1.505 0.034 
NM_019975 2-hydroxyacyl-CoA lyase 1 1.495 0.014 
NM_001080926 low density lipoprotein receptor-related protein 8, apolipoprotein 
e receptor 
1.494 0.038 
NM_007840 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5; predicted gene 12183 1.486 0.038 
NM_025697 RIKEN cDNA 6330409N04 gene 1.485 0.025 
NM_027000 GTP binding protein 4 1.484 0.022 
NM_001163540 plectin 1 1.482 0.003 
NM_199323 transforming, acidic coiled-coil containing protein 1 1.481 0.041 
NM_026228 solute carrier family 39 (metal ion transporter), member 8 1.474 0.011 
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NM_011768 zinc finger protein X-linked; similar to zinc finger protein 1.472 0.029 
NM_026602 breast carcinoma amplified sequence 2 1.469 0.005 
NM_153419 glutamate-rich WD repeat containing 1 1.463 0.038 
NM_009933 collagen, type VI, alpha 1 1.461 0.006 
NM_009295 syntaxin binding protein 1 1.459 0.007 
NM_130864 acetyl-Coenzyme A acyltransferase 1A 1.452 0.001 
NM_009881 chromodomain protein, Y chromosome-like; predicted gene 7584 1.450 0.026 
NM_026020 similar to LOC665931 protein; ribosomal protein, large P2; 
predicted gene 7852; WD repeat domain 89 
1.446 0.028 
NM_009510 ezrin; hypothetical protein LOC100044177 1.445 0.024 
NM_008684 neogenin 1.445 0.015 
NM_025884 zinc finger protein 830 1.437 0.022 
NM_026503 RIKEN cDNA 1110058L19 gene 1.429 0.000 
NM_025551 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 1.423 0.013 
NM_009048 RalBP1 associated Eps domain containing protein 1.422 0.022 
NM_011925 CD97 antigen 1.419 0.020 
NM_001082961 small nuclear ribonucleoprotein N; SNRPN upstream reading 
frame; predicted gene 5802; similar to SNRPN upstream reading 
frame protein 
1.407 0.026 
NM_009112 S100 calcium binding protein A10 (calpactin) 1.407 0.039 
NM_018796 eukaryotic translation elongation factor 1 beta 2 1.402 0.049 
NM_028871 predicted gene 6159; heterogeneous nuclear ribonucleoprotein R 1.400 0.003 
NM_011917 5'-3' exoribonuclease 2 1.399 0.033 
NM_011479 serine palmitoyltransferase, long chain base subunit 2 1.397 0.011 
NM_020586 HERPUD family member 2 1.396 0.021 
NM_026737 PHD finger protein 5A 1.393 0.001 
NM_145610 peter pan homolog (Drosophila) 1.388 0.029 
NM_008133 glutamate dehydrogenase 1; predicted gene 5902 1.386 0.007 
NM_080558 sperm specific antigen 2 1.382 0.015 
NP_062718 Nuclear receptor coactivator 4 1.377 0.037 
NM_001080794 GTPase activating protein (SH3 domain) binding protein 2 1.375 0.016 
NM_001037756 breast cancer metastasis-suppressor 1-like 1.374 0.000 
NM_017382 RAB11a, member RAS oncogene family 1.372 0.012 
NM_008638 methylenetetrahydrofolate dehydrogenase (NAD+ dependent), 
methenyltetrahydrofolate cyclohydrolase 
1.372 0.046 
NM_008364 interleukin 1 receptor accessory protein 1.370 0.038 
NM_010191 predicted gene 6781; farnesyl diphosphate farnesyl transferase 1 1.370 0.046 
NM_026988 parathymosin 1.369 0.022 
NM_016753 latexin 1.366 0.028 
NM_025814 serpine1 mRNA binding protein 1 1.366 0.020 
NM_011327 sterol carrier protein 2, liver 1.363 0.011 
NM_023536 predicted gene 9178; MRT4, mRNA turnover 4, homolog (S. 
cerevisiae); predicted gene 5633 
1.361 0.010 
NM_011300 similar to 40S ribosomal protein S7 (S8); predicted gene 6252; 
predicted gene 5055; predicted gene 4761; ribosomal protein S7; 
predicted gene 7351; predicted gene 6472 
1.358 0.046 
NM_025864 transmembrane protein 206 1.352 0.007 
NM_023144 non-POU-domain-containing, octamer binding protein; predicted 
gene 8806 
1.352 0.029 
NP_001158005 death associated protein 3 1.343 0.004 
NM_011189 predicted gene 7776; proteasome (prosome, macropain) 28 
subunit, alpha 
1.342 0.019 
NM_026933 TP53 regulated inhibitor of apoptosis 1 1.338 0.049 
NM_007842 DEAH (Asp-Glu-Ala-His) box polypeptide 9 1.338 0.019 
NM_009530 alpha thalassemia/mental retardation syndrome X-linked homolog 1.337 0.001 
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(human) 
NM_026482 ATPase, Ca++ transporting, plasma membrane 1 1.331 0.050 
NM_145431 notchless homolog 1 (Drosophila) 1.331 0.004 
NM_010117 rhomboid family 1 (Drosophila) 1.324 0.043 
NM_023764 toll interacting protein 1.320 0.037 
NM_023603 splicing factor proline/glutamine rich (polypyrimidine tract binding 
protein associated); similar to PTB-associated splicing factor 
1.319 0.041 
NM_011287 predicted gene 13573; predicted gene 15451; ribosomal protein 
L10A; predicted gene 7695; similar to ribosomal protein L10a 
1.318 0.023 
NM_007840 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5; predicted gene 12183 1.316 0.043 
NM_019869 RNA binding motif protein 14 1.309 0.021 
NM_009125 ataxin 2 1.304 0.013 
NM_001081293 regulation of nuclear pre-mRNA domain containing 2 1.293 0.045 
NM_025331 guanine nucleotide binding protein (G protein), gamma 11 1.282 0.050 
NP_598452 poly-U binding splicing factor 60 1.281 0.046 
NM_172666 alkylglycerone phosphate synthase 1.275 0.007 
NM_008364 interleukin 1 receptor accessory protein 1.274 0.009 
NM_134080 filamin, beta 1.268 0.008 
NM_001081267 remodeling and spacing factor 1 1.268 0.001 
NM_024436 RAB22A, member RAS oncogene family 1.265 0.008 
NM_178216 histone cluster 2, H3b; histone cluster 1, H3f; histone cluster 1, 
H3e; histone cluster 2, H3c1; histone cluster 1, H3d; histone 
cluster 1, H3c; histone cluster 1, H3b; histone cluster 2, H3c2; 
histone cluster 2, H2aa1; histone cluster 2, H2aa2 
1.254 0.030 
NM_029157 splicing factor 3a, subunit 3 1.254 0.005 
NM_008882 plexin A2 1.253 0.001 
NM_026171 nuclear VCP-like 1.247 0.001 
NM_010726 phytanoyl-CoA hydroxylase 1.241 0.004 
NM_028264 transmembrane protein 55A 1.241 0.036 
NM_153567 SLAIN motif family, member 2 1.237 0.044 
NM_016888 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 1.232 0.045 
NM_011605 thymopoietin 1.229 0.041 
NM_011076 ATP-binding cassette, sub-family B (MDR/TAP), member 1A 1.228 0.026 
NM_013902 FK506 binding protein 3 1.220 0.004 
NM_001081164 OTU domain containing 4 1.216 0.014 
NP_963910 GNAS (guanine nucleotide binding protein, alpha stimulating) 
complex locus 
1.215 0.041 
NM_001163300 scaffold attachment factor B 1.215 0.042 
NP_001258827 Peroxisomal acyl-coenzyme A oxidase 1 1.208 0.011 
NM_020027 HLA-B associated transcript 2 1.206 0.023 
NM_133947 nuclear mitotic apparatus protein 1 1.202 0.015 
NM_009338 acetyl-Coenzyme A acetyltransferase 2 1.202 0.003 
NM_008477 kinectin 1 1.200 0.025 
NM_027901 general transcription factor IIIC, polypeptide 2, beta; Mpv17 
transgene, kidney disease mutant 
-1.206 0.042 
NM_008302 heat shock protein 90 alpha (cytosolic), class B member 1 -1.217 0.050 
NM_010239 ferritin heavy chain 1 -1.219 0.007 
NM_133348 acyl-CoA thioesterase 7 -1.223 0.016 
NM_001025947 dynamin 1-like -1.224 0.014 
NM_175438 aldehyde dehydrogenase 4 family, member A1 -1.224 0.036 
NM_031843 dipeptidylpeptidase 7 -1.229 0.005 
NM_025343 required for meiotic nuclear division 1 homolog (S. cerevisiae); 
predicted gene 5512 
-1.229 0.021 
NM_025845 PRP38 pre-mRNA processing factor 38 (yeast) domain containing 
B; similar to PRP38 pre-mRNA processing factor 38 (yeast) domain 
-1.231 0.030 
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containing B 
NM_019770 transmembrane emp24 domain trafficking protein 2; predicted 
gene 10698; predicted gene 7318 
-1.234 0.031 
NM_133794 glutaminyl-tRNA synthetase -1.235 0.026 
NM_008442 kinesin family member 2A -1.237 0.049 
NM_172674 PHD finger protein 20 -1.238 0.045 
NM_026510 FtsJ homolog 2 (E. coli) -1.242 0.048 
NM_001033293 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 -1.253 0.026 
NM_001081056 exportin, tRNA (nuclear export receptor for tRNAs) -1.261 0.010 
NM_009288 serine/threonine kinase 10 -1.263 0.029 
NM_026474 SGT1, suppressor of G2 allele of SKP1 (S. cerevisiae) -1.263 0.041 
NM_008136 guanine nucleotide binding protein-like 1 -1.263 0.018 
NM_026202 coiled-coil domain containing 50 -1.272 0.049 
NM_028782 lon peptidase 1, mitochondrial -1.282 0.025 
NM_009373 transglutaminase 2, C polypeptide -1.282 0.004 
NM_001160319 ubiquitin protein ligase E3 component n-recognin 4 -1.284 0.046 
NM_145506 erythrocyte protein band 4.1-like 5 -1.291 0.015 
NM_144897 apolipoprotein A-I binding protein -1.295 0.024 
NM_145955 RIKEN cDNA 1110007A13 gene -1.296 0.036 
NP_001156418 pyruvate carboxylase -1.305 0.034 
NM_175372 retinol dehydrogenase 13 (all-trans and 9-cis) -1.310 0.006 
NM_001171582 methionine-tRNA synthetase -1.316 0.013 
NM_144818 non-SMC condensin I complex, subunit H -1.316 0.045 
NM_010562 integrin linked kinase; predicted gene 6263 -1.316 0.030 
NM_025691 signal recognition particle 72 -1.318 0.012 
NM_029635 COMM domain containing 9 -1.323 0.033 
NM_013492 similar to clusterin; clusterin -1.330 0.008 
NM_013691 thrombospondin 3 -1.330 0.014 
NM_029023 serine carboxypeptidase 1 -1.334 0.042 
NM_013818 GTP binding protein 1 -1.334 0.032 
NM_025515 similar to Coiled-coil domain containing 90B; coiled-coil domain 
containing 90B 
-1.341 0.040 
NM_008012 aldo-keto reductase family 1, member B8 -1.347 0.013 
NM_028762 RNA binding motif protein 19 -1.349 0.007 
NM_001164671 predicted gene 15542; predicted gene 7816; similar to DnaJ-like 
protein; predicted gene 6335; DnaJ (Hsp40) homolog, subfamily A, 
member 1, pseudogene; DnaJ (Hsp40) homolog, subfamily A, 
member 1 
-1.350 0.003 
NM_025544 mitochondrial ribosomal protein S15 -1.357 0.002 
NM_018851 hypothetical protein LOC100045969; SAM domain and HD 
domain, 1 
-1.358 0.010 
NM_019564 HtrA serine peptidase 1 -1.359 0.011 
NM_011486 similar to Stat3B; signal transducer and activator of transcription 3 -1.359 0.048 
NM_010421 hexosaminidase A -1.360 0.036 
NM_008948 proteasome (prosome, macropain) 26S subunit, ATPase 3 -1.364 0.017 
NM_198105 family with sequence similarity 120, member C -1.365 0.024 
NM_145507 aspartyl-tRNA synthetase -1.368 0.047 
NM_028198 exportin 5 -1.369 0.011 
NM_007783 c-src tyrosine kinase -1.371 0.036 
NM_030238 dynein cytoplasmic 1 heavy chain 1 -1.379 0.009 
NM_011414 secretory leukocyte peptidase inhibitor -1.384 0.039 
NM_020520 solute carrier family 25 (mitochondrial carnitine/acylcarnitine 
translocase), member 20 
-1.385 0.047 
NM_009190 similar to vacuolar protein sorting 4b; vacuolar protein sorting 4b 
(yeast) 
-1.390 0.037 
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NM_008520 latent transforming growth factor beta binding protein 3 -1.394 0.010 
NM_010546 inhibitor of kappaB kinase beta -1.394 0.012 
NM_009471 uridine monophosphate synthetase -1.395 0.011 
NM_001081066 DENN/MADD domain containing 3 -1.396 0.025 
NM_024267 importin 4 -1.396 0.001 
NM_024258 ubiquitin specific peptidase 16 -1.398 0.038 
NM_027357 proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 -1.400 0.012 
NM_023525 carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, 
and dihydroorotase 
-1.404 0.016 
NM_178719 Smith-Magenis syndrome chromosome region, candidate 7-like 
(human) 
-1.404 0.026 
NM_172990 pantothenate kinase 4 -1.405 0.035 
NM_021295 LanC (bacterial lantibiotic synthetase component C)-like 1 -1.408 0.010 
NM_024194 leucine rich repeat containing 40 -1.412 0.026 
NP_001095925 amyloid beta (A4) precursor-like protein 2 -1.413 0.025 
NP_001157185 predicted gene 9755; Tu translation elongation factor, 
mitochondrial 
-1.421 0.005 
NM_010106 predicted gene 5869; predicted gene 7161; predicted gene 7105; 
predicted gene 5822; similar to eukaryotic translation elongation 
factor 1 alpha 1; predicted gene 6192; predicted gene 6392; 
predicted gene 6767; predicted gene 6170; predicted gene 6548; 
pre 
-1.423 0.001 
NM_029293 phosphohistidine phosphatase 1 -1.433 0.048 
NM_001038589 ubiquitin specific peptidase 14 -1.436 0.009 
NM_178070 vacuolar protein sorting 33B (yeast) -1.441 0.006 
NM_021299 adenylate kinase 3 -1.443 0.004 
NM_019812 sirtuin 1 (silent mating type information regulation 2, homolog) 1 
(S. cerevisiae) 
-1.444 0.009 
NM_007643 CD36 antigen -1.445 0.030 
NM_152801 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 -1.459 0.038 
NM_177727 LSM14 homolog B (SCD6, S. cerevisiae) -1.462 0.008 
NM_009981 phosphate cytidylyltransferase 1, choline, alpha isoform -1.463 0.031 
NM_011723 xanthine dehydrogenase -1.467 0.012 
NM_016748 cytidine 5'-triphosphate synthase -1.480 0.033 
NM_008826 phosphofructokinase, liver, B-type -1.480 0.031 
NM_172404 cysteine conjugate-beta lyase 1 -1.483 0.026 
NM_144915 diacylglycerol lipase, beta -1.492 0.001 
NM_001163126 component of oligomeric golgi complex 5 -1.494 0.024 
NM_178337 tubulin-specific chaperone E -1.500 0.000 
NM_145578 ubiquitin-conjugating enzyme E2M (UBC12 homolog, yeast) -1.501 0.020 
NM_080708 predicted gene 4521; BMP2 inducible kinase -1.504 0.009 
NM_025921 chromatin modifying protein 1B; RIKEN cDNA 2610002M06 gene -1.505 0.048 
NM_144923 biliverdin reductase B (flavin reductase (NADPH)) -1.512 0.016 
NM_026276 aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl 
transferase; hypothetical protein LOC100044211 
-1.515 0.016 
NP_808340 transmembrane protein 201 -1.516 0.004 
NM_134079 adenosine kinase -1.518 0.039 
NM_026079 inhibitor of kappa light polypeptide enhancer in B-cells, kinase 
complex-associated protein 
-1.522 0.007 
NM_013792 alpha-N-acetylglucosaminidase (Sanfilippo disease IIIB) -1.524 0.036 
NM_027815 RIKEN cDNA 9030624J02 gene -1.541 0.010 
NM_177215 oculocerebrorenal syndrome of Lowe -1.546 0.030 
NM_025647 cytidine monophosphate (UMP-CMP) kinase 1; predicted gene 
5867 
-1.547 0.007 
NM_001080748 general transcription factor II I; similar to transcription factor TFII- -1.560 0.005 
Appendix A 
 
- 25 - 
 
I-gamma 
NM_023402 Myosin regulatory light chain 12B -1.563 0.030 
NM_025794 electron transferring flavoprotein, dehydrogenase -1.575 0.004 
NM_178376 Ras-related GTP binding A -1.576 0.032 
NM_016906 Sec61 alpha 1 subunit (S. cerevisiae) -1.582 0.028 
NM_053181 pyridoxal-dependent decarboxylase domain containing 1 -1.586 0.000 
NM_013528 glutamine fructose-6-phosphate transaminase 1 -1.590 0.003 
NM_173443 valosin containing protein (p97)/p47 complex interacting protein 1 -1.591 0.047 
NM_009658 aldo-keto reductase family 1, member B3 (aldose reductase) -1.592 0.001 
NM_009755 bone morphogenetic protein 1 -1.601 0.009 
NM_011340 serine (or cysteine) peptidase inhibitor, clade F, member 1 -1.606 0.009 
NM_025918 coiled-coil domain containing 43 -1.617 0.000 
NM_008826 phosphofructokinase, liver, B-type -1.624 0.025 
NM_029746 component of oligomeric golgi complex 2 -1.637 0.045 
NM_001042501 RIKEN cDNA 5830415L20 gene -1.637 0.001 
NM_134138 proteasome (prosome, macropain) assembly chaperone 2; similar 
to Clast3 protein 
-1.640 0.012 
NM_010049 dihydrofolate reductase -1.648 0.014 
NM_011348 sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3E; hypothetical protein LOC100044162 
-1.650 0.008 
NM_008325 iduronidase, alpha-L- -1.653 0.039 
NM_144804 DEP domain containing 7 -1.655 0.044 
NM_144878 flavin containing monooxygenase 4 -1.656 0.018 
NM_029005 mixed lineage kinase domain-like -1.663 0.026 
NM_011889 septin 3 -1.666 0.031 
NM_008451 kinesin light chain 2 -1.681 0.022 
NM_001004156 pleckstrin homology domain containing, family G (with RhoGef 
domain) member 5 
-1.687 0.015 
NM_021420 serine/threonine kinase 4 -1.690 0.004 
NM_030201 heat shock protein 70 family, member 13 -1.695 0.015 
NM_175465 SEC14 and spectrin domains 1; predicted gene 9165 -1.703 0.002 
NM_001013380 dynein, cytoplasmic 1 light intermediate chain 2 -1.710 0.013 
NP_001136216 RIKEN cDNA 2610110G12 gene -1.712 0.011 
NM_001127346 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly 
factor 2 
-1.714 0.010 
NM_008776 platelet-activating factor acetylhydrolase, isoform 1b, subunit 3 -1.718 0.006 
NM_175180 WD repeat domain 44 -1.723 0.003 
NM_001033318 component of oligomeric golgi complex 7 -1.724 0.005 
NM_011577 transforming growth factor, beta 1 -1.808 0.021 
 
Table 1-C: Differentially regulated CHO DP-12 proteins determined in samples corresponding 
to culture using increased bioprocess media dissolved oxygen content of 110%. 
RefSeq 
Annotation 
Description Fold 
Change 
P-
value 
NM_025364 predicted gene 6563; SAP domain containing ribonucleoprotein 2.000 0.009 
NM_011547 transcription factor AP-2, alpha 1.863 0.018 
NM_007647 ectonucleoside triphosphate diphosphohydrolase 5 1.754 0.033 
NM_021510 heterogeneous nuclear ribonucleoprotein H1 1.741 0.001 
NM_144869 cDNA sequence BC021614 1.739 0.037 
NP_001103618 mannoside acetylglucosaminyltransferase 1 1.732 0.004 
NM_153516 BCL2-like 13 (apoptosis facilitator) 1.732 0.031 
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NM_027435 ATPase family, AAA domain containing 2 1.721 0.010 
NM_146065 activating transcription factor 7 1.714 0.001 
NM_024249 solute carrier family 38, member 10 1.706 0.047 
NP_001157290 protein phosphatase 1, regulatory subunit 10 1.706 0.005 
NM_172710 RIKEN cDNA 2310045A20 gene 1.705 0.014 
NM_027434 regulation of nuclear pre-mRNA domain containing 1B 1.705 0.029 
NP_001239458 Polyglutamine-binding protein 1 1.704 0.003 
NM_011333 chemokine (C-C motif) ligand 2 1.700 0.019 
NM_009624 adenylate cyclase 9 1.694 0.006 
NM_019419 ADP-ribosylation factor-like 6 interacting protein 1 1.690 0.005 
NM_008562 similar to myeloid cell leukemia sequence 1; myeloid cell leukemia 
sequence 1 
1.690 0.022 
NM_009833 cyclin T1 1.679 0.007 
NM_007709 Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-
terminal domain 1 
1.665 0.038 
NM_001163622 prolyl endopeptidase-like 1.662 0.001 
NM_139291 cell division cycle 26; predicted gene 9174 1.661 0.013 
NM_133196 cleavage stimulation factor, 3' pre-RNA subunit 2 1.660 0.034 
NM_010724 proteasome (prosome, macropain) subunit, beta type 8 (large 
multifunctional peptidase 7) 
1.655 0.006 
NM_016709 AU RNA binding protein/enoyl-coenzyme A hydratase 1.654 0.001 
NM_019821 glycolipid transfer protein 1.653 0.031 
NM_025576 protein tyrosine phosphatase, mitochondrial 1 1.649 0.048 
NM_026936 oxidase assembly 1-like 1.646 0.012 
NM_019989 SH3-binding domain glutamic acid-rich protein like 1.637 0.002 
NM_009739 branched chain ketoacid dehydrogenase kinase 1.636 0.012 
NP_598452 poly-U binding splicing factor 60 1.631 0.001 
NM_153168 leucyl-tRNA synthetase, mitochondrial 1.629 0.029 
NM_133435 nicotinamide nucleotide adenylyltransferase 1 1.625 0.034 
NM_010302 guanine nucleotide binding protein, alpha 12; similar to Guanine 
nucleotide-binding protein alpha-12 subunit (G alpha-12) 
1.622 0.049 
NM_028312 coiled-coil domain containing 12; predicted gene 8518 1.618 0.031 
NM_025313 ATP synthase, H+ transporting, mitochondrial F1 complex, delta 
subunit 
1.614 0.020 
NM_172679 RIKEN cDNA 4932438A13 gene 1.611 0.028 
NM_008704 similar to Nucleoside diphosphate kinase A (NDK A) (NDP kinase A) 
(Tumor metastatic process-associated protein) (Metastasis 
inhibition factor NM23) (NDPK-A) (nm23-M1); non-metastatic 
cells 1, protein (NM23A) expressed in 
1.611 0.029 
NM_133823 methylmalonic aciduria (cobalamin deficiency) type A 1.609 0.047 
NM_011434 predicted gene 8566; superoxide dismutase 1, soluble; similar to 
Superoxide dismutase 
1.609 0.028 
NM_029078 cleavage and polyadenylation factor subunit homolog (S. 
cerevisiae) 
1.607 0.048 
NM_016794 vesicle-associated membrane protein 8 1.606 0.002 
NM_134077 RNA binding motif protein 26 1.606 0.009 
NM_007874 receptor accessory protein 5 1.605 0.021 
NM_009032 RNA binding motif protein 4 1.602 0.037 
NM_021563 Erbb2 interacting protein 1.601 0.007 
NP_001003667 keratin 77 1.600 0.000 
NM_029626 glycosyltransferase 8 domain containing 1 1.586 0.002 
NM_172397 similar to epithelial protein lost in neoplasm; LIM domain 
containing 2 
1.586 0.007 
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NM_008155 glucose phosphate isomerase 1 1.581 0.023 
NM_134048 Casitas B-lineage lymphoma-like 1 1.576 0.032 
NM_028767 forkhead box P4 1.574 0.031 
NM_030561 cDNA sequence BC004004 1.574 0.026 
NM_080556 transmembrane 9 superfamily member 2 1.574 0.005 
NM_030004 crystallin, lambda 1 1.572 0.019 
NM_133998 RIKEN cDNA 1810008A18 gene 1.569 0.015 
NM_181407 malic enzyme 3, NADP(+)-dependent, mitochondrial 1.568 0.010 
NM_009031 retinoblastoma binding protein 7; predicted gene 6382 1.563 0.045 
NM_010176 fumarylacetoacetate hydrolase 1.563 0.041 
NM_028754 RIKEN cDNA 0610037L13 gene 1.561 0.018 
NM_175324 nephronophthisis 3 (adolescent); acyl-Coenzyme A dehydrogenase 
family, member 11 
1.555 0.003 
NM_153117 RIKEN cDNA 9530068E07 gene 1.554 0.033 
NM_009883 CCAAT/enhancer binding protein (C/EBP), beta 1.552 0.040 
NM_023041 peroxisomal biogenesis factor 19 1.549 0.035 
NM_011528 transaldolase 1 1.548 0.050 
NM_134063 cDNA sequence BC016423 1.546 0.013 
NM_145553 predicted gene 7527; family with sequence similarity 76, member 
A 
1.535 0.021 
NM_027430 brain protein 44; similar to brain protein 44; predicted gene 3982 1.533 0.027 
NM_023051 calsyntenin 1 1.533 0.040 
NM_019791 melanoma antigen, family D, 1 1.525 0.021 
NM_008881 plexin A1 1.524 0.005 
NM_018858 phosphatidylethanolamine binding protein 1 1.523 0.002 
NM_011933 2-4-dienoyl-Coenzyme A reductase 2, peroxisomal 1.523 0.013 
NM_001024205 nuclear fragile X mental retardation protein interacting protein 2 1.521 0.002 
NM_009242 secreted acidic cysteine rich glycoprotein; similar to Secreted 
acidic cysteine rich glycoprotein 
1.521 0.033 
NM_020618 similar to SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily e, member 1; predicted gene 
1815; predicted gene 8494; SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, subfamily e, member 1; 
pred 
1.521 0.009 
NM_029169 RNA binding motif protein 6 1.520 0.002 
NM_023733 carnitine O-octanoyltransferase 1.519 0.022 
NM_172472 transcription factor E3 1.517 0.009 
NM_009074 macrophage stimulating 1 receptor (c-met-related tyrosine kinase) 1.517 0.026 
NM_001171052 metastasis associated 3 1.516 0.035 
NM_007383 acyl-Coenzyme A dehydrogenase, short chain 1.516 0.021 
NM_182939 similar to protein phosphatase 4, regulatory subunit 2; similar to 
Protein phosphatase 4, regulatory subunit 2; protein phosphatase 
4, regulatory subunit 2 
1.514 0.043 
NM_009270 squalene epoxidase 1.514 0.008 
NM_025952 magnesium transporter 1 1.513 0.002 
NM_026068 mediator of RNA polymerase II transcription, subunit 31 homolog 
(yeast) 
1.507 0.004 
NM_011121 polo-like kinase 1 (Drosophila) 1.504 0.025 
NM_008131 predicted gene 4949; glutamate-ammonia ligase (glutamine 
synthetase) 
1.503 0.025 
XP_619909 predicted gene 5449; small nuclear ribonucleoprotein D2; 
predicted gene 5848; predicted gene 10120 
1.497 0.033 
NM_001001932 early endosome antigen 1 1.497 0.022 
NM_053014 1-acylglycerol-3-phosphate O-acyltransferase 3 1.496 0.035 
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NM_025797 cytochrome b-5 1.490 0.036 
NM_027219 CDC42 effector protein (Rho GTPase binding) 1 1.488 0.037 
NM_010191 predicted gene 6781; farnesyl diphosphate farnesyl transferase 1 1.488 0.011 
NM_026420 polyadenylate-binding protein-interacting protein 2 1.485 0.040 
NM_030732 transducin (beta)-like 1X-linked receptor 1 1.485 0.023 
NM_025822 arginine/serine-rich coiled-coil 1 1.485 0.007 
NM_078478 growth hormone inducible transmembrane protein 1.482 0.019 
NM_010368 glucuronidase, beta 1.481 0.012 
NP_001135450 TPX2, microtubule-associated protein homolog (Xenopus laevis) 1.474 0.026 
NP_001164215 C-terminal binding protein 2 1.473 0.037 
NM_028074 DEAD (Asp-Glu-Ala-Asp) box polypeptide 42 1.472 0.006 
NM_013556 hypoxanthine guanine phosphoribosyl transferase 1 1.469 0.011 
NM_024274 phenylalanine-tRNA synthetase 2 (mitochondrial) 1.469 0.001 
NM_001098225 a disintegrin and metallopeptidase domain 22 1.469 0.010 
NM_198937 hematological and neurological expressed 1-like 1.462 0.022 
NM_001033534 layilin 1.460 0.034 
NM_025682 paraspeckle protein 1 1.456 0.027 
NM_144888 mitochondrial antiviral signaling protein 1.455 0.049 
NM_009009 RAD21 homolog (S. pombe) 1.454 0.021 
NM_010358 similar to Glutathione S-transferase Mu 1 (GST class-mu 1) 
(Glutathione S-transferase GT8.7) (pmGT10) (GST 1-1); predicted 
gene 5562; glutathione S-transferase, mu 1 
1.446 0.006 
NM_138758 trimethyllysine hydroxylase, epsilon 1.445 0.015 
NM_177643 Zinc finger protein 281 1.442 0.002 
NM_172205 suprabasin 1.441 0.026 
NM_009832 cyclin K; similar to cyclin K 1.436 0.034 
NM_008717 zinc finger, matrin-like 1.436 0.010 
NM_008293 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 1 
1.430 0.020 
NM_013502 similar to CtBP1 protein; C-terminal binding protein 1 1.428 0.006 
NM_019693 HLA-B-associated transcript 1A 1.426 0.030 
NM_015735 damage specific DNA binding protein 1 1.425 0.002 
NM_010070 docking protein 1 1.416 0.015 
NM_021521 mediator of RNA polymerase II transcription, subunit 12 homolog 
(yeast) 
1.411 0.030 
NM_009033 RNA binding motif protein, X chromosome retrogene 1.408 0.021 
NM_013534 leprecan-like 2 1.406 0.001 
NM_009503 similar to Transitional endoplasmic reticulum ATPase (TER ATPase) 
(15S Mg(2+)-ATPase p97 subunit) (Valosin-containing protein) 
(VCP); valosin containing protein 
1.403 0.003 
NM_020520 solute carrier family 25 (mitochondrial carnitine/acylcarnitine 
translocase), member 20 
1.402 0.038 
NM_026170 endoplasmic reticulum-golgi intermediate compartment (ERGIC) 1 1.402 0.011 
NM_001080981 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23 1.400 0.035 
NM_026512 biphenyl hydrolase-like (serine hydrolase, breast epithelial mucin-
associated antigen) 
1.396 0.016 
NM_027373 actin filament associated protein 1 1.394 0.016 
NM_025573 splicing factor, arginine/serine rich 9 1.391 0.046 
NM_153412 pleckstrin homology-like domain, family B, member 2 1.387 0.027 
NM_015816 LSM4 homolog, U6 small nuclear RNA associated (S. cerevisiae) 1.385 0.029 
NM_007466 apoptosis inhibitor 5 1.383 0.039 
NM_007749 similar to cytochrome c oxidase, subunit VIIc; predicted gene 
3386; cytochrome c oxidase, subunit VIIc 
1.377 0.008 
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NM_001081422 biorientation of chromosomes in cell division 1-like 1.375 0.002 
NM_009409 topoisomerase (DNA) II beta 1.374 0.041 
NM_026934 predicted gene 5909; zinc finger CCCH-type containing 15 1.373 0.004 
NM_026141 peptidylprolyl isomerase (cyclophilin)-like 4 1.373 0.005 
NM_010729 lysyl oxidase-like 1 1.361 0.042 
NM_133803 dipeptidylpeptidase 3 1.360 0.032 
NM_009774 budding uninhibited by benzimidazoles 3 homolog (S. cerevisiae) 1.358 0.034 
NM_011327 sterol carrier protein 2, liver 1.358 0.017 
NM_024200 mitofusin 1 1.357 0.015 
NM_028793 acyl-Coenzyme A binding domain containing 5 1.357 0.050 
NM_018871 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, gamma polypeptide 
1.349 0.014 
NM_011247 retinoblastoma binding protein 6 1.349 0.036 
NM_001163570 exosome component 8 1.344 0.043 
NM_011378 transcriptional regulator, SIN3A (yeast) 1.342 0.001 
NM_023603 splicing factor proline/glutamine rich (polypyrimidine tract binding 
protein associated); similar to PTB-associated splicing factor 
1.341 0.007 
NM_146131 similar to Pre-B-cell leukemia transcription factor interacting 
protein 1; pre-B-cell leukemia transcription factor interacting 
protein 1 
1.341 0.025 
NM_001044384 tissue inhibitor of metalloproteinase 1 1.341 0.008 
NM_139297 UDP-glucose pyrophosphorylase 2 1.338 0.007 
NM_027375 GRIP and coiled-coil domain containing 2 1.336 0.005 
NM_153552 THO complex 1 1.335 0.046 
NM_008549 mannosidase 2, alpha 1 1.332 0.005 
NM_007690 chromodomain helicase DNA binding protein 1 1.332 0.007 
NM_001081251 polybromo 1 1.330 0.049 
NM_175094 pyruvate dehydrogenase complex, component X; similar to 
pyruvate dehydrogenase complex, component X 
1.326 0.001 
NM_008402 integrin alpha V 1.325 0.008 
NM_027226 forty-two-three domain containing 1 1.325 0.010 
NM_011500 striatin, calmodulin binding protein 1.319 0.042 
NM_010497 isocitrate dehydrogenase 1 (NADP+), soluble 1.315 0.013 
NM_172266 lysophosphatidylglycerol acyltransferase 1 1.313 0.036 
NM_011767 zinc finger RNA binding protein 1.310 0.007 
NM_178592 HLA-B associated transcript 5 1.305 0.023 
NM_001080926 low density lipoprotein receptor-related protein 8, apolipoprotein 
e receptor 
1.305 0.034 
NM_011479 serine palmitoyltransferase, long chain base subunit 2 1.304 0.045 
NM_001077403 neuropilin 2 1.303 0.017 
NM_001013389 MRS2 magnesium homeostasis factor homolog (S. cerevisiae) 1.302 0.007 
NM_008305 perlecan (heparan sulfate proteoglycan 2) 1.302 0.007 
NP_035681 upstream binding transcription factor, RNA polymerase I 1.297 0.047 
NM_133947 nuclear mitotic apparatus protein 1 1.291 0.004 
NM_016666 aryl-hydrocarbon receptor-interacting protein 1.290 0.020 
NM_007981 acyl-CoA synthetase long-chain family member 1 1.287 0.013 
NM_144831 DEAH (Asp-Glu-Ala-His) box polypeptide 8 1.284 0.014 
NP_001185933 Golgin subfamily A member 5 1.281 0.025 
NM_133957 nuclear factor of activated T-cells 5 1.280 0.024 
NM_021507 sulfide quinone reductase-like (yeast) 1.276 0.023 
NM_172965 Sin3A associated protein 1.276 0.023 
NM_007840 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5; predicted gene 12183 1.266 0.035 
NM_001008422 SR-related CTD-associated factor 1 1.261 0.033 
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NM_001163300 scaffold attachment factor B 1.257 0.018 
NM_021549 polynucleotide kinase 3'- phosphatase 1.256 0.016 
NM_011078 PHD finger protein 2 1.256 0.035 
NM_144846 family with sequence similarity 49, member B 1.256 0.005 
NM_011623 topoisomerase (DNA) II alpha 1.256 0.002 
NM_027213 mediator of RNA polymerase II transcription, subunit 6 homolog 
(yeast) 
1.255 0.010 
NM_010357 glutathione S-transferase, alpha 4 1.255 0.020 
NM_025794 electron transferring flavoprotein, dehydrogenase 1.253 0.020 
NM_019869 RNA binding motif protein 14 1.253 0.021 
NM_012042 cullin 1 1.253 0.011 
NM_138747 NOP2 nucleolar protein homolog (yeast) 1.249 0.043 
NM_026644 1-acylglycerol-3-phosphate O-acyltransferase 4 (lysophosphatidic 
acid acyltransferase, delta) 
1.245 0.047 
NM_198249 RIKEN cDNA E130112L23 gene 1.243 0.004 
NM_008765 origin recognition complex, subunit 2-like (S. cerevisiae) 1.238 0.029 
NM_025988 acyl-Coenzyme A binding domain containing 4 1.229 0.040 
NM_145991 cell division cycle 73, Paf1/RNA polymerase II complex 
component, homolog (S. cerevisiae) 
1.229 0.035 
NM_001166406 kinesin family member 20A 1.227 0.049 
NM_011716 Wolfram syndrome 1 homolog (human) 1.226 0.002 
NM_021305 Sec61, alpha subunit 2 (S. cerevisiae) 1.223 0.006 
NM_010561 interleukin enhancer binding factor 3 1.222 0.006 
NM_009011 RAD23b homolog (S. cerevisiae) 1.213 0.039 
NM_008612 menage a trois 1 1.213 0.006 
NM_009388 transketolase 1.205 0.031 
NM_013830 PRP4 pre-mRNA processing factor 4 homolog B (yeast) 1.203 0.034 
NM_010515 insulin-like growth factor 2 receptor -1.201 0.031 
NM_019816 apoptosis antagonizing transcription factor -1.204 0.024 
NM_013559 heat shock 105kDa/110kDa protein 1 -1.207 0.043 
NM_013492 similar to clusterin; clusterin -1.209 0.011 
NM_008927 mitogen-activated protein kinase kinase 1 -1.211 0.035 
NM_001033293 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 -1.217 0.046 
NM_025959 proteasome (prosome, macropain) 26S subunit, ATPase, 6 -1.218 0.029 
NM_012010 eukaryotic translation initiation factor 2, subunit 3, structural gene 
X-linked; similar to translation initiation factor eIF-2 gamma 
subunit; predicted gene 2223 
-1.219 0.042 
NM_153125 SEC16 homolog A (S. cerevisiae) -1.220 0.026 
NM_013647 predicted gene 8731; predicted gene 7504; similar to Rps16 
protein; ribosomal protein S16 
-1.221 0.039 
NM_008872 plasminogen activator, tissue -1.224 0.041 
NM_024261 RIKEN cDNA 1700052N19 gene -1.229 0.016 
NM_023060 eukaryotic elongation factor, selenocysteine-tRNA-specific -1.232 0.005 
NP_001070732 adaptor protein complex AP-2, alpha 1 subunit -1.233 0.034 
NM_024242 RIO kinase 1 (yeast) -1.234 0.029 
NM_010615 kinesin family member 11 -1.235 0.002 
NM_021514 phosphofructokinase, muscle -1.258 0.018 
NM_025691 signal recognition particle 72 -1.264 0.025 
NM_023247 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly 
factor 3 
-1.267 0.036 
NM_027896 Coenzyme A synthase -1.272 0.008 
NM_172381 expressed sequence AI314180 -1.281 0.015 
NM_008788 procollagen C-endopeptidase enhancer protein -1.283 0.011 
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NM_133360 predicted gene 5182; acetyl-Coenzyme A carboxylase alpha -1.283 0.004 
NM_133993 PWP1 homolog (S. cerevisiae) -1.289 0.036 
NM_139302 SH3-domain GRB2-like endophilin B2 -1.290 0.024 
NM_146200 eukaryotic translation initiation factor 3, subunit C; similar to 
Eukaryotic translation initiation factor 3, subunit 8 
-1.293 0.008 
NM_134137 leucyl-tRNA synthetase -1.297 0.006 
NM_007508 ATPase, H+ transporting, lysosomal V1 subunit A -1.298 0.009 
NM_001105667 deoxythymidylate kinase -1.298 0.006 
NM_025648 phenylalanyl-tRNA synthetase, alpha subunit -1.299 0.021 
NM_138315 microtubule associated monoxygenase, calponin and LIM domain 
containing 1 
-1.303 0.009 
NM_011942 lysophospholipase 2 -1.317 0.032 
NM_020009 mechanistic target of rapamycin (serine/threonine kinase) -1.320 0.030 
NM_026000 proteasome (prosome, macropain) 26S subunit, non-ATPase, 9 -1.324 0.006 
NM_025919 predicted gene 10288; predicted gene 7589; ribosomal protein 
L11; predicted gene 10036; predicted gene 7384; predicted gene 
6745; predicted gene 5093 
-1.328 0.039 
NM_145139 eukaryotic translation initiation factor 3, subunit L -1.331 0.000 
NM_145938 ribonuclease P 40 subunit (human) -1.332 0.021 
NM_028071 coactosin-like 1 (Dictyostelium) -1.337 0.029 
NM_026969 Sec31 homolog A (S. cerevisiae) -1.337 0.014 
NM_172265 eukaryotic translation initiation factor 2B, subunit 5 epsilon -1.339 0.050 
NM_138603 coiled-coil domain containing 22 -1.347 0.049 
NM_013755 glycogenin -1.351 0.023 
NM_019827 glycogen synthase kinase 3 beta -1.352 0.039 
NM_029735 similar to Bifunctional aminoacyl-tRNA synthetase; glutamyl-
prolyl-tRNA synthetase 
-1.357 0.009 
NM_183029 insulin-like growth factor 2 mRNA binding protein 2 -1.357 0.020 
NM_030238 dynein cytoplasmic 1 heavy chain 1 -1.364 0.016 
NM_019703 phosphofructokinase, platelet -1.368 0.031 
NM_001164677 programmed cell death 6 interacting protein -1.370 0.036 
NM_008996 RAB1, member RAS oncogene family -1.372 0.019 
NM_001081056 exportin, tRNA (nuclear export receptor for tRNAs) -1.373 0.011 
NM_007638 chaperonin containing Tcp1, subunit 7 (eta) -1.374 0.040 
NM_026195 5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase; similar to 5-
aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase 
-1.376 0.007 
NM_009091 similar to 40S ribosomal protein S15 (RIG protein); predicted gene 
6921; similar to insulinoma protein (rig); predicted gene 8460; 
predicted gene 7121; predicted gene 5781; predicted gene 5508; 
predicted gene 6867; ribosomal protein S15 
-1.377 0.033 
NM_173013 microtubule-associated protein 1S -1.379 0.011 
NM_026295 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) 
phosphatase, subunit 1 
-1.381 0.016 
NM_146217 alanyl-tRNA synthetase -1.384 0.026 
NM_009674 annexin A7 -1.385 0.009 
NM_001081255 leucine-rich repeats and calponin homology (CH) domain 
containing 3 
-1.397 0.005 
NM_007620 predicted gene 5678; carbonyl reductase 1 -1.397 0.019 
NM_009673 annexin A5 -1.398 0.014 
NM_028450 GULP, engulfment adaptor PTB domain containing 1 -1.402 0.032 
NM_013469 annexin A11; predicted gene 2260; predicted gene 2274 -1.409 0.018 
NM_028243 prolylcarboxypeptidase (angiotensinase C) -1.410 0.048 
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NM_001081028 signal-induced proliferation-associated 1 like 3 -1.412 0.003 
NM_001146023 Protein Fam98c -1.414 0.002 
NM_011125 phospholipid transfer protein -1.416 0.034 
NM_007509 ATPase, H+ transporting, lysosomal V1 subunit B2 -1.419 0.006 
NM_008325 iduronidase, alpha-L- -1.420 0.031 
NM_011400 solute carrier family 2 (facilitated glucose transporter), member 1 -1.420 0.008 
NM_001045489 milk fat globule-EGF factor 8 protein -1.427 0.048 
NM_013529 Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 
2 
-1.428 0.010 
NM_178644 OAF homolog (Drosophila) -1.434 0.016 
NM_146229 dynein cytoplasmic 1 light intermediate chain 1 -1.435 0.030 
NM_009190 similar to vacuolar protein sorting 4b; vacuolar protein sorting 4b  -1.441 0.050 
NM_009194 similar to solute carrier family 12, member 2; solute carrier family 
12, member 2 
-1.441 0.025 
NM_011811 phenylalanyl-tRNA synthetase, beta subunit -1.443 0.006 
NM_010546 inhibitor of kappaB kinase beta -1.445 0.006 
NM_001163126 component of oligomeric golgi complex 5 -1.446 0.000 
NM_024218 ribosomal protein L24; predicted gene 9385; predicted gene 7380 -1.447 0.027 
NM_001033318 component of oligomeric golgi complex 7 -1.455 0.031 
NM_172015 isoleucine-tRNA synthetase -1.456 0.006 
NM_133786 structural maintenance of chromosomes 4 -1.457 0.010 
NM_030678 glycogen synthase 1, muscle -1.457 0.014 
NM_181072 myosin IE -1.462 0.019 
NM_033074 threonyl-tRNA synthetase -1.463 0.028 
NP_001107603 protein phosphatase 4, regulatory subunit 1 -1.463 0.028 
NM_133972 armadillo repeat containing 6 -1.467 0.017 
NM_013581 component of oligomeric golgi complex 1 -1.477 0.034 
NM_028181 cell cycle progression 1 -1.478 0.027 
NM_009296 predicted gene 3258; suppressor of Ty 4 homolog 1 (S. cerevisiae) -1.480 0.003 
NM_011051 programmed cell death 6 -1.480 0.031 
NM_029720 cysteine-rich with EGF-like domains 2 -1.483 0.048 
NM_178599 COMM domain containing 8 -1.491 0.039 
NM_008509 lipoprotein lipase; similar to Lipoprotein lipase precursor (LPL) -1.498 0.030 
NM_178389 galactose-4-epimerase, UDP -1.501 0.047 
NM_001038589 ubiquitin specific peptidase 14 -1.503 0.012 
NM_016905 galactokinase 1 -1.507 0.017 
NM_008481 laminin, alpha 2 -1.508 0.016 
NM_017397 DEAD (Asp-Glu-Ala-Asp) box polypeptide 20 -1.512 0.000 
NM_027182 thyroid hormone receptor interactor 13 -1.516 0.040 
NM_010233 fibronectin 1 -1.517 0.007 
NM_015751 ATP-binding cassette, sub-family E (OABP), member 1 -1.518 0.013 
NM_008826 phosphofructokinase, liver, B-type -1.520 0.010 
NM_001160163 neuraminidase 2 -1.521 0.007 
NM_016748 cytidine 5'-triphosphate synthase -1.522 0.004 
NM_013507 eukaryotic translation initiation factor 4, gamma 2 -1.522 0.013 
NM_001033375 RIKEN cDNA A230046K03 gene -1.526 0.001 
NM_011829 inosine 5'-phosphate dehydrogenase 1 -1.529 0.023 
NM_028072 sulfatase 2 -1.529 0.044 
NM_026742 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly 
factor 4 
-1.532 0.000 
NM_024267 importin 4 -1.537 0.002 
NM_026441 penta-EF hand domain containing 1 -1.540 0.028 
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NM_009795 calpain, small subunit 1 -1.546 0.046 
NM_007908 eukaryotic elongation factor-2 kinase -1.558 0.042 
NM_133255 hook homolog 2 (Drosophila) -1.559 0.029 
NM_023290 makorin, ring finger protein, 2 -1.562 0.009 
NM_015805 ATPase, class II, type 9B -1.563 0.047 
NM_026437 RIKEN cDNA 1810055E12 gene -1.565 0.005 
NM_018740 retinoic acid induced 12 -1.565 0.032 
NM_133973 component of oligomeric golgi complex 4 -1.569 0.047 
NM_001037746 mirror-image polydactyly gene 1 homolog (human); 
phosphoribosyl pyrophosphate synthetase 1; phosphoribosyl 
pyrophosphate synthetase 1-like 1 
-1.580 0.016 
NM_028262 SET domain containing 3; similar to CG32732-PA; predicted gene 
7114; predicted gene 14026 
-1.581 0.016 
NM_027769 copine III -1.583 0.019 
NM_021343 spermatogenesis associated 5 -1.584 0.001 
NM_025816 Tax1 (human T-cell leukemia virus type I) binding protein 1 -1.588 0.008 
NM_026364 phosphoribosyl pyrophosphate synthetase-associated protein 1 -1.590 0.046 
NM_007510 ATPase, H+ transporting, lysosomal V1 subunit E1 -1.591 0.018 
NM_007926 aminoacyl tRNA synthetase complex-interacting multifunctional 
protein 1 
-1.594 0.006 
NM_001163567 family with sequence similarity 102, member B -1.603 0.016 
NM_001031667 glycogen synthase kinase 3 alpha -1.605 0.001 
NM_008826 phosphofructokinase, liver, B-type -1.614 0.012 
NM_007544 BH3 interacting domain death agonist -1.616 0.035 
NM_001081132 UPF2 regulator of nonsense transcripts homolog (yeast) -1.616 0.019 
NM_013471 annexin A4 -1.622 0.020 
NM_013562 interferon-related developmental regulator 1 -1.624 0.004 
NM_019437 riboflavin kinase -1.627 0.025 
NM_011956 nucleotide binding protein 2 -1.631 0.005 
NM_145380 eukaryotic translation initiation factor 3, subunit M -1.637 0.014 
NM_028811 elongation protein 3 homolog (S. cerevisiae) -1.640 0.013 
NM_025304 leucine carboxyl methyltransferase 1 -1.643 0.023 
NM_028304 pseudouridylate synthase 10 -1.644 0.016 
NM_010851 myeloid differentiation primary response gene 88 -1.646 0.015 
NM_183106 tetratricopeptide repeat domain 17 -1.655 0.008 
NM_011348 sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3E; hypothetical protein LOC100044162 
-1.661 0.023 
NP_001258788 Beta-adducin -1.681 0.008 
NM_010217 connective tissue growth factor -1.682 0.028 
NM_198613 adaptor-related protein complex 2, sigma 1 subunit -1.684 0.011 
NM_178710 salt inducible kinase 2 -1.707 0.001 
NM_144877 methyltransferase like 13 -1.712 0.013 
NM_007783 c-src tyrosine kinase -1.719 0.007 
NM_144818 non-SMC condensin I complex, subunit H -1.752 0.007 
NM_178883 golgin, RAB6-interacting -1.753 0.002 
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Table 1-D: Differentially regulated CHO DP-12 proteins determined in samples corresponding 
to culture using decreased bioprocess media dissolved oxygen content of 60%. 
RefSeq 
Annotation 
Description Fold 
Change 
P-
Value 
NM_001126047 sema domain, immunoglobulin domain (Ig), transmembrane 
domain (TM) and short cytoplasmic domain, (semaphorin) 4C 
1.894 0.015 
NM_175242 RIKEN cDNA 2310014H01 gene 1.852 0.000 
NP_001103618 mannoside acetylglucosaminyltransferase 1 1.802 0.000 
NM_008681 N-myc downstream regulated gene 1 1.786 0.046 
NM_020010 cytochrome P450, family 51 1.742 0.010 
NM_010015 defender against cell death 1 1.739 0.035 
NM_008562 similar to myeloid cell leukemia sequence 1; myeloid cell 
leukemia sequence 1 
1.728 0.014 
NM_001080926 low density lipoprotein receptor-related protein 8, apolipoprotein 
e receptor 
1.720 0.004 
NM_130862 brain-specific angiogenesis inhibitor 1-associated protein 2 1.706 0.015 
NM_001166024 ADP-ribosylation factor GTPase activating protein 2 1.701 0.005 
NM_001081376 chromodomain helicase DNA binding protein 5 1.701 0.002 
NM_028767 forkhead box P4 1.699 0.006 
NM_145553 predicted gene 7527; family with sequence similarity 76, member 
A 
1.698 0.020 
NP_001157290 protein phosphatase 1, regulatory subunit 10 1.694 0.006 
NM_080556 transmembrane 9 superfamily member 2 1.688 0.007 
NM_010302 guanine nucleotide binding protein, alpha 12; similar to Guanine 
nucleotide-binding protein alpha-12 subunit (G alpha-12) 
1.686 0.025 
NM_001024205 nuclear fragile X mental retardation protein interacting protein 2 1.685 0.016 
NM_172710 RIKEN cDNA 2310045A20 gene 1.680 0.027 
NM_134063 cDNA sequence BC016423 1.680 0.020 
NM_010511 interferon gamma receptor 1 1.678 0.031 
NM_011333 chemokine (C-C motif) ligand 2 1.678 0.031 
NM_010191 predicted gene 6781; farnesyl diphosphate farnesyl transferase 1 1.676 0.006 
NM_016666 aryl-hydrocarbon receptor-interacting protein 1.673 0.004 
NM_027373 actin filament associated protein 1 1.673 0.022 
NM_011284 replication protein A2 1.660 0.045 
NM_145946 Fanconi anemia, complementation group I 1.650 0.007 
NM_175394 predicted gene 14292; Wilms' tumour 1-associating protein 1.647 0.024 
NM_024229 phosphate cytidylyltransferase 2, ethanolamine 1.647 0.037 
NM_009125 ataxin 2 1.642 0.045 
NM_027435 ATPase family, AAA domain containing 2 1.627 0.012 
NM_146065 activating transcription factor 7 1.625 0.001 
NM_029078 cleavage and polyadenylation factor subunit homolog (S. 
cerevisiae) 
1.618 0.007 
NM_011623 topoisomerase (DNA) II alpha 1.614 0.014 
NM_027219 CDC42 effector protein (Rho GTPase binding) 1 1.613 0.032 
NM_030743 ring finger protein 114 1.608 0.003 
NM_028793 acyl-Coenzyme A binding domain containing 5 1.608 0.027 
NM_009242 secreted acidic cysteine rich glycoprotein; similar to Secreted 
acidic cysteine rich glycoprotein 
1.607 0.033 
NM_144804 DEP domain containing 7 1.604 0.050 
NM_145942 similar to Hmgcs1 protein; 3-hydroxy-3-methylglutaryl-Coenzyme 
A synthase 1 
1.598 0.004 
NM_134081 DnaJ (Hsp40) homolog, subfamily C, member 9 1.595 0.028 
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NM_001081359 ubiquitin protein ligase E3 component n-recognin 5 1.587 0.047 
NP_001135450 TPX2, microtubule-associated protein homolog (Xenopus laevis) 1.568 0.021 
NM_011121 polo-like kinase 1 (Drosophila) 1.568 0.023 
NM_145611 KN motif and ankyrin repeat domains 2 1.567 0.033 
NM_009624 adenylate cyclase 9 1.565 0.047 
NM_172472 transcription factor E3 1.563 0.021 
NM_030561 cDNA sequence BC004004 1.563 0.030 
NM_001163570 exosome component 8 1.558 0.005 
NM_028390 anillin, actin binding protein 1.555 0.000 
NM_008402 integrin alpha V 1.554 0.000 
NM_001171052 metastasis associated 3 1.554 0.039 
NM_028283 uveal autoantigen with coiled-coil domains and ankyrin repeats 1.553 0.025 
NM_172205 suprabasin 1.552 0.031 
NM_016963 tropomodulin 3 1.549 0.007 
NM_009103 ribonucleotide reductase M1 1.548 0.005 
NM_009007 RAS-related C3 botulinum substrate 1 1.547 0.025 
NM_008139 guanine nucleotide binding protein, alpha q polypeptide 1.547 0.004 
NM_009270 squalene epoxidase 1.543 0.017 
NM_144901 predicted gene 5064; cold shock domain containing E1, RNA 
binding 
1.543 0.007 
NM_153808 similar to Structural maintenance of chromosomes 5; structural 
maintenance of chromosomes 5 
1.538 0.010 
NM_133435 nicotinamide nucleotide adenylyltransferase 1 1.538 0.021 
NM_053090 family with sequence similarity 126, member A 1.536 0.038 
NM_001044384 tissue inhibitor of metalloproteinase 1 1.535 0.002 
NM_028044 similar to calponin 3, acidic; predicted gene 4815; calponin 3, 
acidic 
1.528 0.009 
NM_172397 similar to epithelial protein lost in neoplasm; LIM domain 
containing 2 
1.520 0.016 
NM_010708 lectin, galactose binding, soluble 9 1.517 0.042 
NM_019813 drebrin 1 1.514 0.027 
NP_001128624 solute carrier family 39 (zinc transporter), member 14 1.513 0.044 
NM_021563 Erbb2 interacting protein 1.513 0.010 
NM_009655 activated leukocyte cell adhesion molecule 1.507 0.003 
NM_010931 ubiquitin-like, containing PHD and RING finger domains, 1; 
predicted gene 5648; similar to nuclear zinc finger protein Np95 
1.501 0.005 
NM_026936 oxidase assembly 1-like 1.501 0.030 
NM_012025 Rac GTPase-activating protein 1; predicted gene 1859 1.500 0.034 
NM_147201 nuclear receptor binding protein 1 1.497 0.007 
NM_028074 DEAD (Asp-Glu-Ala-Asp) box polypeptide 42 1.496 0.000 
NM_153117 RIKEN cDNA 9530068E07 gene 1.495 0.046 
NM_175313 RIKEN cDNA A130022J15 gene 1.495 0.036 
NM_008364 interleukin 1 receptor accessory protein 1.491 0.041 
NM_007840 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5; predicted gene 12183 1.490 0.021 
NM_198249 RIKEN cDNA E130112L23 gene 1.489 0.001 
NM_009074 macrophage stimulating 1 receptor (c-met-related tyrosine 
kinase) 
1.487 0.013 
NM_001163622 prolyl endopeptidase-like 1.487 0.039 
NM_144788 HECT domain containing 1 1.487 0.021 
NP_031641 catenin (cadherin associated protein), delta 1 1.482 0.046 
NM_133781 calcium binding protein 39 1.481 0.047 
NM_007709 Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-
terminal domain 1 
1.476 0.012 
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NM_029169 RNA binding motif protein 6 1.474 0.002 
NM_007602 calpain 5 1.469 0.028 
NM_001081251 polybromo 1 1.455 0.017 
NM_008567 minichromosome maintenance deficient 6 (MIS5 homolog, S. 
pombe) (S. cerevisiae) 
1.455 0.018 
NM_019975 2-hydroxyacyl-CoA lyase 1 1.453 0.044 
NM_026101 hect domain and RLD 4 1.447 0.016 
NM_007394 activin A receptor, type 1 1.444 0.025 
NM_177643 Zinc finger protein 281 1.444 0.001 
NP_733486 RNA binding motif protein 12 1.441 0.016 
NM_021519 predicted gene 11964; endothelial differentiation-related factor 1 1.440 0.009 
NM_025952 magnesium transporter 1 1.437 0.006 
NM_008565 minichromosome maintenance deficient 4 homolog (S. 
cerevisiae) 
1.436 0.040 
NM_013863 BCL2-associated athanogene 3 1.429 0.024 
NM_145139 eukaryotic translation initiation factor 3, subunit L 1.429 0.004 
NM_008047 follistatin-like 1 1.429 0.017 
NM_010070 docking protein 1 1.428 0.006 
NM_028760 centrosomal protein 55 1.427 0.013 
NM_026305 predicted gene 11401; similar to transcription elongation factor B 
(SIII), polypeptide 2; predicted gene 8971; transcription 
elongation factor B (SIII), polypeptide 2 
1.419 0.026 
NM_026934 predicted gene 5909; zinc finger CCCH-type containing 15 1.418 0.024 
NM_009881 chromodomain protein, Y chromosome-like; predicted gene 7584 1.415 0.049 
NM_030113 Rho GTPase activating protein 10 1.414 0.005 
NM_146131 similar to Pre-B-cell leukemia transcription factor interacting 
protein 1; pre-B-cell leukemia transcription factor interacting 
protein 1 
1.412 0.026 
NP_001104536 FK506 binding protein 8 1.412 0.004 
NM_025682 paraspeckle protein 1 1.409 0.031 
NM_197982 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 1.404 0.024 
NM_172666 alkylglycerone phosphate synthase 1.402 0.043 
NM_175127 F-box protein 28 1.402 0.040 
NM_023063 LIM domain and actin binding 1 1.396 0.015 
NM_001166406 kinesin family member 20A 1.396 0.007 
NM_146239 PCTAIRE-motif protein kinase 2 1.396 0.005 
NP_001239458 Polyglutamine-binding protein 1 1.388 0.016 
NM_144831 DEAH (Asp-Glu-Ala-His) box polypeptide 8 1.386 0.040 
NM_023603 splicing factor proline/glutamine rich (polypyrimidine tract 
binding protein associated); similar to PTB-associated splicing 
factor 
1.382 0.001 
NM_172679 RIKEN cDNA 4932438A13 gene 1.381 0.015 
NM_029402 cullin 2 1.381 0.017 
NM_001048267 predicted gene 6493; transportin 1 1.379 0.016 
NM_009510 ezrin; hypothetical protein LOC100044177 1.378 0.022 
NM_175021 sterile alpha motif domain containing 4B 1.378 0.028 
NM_025364 predicted gene 6563; SAP domain containing ribonucleoprotein 1.375 0.005 
NP_598452 poly-U binding splicing factor 60 1.371 0.013 
NM_016794 vesicle-associated membrane protein 8 1.368 0.018 
NM_019408 nuclear factor of kappa light polypeptide gene enhancer in B-cells 
2, p49/p100 
1.366 0.008 
NM_001081242 talin 2 1.364 0.017 
NM_028242 HIV TAT specific factor 1 1.361 0.008 
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NM_146078 ubiquitin protein ligase E3 component n-recognin 2 1.361 0.041 
NM_008619 Moloney leukemia virus 10; predicted gene 7357 1.360 0.036 
NM_011767 zinc finger RNA binding protein 1.359 0.040 
NM_139291 cell division cycle 26; predicted gene 9174 1.357 0.018 
NM_020022 replication factor C (activator 1) 2 1.356 0.032 
NM_025822 arginine/serine-rich coiled-coil 1 1.355 0.036 
NM_183417 cyclin-dependent kinase 2 1.352 0.048 
NM_027434 regulation of nuclear pre-mRNA domain containing 1B 1.351 0.048 
NM_031165 similar to heat shock protein 8; heat shock protein 8 1.351 0.034 
NM_008861 polycystic kidney disease 2 1.344 0.038 
NM_015760 NADPH oxidase 4 1.343 0.022 
NM_019811 acyl-CoA synthetase short-chain family member 2 1.341 0.006 
NM_026653 replication protein A1 1.340 0.017 
NM_009283 signal transducer and activator of transcription 1 1.340 0.045 
NM_008881 plexin A1 1.330 0.030 
NM_080793 SET domain containing (lysine methyltransferase) 7 1.320 0.031 
NM_001048267 predicted gene 6493; transportin 1 1.319 0.039 
NM_011486 similar to Stat3B; signal transducer and activator of transcription 
3 
1.318 0.005 
NM_177296 transportin 3 1.314 0.016 
NM_026497 nudix (nucleoside diphosphate linked moiety X)-type motif 12 1.313 0.008 
NM_011716 Wolfram syndrome 1 homolog (human) 1.311 0.016 
NM_145937 sulfatase modifying factor 1 1.310 0.016 
NM_026872 ubiquitin-associated protein 2 1.305 0.034 
NM_007988 fatty acid synthase 1.298 0.012 
NM_018748 golgi autoantigen, golgin subfamily a, 4 1.293 0.018 
NM_008549 mannosidase 2, alpha 1 1.288 0.018 
NP_001005331 eukaryotic translation initiation factor 4, gamma 1 1.288 0.028 
NM_015735 damage specific DNA binding protein 1 1.286 0.002 
NM_172391 AHA1, activator of heat shock protein ATPase homolog 2 (yeast) 1.285 0.024 
NM_207176 testis derived transcript 1.284 0.013 
NM_024245 kinesin family member 23 1.280 0.008 
NM_010235 fos-like antigen 1 1.277 0.021 
NM_007896 predicted gene 8545; microtubule-associated protein, RP/EB 
family, member 1; similar to Microtubule-associated protein 
RP/EB family member 1 (APC-binding protein EB1) (End-binding 
protein 1) (EB1) 
1.268 0.013 
NM_011378 transcriptional regulator, SIN3A (yeast) 1.267 0.009 
NM_133952 unc-45 homolog A (C. elegans) 1.264 0.038 
NM_021521 mediator of RNA polymerase II transcription, subunit 12 homolog 
(yeast) 
1.263 0.033 
NM_001163540 plectin 1 1.251 0.014 
NM_001003909 ankyrin repeat and IBR domain containing 1 1.250 0.019 
NM_007798 cathepsin B 1.249 0.015 
NM_153774 importin 9 1.245 0.010 
NM_008684 neogenin 1.242 0.018 
NM_001081255 leucine-rich repeats and calponin homology (CH) domain 
containing 3 
1.237 0.012 
NM_008566 minichromosome maintenance deficient 5, cell division cycle 46 
(S. cerevisiae) 
1.234 0.042 
NM_133947 nuclear mitotic apparatus protein 1 1.230 0.001 
NM_029582 thioredoxin domain containing 11 1.230 0.048 
NP_963910 GNAS (guanine nucleotide binding protein, alpha stimulating) 1.219 0.025 
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complex locus 
NM_021549 polynucleotide kinase 3'- phosphatase 1.219 0.003 
NM_027226 forty-two-three domain containing 1 1.216 0.009 
NM_146145 Janus kinase 1 1.211 0.042 
NM_012056 FK506 binding protein 9 1.203 0.007 
NM_134077 RNA binding motif protein 26 1.202 0.046 
NM_011150 lectin, galactoside-binding, soluble, 3 binding protein -1.203 0.026 
NM_138597 predicted gene 5436; similar to ATP synthase, H+ transporting, 
mitochondrial F1 complex, O subunit; ATP synthase, H+ 
transporting, mitochondrial F1 complex, O subunit 
-1.205 0.009 
NM_026688 similar to NADH dehydrogenase (ubiquinone) Fe-S protein 3; 
NADH dehydrogenase (ubiquinone) Fe-S protein 3; predicted 
gene 12251 
-1.208 0.016 
NM_053119 enoyl Coenzyme A hydratase, short chain, 1, mitochondrial -1.209 0.042 
NP_001123951 nucleobindin 2 -1.211 0.027 
NM_007509 ATPase, H+ transporting, lysosomal V1 subunit B2 -1.213 0.027 
NM_013792 alpha-N-acetylglucosaminidase (Sanfilippo disease IIIB) -1.215 0.037 
NM_007643 CD36 antigen -1.216 0.017 
NM_025591 RIKEN cDNA 2010309E21 gene; similar to CG5323-PA; predicted 
gene 6396; predicted gene 6624 
-1.219 0.009 
NM_007653 CD63 antigen -1.221 0.015 
NM_172678 acyl-Coenzyme A dehydrogenase family, member 9 -1.222 0.047 
NM_029103 mesencephalic astrocyte-derived neurotrophic factor -1.224 0.040 
NM_153559 quiescin Q6 sulfhydryl oxidase 2 -1.228 0.024 
NM_001085493 RIKEN cDNA 2310030N02 gene -1.231 0.047 
NM_024242 RIO kinase 1 (yeast) -1.240 0.014 
NP_033778 A kinase (PRKA) anchor protein 1 -1.240 0.003 
NM_029735 similar to Bifunctional aminoacyl-tRNA synthetase; glutamyl-
prolyl-tRNA synthetase 
-1.241 0.043 
NM_007949 excision repair cross-complementing rodent repair deficiency, 
complementation group 2 
-1.244 0.003 
NM_007533 branched chain ketoacid dehydrogenase E1, alpha polypeptide -1.244 0.032 
NM_023646 DnaJ (Hsp40) homolog, subfamily A, member 3 -1.247 0.035 
NM_009296 predicted gene 3258; suppressor of Ty 4 homolog 1 (S. cerevisiae) -1.248 0.043 
NM_028599 WD repeat domain 75 -1.249 0.030 
NM_022410 myosin, heavy polypeptide 9, non-muscle -1.251 0.006 
NM_021607 nicastrin -1.252 0.007 
NM_024434 leucine aminopeptidase 3 -1.253 0.032 
NM_026114 similar to Eukaryotic translation initiation factor 2 subunit 1 
(Eukaryotic translation initiation factor 2 alpha subunit) (eIF-2-
alpha) (EIF-2alpha) (EIF-2A); eukaryotic translation initiation 
factor 2, subunit 1 alpha; predicted gene 7459 
-1.253 0.002 
NM_020045 NFU1 iron-sulfur cluster scaffold homolog (S. cerevisiae); 
predicted gene 7859 
-1.257 0.001 
NM_027569 sperm associated antigen 9 -1.258 0.010 
NM_008828 phosphoglycerate kinase 1; predicted gene, EG668435 -1.262 0.014 
NM_153065 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 -1.268 0.013 
NM_029720 cysteine-rich with EGF-like domains 2 -1.268 0.037 
NM_026011 ADP-ribosylation factor-like 8B -1.275 0.039 
NM_027869 similar to polynucleotide phosphorylase-like protein; 
polyribonucleotide nucleotidyltransferase 1 
-1.279 0.021 
NM_013536 EMG1 nucleolar protein homolog (S. cerevisiae) -1.284 0.036 
NM_019736 acyl-CoA thioesterase 9 -1.286 0.017 
NM_011811 phenylalanyl-tRNA synthetase, beta subunit -1.289 0.024 
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NM_008149 glycerol-3-phosphate acyltransferase, mitochondrial -1.293 0.033 
NM_175121 solute carrier family 38, member 2 -1.301 0.027 
NM_029673 inner membrane protein, mitochondrial -1.301 0.032 
NM_021460 lysosomal acid lipase A -1.302 0.034 
NM_023060 eukaryotic elongation factor, selenocysteine-tRNA-specific -1.304 0.030 
NP_034918 methyl CpG binding protein 2 -1.304 0.021 
NM_018739 retinitis pigmentosa 9 (human) -1.305 0.017 
NM_029556 citrate lyase beta like -1.314 0.041 
NM_133217 beta-carotene oxygenase 2 -1.315 0.034 
NM_007997 ferredoxin reductase -1.316 0.049 
NM_019734 N-acylsphingosine amidohydrolase 1 -1.319 0.040 
NM_008482 laminin B1 subunit 1 -1.319 0.004 
NM_027244 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 11 -1.320 0.000 
NM_010233 fibronectin 1 -1.342 0.004 
NM_030225 dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-
glutarate complex) 
-1.344 0.026 
NM_028243 prolylcarboxypeptidase (angiotensinase C) -1.345 0.011 
NM_016763 hydroxysteroid (17-beta) dehydrogenase 10 -1.346 0.027 
NM_027906 RIKEN cDNA 1300010F03 gene -1.350 0.001 
NM_172015 isoleucine-tRNA synthetase -1.351 0.030 
NM_011594 tissue inhibitor of metalloproteinase 2 -1.354 0.027 
NM_009264 small proline-rich protein 1A -1.358 0.004 
NM_007510 ATPase, H+ transporting, lysosomal V1 subunit E1 -1.359 0.029 
NM_026995 carbohydrate kinase domain containing -1.364 0.001 
NM_008929 DnaJ (Hsp40) homolog, subfamily C, member 3 -1.369 0.027 
NM_013671 superoxide dismutase 2, mitochondrial -1.371 0.040 
NM_008231 hepatoma-derived growth factor -1.373 0.009 
NM_001030014 similar to mitochondrial malonyltransferase isoform b precursor; 
malonyl CoA:ACP acyltransferase (mitochondrial) 
-1.374 0.020 
NM_133895 solute carrier family 15, member 4 -1.377 0.039 
NM_008325 iduronidase, alpha-L- -1.378 0.004 
NM_026192 calcium binding and coiled coil domain 1 -1.379 0.022 
NM_145595 carbonyl reductase 4 -1.380 0.036 
NM_134151 tyrosyl-tRNA synthetase -1.388 0.039 
NM_008323 isocitrate dehydrogenase 3 (NAD+), gamma -1.397 0.040 
NM_133826 ATPase, H+ transporting, lysosomal V1 subunit H -1.401 0.013 
NM_178619 predicted gene 5747; RIKEN cDNA 1810026J23 gene -1.401 0.019 
NM_016804 metaxin 2 -1.402 0.049 
NM_019816 apoptosis antagonizing transcription factor -1.407 0.029 
NM_175287 RIKEN cDNA A430005L14 gene; hypothetical protein LOC676530; 
predicted gene 12247 
-1.407 0.009 
NM_015805 ATPase, class II, type 9B -1.410 0.026 
NM_025816 Tax1 (human T-cell leukemia virus type I) binding protein 1 -1.414 0.009 
NM_030678 glycogen synthase 1, muscle -1.417 0.045 
NM_011414 secretory leukocyte peptidase inhibitor -1.417 0.046 
NM_026969 Sec31 homolog A (S. cerevisiae) -1.429 0.006 
NM_025403 NOP10 ribonucleoprotein homolog (yeast) -1.430 0.046 
NM_016709 AU RNA binding protein/enoyl-coenzyme A hydratase -1.434 0.024 
NM_028900 golgi coiled coil 1 -1.434 0.032 
NM_144897 apolipoprotein A-I binding protein -1.436 0.003 
NM_024197 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10 -1.440 0.027 
NM_024201 coiled-coil domain containing 127 -1.449 0.048 
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NM_172436 solute carrier family 25 (mitochondrial carrier, Aralar), member 
12 
-1.451 0.035 
NM_010239 ferritin heavy chain 1 -1.451 0.013 
NM_029364 glucosamine (N-acetyl)-6-sulfatase -1.455 0.024 
NM_001177602 Adenylate kinase 4, mitochondrial -1.457 0.039 
NM_001171582 methionine-tRNA synthetase -1.457 0.015 
NM_001081056 exportin, tRNA (nuclear export receptor for tRNAs) -1.464 0.034 
NM_025304 leucine carboxyl methyltransferase 1 -1.472 0.026 
NM_001113356 complement component 1, r subcomponent; predicted gene 
8551 
-1.473 0.042 
NM_134007 CDGSH iron sulfur domain 1 -1.473 0.021 
NM_008605 matrix metallopeptidase 12 -1.474 0.007 
NM_010764 mannosidase 2, alpha B1 -1.481 0.002 
NM_013657 sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3C 
-1.481 0.012 
NM_001127338 aldehyde dehydrogenase family 7, member A1 -1.481 0.015 
NM_001111121 coiled-coil domain containing 6 -1.485 0.024 
NM_172745 predicted gene 9755; Tu translation elongation factor, 
mitochondrial 
-1.487 0.030 
NM_026742 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 
assembly factor 4 
-1.489 0.022 
NM_026452 coenzyme Q9 homolog (yeast) -1.489 0.047 
NM_029956 methylmalonic aciduria (cobalamin deficiency) type B homolog 
(human) 
-1.489 0.017 
NM_183106 tetratricopeptide repeat domain 17 -1.492 0.014 
NM_033074 threonyl-tRNA synthetase -1.505 0.005 
NM_011695 similar to Voltage-dependent anion-selective channel protein 2 
(VDAC-2) (mVDAC2) (mVDAC6) (Outer mitochondrial membrane 
protein porin 2); predicted gene 7832; voltage-dependent anion 
channel 2 
-1.507 0.002 
NM_145501 phosphatidylinositol 4-kinase type 2 alpha -1.507 0.013 
NM_146229 dynein cytoplasmic 1 light intermediate chain 1 -1.511 0.023 
NM_134147 MACRO domain containing 1 -1.518 0.011 
NM_013768 protein arginine N-methyltransferase 5 -1.521 0.020 
NM_008212 hydroxyacyl-Coenzyme A dehydrogenase -1.524 0.033 
NM_029023 serine carboxypeptidase 1 -1.524 0.023 
NM_030026 methylcrotonoyl-Coenzyme A carboxylase 2 (beta) -1.534 0.006 
NM_019758 mitochondrial carrier homolog 2 (C. elegans); predicted gene, 
100039384; predicted gene, 100039506 
-1.534 0.015 
NP_001156418 pyruvate carboxylase -1.534 0.029 
NM_008788 procollagen C-endopeptidase enhancer protein -1.535 0.008 
NM_023247 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 
assembly factor 3 
-1.542 0.022 
NM_008131 predicted gene 4949; glutamate-ammonia ligase (glutamine 
synthetase) 
-1.552 0.025 
NM_025835 propionyl Coenzyme A carboxylase, beta polypeptide -1.555 0.002 
NM_001163126 component of oligomeric golgi complex 5 -1.555 0.000 
NM_010438 hexokinase 1 -1.558 0.017 
NM_026295 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide 
A) phosphatase, subunit 1 
-1.566 0.011 
NM_008509 lipoprotein lipase; similar to Lipoprotein lipase precursor (LPL) -1.569 0.041 
NM_024243 fucosidase, alpha-L- 1, tissue -1.570 0.002 
NM_007383 acyl-Coenzyme A dehydrogenase, short chain -1.574 0.025 
NM_010261 Rab acceptor 1 (prenylated) -1.576 0.023 
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NM_026744 mitochondrial ribosomal protein L53 -1.580 0.015 
NM_029884 heparan-alpha-glucosaminide N-acetyltransferase -1.581 0.004 
NM_175109 ribosomal protein S19 binding protein 1 -1.585 0.001 
NM_011400 solute carrier family 2 (facilitated glucose transporter), member 1 -1.586 0.002 
NM_007861 dihydrolipoamide dehydrogenase -1.591 0.029 
NM_008095 glioblastoma amplified sequence -1.593 0.015 
NM_001160163 neuraminidase 2 -1.596 0.021 
NM_013492 similar to clusterin; clusterin -1.599 0.000 
NM_201642 similar to UDP glycosyltransferase 1 family polypeptide A13; 
similar to UGT1.6; UDP glucuronosyltransferase 1 family, 
polypeptide A1; UDP glucuronosyltransferase 1 family, 
polypeptide A2; UDP glycosyltransferase 1 family, polypeptide 
A10; UDP glucuronosyl 
-1.601 0.002 
NM_053071 predicted gene 6265; similar to cytochrome c oxidase, subunit 
VIc; cytochrome c oxidase, subunit VIc 
-1.613 0.028 
NM_024220 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2; 
similar to NADH dehydrogenase (ubiquinone) 1, subcomplex 
unknown, 2 
-1.617 0.023 
NM_026364 phosphoribosyl pyrophosphate synthetase-associated protein 1 -1.617 0.029 
NM_016918 nudix (nucleoside diphosphate linked moiety X)-type motif 5 -1.619 0.005 
NM_028876 transmembrane emp24 protein transport domain containing 5; 
similar to Transmembrane emp24 protein transport domain 
containing 5 
-1.620 0.002 
NM_007544 BH3 interacting domain death agonist -1.620 0.001 
NM_025859 ADP-ribosylation factor-like 1 -1.623 0.000 
NM_010421 hexosaminidase A -1.624 0.001 
NM_009194 similar to solute carrier family 12, member 2; solute carrier family 
12, member 2 
-1.626 0.024 
NM_026432 transmembrane protein 66 -1.628 0.002 
NM_013556 hypoxanthine guanine phosphoribosyl transferase 1 -1.630 0.001 
NM_001045489 milk fat globule-EGF factor 8 protein -1.636 0.005 
NM_153561 nudix (nucleoside diphosphate linked moiety X)-type motif 6 -1.643 0.014 
NM_009731 aldo-keto reductase family 1, member B7 -1.649 0.037 
NM_007639 CD1d1 antigen; CD1d2 antigen -1.655 0.020 
NM_008481 laminin, alpha 2 -1.664 0.014 
NM_178644 OAF homolog (Drosophila) -1.670 0.001 
NM_011348 sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3E; hypothetical protein LOC100044162 
-1.671 0.031 
NM_025369 predicted gene 10078; predicted gene 3544; similar to 
mitochondrial ribosomal protein S36; mitochondrial ribosomal 
protein S36; predicted gene 7258; predicted gene 4676 
-1.684 0.003 
NM_026512 biphenyl hydrolase-like (serine hydrolase, breast epithelial mucin-
associated antigen) 
-1.686 0.004 
NM_011125 phospholipid transfer protein -1.692 0.010 
NM_028181 cell cycle progression 1 -1.702 0.016 
NM_053179 N-acetylneuraminic acid synthase (sialic acid synthase) -1.704 0.029 
NM_017393 caseinolytic peptidase, ATP-dependent, proteolytic subunit 
homolog (E. coli) 
-1.711 0.005 
NM_028152 MMS19 (MET18 S. cerevisiae) -1.714 0.010 
NM_011942 lysophospholipase 2 -1.715 0.001 
NM_013562 interferon-related developmental regulator 1 -1.751 0.006 
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Table 1-E: Differentially regulated CHO DP-12 proteins determined in samples corresponding 
to culture using an increased bioprocess media pH of 7.2. 
RefSeq 
Annotation 
Description Fold 
Change 
P-
value 
NM_011638 transferrin receptor 1.893 0.017 
NM_010736 lymphotoxin B receptor 1.776 0.014 
NM_011019 oncostatin M receptor 1.725 0.002 
NM_144930 expressed sequence AU018778 1.706 0.005 
NM_021895 actinin alpha 4 1.650 0.012 
NM_009201 solute carrier family 1 (neutral amino acid transporter), member 5 1.648 0.018 
NM_010235 fos-like antigen 1 1.644 0.020 
NM_009418 tripeptidyl peptidase II 1.623 0.005 
NM_026693 gamma-aminobutyric acid (GABA) A receptor-associated protein-
like 2; predicted gene 3724 
1.620 0.015 
NM_011886 secretory carrier membrane protein 3 1.617 0.024 
NM_011296 predicted gene 10027; hypothetical protein LOC674425; predicted 
gene 6794; predicted gene 9175; similar to ribosomal protein S18; 
similar to ribosomal protein; ribosomal protein S18; predicted 
gene 11230; predicted gene 5321; predicted gene 10260; predict 
1.605 0.003 
NM_001024205 nuclear fragile X mental retardation protein interacting protein 2 1.603 0.003 
NM_026497 nudix (nucleoside diphosphate linked moiety X)-type motif 12 1.603 0.023 
NM_016797 syntaxin 7 1.599 0.028 
NM_030248 CDK5 regulatory subunit associated protein 3 1.588 0.003 
NP_035863 cold shock domain protein A 1.577 0.013 
NM_001081378 kinase D-interacting substrate 220 1.570 0.030 
NM_011563 peroxiredoxin 2 1.567 0.003 
NM_009842 CD151 antigen 1.563 0.010 
NM_001037847 CCR4-NOT transcription complex, subunit 2 1.559 0.016 
NM_198631 zinc finger CCCH-type containing 4 1.558 0.012 
NM_007643 CD36 antigen 1.556 0.046 
NM_007932 endoglin 1.555 0.005 
NP_001003667 keratin 77 1.552 0.002 
NM_028450 GULP, engulfment adaptor PTB domain containing 1 1.526 0.002 
NM_181348 RIKEN cDNA A230083H22 gene 1.525 0.030 
NM_029565 transmembrane protein 59 1.517 0.004 
NM_016714 nucleoporin 50 1.515 0.030 
NM_001111279 WD repeat and FYVE domain containing 1 1.514 0.032 
NM_181848 optineurin 1.504 0.002 
NM_008684 neogenin 1.500 0.001 
NM_009370 transforming growth factor, beta receptor I 1.483 0.033 
NM_026842 ubiquilin 1 1.474 0.014 
NM_030116 mitochondrial ribosomal protein L9 1.473 0.007 
NM_146090 zinc binding alcohol dehydrogenase, domain containing 2 1.463 0.028 
NM_007513 solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 1 
1.462 0.020 
NP_034336 fibroblast growth factor receptor 1 1.461 0.031 
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NM_010730 annexin A1 1.459 0.030 
NM_009074 macrophage stimulating 1 receptor (c-met-related tyrosine kinase) 1.457 0.038 
NM_133900 phosphoserine phosphatase 1.456 0.000 
NM_024287 similar to Rab6 protein; predicted gene 13082; RAB6, member RAS 
oncogene family 
1.452 0.035 
NM_008410 integral membrane protein 2B 1.444 0.048 
NM_009643 AHNAK nucleoprotein (desmoyokin) 1.443 0.018 
NM_021895 actinin alpha 4 1.434 0.040 
NM_016696 glypican 1 1.428 0.024 
NM_019813 drebrin 1 1.428 0.036 
NP_001128624 solute carrier family 39 (zinc transporter), member 14 1.425 0.004 
NM_026911 signal peptidase complex subunit 1 homolog (S. cerevisiae) 1.414 0.015 
NM_011930 chloride channel 7 1.399 0.017 
NM_010655 similar to ribosomal protein L38; predicted gene 13020; ribosomal 
protein L38; predicted gene 4991; karyopherin (importin) alpha 2; 
predicted gene 9028; predicted gene 8129; predicted gene 7123; 
predicted gene 5832; predicted gene 10184; predicted gene 73 
1.394 0.049 
NM_153680 sorting nexin 17 1.392 0.023 
NM_027927 integrator complex subunit 12 1.389 0.008 
NM_011197 prostaglandin F2 receptor negative regulator 1.385 0.040 
NM_009371 transforming growth factor, beta receptor II 1.384 0.012 
NM_007475 predicted gene 9625; predicted gene 14165; similar to acidic 
ribosomal phosphoprotein P0; predicted gene 8730; predicted 
gene 9093; ribosomal protein, large, P0 
1.365 0.022 
NM_025374 glyoxalase 1 1.353 0.020 
NM_028817 acyl-CoA synthetase long-chain family member 3 1.339 0.019 
NM_013933 vesicle-associated membrane protein, associated protein A 1.338 0.002 
NM_021895 actinin alpha 4 1.334 0.002 
NM_139001 chondroitin sulfate proteoglycan 4 1.328 0.045 
NM_031165 similar to heat shock protein 8; heat shock protein 8 1.327 0.003 
NM_133738 anthrax toxin receptor 2 1.324 0.026 
NM_173784 ubiquitin domain containing 2 1.321 0.041 
NM_025816 Tax1 (human T-cell leukemia virus type I) binding protein 1 1.307 0.007 
NM_026029 glyoxalase domain containing 4 1.306 0.022 
NM_026159 retinol saturase (all trans retinol 13,14 reductase) 1.306 0.026 
NM_172666 alkylglycerone phosphate synthase 1.305 0.007 
NM_019661 YKT6 homolog (S. Cerevisiae) 1.302 0.015 
NM_026752 zinc finger, FYVE domain containing 21 1.293 0.014 
NM_027168 HD domain containing 2 1.292 0.012 
NP_083142 WD repeat domain 33 1.288 0.035 
NM_010833 moesin 1.280 0.035 
NM_009503 similar to Transitional endoplasmic reticulum ATPase (TER ATPase) 
(15S Mg(2+)-ATPase p97 subunit) (Valosin-containing protein) 
(VCP); valosin containing protein 
1.279 0.009 
NM_028390 anillin, actin binding protein 1.277 0.017 
NM_008377 leucine-rich repeats and immunoglobulin-like domains 1 1.272 0.020 
NM_028779 adenosine monophosphate deaminase 2 (isoform L) 1.269 0.010 
NM_016677 hippocalcin-like 1 1.263 0.043 
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NM_001001932 early endosome antigen 1 1.257 0.012 
NM_009628 activity-dependent neuroprotective protein 1.251 0.038 
NM_133807 leucine rich repeat containing 59 1.251 0.016 
NM_019961 peroxisomal biogenesis factor 3 1.251 0.045 
NM_009081 predicted gene 13226; predicted gene 15435; ribosomal protein 
L28; predicted gene 12938 
1.250 0.045 
NM_008676 neighbor of Brca1 gene 1 1.248 0.008 
NM_008525 aminolevulinate, delta-, dehydratase 1.245 0.050 
NM_019650 golgi SNAP receptor complex member 2 1.238 0.015 
NM_009078 predicted gene 5202; predicted gene 14449; predicted gene 6975; 
predicted gene 9188; predicted gene 6196; predicted gene 7801; 
similar to ribosomal protein L19; predicted gene 8936; ribosomal 
protein L19; predicted gene 15360; predicted gene 15424 
1.235 0.025 
NP_083939 predicted gene 11675; eukaryotic translation elongation factor 1 
delta (guanine nucleotide exchange protein) 
1.231 0.015 
NM_011968 proteasome (prosome, macropain) subunit, alpha type 6 1.230 0.017 
NM_021557 retinol dehydrogenase 11 1.221 0.027 
NM_007874 receptor accessory protein 5 1.207 0.024 
NM_053170 tripartite motif-containing 33 1.204 0.000 
NM_009795 calpain, small subunit 1 -1.201 0.048 
NM_008565 minichromosome maintenance deficient 4 homolog (S. cerevisiae) -1.201 0.008 
NM_133952 unc-45 homolog A (C. elegans) -1.207 0.004 
NM_007879 developmentally regulated GTP binding protein 1 -1.208 0.038 
NM_011654 predicted gene 3756; tubulin, alpha 1B; predicted gene 5620; 
similar to alpha-tubulin isotype M-alpha-2; predicted gene 14150; 
predicted gene 3226 
-1.220 0.043 
NM_133350 microtubule-associated protein, RP/EB family, member 3 -1.223 0.026 
NM_022332 suppression of tumorigenicity 7 -1.227 0.005 
NM_025982 tetraspanin 31 -1.233 0.024 
NM_177680 YTH domain containing 1 -1.238 0.049 
NM_026876 RIKEN cDNA 1190005F20 gene -1.240 0.003 
NM_010106 predicted gene 5869; predicted gene 7161; predicted gene 7105; 
predicted gene 5822; similar to eukaryotic translation elongation 
factor 1 alpha 1; predicted gene 6192; predicted gene 6392; 
predicted gene 6767; predicted gene 6170; predicted gene 6548; 
pre 
-1.241 0.028 
NM_026154 mitochondrial ribosomal protein L10 -1.248 0.050 
NM_025440 mitochondrial ribosomal protein S16; predicted gene 9173 -1.257 0.014 
NM_025647 cytidine monophosphate (UMP-CMP) kinase 1; predicted gene 
5867 
-1.259 0.019 
NM_010360 glutathione S-transferase, mu 5 -1.260 0.002 
NM_144901 predicted gene 5064; cold shock domain containing E1, RNA 
binding 
-1.267 0.035 
NM_008567 minichromosome maintenance deficient 6 (MIS5 homolog, S. 
pombe) (S. cerevisiae) 
-1.273 0.006 
NM_147778 COMM domain containing 3 -1.282 0.009 
NM_172832 prenylcysteine oxidase 1 like -1.283 0.015 
NM_027852 retinoic acid receptor responder (tazarotene induced) 2 -1.284 0.015 
NM_001025156 coiled-coil domain containing 93 -1.294 0.026 
NM_008628 mutS homolog 2 (E. coli) -1.300 0.026 
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NM_134023 TBC1 domain family, member 10a -1.306 0.009 
NM_025392 BRCA2 and CDKN1A interacting protein -1.306 0.004 
NM_026318 RIKEN cDNA 2310003F16 gene -1.310 0.005 
NP_001186624 Alpha-taxilin -1.313 0.015 
NM_025922 inosine triphosphatase (nucleoside triphosphate 
pyrophosphatase) 
-1.316 0.002 
NM_008927 mitogen-activated protein kinase kinase 1 -1.317 0.018 
NM_026934 predicted gene 5909; zinc finger CCCH-type containing 15 -1.318 0.009 
NM_144923 biliverdin reductase B (flavin reductase (NADPH)) -1.318 0.015 
NM_013559 heat shock 105kDa/110kDa protein 1 -1.320 0.010 
NM_015765 heat shock protein 14 -1.326 0.044 
NM_001009947 dedicator of cytokinesis 11 -1.333 0.025 
NM_016682 ubiquitin-like modifier activating enzyme 2 -1.346 0.006 
NM_028761 poly(A)-specific ribonuclease (deadenylation nuclease) -1.353 0.033 
NP_001070830 four and a half LIM domains 1 -1.355 0.043 
NM_019758 mitochondrial carrier homolog 2 (C. elegans); predicted gene, 
100039384; predicted gene, 100039506 
-1.362 0.009 
NM_027276 CDC16 cell division cycle 16 homolog (S. cerevisiae) -1.365 0.047 
NM_025996 translocase of outer mitochondrial membrane 34 -1.375 0.023 
NM_173443 valosin containing protein (p97)/p47 complex interacting protein 1 -1.375 0.042 
NM_028299 RIKEN cDNA 2700029M09 gene -1.377 0.017 
NM_009755 bone morphogenetic protein 1 -1.381 0.008 
NM_009097 ribosomal protein S6 kinase polypeptide 1 -1.387 0.021 
NM_001033259 coiled-coil domain containing 109A -1.388 0.016 
NM_027475 ecdysoneless homolog (Drosophila) -1.413 0.010 
NM_023716 Tubulin beta-2B chain -1.416 0.032 
NM_013492 similar to clusterin; clusterin -1.422 0.007 
NM_001029979 scaffold attachment factor B2 -1.441 0.014 
NM_026512 biphenyl hydrolase-like (serine hydrolase, breast epithelial mucin-
associated antigen) 
-1.442 0.032 
NM_198622 H1 histone family, member X -1.451 0.007 
NM_011131 polymerase (DNA directed), delta 1, catalytic subunit -1.458 0.010 
NM_010106 predicted gene 5869; predicted gene 7161; predicted gene 7105; 
predicted gene 5822; similar to eukaryotic translation elongation 
factor 1 alpha 1; predicted gene 6192; predicted gene 6392; 
predicted gene 6767; predicted gene 6170; predicted gene 6548; 
pre 
-1.469 0.034 
NM_011340 serine (or cysteine) peptidase inhibitor, clade F, member 1 -1.483 0.002 
NM_138587 family with sequence similarity 3, member C -1.485 0.015 
NM_007620 predicted gene 5678; carbonyl reductase 1 -1.485 0.010 
NM_019464 SH3-domain GRB2-like B1 (endophilin) -1.486 0.047 
NM_134078 CHMP family, member 7 -1.488 0.005 
NM_021412 matrix metallopeptidase 19 -1.488 0.022 
NM_008872 plasminogen activator, tissue -1.489 0.043 
NM_013529 Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 
2 
-1.501 0.048 
NM_001081130 oxoglutarate dehydrogenase-like -1.509 0.007 
NM_009398 similar to TNF-stimulated gene 6 protein; tumor necrosis factor 
alpha induced protein 6 
-1.511 0.007 
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NM_025599 RIKEN cDNA 2610528E23 gene -1.517 0.016 
NM_146171 non-SMC condensin I complex, subunit D2 -1.524 0.026 
NM_029023 serine carboxypeptidase 1 -1.538 0.008 
NM_173441 IWS1 homolog (S. cerevisiae) -1.540 0.036 
NM_147201 nuclear receptor binding protein 1 -1.547 0.038 
NM_008605 matrix metallopeptidase 12 -1.552 0.030 
NM_181414 phosphoinositide-3-kinase, class 3 -1.553 0.018 
NM_001080773 3-phosphoinositide dependent protein kinase-1 -1.560 0.032 
NM_008921 DNA primase, p49 subunit -1.569 0.033 
NM_011871 protein kinase, interferon inducible double stranded RNA 
dependent activator 
-1.576 0.017 
NM_178708 PCI domain containing 2 -1.577 0.003 
NM_172703 eukaryotic translation initiation factor 4 gamma, 3; similar to 
Eukaryotic translation initiation factor 4 gamma 3 (eIF-4-gamma 3) 
(eIF-4G 3) (eIF4G 3) (eIF-4-gamma II) (eIF4GII) 
-1.618 0.021 
NM_008788 procollagen C-endopeptidase enhancer protein -1.638 0.045 
NM_010217 connective tissue growth factor -1.641 0.015 
NM_178919 lipase maturation factor 2 -1.652 0.046 
NM_009713 arylsulfatase A -1.652 0.006 
NM_007620 predicted gene 5678; carbonyl reductase 1 -1.654 0.028 
NM_011198 prostaglandin-endoperoxide synthase 2 -1.685 0.007 
NM_183417 cyclin-dependent kinase 2 -1.686 0.001 
NM_021605 NIMA (never in mitosis gene a)-related expressed kinase 7 -1.703 0.007 
NM_025692 ubiquitin-like modifier activating enzyme 5 -1.711 0.002 
NM_080445 similar to UDP-Gal:betaGal beta 1,3-galactosyltransferase, 
polypeptide 6; UDP-Gal:betaGal beta 1,3-galactosyltransferase, 
polypeptide 6 
-1.770 0.003 
 
 
 
Table 1-F: Differentially regulated CHO DP-12 proteins determined in samples corresponding 
to culture using a decreased bioprocess media pH of 6.8. 
RefSeq 
Annotation 
Description Fold 
Change 
P-
value 
NM_009075 ribose 5-phosphate isomerase A 1.815 0.004 
NM_025797 cytochrome b-5  1.803 0.035 
NM_009321 tubulin cofactor A; predicted gene 4374; predicted gene 6142; 
similar to cofactor A 
1.752 0.048 
NM_144930 expressed sequence AU018778 1.738 0.012 
NM_029556 citrate lyase beta like 1.737 0.004 
NM_138587 family with sequence similarity 3, member C 1.721 0.003 
NM_010893 neuraminidase 1 1.720 0.036 
NM_026842 ubiquilin 1 1.717 0.008 
NM_146090 zinc binding alcohol dehydrogenase, domain containing 2 1.716 0.012 
NM_011341 stromal cell derived factor 4 1.716 0.018 
NM_144896 PET112-like (yeast) 1.716 0.008 
NM_026013 transmembrane protein 77 1.716 0.009 
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NM_009632 poly (ADP-ribose) polymerase family, member 2 1.715 0.008 
NM_008548 mannosidase 1, alpha 1.711 0.017 
NM_145630 pyruvate dehydrogenase kinase, isoenzyme 3 1.707 0.039 
NM_016797 syntaxin 7 1.697 0.004 
NM_027430 brain protein 44; similar to brain protein 44; predicted gene 3982 1.696 0.005 
NM_146108 3-hydroxyisobutyryl-Coenzyme A hydrolase 1.695 0.028 
NM_015753 zinc finger E-box binding homeobox 2 1.693 0.021 
NM_021895 actinin alpha 4 1.689 0.018 
NM_024166 coiled-coil-helix-coiled-coil-helix domain containing 2; predicted 
gene 13202; similar to coiled-coil-helix-coiled-coil-helix domain 
containing 2; predicted gene 12350 
1.688 0.025 
NM_057172 far upstream element (FUSE) binding protein 1 1.687 0.025 
NM_175103 bolA-like 2 (E. coli) 1.686 0.023 
NM_023625 phospholipase B domain containing 2 1.682 0.016 
NM_016844 similar to 40S ribosomal protein S28; predicted gene 10443; 
predicted gene 12943; predicted gene 13192; similar to ribosomal 
protein S28; predicted gene 10263; predicted gene 3511; 
ribosomal protein S28 
1.676 0.028 
NP_001104536 FK506 binding protein 8 1.675 0.018 
NM_010931 ubiquitin-like, containing PHD and RING finger domains, 1; 
predicted gene 5648; similar to nuclear zinc finger protein Np95 
1.675 0.009 
NM_027435 ATPase family, AAA domain containing 2 1.673 0.024 
NM_001081130 oxoglutarate dehydrogenase-like 1.669 0.001 
NM_153406 cytospin A 1.669 0.021 
NP_001157089 threonyl-tRNA synthetase 2, mitochondrial (putative) 1.668 0.009 
NM_029840 RIKEN cDNA 2610029I01 gene 1.667 0.024 
NM_009264 small proline-rich protein 1A 1.666 0.038 
NM_001033242 ceroid-lipofuscinosis, neuronal 5 1.666 0.030 
NM_177231 arrestin, beta 1 1.664 0.015 
NM_027168 HD domain containing 2 1.659 0.001 
NM_001163501 RIKEN cDNA C130039O16 gene 1.658 0.021 
NM_023130 RIKEN cDNA C130057N11 gene; hnRNP-associated with lethal 
yellow 
1.658 0.015 
NM_016690 heterogeneous nuclear ribonucleoprotein D-like 1.657 0.017 
NM_133435 nicotinamide nucleotide adenylyltransferase 1 1.656 0.014 
NM_001111279 WD repeat and FYVE domain containing 1 1.654 0.021 
NM_134147 MACRO domain containing 1 1.652 0.006 
NM_010368 glucuronidase, beta 1.651 0.043 
NM_134042 aldehyde dehydrogenase family 6, subfamily A1 1.646 0.009 
NM_025334 thioredoxin domain containing 12 (endoplasmic reticulum) 1.646 0.044 
NM_019711 RNA binding motif, single stranded interacting protein 2 1.644 0.011 
NM_023065 interferon gamma inducible protein 30 1.640 0.016 
NM_019813 drebrin 1 1.639 0.007 
NM_026410 cell division cycle associated 5 1.639 0.034 
NM_016722 galactosamine (N-acetyl)-6-sulfate sulfatase 1.637 0.003 
NM_025700 phosphoglucomutase 1 1.637 0.012 
NM_201639 synemin, intermediate filament protein 1.635 0.002 
NM_011638 transferrin receptor 1.620 0.047 
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NM_024249 solute carrier family 38, member 10 1.619 0.038 
NM_028767 forkhead box P4 1.618 0.009 
NM_026497 nudix (nucleoside diphosphate linked moiety X)-type motif 12 1.617 0.013 
NM_029872 heterogeneous nuclear ribonucleoprotein A0 1.613 0.039 
NM_009211 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily c, member 1; predicted gene 7004 
1.611 0.010 
NM_007803 cortactin; predicted gene 8786 1.609 0.033 
NM_177592 transmembrane protein 164 1.607 0.019 
NM_025305 mitchondrial ribosomal protein S7 1.607 0.045 
NM_025526 IscU iron-sulfur cluster scaffold homolog (E. coli); similar to 
nitrogen fixation cluster-like 
1.607 0.006 
NM_010729 lysyl oxidase-like 1 1.606 0.017 
NM_001163622 prolyl endopeptidase-like 1.603 0.001 
NM_023063 LIM domain and actin binding 1 1.600 0.021 
NM_010027 D-dopachrome tautomerase 1.596 0.042 
NM_013463 galactosidase, alpha 1.595 0.000 
NM_010023 dodecenoyl-Coenzyme A delta isomerase (3,2 trans-enoyl-
Coenyme A isomerase) 
1.593 0.006 
NM_008562 similar to myeloid cell leukemia sequence 1; myeloid cell leukemia 
sequence 1 
1.591 0.002 
NM_023733 carnitine O-octanoyltransferase 1.589 0.015 
NM_011035 p21 protein (Cdc42/Rac)-activated kinase 1 1.588 0.008 
NP_001191902 Bromodomain-containing protein 2 1.587 0.013 
NM_080445 similar to UDP-Gal:betaGal beta 1,3-galactosyltransferase, 
polypeptide 6; UDP-Gal:betaGal beta 1,3-galactosyltransferase, 
polypeptide 6 
1.586 0.005 
NM_138753 hexamethylene bis-acetamide inducible 1 1.585 0.004 
NM_153561 nudix (nucleoside diphosphate linked moiety X)-type motif 6 1.583 0.045 
NM_026080 mitochondrial ribosomal protein S24 1.582 0.033 
NM_026988 parathymosin 1.581 0.040 
NM_175251 AT rich interactive domain 2 (ARID, RFX-like); RIKEN cDNA 
1700124K17 gene 
1.578 0.044 
NM_008917 palmitoyl-protein thioesterase 1 1.577 0.010 
NM_153176 spastic paraplegia 7 homolog (human) 1.574 0.005 
NM_027289 5'-nucleotidase domain containing 2 1.571 0.031 
NM_011933 2-4-dienoyl-Coenzyme A reductase 2, peroxisomal 1.570 0.001 
NM_009074 macrophage stimulating 1 receptor (c-met-related tyrosine kinase) 1.569 0.025 
NM_008305 perlecan (heparan sulfate proteoglycan 2) 1.569 0.005 
NM_025988 acyl-Coenzyme A binding domain containing 4 1.569 0.001 
NM_026672 glutathione S-transferase, mu 7 1.568 0.016 
NM_016786 ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast) 1.567 0.017 
NM_008549 mannosidase 2, alpha 1 1.567 0.000 
NM_011296 predicted gene 10027; hypothetical protein LOC674425; predicted 
gene 6794; predicted gene 9175; similar to ribosomal protein S18; 
similar to ribosomal protein; ribosomal protein S18; predicted 
gene 11230; predicted gene 5321; predicted gene 10260; predict 
1.561 0.010 
NM_021278 thymosin, beta 4, X chromosome; similar to thymosin beta-4 1.552 0.035 
NM_001045523 bromo adjacent homology domain containing 1 1.551 0.040 
NM_009270 squalene epoxidase 1.549 0.002 
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NP_001135450 TPX2, microtubule-associated protein homolog (Xenopus laevis) 1.545 0.016 
NM_009054 tripartite motif-containing 27 1.545 0.031 
NM_013782 phosphatidylserine synthase 2 1.544 0.012 
NM_008669 N-acetyl galactosaminidase, alpha 1.540 0.003 
NM_015734 collagen, type V, alpha 1 1.540 0.004 
NM_023128 paralemmin 1.540 0.023 
NM_030749 endoplasmic reticulum chaperone SIL1 homolog (S. cerevisiae) 1.538 0.026 
NM_026933 TP53 regulated inhibitor of apoptosis 1 1.533 0.001 
NM_001024205 nuclear fragile X mental retardation protein interacting protein 2 1.532 0.000 
NM_025657 leucine rich repeat containing 57 1.530 0.004 
NP_001171340 Ras-responsive element-binding protein 1 1.528 0.028 
NM_153053 predicted gene 7935; splicing factor 3b, subunit 4 1.526 0.019 
NM_181348 RIKEN cDNA A230083H22 gene 1.524 0.020 
NM_053158 mitochondrial ribosomal protein L1 1.523 0.001 
NM_138670 mercaptopyruvate sulfurtransferase 1.521 0.022 
NM_026329 polymerase (RNA) II (DNA directed) polypeptide G 1.521 0.006 
NM_001076554 spectrin alpha 2 1.521 0.001 
NM_021460 lysosomal acid lipase A 1.521 0.023 
NM_144846 family with sequence similarity 49, member B 1.520 0.005 
NM_026004 5'-nucleotidase, cytosolic III 1.517 0.004 
NM_134076 abhydrolase domain containing 4 1.515 0.007 
NM_026159 retinol saturase (all trans retinol 13,14 reductase) 1.511 0.005 
NP_035863 cold shock domain protein A 1.509 0.032 
NM_011421 sphingomyelin phosphodiesterase 1, acid lysosomal 1.509 0.016 
NM_133998 RIKEN cDNA 1810008A18 gene 1.509 0.013 
NM_013897 translocase of inner mitochondrial membrane 8 homolog b (yeast) 1.509 0.021 
NM_009533 X-ray repair complementing defective repair in Chinese hamster 
cells 5 
1.508 0.035 
NM_019734 N-acylsphingosine amidohydrolase 1 1.504 0.017 
NM_021299 adenylate kinase 3 1.503 0.005 
NM_173371 hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) 1.503 0.020 
NP_001003667 keratin 77 1.502 0.006 
NM_030597 LSM2 homolog, U6 small nuclear RNA associated (S. cerevisiae) 1.502 0.023 
NP_444310 Aldehyde dehydrogenase family 1 member A3 1.501 0.007 
NM_011586 myosin XVIIIA 1.499 0.008 
NM_133716 stromal membrane-associated GTPase-activating protein 2 1.498 0.026 
NM_016677 hippocalcin-like 1 1.498 0.042 
NM_175489 oxysterol binding protein-like 8 1.496 0.005 
NM_007415 poly (ADP-ribose) polymerase family, member 1 1.496 0.016 
NM_144870 NADH dehydrogenase (ubiquinone) Fe-S protein 8 1.491 0.005 
NM_183144 inositol polyphosphate-5-phosphatase A 1.491 0.041 
NM_025537 Ts translation elongation factor, mitochondrial 1.491 0.024 
NM_025948 LSM14 homolog A (SCD6, S. cerevisiae) 1.491 0.016 
NM_029909 RIKEN cDNA C330018D20 gene 1.490 0.017 
NM_139001 chondroitin sulfate proteoglycan 4 1.490 0.020 
NM_172736 leukocyte receptor cluster (LRC) member 8 1.490 0.008 
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NM_001080775 similar to nuclear myosin I beta; myosin IC 1.487 0.009 
NM_172472 transcription factor E3 1.486 0.013 
NM_025587 predicted gene 5963; ribosomal protein S21 1.484 0.027 
NM_008512 low density lipoprotein receptor-related protein 1 1.482 0.002 
NM_172532 aldhehyde dehydrogenase family 5, subfamily A1 1.482 0.003 
NM_178605 NOP16 nucleolar protein homolog (yeast) 1.480 0.003 
NM_027434 regulation of nuclear pre-mRNA domain containing 1B 1.479 0.035 
NM_001163481 FK506 binding protein 10 1.478 0.031 
NM_028611 RIKEN cDNA 2410091C18 gene 1.478 0.006 
NM_026444 citrate synthase 1.477 0.036 
NM_030116 mitochondrial ribosomal protein L9 1.477 0.021 
NM_001033136 family with sequence similarity 82, member A2 1.477 0.040 
NM_030225 dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-
glutarate complex) 
1.476 0.031 
NP_598452 poly-U binding splicing factor 60 1.476 0.018 
NM_078478 growth hormone inducible transmembrane protein 1.475 0.003 
NM_028390 anillin, actin binding protein 1.475 0.041 
NM_007647 ectonucleoside triphosphate diphosphohydrolase 5 1.473 0.002 
NM_010135 enabled homolog (Drosophila) 1.471 0.015 
NP_064426 molybdenum cofactor synthesis 1 1.466 0.025 
NM_021895 actinin alpha 4 1.465 0.025 
NM_007383 acyl-Coenzyme A dehydrogenase, short chain 1.463 0.039 
NM_009752 galactosidase, beta 1 1.462 0.005 
NM_010299 GM2 ganglioside activator protein 1.462 0.024 
NM_030721 acyl-Coenzyme A oxidase 3, pristanoyl 1.461 0.044 
NM_010436 H2A histone family, member X 1.459 0.010 
NM_024434 leucine aminopeptidase 3 1.457 0.031 
NM_021604 agrin 1.455 0.023 
NM_025835 propionyl Coenzyme A carboxylase, beta polypeptide 1.455 0.003 
NM_023645 KDEL (Lys-Asp-Glu-Leu) containing 1 1.455 0.035 
NM_011563 peroxiredoxin 2 1.454 0.018 
NM_207625 acyl-CoA synthetase long-chain family member 4 1.454 0.002 
NM_009502 vinculin 1.453 0.017 
NM_007840 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5; predicted gene 12183 1.449 0.003 
NM_027216 similar to Solute carrier family 39 (metal ion transporter), member 
11; solute carrier family 39 (metal ion transporter), member 11 
1.446 0.009 
NM_026732 mitochondrial ribosomal protein L14 1.438 0.042 
NM_008986 polymerase I and transcript release factor 1.437 0.022 
NM_007996 ferredoxin 1 1.435 0.038 
NM_027314 predicted gene 7684; membrane-associated ring finger (C3HC4) 5 1.430 0.038 
NM_001177464 Zinc finger protein 516 1.427 0.048 
NM_015735 damage specific DNA binding protein 1 1.426 0.007 
NM_146234 membrane magnesium transporter 1 1.426 0.035 
NM_024233 REX2, RNA exonuclease 2 homolog (S. cerevisiae) 1.426 0.037 
NM_019961 peroxisomal biogenesis factor 3 1.425 0.047 
NM_008402 integrin alpha V 1.424 0.011 
NM_001081034 F-box protein 11 1.423 0.035 
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NM_026964 coiled-coil domain containing 124 1.423 0.029 
NM_001080794 GTPase activating protein (SH3 domain) binding protein 2 1.419 0.030 
NM_027906 RIKEN cDNA 1300010F03 gene 1.418 0.015 
NM_021895 actinin alpha 4 1.418 0.003 
NM_020050 TMEM9 domain family, member B 1.418 0.011 
NM_026170 endoplasmic reticulum-golgi intermediate compartment (ERGIC) 1 1.418 0.028 
NM_134080 filamin, beta 1.418 0.000 
NM_013671 superoxide dismutase 2, mitochondrial 1.417 0.020 
NM_020520 solute carrier family 25 (mitochondrial carnitine/acylcarnitine 
translocase), member 20 
1.416 0.015 
NM_011490 staufen (RNA binding protein) homolog 1 (Drosophila) 1.416 0.015 
NM_029023 serine carboxypeptidase 1 1.412 0.001 
NM_001163662 nucleobindin 1 1.410 0.003 
NM_133798 exonuclease 3'-5' domain containing 2 1.410 0.038 
NM_026819 dehydrogenase/reductase (SDR family) member 1 1.407 0.043 
NM_144784 acetyl-Coenzyme A acetyltransferase 1 1.407 0.007 
NM_133947 nuclear mitotic apparatus protein 1 1.406 0.008 
NM_027159 coiled-coil domain containing 115; predicted gene 7774 1.406 0.042 
NM_010948 nuclear distribution gene C homolog (Aspergillus), pseudogene 1; 
nuclear distribution gene C homolog (Aspergillus) 
1.404 0.002 
NM_013604 metaxin 1 1.404 0.006 
NM_001033759 transmembrane protein 2 1.402 0.009 
NM_009295 syntaxin binding protein 1 1.402 0.001 
NM_016710 predicted gene 11914; nucleosome binding protein 1 1.401 0.040 
NM_133823 methylmalonic aciduria (cobalamin deficiency) type A 1.400 0.009 
NP_001156418 pyruvate carboxylase 1.400 0.012 
NM_177319 zinc finger, FYVE domain containing 27 1.400 0.049 
NM_009784 calcium channel, voltage-dependent, alpha2/delta subunit 1 1.398 0.012 
NM_011414 secretory leukocyte peptidase inhibitor 1.398 0.031 
NP_001095925 amyloid beta (A4) precursor-like protein 2 1.394 0.011 
NM_010302 guanine nucleotide binding protein, alpha 12; similar to Guanine 
nucleotide-binding protein alpha-12 subunit (G alpha-12) 
1.392 0.031 
NM_001001932 early endosome antigen 1 1.384 0.038 
NM_011197 prostaglandin F2 receptor negative regulator 1.383 0.030 
NM_026373 Cyclin-dependent kinase 2-associated protein 2 1.381 0.024 
NM_173011 isocitrate dehydrogenase 2 (NADP+), mitochondrial 1.380 0.023 
NM_197982 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 1.378 0.027 
NM_153807 acyl-CoA synthetase family member 2 1.375 0.000 
NM_008650 methylmalonyl-Coenzyme A mutase 1.368 0.041 
NM_001163540 plectin 1 1.368 0.011 
NM_010888 similar to NADH dehydrogenase (ubiquinone) Fe-S protein 6; 
NADH dehydrogenase (ubiquinone) Fe-S protein 6; predicted gene 
6415 
1.368 0.004 
NM_001033284 cDNA sequence BC026585 1.367 0.009 
NM_011507 succinate-Coenzyme A ligase, GDP-forming, beta subunit 1.366 0.026 
NM_001040026 SCO cytochrome oxidase deficient homolog 1 (yeast) 1.363 0.024 
NM_019736 acyl-CoA thioesterase 9 1.363 0.001 
NM_008095 glioblastoma amplified sequence 1.362 0.003 
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NM_021559 zinc finger protein 191 1.361 0.014 
NP_001035493 flotillin 2 1.360 0.001 
NM_025500 mitochondrial ribosomal protein L37 1.360 0.021 
NM_026512 biphenyl hydrolase-like (serine hydrolase, breast epithelial mucin-
associated antigen) 
1.358 0.004 
NM_026175 splicing factor 3a, subunit 1 1.349 0.017 
NM_019767 actin related protein 2/3 complex, subunit 1A 1.344 0.037 
NM_138601 similar to es1 protein; DNA segment, Chr 10, Johns Hopkins 
University 81 expressed 
1.343 0.037 
NP_001157185 predicted gene 9755; Tu translation elongation factor, 
mitochondrial 
1.339 0.046 
NM_134089 scribbled homolog (Drosophila) 1.339 0.034 
NM_194342 unc-84 homolog B (C. elegans) 1.334 0.038 
NM_030717 similar to lactamase, beta; lactamase, beta 1.332 0.050 
NM_009503 similar to Transitional endoplasmic reticulum ATPase (TER ATPase) 
(15S Mg(2+)-ATPase p97 subunit) (Valosin-containing protein) 
(VCP); valosin containing protein 
1.332 0.032 
NM_008576 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 1.327 0.038 
NM_198608 alanyl-tRNA synthetase 2, mitochondrial (putative) 1.326 0.047 
NM_010837 microtubule-associated protein 6 1.325 0.028 
NM_027862 predicted gene 10250; hypothetical protein LOC676483; predicted 
gene 5051; ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit d; predicted gene 4953; similar to ATP synthase, 
H+ transporting, mitochondrial F0 complex, subunit d 
1.323 0.031 
NM_024181 DnaJ (Hsp40) homolog, subfamily C, member 10 1.320 0.016 
NM_001039179 bicaudal D homolog 2 (Drosophila) 1.317 0.004 
NM_029759 family with sequence similarity 54, member B 1.316 0.048 
NP_001258827 Peroxisomal acyl-coenzyme A oxidase 1 1.314 0.015 
NM_026095 small nuclear ribonucleoprotein D3 1.314 0.013 
NM_007838 dolichyl-di-phosphooligosaccharide-protein glycotransferase 1.312 0.049 
NM_019402 poly(A) binding protein, nuclear 1 1.311 0.035 
NM_001038492 cathepsin A 1.310 0.016 
NM_011876 twinfilin, actin-binding protein, homolog 2 (Drosophila) 1.304 0.040 
NM_016739 cell cycle associated protein 1 1.302 0.002 
NM_025814 serpine1 mRNA binding protein 1 1.301 0.024 
NM_007757 coproporphyrinogen oxidase 1.300 0.007 
NM_022314 predicted gene 7848; predicted gene 7839; predicted gene 4157; 
similar to tropomyosin 3, gamma; tropomyosin 3, gamma; 
predicted gene 4903 
1.300 0.016 
NP_036122 reticulocalbin 2 1.299 0.023 
NM_013511 erythrocyte protein band 4.1-like 2 1.296 0.004 
NM_023054 UTP3, small subunit (SSU) processome component, homolog (S. 
cerevisiae) 
1.295 0.047 
NM_172666 alkylglycerone phosphate synthase 1.295 0.029 
NM_145575 caldesmon 1 1.291 0.046 
NM_198653 isoleucine-tRNA synthetase 2, mitochondrial; similar to isoleucine-
tRNA synthetase 2, mitochondrial 
1.291 0.021 
NM_008149 glycerol-3-phosphate acyltransferase, mitochondrial 1.290 0.015 
NM_054081 similar to metastasis-associated protein; metastasis associated 1; 
similar to MTA1 
1.290 0.043 
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NM_013651 splicing factor 3a, subunit 2 1.289 0.036 
NM_001081260 tankyrase 1 binding protein 1 1.288 0.014 
NM_172698 RIKEN cDNA 4732418C07 gene 1.284 0.022 
NM_053123 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 1 
1.280 0.004 
NM_025366 coiled-coil-helix-coiled-coil-helix domain containing 1 1.279 0.019 
NM_011378 transcriptional regulator, SIN3A (yeast) 1.276 0.002 
NM_026172 2,4-dienoyl CoA reductase 1, mitochondrial 1.274 0.004 
NM_146176 CCR4-NOT transcription complex, subunit 3 1.269 0.003 
NM_011173 protein S (alpha) 1.266 0.032 
NM_019783 leprecan 1 1.265 0.032 
NM_172591 FCH domain only 2 1.261 0.043 
NM_021345 protein tyrosine phosphatase-like A domain containing 1 1.261 0.036 
NM_025429 serine (or cysteine) peptidase inhibitor, clade B, member 1a 1.256 0.040 
NM_016804 metaxin 2 1.249 0.000 
NM_146034 CTAGE family, member 5 1.248 0.018 
NM_146211 glycosyltransferase 25 domain containing 1 1.248 0.012 
NM_016714 nucleoporin 50 1.243 0.044 
NM_138747 NOP2 nucleolar protein homolog (yeast) 1.236 0.011 
NM_011431 elongation factor Tu GTP binding domain containing 2 1.230 0.006 
NM_175372 retinol dehydrogenase 13 (all-trans and 9-cis) 1.226 0.024 
NM_019823 cytochrome P450, family 2, subfamily d, polypeptide 22 1.224 0.033 
NM_008638 methylenetetrahydrofolate dehydrogenase (NAD+ dependent), 
methenyltetrahydrofolate cyclohydrolase 
1.219 0.005 
NM_009409 topoisomerase (DNA) II beta 1.217 0.020 
NM_011333 chemokine (C-C motif) ligand 2 1.214 0.018 
NM_009315 TAF6 RNA polymerase II, TATA box binding protein (TBP)-
associated factor 
1.212 0.001 
NM_198326 NSFL1 (p97) cofactor (p47) 1.212 0.031 
NM_007798 cathepsin B 1.210 0.010 
NM_023409 Niemann Pick type C2 1.207 0.005 
NM_172205 suprabasin 1.205 0.011 
NM_019584 beclin 1, autophagy related -1.202 0.045 
NM_009418 tripeptidyl peptidase II -1.202 0.011 
NM_178405 ATPase, Na+/K+ transporting, alpha 2 polypeptide -1.204 0.013 
NM_178347 CDC23 (cell division cycle 23, yeast, homolog) -1.207 0.038 
NM_007414 ADP-ribosylarginine hydrolase -1.208 0.025 
NM_007700 conserved helix-loop-helix ubiquitous kinase -1.210 0.025 
NM_010546 inhibitor of kappaB kinase beta -1.212 0.035 
NM_010890 neural precursor cell expressed, developmentally down-regulated 
4 
-1.213 0.004 
NM_024172 HSPA (heat shock 70kDa) binding protein, cytoplasmic 
cochaperone 1 
-1.216 0.041 
NM_011099 predicted gene 6560; predicted gene 2124; predicted gene 6992; 
pyruvate kinase, muscle; similar to M2-type pyruvate kinase 
-1.221 0.009 
NM_198249 RIKEN cDNA E130112L23 gene -1.228 0.010 
NM_007638 chaperonin containing Tcp1, subunit 7 (eta) -1.230 0.042 
NM_001081193 LEM domain containing 3 -1.248 0.025 
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NM_181848 optineurin -1.249 0.016 
NM_133708 GDP-mannose pyrophosphorylase A -1.250 0.037 
NM_183417 cyclin-dependent kinase 2 -1.266 0.007 
NM_134014 exportin 1, CRM1 homolog (yeast) -1.266 0.002 
NM_153800 Rho GTPase activating protein 22 -1.269 0.041 
NM_008684 neogenin -1.279 0.014 
NM_001081011 SLIT-ROBO Rho GTPase activating protein 2 -1.279 0.012 
NP_001116240 leucine rich repeat containing 8D -1.281 0.005 
NM_013560 heat shock protein 1 -1.283 0.030 
NM_001160319 ubiquitin protein ligase E3 component n-recognin 4 -1.287 0.047 
NM_001163126 component of oligomeric golgi complex 5 -1.291 0.016 
NM_025647 cytidine monophosphate (UMP-CMP) kinase 1; predicted gene 
5867 
-1.296 0.014 
NM_001077363 polypyrimidine tract binding protein 1; predicted gene 4900 -1.302 0.023 
NM_144913 methylphosphate capping enzyme -1.304 0.001 
NM_133884 GPN-loop GTPase 2 -1.304 0.050 
NM_029332 A kinase (PRKA) anchor protein 13 -1.304 0.019 
NM_015765 heat shock protein 14 -1.306 0.015 
NM_172277 sorting nexin 8 -1.310 0.022 
NM_008302 heat shock protein 90 alpha (cytosolic), class B member 1 -1.310 0.017 
NM_011018 sequestosome 1 -1.310 0.024 
NM_008563 minichromosome maintenance deficient 3 (S. cerevisiae) -1.314 0.003 
NM_008300 heat shock protein 4 -1.314 0.044 
NM_001146268 platelet derived growth factor receptor, beta polypeptide -1.315 0.032 
NM_133794 glutaminyl-tRNA synthetase -1.318 0.010 
NM_133714 RIKEN cDNA 2310037I24 gene -1.318 0.015 
NM_027350 asparaginyl-tRNA synthetase -1.319 0.009 
NM_178616 predicted gene 14048; proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 11 
-1.319 0.037 
NM_021884 tumor susceptibility gene 101 -1.319 0.041 
NM_025599 RIKEN cDNA 2610528E23 gene -1.319 0.036 
NM_146229 dynein cytoplasmic 1 light intermediate chain 1 -1.323 0.049 
NM_145942 similar to Hmgcs1 protein; 3-hydroxy-3-methylglutaryl-Coenzyme 
A synthase 1 
-1.328 0.045 
NM_008328 similar to Interferon-activatable protein 203 (Ifi-203) (Interferon-
inducible protein p203); similar to interferon activated gene 203; 
interferon activated gene 203 
-1.339 0.013 
NM_133838 EH-domain containing 4 -1.348 0.039 
NM_023294 NDC80 homolog, kinetochore complex component (S. cerevisiae) -1.349 0.026 
NM_009398 similar to TNF-stimulated gene 6 protein; tumor necrosis factor 
alpha induced protein 6 
-1.351 0.009 
NM_133360 predicted gene 5182; acetyl-Coenzyme A carboxylase alpha -1.353 0.015 
NM_130862 brain-specific angiogenesis inhibitor 1-associated protein 2 -1.354 0.017 
NM_033444 chloride intracellular channel 1 -1.354 0.032 
NM_022410 myosin, heavy polypeptide 9, non-muscle -1.355 0.035 
NM_008826 phosphofructokinase, liver, B-type -1.356 0.007 
NM_026114 similar to Eukaryotic translation initiation factor 2 subunit 1 
(Eukaryotic translation initiation factor 2 alpha subunit) (eIF-2-
alpha) (EIF-2alpha) (EIF-2A); eukaryotic translation initiation factor 
-1.357 0.017 
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2, subunit 1 alpha; predicted gene 7459 
NM_025691 signal recognition particle 72 -1.364 0.029 
NM_011035 p21 protein (Cdc42/Rac)-activated kinase 1 -1.364 0.022 
NM_026370 MYST histone acetyltransferase 1 -1.365 0.036 
NM_009673 annexin A5 -1.371 0.011 
NM_026879 chromatin modifying protein 2B -1.371 0.001 
NM_008565 minichromosome maintenance deficient 4 homolog (S. cerevisiae) -1.377 0.023 
NM_012025 Rac GTPase-activating protein 1; predicted gene 1859 -1.383 0.000 
NM_009840 chaperonin containing Tcp1, subunit 8 (theta) -1.384 0.029 
NM_022022 ubiquitination factor E4B, UFD2 homolog (S. cerevisiae) -1.391 0.046 
NM_009272 spermidine synthase -1.391 0.008 
NM_180678 glycyl-tRNA synthetase -1.394 0.014 
NM_009097 ribosomal protein S6 kinase polypeptide 1 -1.395 0.015 
NM_030238 dynein cytoplasmic 1 heavy chain 1 -1.396 0.015 
NM_001029895 arginyltransferase 1 -1.398 0.024 
NM_144923 biliverdin reductase B (flavin reductase (NADPH)) -1.400 0.031 
NM_080638 major vault protein -1.400 0.002 
NM_025304 leucine carboxyl methyltransferase 1 -1.403 0.016 
NM_027236 eukaryotic translation initiation factor 1A domain containing -1.403 0.038 
NM_027807 cullin 5 -1.403 0.043 
NM_008410 integral membrane protein 2B -1.410 0.034 
NM_011830 predicted gene 15210; inosine 5'-phosphate dehydrogenase 2 -1.410 0.020 
NM_145139 eukaryotic translation initiation factor 3, subunit L -1.411 0.025 
NM_133826 ATPase, H+ transporting, lysosomal V1 subunit H -1.415 0.003 
NM_001009947 dedicator of cytokinesis 11 -1.417 0.038 
NM_025380 eukaryotic translation elongation factor 1 epsilon 1 -1.418 0.029 
NM_016843 ataxin 10 -1.418 0.019 
NM_013854 ATP-binding cassette, sub-family F (GCN20), member 1 -1.421 0.004 
NM_007835 dynactin 1 -1.422 0.024 
NM_029735 similar to Bifunctional aminoacyl-tRNA synthetase; glutamyl-
prolyl-tRNA synthetase 
-1.423 0.000 
NM_201226 leucine rich repeat containing 47; similar to leucine rich repeat 
containing 47 
-1.425 0.020 
NM_009481 ubiquitin specific peptidase 9, X chromosome -1.426 0.011 
NM_024267 importin 4 -1.426 0.011 
NM_013477 ATPase, H+ transporting, lysosomal V0 subunit D1 -1.427 0.040 
NM_026007 predicted gene 4462; similar to eukaryotic translation elongation 
factor 1 gamma; predicted gene 9276; predicted gene 5525; 
eukaryotic translation elongation factor 1 gamma; similar to 
Elongation factor 1-gamma (EF-1-gamma) (eEF-1B gamma); 
predicted gene  
-1.427 0.010 
NM_139144 O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase) 
-1.428 0.039 
NM_013559 heat shock 105kDa/110kDa protein 1 -1.429 0.023 
NM_025864 transmembrane protein 206 -1.430 0.034 
NM_022563 discoidin domain receptor family, member 2 -1.431 0.007 
NM_152801 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 -1.432 0.013 
NM_027498 similar to Serine/threonine-protein kinase QSK; cDNA sequence -1.433 0.033 
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BC033915 
NM_008567 minichromosome maintenance deficient 6 (MIS5 homolog, S. 
pombe) (S. cerevisiae) 
-1.435 0.001 
NM_009842 CD151 antigen -1.435 0.008 
NM_028864 zinc finger CCCH type, antiviral 1 -1.437 0.003 
NM_027896 Coenzyme A synthase -1.439 0.043 
NM_019780 vacuolar protein sorting 29 (S. pombe) -1.440 0.045 
NM_021473 aldo-keto reductase family 1, member A4 (aldehyde reductase) -1.444 0.025 
NP_663401 Microfibril-associated glycoprotein 3 -1.445 0.021 
NM_010724 proteasome (prosome, macropain) subunit, beta type 8 (large 
multifunctional peptidase 7) 
-1.447 0.008 
NM_173010 ubiquitin protein ligase E3A -1.449 0.014 
NM_146171 non-SMC condensin I complex, subunit D2 -1.451 0.024 
NM_025697 RIKEN cDNA 6330409N04 gene -1.453 0.022 
NM_016966 predicted gene 7669; predicted gene 5207; predicted gene 9252; 
predicted gene 8096; predicted gene 13337; predicted gene 9210; 
predicted gene 8341; predicted gene 5847; predicted gene 7901; 
predicted gene 9347; predicted gene, EG627427; similar to 3-
phosp 
-1.453 0.013 
NM_012010 eukaryotic translation initiation factor 2, subunit 3, structural gene 
X-linked; similar to translation initiation factor eIF-2 gamma 
subunit; predicted gene 2223 
-1.455 0.001 
NM_172265 eukaryotic translation initiation factor 2B, subunit 5 epsilon -1.457 0.017 
NM_177045 coiled-coil and C2 domain containing 1B -1.460 0.002 
NM_026693 gamma-aminobutyric acid (GABA) A receptor-associated protein-
like 2; predicted gene 3724 
-1.468 0.007 
NM_030210 acetoacetyl-CoA synthetase -1.468 0.018 
NM_009072 Rho-associated coiled-coil containing protein kinase 2 -1.468 0.006 
NM_028198 exportin 5 -1.471 0.005 
NM_008084 predicted gene 4691; predicted gene 6944; predicted gene 10290; 
predicted gene 10566; predicted gene 10291; predicted gene 
3200; predicted gene 12070; predicted gene 7286; predicted gene 
6946; predicted gene 8825; predicted gene 9081; glyceraldehyde-
3-pho 
-1.476 0.012 
NM_026295 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) 
phosphatase, subunit 1 
-1.478 0.006 
NM_008605 matrix metallopeptidase 12 -1.478 0.028 
NM_145527 MAP-kinase activating death domain -1.480 0.032 
NM_008921 DNA primase, p49 subunit -1.486 0.048 
NM_130862 brain-specific angiogenesis inhibitor 1-associated protein 2 -1.488 0.026 
NM_134078 CHMP family, member 7 -1.491 0.021 
NM_013471 annexin A4 -1.492 0.005 
NM_021504 N-glycanase 1 -1.493 0.015 
NM_177876 vacuolar protein sorting 37B (yeast) -1.494 0.007 
NM_033074 threonyl-tRNA synthetase -1.494 0.007 
XM_001479591 similar to Eukaryotic translation initiation factor 5; eukaryotic 
translation initiation factor 5 
-1.495 0.036 
NM_025816 Tax1 (human T-cell leukemia virus type I) binding protein 1 -1.495 0.012 
NM_028032 protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), 
alpha isoform 
-1.496 0.022 
NM_001031667 glycogen synthase kinase 3 alpha -1.497 0.035 
Appendix A 
 
- 57 - 
 
NM_013472 annexin A6 -1.497 0.011 
NM_016721 IQ motif containing GTPase activating protein 1 -1.501 0.047 
NM_015760 NADPH oxidase 4 -1.501 0.009 
NM_145605 kelch domain containing 4 -1.501 0.043 
NM_011596 ATPase, H+ transporting, lysosomal V0 subunit A2 -1.502 0.032 
NM_018799 eukaryotic translation initiation factor 3, subunit I -1.504 0.026 
NM_138745 methylenetetrahydrofolate dehydrogenase (NADP+ dependent), 
methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate 
synthase 
-1.506 0.050 
NM_133685 RAB31, member RAS oncogene family -1.507 0.008 
NM_009674 annexin A7 -1.507 0.015 
NM_001162870 spastin -1.508 0.013 
NM_027815 RIKEN cDNA 9030624J02 gene -1.508 0.016 
NM_011654 predicted gene 3756; tubulin, alpha 1B; predicted gene 5620; 
similar to alpha-tubulin isotype M-alpha-2; predicted gene 14150; 
predicted gene 3226 
-1.512 0.002 
NM_010620 kinesin family member 15 -1.515 0.018 
NM_138315 microtubule associated monoxygenase, calponin and LIM domain 
containing 1 
-1.516 0.009 
NM_001164677 programmed cell death 6 interacting protein -1.516 0.048 
NM_016807 similar to syntenin; syndecan binding protein -1.519 0.050 
NM_177152 leucine-rich repeats and immunoglobulin-like domains 3 -1.521 0.007 
NM_008136 guanine nucleotide binding protein-like 1 -1.522 0.001 
NM_025550 proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 -1.523 0.005 
NM_010562 integrin linked kinase; predicted gene 6263 -1.524 0.009 
NM_133758 ubiquitin specific peptidase 47 -1.526 0.001 
NM_001025156 coiled-coil domain containing 93 -1.528 0.002 
NM_009837 chaperonin containing Tcp1, subunit 4 (delta) -1.529 0.000 
NM_020578 EH-domain containing 3 -1.529 0.025 
NM_148945 ribosomal protein S6 kinase polypeptide 3 -1.531 0.006 
NM_028811 elongation protein 3 homolog (S. cerevisiae) -1.534 0.013 
NM_028632 predicted gene 11221; similar to Protein C14orf111 homolog; 
predicted gene 4893; FCF1 small subunit (SSU) processome 
component homolog (S. cerevisiae) 
-1.535 0.013 
NM_013507 eukaryotic translation initiation factor 4, gamma 2 -1.540 0.004 
NM_134037 ATP citrate lyase -1.540 0.006 
NM_153569 cyclin G associated kinase -1.545 0.004 
NM_001146023 Protein Fam98c -1.546 0.034 
NM_173443 valosin containing protein (p97)/p47 complex interacting protein 1 -1.548 0.027 
NM_022309 core binding factor beta -1.549 0.023 
NM_013492 similar to clusterin; clusterin -1.552 0.003 
NM_016748 cytidine 5'-triphosphate synthase -1.555 0.005 
NM_146217 alanyl-tRNA synthetase -1.556 0.016 
NM_007988 fatty acid synthase -1.560 0.004 
NM_008468 karyopherin (importin) alpha 6 -1.564 0.030 
NM_019942 septin 6 -1.568 0.019 
NM_010615 kinesin family member 11 -1.569 0.008 
NM_001037746 mirror-image polydactyly gene 1 homolog (human); -1.573 0.001 
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phosphoribosyl pyrophosphate synthetase 1; phosphoribosyl 
pyrophosphate synthetase 1-like 1 
NM_080555 phosphatidic acid phosphatase type 2B -1.575 0.032 
NM_013818 GTP binding protein 1 -1.575 0.042 
NM_024281 ribosome binding protein 1 -1.576 0.004 
NM_133786 structural maintenance of chromosomes 4 -1.578 0.035 
NM_009370 transforming growth factor, beta receptor I -1.584 0.012 
NM_008927 mitogen-activated protein kinase kinase 1 -1.584 0.035 
NM_175195 RIKEN cDNA 3110056O03 gene -1.585 0.017 
NM_023716 Tubulin beta-2B chain -1.590 0.029 
NM_028724 similar to Ras and Rab interactor 2; Ras and Rab interactor 2 -1.592 0.015 
NM_178376 Ras-related GTP binding A -1.592 0.004 
NM_019795 DnaJ (Hsp40) homolog, subfamily C, member 7 -1.593 0.005 
NM_009371 transforming growth factor, beta receptor II -1.600 0.009 
NM_008788 procollagen C-endopeptidase enhancer protein -1.603 0.026 
NM_029565 transmembrane protein 59 -1.605 0.000 
NM_013529 Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 
2 
-1.609 0.039 
NM_030201 heat shock protein 70 family, member 13 -1.610 0.024 
NM_001080773 3-phosphoinositide dependent protein kinase-1 -1.611 0.039 
NM_172558 gem (nuclear organelle) associated protein 5 -1.616 0.013 
NM_026662 phosphoribosyl pyrophosphate synthetase 2 -1.619 0.024 
NM_153680 sorting nexin 17 -1.621 0.031 
NM_008708 N-myristoyltransferase 2 -1.622 0.016 
NM_025664 similar to Sorting nexin 9; sorting nexin 9 -1.624 0.000 
NM_134100 major facilitator superfamily domain containing 5 -1.630 0.010 
NM_009068 receptor (TNFRSF)-interacting serine-threonine kinase 1 -1.631 0.011 
NM_009795 calpain, small subunit 1 -1.632 0.006 
NM_198710 synaptophysin-like protein -1.645 0.022 
NM_010233 fibronectin 1 -1.646 0.001 
NM_007502 ATPase, Na+/K+ transporting, beta 3 polypeptide -1.649 0.010 
NM_024229 phosphate cytidylyltransferase 2, ethanolamine -1.651 0.050 
NM_013562 interferon-related developmental regulator 1 -1.653 0.006 
NM_013469 annexin A11; predicted gene 2260; predicted gene 2274 -1.654 0.002 
NM_147778 COMM domain containing 3 -1.661 0.024 
NM_015747 solute carrier family 20, member 1 -1.662 0.022 
NM_026969 Sec31 homolog A (S. cerevisiae) -1.663 0.007 
NM_008668 Ngfi-A binding protein 2 -1.665 0.039 
NM_146121 RAB GTPase activating protein 1 -1.666 0.009 
NM_001102565 neural regeneration protein; alkB, alkylation repair homolog 1 (E. 
coli) 
-1.671 0.009 
NM_022332 suppression of tumorigenicity 7 -1.674 0.002 
NM_010217 connective tissue growth factor -1.678 0.014 
NM_007653 CD63 antigen -1.680 0.026 
NM_028181 cell cycle progression 1 -1.681 0.006 
NM_010684 lysosomal-associated membrane protein 1 -1.687 0.020 
NM_153774 importin 9 -1.687 0.015 
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NM_007620 predicted gene 5678; carbonyl reductase 1 -1.697 0.020 
NM_001159519 phosphoribosylformylglycinamidine synthase (FGAR 
amidotransferase) 
-1.703 0.045 
NM_026441 penta-EF hand domain containing 1 -1.710 0.027 
NM_177304 ectonucleotide pyrophosphatase/phosphodiesterase 6 -1.712 0.000 
NM_175121 solute carrier family 38, member 2 -1.714 0.011 
NM_025343 required for meiotic nuclear division 1 homolog (S. cerevisiae); 
predicted gene 5512 
-1.715 0.001 
NM_012032 serine incorporator 3 -1.719 0.008 
NM_181414 phosphoinositide-3-kinase, class 3 -1.720 0.007 
NM_010169 coagulation factor II (thrombin) receptor -1.720 0.007 
NM_010106 predicted gene 5869; predicted gene 7161; predicted gene 7105; 
predicted gene 5822; similar to eukaryotic translation elongation 
factor 1 alpha 1; predicted gene 6192; predicted gene 6392; 
predicted gene 6767; predicted gene 6170; predicted gene 6548; 
pre 
-1.721 0.005 
NP_062718 Nuclear receptor coactivator 4 -1.726 0.018 
NM_018737 cytidine 5'-triphosphate synthase 2 -1.752 0.040 
NM_010212 four and a half LIM domains 2 -1.754 0.011 
NM_008676 neighbor of Brca1 gene 1 -1.771 0.005 
NM_011930 chloride channel 7 -1.787 0.040 
NM_153507 copine II -1.787 0.012 
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Appendix B 
CHO K1 proteins determined to be significantly differentially regulated in CHO K1 cultures 
prepared using spent media from CHO DP-12 cells cultured at altered Bioprocessing conditions 
when compared to CHO K1 cells cultured using spent media from CHO DP-12 cells cultured 
using standard Bioprocessing conditions. Proteomic samples were analysed using 2D-LC-MS3 
and data analysed using Thermo Fisher ScientificTM Proteome DiscovererTM version 2.1.0.81 
and InfernoRDN version 1.1.5970.31895. 
 
Table 2-A: Differentially regulated CHO K1 proteins determined in samples corresponding to 
culture using spent media from CHO DP-12 cells prepared under an increased bioprocess 
temperature of 39.5oC. 
RefSeq 
Annotation 
Description Fold 
Change 
P-
value 
NM_008669 N-acetyl galactosaminidase, alpha 1.809 0.002 
NM_009082 similar to ribosomal protein; predicted gene 6344; predicted gene 
11449; predicted gene 13841; predicted gene 8210; hypothetical 
protein LOC675793; ribosomal protein L29; predicted gene 12704; 
predicted gene 7252; predicted gene 8965; predicted gene 13213 
1.768 0.026 
NM_007737 collagen, type V, alpha 2 1.761 0.005 
NM_015734 collagen, type V, alpha 1 1.751 0.005 
NM_021519 predicted gene 11964; endothelial differentiation-related factor 1 1.749 0.011 
NM_172262 amine oxidase, flavin containing 1 1.745 0.035 
NM_177068 olfactomedin-like 2B 1.742 0.014 
NM_028266 collagen, type XVI, alpha 1 1.718 0.003 
NM_008047 follistatin-like 1 1.717 0.002 
NM_207298 cerebral endothelial cell adhesion molecule 1.717 0.005 
NM_009981 phosphate cytidylyltransferase 1, choline, alpha isoform 1.711 0.001 
NM_011146 peroxisome proliferator activated receptor gamma 1.708 0.000 
NP_001020788 calcium activated nucleotidase 1 1.706 0.015 
NM_133886 expressed sequence AU040320 1.702 0.003 
NM_001003949 open reading frame 61 1.698 0.014 
NM_010191 predicted gene 6781; farnesyl diphosphate farnesyl transferase 1 1.692 0.008 
NM_011341 stromal cell derived factor 4 1.691 0.015 
NM_023232 diablo homolog (Drosophila) 1.686 0.027 
NM_008675 neuroblastoma, suppression of tumorigenicity 1 1.683 0.028 
NP_080444 ERGIC and golgi 2 1.681 0.030 
NM_025571 predicted gene 9803; mitochondria-associated protein involved in 
granulocyte-macrophage colony-stimulating factor signal 
transduction 
1.678 0.001 
NM_026560 cell division cycle associated 8 1.677 0.011 
NM_009346 TEA domain family member 1 1.671 0.035 
NM_010756 similar to mafG; v-maf musculoaponeurotic fibrosarcoma 1.671 0.015 
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oncogene family, protein G (avian) 
NM_133766 EFR3 homolog A (S. cerevisiae) 1.669 0.022 
NM_011333 chemokine (C-C motif) ligand 2 1.669 0.006 
NM_172205 suprabasin 1.664 0.031 
NM_011173 protein S (alpha) 1.659 0.001 
NP_663432 polyadenylate binding protein-interacting protein 1; similar to 
poly(A) binding protein interacting protein 1 
1.659 0.012 
NM_145606 chromatin modifying protein 1A; predicted gene 8515 1.650 0.038 
NM_010517 insulin-like growth factor binding protein 4 1.646 0.042 
NM_027478 RIKEN cDNA 5730494N06 gene; predicted gene 7368 1.644 0.000 
NM_175021 sterile alpha motif domain containing 4B 1.633 0.004 
NM_007801 cathepsin H 1.628 0.020 
NM_010516 cysteine rich protein 61 1.624 0.003 
NP_082223 zinc finger and BTB domain containing 43 1.624 0.037 
NM_010380 histocompatibility 2, D region; histocompatibility 2, D region locus 
1 
1.623 0.014 
NM_026752 zinc finger, FYVE domain containing 21 1.623 0.016 
NM_008689 nuclear factor of kappa light polypeptide gene enhancer in B-cells 
1, p105 
1.623 0.043 
NM_009101 Harvey rat sarcoma oncogene, subgroup R 1.621 0.006 
NM_027852 retinoic acid receptor responder (tazarotene induced) 2 1.620 0.045 
NM_010917 similar to Nidogen precursor (Entactin); nidogen 1; similar to Nid1 
protein 
1.616 0.016 
NM_146065 activating transcription factor 7 1.616 0.040 
NM_008305 perlecan (heparan sulfate proteoglycan 2) 1.615 0.003 
NM_028945 DNA segment, Chr 14, Abbott 1 expressed 1.614 0.010 
NM_144857 cDNA sequence BC011248 1.608 0.016 
NM_130888 nuclear RNA export factor 7 1.606 0.015 
NM_020010 cytochrome P450, family 51 1.604 0.034 
NM_010592 Jun proto-oncogene related gene d 1.602 0.043 
NM_012056 FK506 binding protein 9 1.601 0.019 
NM_001039644 ER degradation enhancer, mannosidase alpha-like 3 1.596 0.016 
NM_008139 guanine nucleotide binding protein, alpha q polypeptide 1.596 0.044 
NM_022985 zinc finger, AN1-type domain 6 1.594 0.025 
NM_028017 N-ethylmaleimide sensitive fusion protein attachment protein 
gamma 
1.592 0.003 
NM_015804 ATPase, class VI, type 11A 1.588 0.002 
NM_181070 RAB18, member RAS oncogene family 1.583 0.013 
NM_181278 RIKEN cDNA B230219D22 gene 1.577 0.015 
NM_010931 ubiquitin-like, containing PHD and RING finger domains, 1; 
predicted gene 5648; similar to nuclear zinc finger protein Np95 
1.576 0.010 
NM_017478 coatomer protein complex, subunit gamma 2 1.574 0.024 
NM_001037166 predicted gene 4925 1.574 0.016 
NM_029658 family with sequence similarity 101, member B 1.572 0.015 
NM_013866 zinc finger protein 385A 1.553 0.019 
NM_025573 splicing factor, arginine/serine rich 9 1.550 0.020 
NM_011961 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 1.548 0.040 
NM_022328 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 1.548 0.001 
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Drosophila); translocated to, 1 
NM_025673 golgi phosphoprotein 3 1.546 0.009 
NM_183417 cyclin-dependent kinase 2 1.536 0.027 
NM_001113573 bromodomain containing 3 1.536 0.006 
NM_026844 RIKEN cDNA 2310061C15 gene 1.535 0.035 
NM_172272 prolyl-tRNA synthetase (mitochondrial)(putative) 1.535 0.005 
NM_007552 Bmi1 polycomb ring finger oncogene 1.532 0.024 
NM_009270 squalene epoxidase 1.526 0.002 
NM_001134717 RIKEN cDNA 2810006K23 gene 1.525 0.001 
NP_034835 lectin, galactose binding, soluble 3 1.520 0.008 
NM_019832 G kinase anchoring protein 1 1.520 0.010 
NM_194342 unc-84 homolog B (C. elegans) 1.516 0.009 
NM_145985 similar to Archain 1; archain 1; similar to coat protein delta-cop; 
predicted gene 8752; predicted gene 8750; similar to archain 
1.516 0.019 
NM_007725 calponin 2 1.512 0.021 
NM_054078 bromodomain adjacent to zinc finger domain, 2A 1.510 0.033 
NM_010299 GM2 ganglioside activator protein 1.505 0.020 
NM_029619 methionine sulfoxide reductase B2 1.504 0.050 
NM_001001932 early endosome antigen 1 1.501 0.009 
NM_001013786 zinc finger protein 187 1.500 0.015 
NM_018774 polyhomeotic-like 2 (Drosophila) 1.494 0.045 
NM_027307 golgi membrane protein 1 1.492 0.007 
NM_011871 protein kinase, interferon inducible double stranded RNA 
dependent activator 
1.492 0.031 
NM_025657 leucine rich repeat containing 57 1.485 0.043 
NM_010312 guanine nucleotide binding protein (G protein), beta 2 1.481 0.015 
NM_001081218 host cell factor C2 1.479 0.005 
NM_008619 Moloney leukemia virus 10; predicted gene 7357 1.478 0.035 
NP_033030 kinesin family member 20A 1.478 0.024 
NM_007792 cysteine and glycine-rich protein 2 1.473 0.003 
NM_172120 vacuolar protein sorting 41 (yeast) 1.473 0.027 
NM_201642 similar to UDP glycosyltransferase 1 family polypeptide A13; similar 
to UGT1.6; UDP glucuronosyltransferase 1 family, polypeptide A1; 
UDP glucuronosyltransferase 1 family, polypeptide A2; UDP 
glycosyltransferase 1 family, polypeptide A10; UDP glucuronosyl 
1.473 0.021 
NM_021604 agrin 1.471 0.001 
NM_010398 histocompatibility 2, T region locus 23; similar to RT1 class Ib, locus 
H2-Q-like, grc region 
1.463 0.016 
NM_008408 STT3, subunit of the oligosaccharyltransferase complex, homolog A 
(S. cerevisiae) 
1.461 0.024 
NM_031874 RAB3D, member RAS oncogene family 1.461 0.039 
NM_013902 FK506 binding protein 3 1.455 0.037 
NM_153150 solute carrier family 25 (mitochondrial carrier, citrate transporter), 
member 1 
1.451 0.000 
NM_022325 cathepsin Z 1.449 0.006 
NM_146211 glycosyltransferase 25 domain containing 1 1.448 0.009 
NM_009003 RAB4A, member RAS oncogene family 1.442 0.026 
NM_013885 chloride intracellular channel 4 (mitochondrial) 1.440 0.020 
NM_008684 neogenin 1.438 0.025 
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NM_008774 poly(A) binding protein, cytoplasmic 1 1.435 0.026 
NM_010655 similar to ribosomal protein L38; predicted gene 13020; ribosomal 
protein L38; predicted gene 4991; karyopherin (importin) alpha 2; 
predicted gene 9028; predicted gene 8129; predicted gene 7123; 
predicted gene 5832; predicted gene 10184; predicted gene 73 
1.433 0.011 
NM_008138 guanine nucleotide binding protein (G protein), alpha inhibiting 2; 
similar to Guanine nucleotide-binding protein G(i), alpha-2 subunit 
(Adenylate cyclase-inhibiting G alpha protein) 
1.433 0.008 
NM_133983 CD276 antigen 1.431 0.031 
NM_021310 junction-mediating and regulatory protein 1.431 0.000 
NM_011306 retinoid X receptor beta 1.430 0.034 
NM_009983 cathepsin D 1.430 0.048 
NM_010864 myosin VA 1.430 0.024 
NM_010580 integrin beta 5 1.427 0.019 
NM_019783 leprecan 1 1.425 0.024 
NM_010189 Fc receptor, IgG, alpha chain transporter 1.422 0.003 
NM_001039137 short coiled-coil protein 1.416 0.012 
NM_007379 ATP-binding cassette, sub-family A (ABC1), member 2 1.415 0.040 
NM_009655 activated leukocyte cell adhesion molecule 1.414 0.039 
NM_019821 glycolipid transfer protein 1.409 0.033 
NM_019642 ribophorin II 1.405 0.006 
NM_011197 prostaglandin F2 receptor negative regulator 1.395 0.002 
NM_175933 peroxisomal biogenesis factor 5 1.391 0.008 
NM_019776 staphylococcal nuclease and tudor domain containing 1 1.387 0.002 
NM_028262 SET domain containing 3; similar to CG32732-PA; predicted gene 
7114; predicted gene 14026 
1.381 0.008 
NM_024181 DnaJ (Hsp40) homolog, subfamily C, member 10 1.379 0.001 
NM_010015 defender against cell death 1 1.378 0.000 
NM_028295 protein disulfide isomerase associated 5 1.374 0.024 
NM_007481 ADP-ribosylation factor 6 1.372 0.002 
NM_183270 coiled-coil-helix-coiled-coil-helix domain containing 8 1.369 0.032 
NM_133350 microtubule-associated protein, RP/EB family, member 3 1.369 0.030 
NM_010235 fos-like antigen 1 1.369 0.007 
NM_015827 coatomer protein complex, subunit beta 2 (beta prime) 1.366 0.001 
NM_011029 predicted gene 9323; predicted gene 7516; ribosomal protein SA 
pseudogene; predicted gene 9819; predicted gene 6339; predicted 
gene 9083; ribosomal protein SA; predicted gene 13374; predicted 
gene 12595; similar to laminin receptor 1 (ribosomal protein SA 
1.359 0.001 
NM_007879 developmentally regulated GTP binding protein 1 1.359 0.030 
NM_010421 hexosaminidase A 1.356 0.047 
NM_023040 growth factor, erv1 (S. cerevisiae)-like (augmenter of liver 
regeneration) 
1.355 0.020 
NM_026666 ubinuclein 1 1.355 0.006 
NM_144861 regulation of nuclear pre-mRNA domain containing 1A 1.353 0.007 
NM_013531 guanine nucleotide binding protein (G protein), beta 4 1.337 0.023 
NM_009153 sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3B 
1.335 0.007 
NM_001111279 WD repeat and FYVE domain containing 1 1.334 0.002 
NM_183250 multiple EGF-like-domains 8; similar to coiled-coil domain 1.331 0.029 
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containing 72; coiled-coil domain containing 72; predicted gene 
7526; predicted gene 9613; predicted gene 15235; predicted gene 
14200 
NM_007798 cathepsin B 1.330 0.034 
NM_001076554 spectrin alpha 2 1.321 0.017 
NM_008686 nuclear factor, erythroid derived 2,-like 1 1.319 0.018 
NM_019734 N-acylsphingosine amidohydrolase 1 1.318 0.031 
NM_133808 high density lipoprotein (HDL) binding protein 1.318 0.045 
NM_026533 similar to ribosomal protein S13; predicted gene 12270; predicted 
gene 6834; predicted gene 15483; predicted gene 6573; ribosomal 
protein S13; predicted gene 10159 
1.311 0.016 
NM_009033 RNA binding motif protein, X chromosome retrogene 1.307 0.015 
NM_178628 predicted gene 3086; atlastin GTPase 1; similar to Spg3a protein 1.300 0.006 
NM_010368 glucuronidase, beta 1.297 0.021 
NM_011127 paired related homeobox 1 1.296 0.048 
NM_010757 v-maf musculoaponeurotic fibrosarcoma oncogene family, protein 
K (avian) 
1.293 0.018 
NP_001029138 similar to adenylate kinase 2; adenylate kinase 2 1.286 0.011 
NM_010435 histone cell cycle regulation defective homolog A (S. cerevisiae) 1.286 0.016 
NM_033370 coatomer protein complex, subunit beta 1 1.280 0.001 
NM_008064 glucosidase, alpha, acid 1.270 0.016 
NM_007475 predicted gene 9625; predicted gene 14165; similar to acidic 
ribosomal phosphoprotein P0; predicted gene 8730; predicted 
gene 9093; ribosomal protein, large, P0 
1.269 0.044 
NM_020296 RNA binding motif, single stranded interacting protein 1 1.264 0.022 
NM_001163481 FK506 binding protein 10 1.262 0.018 
NP_001164011 predicted gene 9308; basic transcription factor 3; predicted gene 
3531; predicted gene 7973 
1.256 0.026 
NM_178660 RNA binding motif, single stranded interacting protein 1.254 0.016 
NM_145553 predicted gene 7527; family with sequence similarity 76, member 
A 
1.251 0.041 
NM_007602 calpain 5 1.250 0.007 
NM_001168488 multiple endocrine neoplasia 1 1.247 0.030 
NM_019806 vesicle-associated membrane protein, associated protein B and C 1.242 0.021 
NM_175115 IKAROS family zinc finger 5 1.239 0.017 
NM_009784 calcium channel, voltage-dependent, alpha2/delta subunit 1 1.239 0.008 
NM_173371 hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) 1.237 0.006 
NM_023348 synaptosomal-associated protein 29 1.229 0.021 
NM_133933 ribophorin I 1.228 0.026 
NM_207176 testis derived transcript 1.228 0.039 
NM_009938 coatomer protein complex subunit alpha 1.225 0.002 
NM_007886 dystrobrevin, beta 1.223 0.028 
NM_022997 vacuolar protein sorting 35 1.222 0.022 
NM_011289 predicted gene 6599; predicted gene 6199; predicted gene 6341; 
predicted gene 6301; predicted gene 11518; similar to ribosomal 
protein L27; ribosomal protein L27; predicted gene 7053; predicted 
gene 11552; predicted gene 15730 
1.222 0.036 
NM_008416 Jun-B oncogene 1.212 0.040 
NM_026620 family with sequence similarity 98, member B 1.211 0.032 
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NM_025846 related RAS viral (r-ras) oncogene homolog 2 1.209 0.041 
NM_009075 ribose 5-phosphate isomerase A 1.207 0.033 
NM_207625 acyl-CoA synthetase long-chain family member 4 1.205 0.010 
NM_001081288 TAF2 RNA polymerase II, TATA box binding protein (TBP)-
associated factor 
1.202 0.005 
NM_009212 immunoglobulin mu binding protein 2 -1.205 0.005 
NM_007842 DEAH (Asp-Glu-Ala-His) box polypeptide 9 -1.206 0.048 
NM_011189 predicted gene 7776; proteasome (prosome, macropain) 28 
subunit, alpha 
-1.208 0.019 
NM_008379 karyopherin (importin) beta 1 -1.210 0.039 
NM_172456 endo/exonuclease (5'-3'), endonuclease G-like -1.210 0.007 
NM_009838 chaperonin containing Tcp1, subunit 6a (zeta) -1.211 0.006 
NM_178610 KRR1, small subunit (SSU) processome component, homolog 
(yeast) 
-1.212 0.035 
NM_180678 glycyl-tRNA synthetase -1.212 0.010 
NM_146066 G1 to S phase transition 1 -1.215 0.039 
NM_012019 apoptosis-inducing factor, mitochondrion-associated 1 -1.221 0.018 
NM_010438 hexokinase 1 -1.232 0.024 
NM_007637 chaperonin containing Tcp1, subunit 5 (epsilon) -1.238 0.014 
NM_009418 tripeptidyl peptidase II -1.242 0.030 
NM_028812 general transcription factor II E, polypeptide 1 (alpha subunit) -1.244 0.000 
NM_009048 RalBP1 associated Eps domain containing protein -1.249 0.026 
NP_001185796 Dynactin subunit 1 -1.251 0.040 
NM_010360 glutathione S-transferase, mu 5 -1.252 0.033 
NM_007907 predicted gene 13050; eukaryotic translation elongation factor 2 -1.254 0.000 
NM_026894 RIKEN cDNA 1500001M20 gene -1.255 0.036 
NM_130867 kin of IRRE like (Drosophila) -1.255 0.000 
NM_009466 UDP-glucose dehydrogenase -1.256 0.036 
NM_152807 coiled-coil domain containing 137 -1.259 0.027 
NM_024281 ribosome binding protein 1 -1.265 0.037 
NM_027236 eukaryotic translation initiation factor 1A domain containing -1.266 0.005 
NM_028074 DEAD (Asp-Glu-Ala-Asp) box polypeptide 42 -1.269 0.009 
NM_053069 autophagy-related 5 (yeast) -1.270 0.023 
NM_001171582 methionine-tRNA synthetase -1.270 0.011 
NM_011240 RAN binding protein 2 -1.271 0.003 
NM_028276 UTP14, U3 small nucleolar ribonucleoprotein, homolog A (yeast) -1.277 0.026 
NM_024220 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2; 
similar to NADH dehydrogenase (ubiquinone) 1, subcomplex 
unknown, 2 
-1.278 0.006 
NM_016661 similar to Adenosylhomocysteinase (S-adenosyl-L-homocysteine 
hydrolase) (AdoHcyase) (Liver copper-binding protein) (CUBP); S-
adenosylhomocysteine hydrolase 
-1.281 0.017 
NM_134123 RNA binding motif protein 16 -1.286 0.043 
NM_028597 THO complex 3 -1.287 0.000 
NM_011655 tubulin, beta 5 -1.288 0.030 
NM_177367 gem (nuclear organelle) associated protein 4 -1.290 0.010 
NM_019805 anaphase promoting complex subunit 7 -1.290 0.027 
NM_053183 predicted gene 8228; DEAD (Asp-Glu-Ala-Asp) box polypeptide 50 -1.290 0.010 
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NM_025824 predicted gene 11652; predicted gene 5191; basic leucine zipper 
and W2 domains 1 
-1.291 0.002 
NM_011680 similar to USF2; upstream transcription factor 2 -1.292 0.033 
NM_001039474 transcription elongation regulator 1 (CA150) -1.293 0.022 
NM_010173 fatty acid amide hydrolase -1.296 0.043 
NM_029525 phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange 
factor 2 
-1.297 0.004 
NM_178700 G-rich RNA sequence binding factor 1 -1.298 0.005 
NM_007687 cofilin 1, non-muscle; similar to Cofilin-1 (Cofilin, non-muscle 
isoform); predicted gene 6180 
-1.299 0.001 
NM_026114 similar to Eukaryotic translation initiation factor 2 subunit 1 
(Eukaryotic translation initiation factor 2 alpha subunit) (eIF-2-
alpha) (EIF-2alpha) (EIF-2A); eukaryotic translation initiation factor 
2, subunit 1 alpha; predicted gene 7459 
-1.301 0.007 
NM_016799 serine/arginine repetitive matrix 1 -1.303 0.018 
NM_025692 ubiquitin-like modifier activating enzyme 5 -1.303 0.019 
NM_030035 golgi autoantigen, golgin subfamily b, macrogolgin 1 -1.304 0.003 
NM_011319 seryl-aminoacyl-tRNA synthetase -1.307 0.007 
NM_017379 tubulin, alpha 8 -1.307 0.020 
NM_178213 histone cluster 2, H2ab -1.308 0.014 
NM_009088 polymerase (RNA) I polypeptide A -1.311 0.012 
NM_134125 thyroid hormone receptor interactor 10 -1.313 0.026 
NM_008014 protein phosphatase 1G (formerly 2C), magnesium-dependent, 
gamma isoform 
-1.319 0.027 
NM_133925 RNA binding motif protein 28 -1.323 0.008 
NM_175294 nuclear casein kinase and cyclin-dependent kinase substrate 1 -1.329 0.036 
NM_008481 laminin, alpha 2 -1.335 0.035 
NM_001081247 polymerase (RNA) III (DNA directed) polypeptide A -1.335 0.030 
NM_030238 dynein cytoplasmic 1 heavy chain 1 -1.339 0.030 
NM_198303 eukaryotic translation initiation factor 5B -1.339 0.022 
NM_026171 nuclear VCP-like -1.340 0.005 
NM_028782 lon peptidase 1, mitochondrial -1.344 0.006 
NM_026816 general transcription factor IIF, polypeptide 2 -1.345 0.001 
NM_133716 stromal membrane-associated GTPase-activating protein 2 -1.346 0.039 
NM_152803 heparanase -1.349 0.004 
NM_009933 collagen, type VI, alpha 1 -1.358 0.042 
NM_146229 dynein cytoplasmic 1 light intermediate chain 1 -1.358 0.010 
NM_172381 expressed sequence AI314180 -1.359 0.020 
NM_011714 bromodomain adjacent to zinc finger domain, 1B -1.364 0.018 
NM_007858 diaphanous homolog 1 (Drosophila) -1.367 0.035 
NM_023119 predicted gene 4735; enolase 1, alpha non-neuron; similar to 
enolase 1, alpha non-neuron; hypothetical protein LOC100044223; 
predicted gene 5506; predicted gene 5855; hypothetical protein 
LOC100045967 
-1.371 0.015 
NM_009388 transketolase -1.374 0.003 
NM_026662 phosphoribosyl pyrophosphate synthetase 2 -1.376 0.002 
NM_008826 phosphofructokinase, liver, B-type -1.380 0.030 
NM_007949 excision repair cross-complementing rodent repair deficiency, 
complementation group 2 
-1.380 0.017 
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NM_007530 B-cell receptor-associated protein 29 -1.381 0.006 
NM_008537 alpha-methylacyl-CoA racemase -1.388 0.023 
NM_019869 RNA binding motif protein 14 -1.395 0.000 
NM_144825 TAO kinase 1 -1.396 0.033 
NM_145625 eukaryotic translation initiation factor 4B -1.397 0.006 
NM_021884 tumor susceptibility gene 101 -1.401 0.008 
NM_172407 CDKN2A interacting protein -1.412 0.001 
NP_001106817 similar to Transcriptional repressor p66 alpha (GATA zinc finger 
domain-containing protein 2A); GATA zinc finger domain 
containing 2A 
-1.414 0.042 
NM_015728 solute carrier family 33 (acetyl-CoA transporter), member 1 -1.417 0.041 
NM_021511 predicted gene 5067; RRS1 ribosome biogenesis regulator homolog 
(S. cerevisiae) 
-1.420 0.025 
NM_144731 UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-
acetylgalactosaminyltransferase 7 
-1.422 0.012 
NM_145416 KRI1 homolog (S. cerevisiae) -1.426 0.002 
NM_001081043 protein tyrosine phosphatase, non-receptor type 23 -1.429 0.008 
NM_010830 mutS homolog 6 (E. coli) -1.432 0.028 
NM_019763 SPEN homolog, transcriptional regulator (Drosophila) -1.433 0.038 
NM_027016 SEC62 homolog (S. cerevisiae) -1.439 0.017 
NM_011076 ATP-binding cassette, sub-family B (MDR/TAP), member 1A -1.441 0.009 
NM_013768 protein arginine N-methyltransferase 5 -1.442 0.006 
NM_029437 cytoskeleton associated protein 5 -1.442 0.005 
NM_026476 RIKEN cDNA 2610101N10 gene -1.448 0.016 
NM_028083 chromatin assembly factor 1, subunit B (p60) -1.450 0.013 
NM_011574 cirrhosis, autosomal recessive 1A (human) -1.457 0.007 
NM_144543 thymocyte nuclear protein 1 -1.457 0.004 
NM_133921 nuclear transcription factor, X-box binding-like 1 -1.457 0.007 
NM_009481 ubiquitin specific peptidase 9, X chromosome -1.461 0.004 
NM_029600 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 -1.462 0.007 
NM_027379 fatty acyl CoA reductase 1 -1.464 0.025 
NM_026370 MYST histone acetyltransferase 1 -1.465 0.038 
NM_027346 coiled-coil domain containing 44 -1.468 0.009 
NM_011654 predicted gene 3756; tubulin, alpha 1B; predicted gene 5620; 
similar to alpha-tubulin isotype M-alpha-2; predicted gene 14150; 
predicted gene 3226 
-1.470 0.025 
NM_178923 splicing factor, arginine/serine-rich 15 -1.479 0.035 
NP_001258788 Beta-adducin -1.481 0.018 
NM_019553 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 -1.481 0.002 
NM_013507 eukaryotic translation initiation factor 4, gamma 2 -1.482 0.009 
NM_011830 predicted gene 15210; inosine 5'-phosphate dehydrogenase 2 -1.483 0.014 
NM_010925 ribosomal RNA processing 1 homolog (S. cerevisiae) -1.488 0.001 
NM_013700 ubiquitin specific peptidase 5 (isopeptidase T) -1.489 0.019 
NM_025959 proteasome (prosome, macropain) 26S subunit, ATPase, 6 -1.489 0.003 
NM_145358 calcium/calmodulin-dependent protein kinase kinase 2, beta -1.490 0.021 
NM_023871 predicted gene, EG625349; predicted gene 5789; predicted gene 
7085; predicted gene 5708; predicted gene 6847; SET 
translocation; cDNA sequence BC085271; predicted gene 7239; 
similar to protein phosphatase 2A inhibitor-2 I-2PP2A; predicted 
-1.490 0.012 
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gene 9531 
NM_134188 acyl-CoA thioesterase 2 -1.492 0.000 
NP_997603 widely-interspaced zinc finger motifs -1.504 0.008 
NM_145954 aldehyde dehydrogenase 16 family, member A1 -1.504 0.011 
NM_028032 protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), 
alpha isoform 
-1.518 0.002 
NM_080287 engulfment and cell motility 2, ced-12 homolog (C. elegans) -1.522 0.028 
NM_025623 nipsnap homolog 3A (C. elegans) -1.527 0.028 
NM_029746 component of oligomeric golgi complex 2 -1.530 0.012 
NM_172712 ubiquitin-like modifier activating enzyme 6 -1.531 0.022 
NM_178883 golgin, RAB6-interacting -1.534 0.036 
NM_133702 nucleolar protein 11 -1.542 0.008 
NM_198411 subacute ozone induced inflammation; RIKEN cDNA 2610204M08 
gene 
-1.543 0.004 
NM_016721 IQ motif containing GTPase activating protein 1 -1.549 0.005 
NM_026160 microtubule-associated protein 1 light chain 3 beta -1.558 0.036 
NM_134151 tyrosyl-tRNA synthetase -1.563 0.002 
NM_007714 CDC like kinase 4 -1.569 0.015 
NM_030678 glycogen synthase 1, muscle -1.571 0.043 
NM_021505 anaphase-promoting complex subunit 5; similar to anaphase-
promoting complex subunit 5 
-1.575 0.006 
NM_177992 guanosine monophosphate reductase 2 -1.575 0.006 
NM_026550 PAK1 interacting protein 1 -1.576 0.015 
NM_133826 ATPase, H+ transporting, lysosomal V1 subunit H -1.576 0.009 
NM_145147 GTP binding protein 6 (putative) -1.590 0.024 
NM_029775 DCN1, defective in cullin neddylation 1, domain containing 5 (S. 
cerevisiae) 
-1.599 0.000 
NM_025816 Tax1 (human T-cell leukemia virus type I) binding protein 1 -1.604 0.040 
NM_001039388 WD repeat domain 37 -1.607 0.006 
NM_133806 UDP-N-acetylglucosamine pyrophosphorylase 1 -1.611 0.013 
NM_028181 cell cycle progression 1 -1.613 0.008 
XM_001479591 similar to Eukaryotic translation initiation factor 5; eukaryotic 
translation initiation factor 5 
-1.621 0.035 
NM_024436 RAB22A, member RAS oncogene family -1.627 0.030 
NM_011723 xanthine dehydrogenase -1.642 0.016 
NM_019746 predicted gene 3837; programmed cell death 5 -1.645 0.047 
NM_023554 nucleolar protein 7 -1.648 0.029 
NM_011018 sequestosome 1 -1.649 0.037 
NP_001240821 Anion exchange protein 2 -1.650 0.010 
NM_026432 transmembrane protein 66 -1.651 0.047 
NM_009254 serine (or cysteine) peptidase inhibitor, clade B, member 6a -1.651 0.003 
NM_020587 splicing factor, arginine/serine-rich 4 (SRp75) -1.666 0.001 
NM_001033293 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 -1.673 0.004 
NM_172952 gephyrin -1.675 0.019 
NM_010442 heme oxygenase (decycling) 1 -1.678 0.016 
NP_001107603 protein phosphatase 4, regulatory subunit 1 -1.679 0.014 
NM_009288 serine/threonine kinase 10 -1.691 0.012 
NM_175121 solute carrier family 38, member 2 -1.702 0.017 
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NM_013678 surfeit gene 2 -1.709 0.013 
NM_009628 activity-dependent neuroprotective protein -1.710 0.017 
NM_027371 brix domain containing 5 -1.730 0.001 
NM_016766 microspherule protein 1; predicted gene 13127 -1.731 0.000 
NM_144806 predicted gene 13651; phosphoribosyl pyrophosphate synthetase-
associated protein 2 
-1.734 0.022 
NM_010685 lysosomal-associated membrane protein 2 -1.738 0.012 
NM_001081045 hypothetical protein LOC100043982; RIKEN cDNA 1700081L11 
gene 
-1.744 0.014 
NM_001080928 recombination signal binding protein for immunoglobulin kappa J 
region 
-1.748 0.007 
NM_001111288 SCO cytochrome oxidase deficient homolog 2 (yeast) -1.760 0.014 
NM_183106 tetratricopeptide repeat domain 17 -1.760 0.002 
NM_019965 DnaJ (Hsp40) homolog, subfamily B, member 12 -1.846 0.025 
NM_001029895 arginyltransferase 1 -1.875 0.019 
 
 
Table 2-B: Differentially regulated CHO K1 proteins determined in samples corresponding to 
culture using spent media from CHO DP-12 cells prepared under a reduced bioprocess 
temperature of 32.0oC. 
RefSeq 
Annotation 
Description Fold 
Change 
P-
Value 
NM_028266 collagen, type XVI, alpha 1 1.676 0.019 
NM_009810 caspase 3 1.594 0.039 
NM_025700 phosphoglucomutase 1 1.554 0.005 
NM_011127 paired related homeobox 1 1.499 0.031 
NM_007406 adenylate cyclase 7 1.489 0.016 
NM_001003949 open reading frame 61 1.470 0.019 
NM_009939 COP9 (constitutive photomorphogenic) homolog, subunit 2 
(Arabidopsis thaliana) 
1.450 0.021 
NM_146252 TBC1 domain family, member 13 1.442 0.020 
NM_146258 StAR-related lipid transfer (START) domain containing 13; similar to 
serologically defined colon cancer antigen 13 
1.435 0.026 
NM_010906 nuclear factor I/X 1.428 0.010 
NM_175115 IKAROS family zinc finger 5 1.400 0.018 
NM_007392 actin, alpha 2, smooth muscle, aorta 1.400 0.046 
NM_175113 tRNA methyltransferase 6 homolog (S. cerevisiae) 1.396 0.043 
NM_001009818 septin 11 1.363 0.049 
NM_019542 N-acetylglucosamine kinase 1.347 0.043 
NM_025968 prostaglandin reductase 1 1.331 0.016 
NM_022988 Ngg1 interacting factor 3-like 1 (S. pombe) 1.327 0.007 
NM_022653 thimet oligopeptidase 1 1.301 0.023 
NM_001077529 predicted gene 7730; non-metastatic cells 2, protein (NM23B) 
expressed in; predicted gene 5566; predicted gene 5425; similar to 
Nucleoside diphosphate kinase B (NDK B) (NDP kinase B) (P18) 
1.296 0.016 
NM_144846 family with sequence similarity 49, member B 1.294 0.045 
NM_001037166 predicted gene 4925 1.285 0.024 
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NM_009289 STE20-like kinase (yeast) 1.268 0.003 
NM_025958 cullin-associated and neddylation-dissociated 2 (putative) 1.268 0.029 
NM_001033533 coiled-coil domain containing 102A 1.247 0.045 
NM_023248 Shwachman-Bodian-Diamond syndrome homolog (human) 1.240 0.028 
NM_009075 ribose 5-phosphate isomerase A 1.223 0.023 
NM_011862 protein kinase C and casein kinase substrate in neurons 2 1.215 0.033 
NM_028975 transmembrane protein 33 -1.204 0.025 
NM_010303 guanine nucleotide binding protein, alpha 13 -1.217 0.047 
NM_028083 chromatin assembly factor 1, subunit B (p60) -1.218 0.002 
NM_175094 pyruvate dehydrogenase complex, component X; similar to 
pyruvate dehydrogenase complex, component X 
-1.225 0.001 
NP_001106817 similar to Transcriptional repressor p66 alpha (GATA zinc finger 
domain-containing protein 2A); GATA zinc finger domain 
containing 2A 
-1.230 0.049 
NM_022018 family with sequence similarity 129, member A -1.235 0.028 
NM_024220 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2; 
similar to NADH dehydrogenase (ubiquinone) 1, subcomplex 
unknown, 2 
-1.241 0.024 
NM_001081252 UDP-glucose ceramide glucosyltransferase-like 2 -1.246 0.015 
NM_001033293 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 -1.268 0.028 
NM_024281 ribosome binding protein 1 -1.272 0.017 
NM_012025 Rac GTPase-activating protein 1; predicted gene 1859 -1.276 0.001 
NM_013495 carnitine palmitoyltransferase 1a, liver -1.283 0.014 
NM_130867 kin of IRRE like (Drosophila) -1.291 0.002 
NM_175212 transmembrane protein 65 -1.315 0.006 
NM_001111279 WD repeat and FYVE domain containing 1 -1.320 0.001 
NM_025816 Tax1 (human T-cell leukemia virus type I) binding protein 1 -1.333 0.030 
NM_027371 brix domain containing 5 -1.352 0.029 
NM_133983 CD276 antigen -1.365 0.016 
NM_020587 splicing factor, arginine/serine-rich 4 (SRp75) -1.366 0.014 
NM_020003 RIKEN cDNA 0610031J06 gene -1.420 0.044 
NM_145541 predicted gene 9392; similar to Raichu404X; RAS-related protein-
1a 
-1.432 0.001 
NM_001111288 SCO cytochrome oxidase deficient homolog 2 (yeast) -1.433 0.037 
NM_176849 arginine and glutamate rich 1 -1.434 0.021 
NM_024245 kinesin family member 23 -1.502 0.000 
NM_146145 Janus kinase 1 -1.508 0.002 
NM_152803 heparanase -1.566 0.002 
NM_027213 mediator of RNA polymerase II transcription, subunit 6 homolog 
(yeast) 
-1.582 0.030 
NM_023056 transmembrane protein 176B -1.607 0.034 
NM_026160 microtubule-associated protein 1 light chain 3 beta -1.647 0.003 
NM_024436 RAB22A, member RAS oncogene family -1.684 0.028 
NM_028181 cell cycle progression 1 -1.723 0.003 
NM_183106 tetratricopeptide repeat domain 17 -1.896 0.001 
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Table 2-C: Differentially regulated CHO K1 proteins determined in samples corresponding to 
culture using spent media from CHO DP-12 cells prepared using a media dissolved oxygen 
content of 110%. 
RefSeq 
Annotation 
Description Fold 
Change 
p-
value 
NM_028975 transmembrane protein 33 1.826 0.020 
NM_025538 alkB, alkylation repair homolog 7 (E. coli) 1.821 0.035 
NM_011594 tissue inhibitor of metalloproteinase 2 1.803 0.004 
NM_011333 chemokine (C-C motif) ligand 2 1.776 0.002 
NM_009105 Ras suppressor protein 1 1.770 0.001 
NM_146015 epidermal growth factor-containing fibulin-like extracellular matrix 
protein 1 
1.751 0.014 
NM_021528 carbohydrate sulfotransferase 12 1.728 0.002 
NM_009103 ribonucleotide reductase M1 1.727 0.003 
NM_133804 transmembrane protein 132A 1.727 0.003 
NM_183016 CDC42 binding protein kinase beta 1.726 0.020 
NM_145376 lysophosphatidylcholine acyltransferase 1 1.726 0.003 
NM_177592 transmembrane protein 164 1.723 0.001 
NM_001039644 ER degradation enhancer, mannosidase alpha-like 3 1.722 0.000 
NM_009861 cell division cycle 42 homolog (S. cerevisiae); predicted gene 7407 1.721 0.006 
NM_010517 insulin-like growth factor binding protein 4 1.719 0.001 
NM_011961 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 1.718 0.006 
NM_001013786 zinc finger protein 187 1.712 0.012 
NM_001013616 tripartite motif-containing 6; similar to Tripartite motif protein 6 1.710 0.004 
NM_011341 stromal cell derived factor 4 1.707 0.002 
NM_001081357 mitogen-activated protein kinase kinase kinase kinase 3; similar to 
mitogen-activated protein kinase kinase kinase kinase 3 
1.706 0.005 
NP_067263 thymidylate synthase 1.705 0.015 
NM_172769 sterol-C5-desaturase (fungal ERG3, delta-5-desaturase) homolog 
(S. cerevisae) 
1.698 0.018 
NM_030743 ring finger protein 114 1.698 0.016 
NM_026186 coiled-coil domain containing 49 1.698 0.028 
NM_011258 replication factor C (activator 1) 1 1.697 0.014 
NM_011497 aurora kinase A 1.697 0.002 
NM_199032 centrosomal protein 135 1.697 0.007 
NM_009873 cyclin-dependent kinase 6 1.695 0.024 
NM_001003949 open reading frame 61 1.693 0.022 
NM_021519 predicted gene 11964; endothelial differentiation-related factor 1 1.688 0.031 
NM_025364 predicted gene 6563; SAP domain containing ribonucleoprotein 1.688 0.012 
NM_025788 nucleus accumbens associated 1, BEN and BTB (POZ) domain 
containing 
1.688 0.011 
NM_007838 dolichyl-di-phosphooligosaccharide-protein glycotransferase 1.688 0.005 
NM_001033192 expressed sequence C78339 1.687 0.024 
NM_029730 motile sperm domain containing 2 1.685 0.002 
NM_011870 calcium and integrin binding 1 (calmyrin) 1.682 0.010 
NM_025436 sterol-C4-methyl oxidase-like 1.680 0.009 
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NM_008562 similar to myeloid cell leukemia sequence 1; myeloid cell leukemia 
sequence 1 
1.679 0.018 
NM_011521 syndecan 4 1.679 0.002 
NM_022985 zinc finger, AN1-type domain 6 1.678 0.022 
NM_026560 cell division cycle associated 8 1.677 0.032 
NM_025800 predicted gene 5490; protein phosphatase 1, regulatory (inhibitor) 
subunit 2; predicted gene 2780; predicted gene 7749; predicted 
gene 2802; hypothetical protein LOC639433 
1.677 0.021 
NM_018794 ATPase, H+ transporting, lysosomal accessory protein 1 1.675 0.005 
NM_011068 peroxisomal biogenesis factor 11 alpha 1.674 0.011 
NM_027194 TM2 domain containing 2 1.674 0.024 
NM_144959 helicase-like transcription factor 1.669 0.040 
NM_008163 growth factor receptor bound protein 2; predicted gene 12791 1.668 0.033 
NM_007924 elongation factor RNA polymerase II 1.667 0.019 
NM_177386 Scm-like with four mbt domains 2 1.665 0.039 
NM_010189 Fc receptor, IgG, alpha chain transporter 1.664 0.037 
NM_145150 protein regulator of cytokinesis 1 1.663 0.020 
NM_009842 CD151 antigen 1.663 0.009 
NM_009404 tumor necrosis factor (ligand) superfamily, member 9 1.658 0.001 
NM_020010 cytochrome P450, family 51 1.658 0.043 
NM_009177 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 1.656 0.005 
NM_054078 bromodomain adjacent to zinc finger domain, 2A 1.651 0.006 
NM_144807 RIKEN cDNA 7120451J01 gene; choline phosphotransferase 1 1.650 0.006 
NM_177619 MYST histone acetyltransferase 2 1.650 0.047 
NM_020586 HERPUD family member 2 1.646 0.019 
NM_001033533 coiled-coil domain containing 102A 1.646 0.033 
NM_025401 predicted gene 5955; predicted gene 6803; ubiquitin-like 5; 
predicted gene 2001; similar to beacon 
1.645 0.034 
NM_176963 galactose mutarotase 1.644 0.047 
NM_026176 phosducin-like 1.644 0.015 
NM_028127 predicted gene 5780; FERM domain containing 6 1.642 0.008 
NM_020559 aminolevulinic acid synthase 1 1.641 0.039 
NP_001135450 TPX2, microtubule-associated protein homolog (Xenopus laevis) 1.639 0.008 
NP_001104536 FK506 binding protein 8 1.637 0.005 
NM_010917 similar to Nidogen precursor (Entactin); nidogen 1; similar to Nid1 
protein 
1.634 0.016 
NM_010027 D-dopachrome tautomerase 1.626 0.006 
NM_008684 neogenin 1.626 0.033 
NM_025740 coiled-coil domain containing 104 1.625 0.003 
NM_013615 outer dense fiber of sperm tails 2; similar to outer dense fiber of 
sperm tails 2 
1.624 0.017 
NM_201245 myosin phosphatase Rho interacting protein; predicted gene 8086 1.622 0.005 
NP_032723 ninein 1.622 0.030 
NM_008139 guanine nucleotide binding protein, alpha q polypeptide 1.619 0.036 
NM_011173 protein S (alpha) 1.618 0.012 
NM_172205 suprabasin 1.618 0.005 
NM_138596 mediator of RNA polymerase II transcription, subunit 10 homolog 
(NUT2, S. cerevisiae) 
1.618 0.001 
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NM_001033534 layilin 1.616 0.042 
NP_001095925 amyloid beta (A4) precursor-like protein 2 1.615 0.028 
NM_001163622 prolyl endopeptidase-like 1.613 0.005 
NM_010015 defender against cell death 1 1.613 0.020 
NP_001258682 DNA (cytosine-5)-methyltransferase 3A 1.612 0.020 
NM_146211 glycosyltransferase 25 domain containing 1 1.611 0.003 
NM_001143689 MHC class I like protein GS10 1.610 0.008 
NM_144516 zinc finger, MYND domain containing 11 1.600 0.006 
NM_011879 IK cytokine 1.596 0.009 
NM_010117 rhomboid family 1 (Drosophila) 1.594 0.036 
NM_010176 fumarylacetoacetate hydrolase 1.587 0.011 
NM_025872 golgi transport 1 homolog B (S. cerevisiae) 1.579 0.046 
NM_026950 OCIA domain containing 2 1.577 0.021 
NM_021535 smu-1 suppressor of mec-8 and unc-52 homolog (C. elegans) 1.577 0.009 
NM_133957 nuclear factor of activated T-cells 5 1.575 0.002 
NM_145542 S-adenosylhomocysteine hydrolase-like 1 1.574 0.020 
NM_053272 24-dehydrocholesterol reductase 1.573 0.044 
NM_019883 predicted gene 5928; predicted gene 12617; predicted gene 4802; 
similar to ribosomal protein S27a; predicted gene 13215; predicted 
gene 6111; predicted gene 7808; predicted gene 6014; predicted 
gene 8317; ubiquitin C; ubiquitin B; similar to fusion protei 
1.571 0.035 
NM_013659 sema domain, immunoglobulin domain (Ig), transmembrane 
domain (TM) and short cytoplasmic domain, (semaphorin) 4B 
1.565 0.046 
NM_197980 COX19 cytochrome c oxidase assembly homolog (S. cerevisiae) 1.565 0.027 
NM_001001932 early endosome antigen 1 1.563 0.004 
NP_663432 polyadenylate binding protein-interacting protein 1; similar to 
poly(A) binding protein interacting protein 1 
1.558 0.028 
NM_175251 AT rich interactive domain 2 (ARID, RFX-like); RIKEN cDNA 
1700124K17 gene 
1.558 0.025 
NM_008408 STT3, subunit of the oligosaccharyltransferase complex, homolog A 
(S. cerevisiae) 
1.558 0.027 
NM_175096 starch binding domain 1 1.558 0.040 
NM_133913 RIKEN cDNA 2010209O12 gene 1.558 0.027 
NM_024200 mitofusin 1 1.556 0.023 
NM_012056 FK506 binding protein 9 1.554 0.002 
NM_018864 inositol (myo)-1(or 4)-monophosphatase 1 1.546 0.021 
NM_007841 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 1.545 0.000 
NM_001039200 RIKEN cDNA C230096C10 gene 1.535 0.023 
NM_008305 perlecan (heparan sulfate proteoglycan 2) 1.532 0.034 
NM_019642 ribophorin II 1.532 0.011 
NM_133662 immediate early response 3 1.530 0.019 
NM_009883 CCAAT/enhancer binding protein (C/EBP), beta 1.524 0.040 
NM_007659 cell division cycle 2 homolog A (S. pombe) 1.523 0.019 
NM_139139 DnaJ (Hsp40) homolog, subfamily C, member 17; predicted gene 
6257 
1.522 0.032 
NM_011414 secretory leukocyte peptidase inhibitor 1.516 0.014 
NM_020050 TMEM9 domain family, member B 1.508 0.039 
NM_027434 regulation of nuclear pre-mRNA domain containing 1B 1.504 0.002 
NM_008539 MAD homolog 1 (Drosophila) 1.503 0.019 
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NM_146131 similar to Pre-B-cell leukemia transcription factor interacting 
protein 1; pre-B-cell leukemia transcription factor interacting 
protein 1 
1.503 0.005 
NM_028762 RNA binding motif protein 19 1.502 0.015 
NM_018888 ubiquinol-cytochrome c reductase complex chaperone, CBP3 
homolog (yeast) 
1.500 0.011 
NM_145997 lysine (K)-specific demethylase 5A 1.499 0.013 
NM_197991 RIKEN cDNA 2310044H10 gene 1.499 0.012 
NM_013885 chloride intracellular channel 4 (mitochondrial) 1.497 0.036 
NM_001033297 predicted gene 561 1.497 0.009 
NM_212450 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) 
small phosphatase like 2 
1.497 0.005 
NM_172276 splicing factor, arginine/serine-rich 8 1.495 0.008 
NM_013626 peptidylglycine alpha-amidating monooxygenase 1.493 0.022 
NM_133900 phosphoserine phosphatase 1.490 0.000 
NP_001034283 apoptosis-inducing factor, mitochondrion-associated 2 1.489 0.012 
NM_133669 retinitis pigmentosa 2 homolog (human) 1.489 0.007 
NM_133803 dipeptidylpeptidase 3 1.487 0.004 
NM_172266 lysophosphatidylglycerol acyltransferase 1 1.486 0.017 
NM_019693 HLA-B-associated transcript 1A 1.481 0.002 
NM_011711 formin-like 3 1.474 0.014 
NM_016786 ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast) 1.473 0.025 
NM_009145 neuroplastin 1.471 0.030 
NM_019832 G kinase anchoring protein 1 1.470 0.014 
NM_007471 amyloid beta (A4) precursor protein 1.464 0.006 
NM_172528 leucine rich repeat containing 1 1.462 0.040 
NM_018768 syntaxin 8 1.458 0.004 
NM_001001738 inositol 1,4,5-triphosphate receptor interacting protein 1.457 0.004 
NM_053252 EH domain binding protein 1-like 1 1.457 0.009 
NM_026964 coiled-coil domain containing 124 1.457 0.044 
NM_010577 integrin alpha 5 (fibronectin receptor alpha) 1.453 0.033 
NM_011962 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 1.448 0.001 
NM_009833 cyclin T1 1.444 0.033 
NM_013790 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 1.443 0.035 
NM_145500 ubiquitin domain containing 1 1.442 0.039 
NM_011693 vascular cell adhesion molecule 1 1.437 0.019 
NM_175414 tetraspanin 9 1.433 0.023 
NM_007886 dystrobrevin, beta 1.431 0.049 
NM_019773 RAB9, member RAS oncogene family; predicted gene 9181 1.424 0.012 
NM_011083 phosphatidylinositol 3-kinase, C2 domain containing, alpha 
polypeptide 
1.420 0.040 
NM_021548 cAMP-regulated phosphoprotein 19 1.420 0.025 
NM_001004140 cytoskeleton associated protein 2 1.418 0.005 
NM_009941 cytochrome c oxidase subunit IV isoform 1 1.417 0.002 
NM_145553 predicted gene 7527; family with sequence similarity 76, member 
A 
1.417 0.008 
NM_207625 acyl-CoA synthetase long-chain family member 4 1.416 0.019 
NM_207298 cerebral endothelial cell adhesion molecule 1.411 0.038 
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NM_001164663 hypothetical protein LOC639171; RIKEN cDNA 9830001H06 gene; 
similar to C34E11.3 
1.409 0.016 
NM_011218 protein tyrosine phosphatase, receptor type, S 1.405 0.036 
NM_207209 similar to SEC24 related gene family, member B (S. cerevisiae); 
Sec24 related gene family, member B (S. cerevisiae) 
1.404 0.020 
NM_008875 phospholipase D1 1.398 0.035 
NM_019975 2-hydroxyacyl-CoA lyase 1 1.396 0.015 
NM_010755 v-maf musculoaponeurotic fibrosarcoma oncogene family, protein 
F (avian) 
1.395 0.033 
NM_008255 3-hydroxy-3-methylglutaryl-Coenzyme A reductase 1.387 0.028 
NM_026130 signal recognition particle receptor ('docking protein') 1.385 0.028 
NM_008047 follistatin-like 1 1.385 0.020 
NM_026252 cytoplasmic polyadenylation element binding protein 4 1.382 0.008 
NM_027450 GLI pathogenesis-related 2 1.381 0.049 
NM_025594 zinc finger, matrin type 2 1.379 0.030 
NM_008972 predicted gene 12504; predicted gene 9800; predicted gene 4617; 
predicted gene 6625; predicted gene 7614; similar to prothymosin 
alpha; prothymosin alpha; predicted gene 9009 
1.371 0.042 
NM_027238 tetratricopeptide repeat domain 39B 1.370 0.009 
NM_001123371 purine-nucleoside phosphorylase 2 1.370 0.007 
NM_010833 moesin 1.369 0.019 
NM_015804 ATPase, class VI, type 11A 1.364 0.015 
NM_197982 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 1.363 0.012 
NM_010516 cysteine rich protein 61 1.361 0.030 
NM_025463 hypothetical protein LOC100048454; RIKEN cDNA 1810009A15 
gene 
1.358 0.029 
NM_021460 lysosomal acid lipase A 1.358 0.037 
NM_199199 transmembrane protein 199 1.350 0.044 
NM_010580 integrin beta 5 1.349 0.018 
NP_031641 catenin (cadherin associated protein), delta 1 1.349 0.006 
NM_001166450 solute carrier family 25 (mitochondrial carrier, brain), member 14 1.347 0.035 
NM_053257 predicted gene 10191; predicted gene 7689; predicted gene 9401; 
similar to ribosomal protein L31; hypothetical protein LOC675768; 
predicted gene 13004; predicted gene 9228; predicted gene 
10072; predicted gene 5437; predicted gene 9154; ribosomal 
protein  
1.344 0.021 
NM_030252 cDNA sequence BC003266 1.344 0.017 
NM_010356 glutathione S-transferase, alpha 3 1.342 0.046 
NM_009480 upstream transcription factor 1 1.341 0.004 
NM_025983 ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon 
subunit 
1.339 0.045 
NM_053075 Ras homolog enriched in brain; similar to RAS-homolog enriched in 
brain 
1.338 0.009 
NM_025846 related RAS viral (r-ras) oncogene homolog 2 1.337 0.000 
NM_153807 acyl-CoA synthetase family member 2 1.331 0.016 
NP_001186624 Alpha-taxilin 1.330 0.002 
NM_133933 ribophorin I 1.326 0.003 
NM_175512 dehydrogenase/reductase (SDR family) member 9 1.326 0.018 
NM_194342 unc-84 homolog B (C. elegans) 1.325 0.012 
NM_033320 glucuronyl C5-epimerase 1.322 0.008 
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NM_007404 a disintegrin and metallopeptidase domain 9 (meltrin gamma) 1.319 0.014 
NM_007879 developmentally regulated GTP binding protein 1 1.318 0.041 
NM_133808 high density lipoprotein (HDL) binding protein 1.318 0.005 
NM_007840 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5; predicted gene 12183 1.317 0.033 
NM_001081282 inhibitor of Bruton agammaglobulinemia tyrosine kinase 1.316 0.025 
NM_019640 phosphatidylinositol transfer protein, beta 1.316 0.041 
NM_001045529 microrchidia 3 1.315 0.004 
NM_026420 polyadenylate-binding protein-interacting protein 2 1.313 0.010 
NM_001081251 polybromo 1 1.313 0.013 
NM_134063 cDNA sequence BC016423 1.311 0.019 
NM_019972 sortilin 1 1.309 0.040 
NM_009825 serine (or cysteine) peptidase inhibitor, clade H, member 1 1.305 0.007 
NM_007616 caveolin 1, caveolae protein 1.298 0.039 
NM_021412 matrix metallopeptidase 19 1.293 0.012 
NM_025516 ERGIC and golgi 3 1.290 0.029 
NM_175021 sterile alpha motif domain containing 4B 1.290 0.012 
NM_145959 DNA segment, Chr 15, ERATO Doi 621, expressed 1.289 0.035 
NP_001153413 potassium channel tetramerisation domain containing 10 1.288 0.035 
NM_144937 ubiquitin specific peptidase 3 1.283 0.008 
NM_011116 phospholipase D family, member 3 1.283 0.025 
NM_032008 sarcolemma associated protein 1.280 0.002 
NM_021336 small nuclear ribonucleoprotein polypeptide A' 1.279 0.014 
NM_021414 S-adenosylhomocysteine hydrolase-like 2 1.275 0.000 
NM_027153 pirin 1.270 0.004 
NM_133943 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 7 
1.259 0.013 
NM_175646 thioredoxin-like 4B 1.258 0.027 
NM_134077 RNA binding motif protein 26 1.256 0.034 
NM_009153 sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3B 
1.255 0.025 
NM_001033136 family with sequence similarity 82, member A2 1.255 0.040 
NM_175226 ring finger protein 139 1.253 0.049 
NM_053187 golgi associated PDZ and coiled-coil motif containing 1.243 0.024 
NM_013502 similar to CtBP1 protein; C-terminal binding protein 1 1.242 0.046 
NM_009273 signal recognition particle 14 1.237 0.035 
NM_011738 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, eta polypeptide 
1.233 0.008 
NP_001258827 Peroxisomal acyl-coenzyme A oxidase 1 1.233 0.030 
NM_017478 coatomer protein complex, subunit gamma 2 1.219 0.028 
NM_024459 protein phosphatase 3, regulatory subunit B, alpha isoform 
(calcineurin B, type I) 
1.216 0.050 
NP_001123951 nucleobindin 2 1.211 0.024 
NM_026844 RIKEN cDNA 2310061C15 gene 1.209 0.032 
NM_025429 serine (or cysteine) peptidase inhibitor, clade B, member 1a 1.207 0.016 
NM_011035 p21 protein (Cdc42/Rac)-activated kinase 1 1.206 0.014 
NM_019663 protein inhibitor of activated STAT 1 1.203 0.011 
NM_019783 leprecan 1 1.202 0.011 
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NM_001039162 CAP-GLY domain containing linker protein 2 -1.203 0.019 
NM_133826 ATPase, H+ transporting, lysosomal V1 subunit H -1.203 0.004 
NM_180678 glycyl-tRNA synthetase -1.207 0.019 
NM_177474 DNA segment, Chr 19, Brigham & Women's Genetics 1357 
expressed 
-1.210 0.017 
NM_024281 ribosome binding protein 1 -1.211 0.026 
NM_013676 suppressor of Ty 5 homolog (S. cerevisiae) -1.212 0.001 
NM_001163026 DnaJ (Hsp40) homolog, subfamily C, member 13 -1.212 0.005 
NM_025996 translocase of outer mitochondrial membrane 34 -1.215 0.010 
NM_181072 myosin IE -1.218 0.020 
NM_138579 TRIO and F-actin binding protein -1.222 0.036 
NM_010546 inhibitor of kappaB kinase beta -1.227 0.013 
NM_001035854 adaptor-related protein complex 2, beta 1 subunit -1.230 0.014 
NM_153569 cyclin G associated kinase -1.231 0.025 
NM_001080775 similar to nuclear myosin I beta; myosin IC -1.232 0.013 
NM_133771 mediator of cell motility 1; similar to Memo1 protein -1.233 0.028 
NM_057171 HLA-B-associated transcript 3 -1.234 0.023 
NM_022811 polymerase (RNA) I polypeptide E -1.235 0.036 
NM_011150 lectin, galactoside-binding, soluble, 3 binding protein -1.239 0.012 
NM_025513 exosome component 3 -1.239 0.029 
NM_175155 SAM and SH3 domain containing 1; predicted gene 2082 -1.242 0.032 
NM_029103 mesencephalic astrocyte-derived neurotrophic factor -1.243 0.026 
NM_145354 NOL1/NOP2/Sun domain family member 2 -1.248 0.019 
NM_153774 importin 9 -1.256 0.006 
NM_133692 polymerase (DNA-directed), delta 3, accessory subunit -1.256 0.009 
NM_028162 TBC1 domain family, member 5 -1.259 0.021 
NM_138745 methylenetetrahydrofolate dehydrogenase (NADP+ dependent), 
methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate 
synthase 
-1.260 0.016 
NM_007803 cortactin; predicted gene 8786 -1.260 0.003 
NM_021888 queuine tRNA-ribosyltransferase 1 -1.260 0.046 
NM_027604 ubiquitin specific peptidase 15 -1.267 0.005 
NM_023912 SCY1-like 1 (S. cerevisiae) -1.267 0.045 
NM_007508 ATPase, H+ transporting, lysosomal V1 subunit A -1.269 0.004 
NM_026833 open reading frame 19 -1.280 0.017 
NM_011874 proteasome (prosome, macropain) 26S subunit, ATPase, 4 -1.284 0.010 
NM_023644 methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) -1.284 0.047 
NM_022018 family with sequence similarity 129, member A -1.286 0.013 
NM_153585 CCR4-NOT transcription complex, subunit 10 -1.295 0.023 
NM_009439 proteasome (prosome, macropain) 26S subunit, non-ATPase, 3 -1.298 0.002 
NM_134137 leucyl-tRNA synthetase -1.304 0.020 
NM_001030307 dyskeratosis congenita 1, dyskerin homolog (human) -1.304 0.016 
NM_021552 predicted gene 15596; RIKEN cDNA 5730427N09 gene; similar to 
TGF beta-inducible nuclear protein 1 (L-name related LNR42); 
predicted gene 7966; predicted gene 5515; predicted gene 9722; 
predicted gene 6451; predicted gene 9634 
-1.307 0.046 
NM_054056 PRKC, apoptosis, WT1, regulator -1.308 0.039 
NM_030210 acetoacetyl-CoA synthetase -1.314 0.030 
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NP_001005331 eukaryotic translation initiation factor 4, gamma 1 -1.315 0.042 
NM_009837 chaperonin containing Tcp1, subunit 4 (delta) -1.316 0.031 
NM_001160319 ubiquitin protein ligase E3 component n-recognin 4 -1.317 0.015 
NM_026658 mitochondrial translation optimization 1 homolog (S. cerevisiae) -1.322 0.012 
NM_026653 replication protein A1 -1.328 0.018 
NM_022027 synaptic nuclear envelope 1 -1.329 0.043 
NM_022410 myosin, heavy polypeptide 9, non-muscle -1.344 0.029 
NM_027250 RIKEN cDNA 2010305A19 gene -1.345 0.050 
NM_016748 cytidine 5'-triphosphate synthase -1.346 0.018 
NP_033778 A kinase (PRKA) anchor protein 1 -1.346 0.005 
NM_015787 histone cluster 1, H1e -1.348 0.031 
NM_009679 predicted gene 8717; adaptor protein complex AP-2, mu1 -1.349 0.009 
NM_011811 phenylalanyl-tRNA synthetase, beta subunit -1.354 0.013 
NM_021315 nucleolar complex associated 3 homolog (S. cerevisiae) -1.354 0.004 
NM_198645 coiled-coil domain containing 58 -1.354 0.033 
NP_705782 aldehyde dehydrogenase 18 family, member A1 -1.355 0.012 
NM_007509 ATPase, H+ transporting, lysosomal V1 subunit B2 -1.359 0.001 
NM_011654 predicted gene 3756; tubulin, alpha 1B; predicted gene 5620; 
similar to alpha-tubulin isotype M-alpha-2; predicted gene 14150; 
predicted gene 3226 
-1.359 0.003 
NM_011777 zyxin -1.360 0.018 
NM_029878 tubulin-specific chaperone d -1.360 0.004 
NM_133916 hypothetical protein LOC100047993; eukaryotic translation 
initiation factor 3, subunit B 
-1.362 0.010 
NM_001033375 RIKEN cDNA A230046K03 gene -1.370 0.019 
NP_001185796 Dynactin subunit 1 -1.371 0.041 
NM_011049 PCTAIRE-motif protein kinase 1 -1.371 0.038 
NM_001164677 programmed cell death 6 interacting protein -1.377 0.033 
NM_026396 brix domain containing 2 -1.380 0.016 
NM_019966 malonyl-CoA decarboxylase -1.384 0.007 
NM_027815 RIKEN cDNA 9030624J02 gene -1.385 0.046 
NM_139063 muted -1.387 0.028 
XP_003085306 Polyadenylate -binding protein 1-like 2 -1.390 0.005 
NM_138593 similar to La ribonucleoprotein domain family, member 7; La 
ribonucleoprotein domain family, member 7 
-1.391 0.010 
NM_021473 aldo-keto reductase family 1, member A4 (aldehyde reductase) -1.393 0.010 
NM_019553 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 -1.394 0.033 
NM_021514 phosphofructokinase, muscle -1.395 0.010 
NM_080463 protein O-fucosyltransferase 1 -1.398 0.010 
NM_080445 similar to UDP-Gal:betaGal beta 1,3-galactosyltransferase, 
polypeptide 6; UDP-Gal:betaGal beta 1,3-galactosyltransferase, 
polypeptide 6 
-1.398 0.006 
NM_029633 CLIP associating protein 2 -1.401 0.041 
NM_021303 nucleolar complex associated 2 homolog (S. cerevisiae) -1.411 0.019 
NM_001128601 5, 10-methenyltetrahydrofolate synthetase; predicted gene 2372; 
predicted gene 2382 
-1.427 0.046 
NM_199447 ribosomal RNA processing 12 homolog (S. cerevisiae) -1.427 0.018 
NM_146200 eukaryotic translation initiation factor 3, subunit C; similar to 
Eukaryotic translation initiation factor 3, subunit 8 
-1.427 0.019 
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NM_011714 bromodomain adjacent to zinc finger domain, 1B -1.430 0.029 
NM_023525 carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, 
and dihydroorotase 
-1.434 0.005 
NM_009703 v-raf murine sarcoma 3611 viral oncogene homolog -1.435 0.014 
NM_175287 RIKEN cDNA A430005L14 gene; hypothetical protein LOC676530; 
predicted gene 12247 
-1.435 0.041 
NM_017379 tubulin, alpha 8 -1.436 0.022 
NM_025536 COMM domain containing 5 -1.449 0.033 
NM_030238 dynein cytoplasmic 1 heavy chain 1 -1.451 0.001 
NM_009288 serine/threonine kinase 10 -1.453 0.018 
NM_018799 eukaryotic translation initiation factor 3, subunit I -1.456 0.020 
NM_026825 leucine rich repeat containing 16A -1.457 0.034 
NM_199068 forkhead box K1 -1.457 0.034 
NM_011125 phospholipid transfer protein -1.460 0.008 
NM_025706 TBC1 domain family, member 15 -1.461 0.010 
NM_016905 galactokinase 1 -1.461 0.008 
NM_013507 eukaryotic translation initiation factor 4, gamma 2 -1.463 0.029 
NM_010123 eukaryotic translation initiation factor 3, subunit A -1.464 0.003 
NM_033074 threonyl-tRNA synthetase -1.467 0.000 
NM_147778 COMM domain containing 3 -1.468 0.040 
NM_026969 Sec31 homolog A (S. cerevisiae) -1.481 0.018 
NM_001033293 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 -1.482 0.000 
NM_146066 G1 to S phase transition 1 -1.482 0.029 
NM_026473 tubulin, beta 6 -1.485 0.024 
NM_146217 alanyl-tRNA synthetase -1.485 0.013 
NM_007408 adipose differentiation related protein -1.486 0.021 
NM_028003 RNA polymerase II associated protein 3; predicted gene 5697 -1.496 0.028 
NM_022314 predicted gene 7848; predicted gene 7839; predicted gene 4157; 
similar to tropomyosin 3, gamma; tropomyosin 3, gamma; 
predicted gene 4903 
-1.505 0.009 
NM_177644 RAS protein activator like 2 -1.510 0.004 
NM_175109 ribosomal protein S19 binding protein 1 -1.515 0.034 
NM_021312 WD repeat domain 12; predicted gene 4879 -1.517 0.009 
NM_008892 polymerase (DNA directed), alpha 1 -1.523 0.040 
NM_153065 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 -1.524 0.015 
NP_001165617 aminoacyl tRNA synthetase complex-interacting multifunctional 
protein 2 
-1.526 0.001 
NM_027000 GTP binding protein 4 -1.530 0.005 
NM_025595 mitochondrial ribosomal protein L51 -1.535 0.015 
NP_733469 copine I -1.538 0.004 
NM_153119 pleckstrin homology domain containing, family O member 2 -1.542 0.005 
NM_025310 FtsJ homolog 3 (E. coli) -1.545 0.018 
NM_080638 major vault protein -1.546 0.002 
NM_145620 RRP9, small subunit (SSU) processome component, homolog 
(yeast) 
-1.566 0.008 
NM_025664 similar to Sorting nexin 9; sorting nexin 9 -1.567 0.010 
NM_027375 GRIP and coiled-coil domain containing 2 -1.578 0.043 
NM_007510 ATPase, H+ transporting, lysosomal V1 subunit E1 -1.579 0.005 
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NM_011830 predicted gene 15210; inosine 5'-phosphate dehydrogenase 2 -1.579 0.017 
NM_145507 aspartyl-tRNA synthetase -1.585 0.015 
NM_013742 cysteinyl-tRNA synthetase -1.585 0.024 
NM_011829 inosine 5'-phosphate dehydrogenase 1 -1.593 0.016 
NP_001107603 protein phosphatase 4, regulatory subunit 1 -1.594 0.017 
NM_010212 four and a half LIM domains 2 -1.596 0.001 
NM_008033 farnesyltransferase, CAAX box, alpha; similar to farnesyltransferase 
alpha subunit 
-1.603 0.025 
NM_001038589 ubiquitin specific peptidase 14 -1.605 0.007 
NM_026788 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-
like 
-1.607 0.008 
NM_021448 elongation protein 2 homolog (S. cerevisiae) -1.610 0.020 
NM_025918 coiled-coil domain containing 43 -1.618 0.022 
NM_027498 similar to Serine/threonine-protein kinase QSK; cDNA sequence 
BC033915 
-1.621 0.007 
NM_025380 eukaryotic translation elongation factor 1 epsilon 1 -1.625 0.000 
NM_025494 ATPase, H+ transporting, lysosomal V1 subunit C1 -1.636 0.005 
NM_013562 interferon-related developmental regulator 1 -1.636 0.006 
NM_001033318 component of oligomeric golgi complex 7 -1.645 0.043 
NM_133775 interleukin 33 -1.647 0.041 
NM_153125 SEC16 homolog A (S. cerevisiae) -1.659 0.027 
NM_134188 acyl-CoA thioesterase 2 -1.660 0.021 
NM_029005 mixed lineage kinase domain-like -1.663 0.040 
NM_178623 RIKEN cDNA 2010005J08 gene -1.663 0.018 
NM_019795 DnaJ (Hsp40) homolog, subfamily C, member 7 -1.667 0.018 
NM_153116 GTP-binding protein 10 (putative); predicted gene 6877 -1.675 0.029 
NM_013752 nibrin -1.686 0.018 
NM_001037746 mirror-image polydactyly gene 1 homolog (human); 
phosphoribosyl pyrophosphate synthetase 1; phosphoribosyl 
pyrophosphate synthetase 1-like 1 
-1.688 0.028 
NM_181348 RIKEN cDNA A230083H22 gene -1.696 0.010 
NM_153164 predicted gene 6158; CCR4-NOT transcription complex, subunit 1 -1.707 0.033 
NM_028427 transmembrane protein 192 -1.711 0.011 
NM_172582 coenzyme Q6 homolog (yeast) -1.714 0.011 
NM_054102 influenza virus NS1A binding protein -1.718 0.001 
NM_054099 RIKEN cDNA 1110038F14 gene -1.729 0.001 
NM_138603 coiled-coil domain containing 22 -1.731 0.012 
 
 
Table 2-D: Differentially regulated CHO K1 proteins determined in samples corresponding to 
culture using spent media from CHO DP-12 cells prepared using a media dissolved oxygen 
content of 60%. 
RefSeq 
Annotation 
Description Fold 
Change 
p-
value 
NM_011333 chemokine (C-C motif) ligand 2 1.761 0.004 
NM_054078 bromodomain adjacent to zinc finger domain, 2A 1.749 0.010 
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NM_133957 nuclear factor of activated T-cells 5 1.730 0.017 
NP_001258682 DNA (cytosine-5)-methyltransferase 3A 1.728 0.002 
NM_021528 carbohydrate sulfotransferase 12 1.707 0.014 
NM_028945 DNA segment, Chr 14, Abbott 1 expressed 1.701 0.018 
NM_009103 ribonucleotide reductase M1 1.699 0.029 
NM_199032 centrosomal protein 135 1.692 0.007 
NM_001013616 tripartite motif-containing 6; similar to Tripartite motif protein 6 1.691 0.011 
NM_011341 stromal cell derived factor 4 1.690 0.001 
NM_010235 fos-like antigen 1 1.685 0.027 
NM_011961 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 1.683 0.005 
NM_025788 nucleus accumbens associated 1, BEN and BTB (POZ) domain 
containing 
1.678 0.010 
NM_001033534 layilin 1.665 0.045 
NM_001081357 mitogen-activated protein kinase kinase kinase kinase 3; similar to 
mitogen-activated protein kinase kinase kinase kinase 3 
1.656 0.007 
NM_001039644 ER degradation enhancer, mannosidase alpha-like 3 1.653 0.005 
NP_067263 thymidylate synthase 1.644 0.040 
NM_133804 transmembrane protein 132A 1.641 0.011 
NM_010117 rhomboid family 1 (Drosophila) 1.637 0.047 
NM_197999 RIKEN cDNA 2210023G05 gene 1.621 0.049 
NM_172205 suprabasin 1.620 0.018 
NM_009186 transformer 2 beta homolog (Drosophila); predicted gene 6439 1.612 0.016 
NM_001039522 Leo1, Paf1/RNA polymerase II complex component, homolog (S. 
cerevisiae) 
1.611 0.038 
NM_001080931 mediator complex subunit 13 1.611 0.047 
NM_012056 FK506 binding protein 9 1.610 0.008 
NM_024459 protein phosphatase 3, regulatory subunit B, alpha isoform 
(calcineurin B, type I) 
1.608 0.002 
NM_001081163 similar to mKIAA0990 protein; chondroitin sulfate synthase 1 1.601 0.039 
NM_028762 RNA binding motif protein 19 1.595 0.030 
NM_028975 transmembrane protein 33 1.595 0.024 
NM_009177 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 1.590 0.006 
NM_009404 tumor necrosis factor (ligand) superfamily, member 9 1.584 0.003 
NM_146211 glycosyltransferase 25 domain containing 1 1.577 0.013 
NM_029730 motile sperm domain containing 2 1.569 0.007 
NM_212450 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) 
small phosphatase like 2 
1.567 0.001 
NM_029581 mitochondrial translational initiation factor 3 1.561 0.013 
NM_011962 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 1.560 0.000 
NM_144814 REST corepressor 3 1.544 0.031 
NM_010517 insulin-like growth factor binding protein 4 1.540 0.028 
NM_023645 KDEL (Lys-Asp-Glu-Leu) containing 1 1.525 0.045 
NM_021460 lysosomal acid lipase A 1.519 0.002 
NM_008255 3-hydroxy-3-methylglutaryl-Coenzyme A reductase 1.516 0.049 
NM_001033297 predicted gene 561 1.490 0.044 
NM_001033533 coiled-coil domain containing 102A 1.482 0.023 
NM_172266 lysophosphatidylglycerol acyltransferase 1 1.481 0.040 
NM_010516 cysteine rich protein 61 1.479 0.004 
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NP_001106817 similar to Transcriptional repressor p66 alpha (GATA zinc finger 
domain-containing protein 2A); GATA zinc finger domain 
containing 2A 
1.477 0.016 
NM_026950 OCIA domain containing 2 1.465 0.020 
NM_011580 thrombospondin 1; similar to thrombospondin 1 1.444 0.012 
NM_025740 coiled-coil domain containing 104 1.433 0.016 
NP_001159505 general transcription factor IIIC, polypeptide 4 1.433 0.007 
NM_010799 predicted gene 12818; multiple inositol polyphosphate histidine 
phosphatase 1 
1.432 0.023 
NM_011879 IK cytokine 1.423 0.000 
NM_001146296 adenosine deaminase, RNA-specific 1.421 0.044 
NM_027658 similar to hexamthylene bis-acetamide inducible 2; hexamthylene 
bis-acetamide inducible 2 
1.409 0.012 
NM_029620 procollagen C-endopeptidase enhancer 2 1.390 0.047 
NM_008917 palmitoyl-protein thioesterase 1 1.389 0.040 
NM_026186 coiled-coil domain containing 49 1.386 0.048 
NM_153421 polyhomeotic-like 3 (Drosophila) 1.384 0.039 
NM_080558 sperm specific antigen 2 1.379 0.010 
NM_001081340 SET domain containing 2 1.373 0.002 
NM_007392 actin, alpha 2, smooth muscle, aorta 1.371 0.027 
NM_138596 mediator of RNA polymerase II transcription, subunit 10 homolog 
(NUT2, S. cerevisiae) 
1.371 0.002 
NM_010580 integrin beta 5 1.365 0.024 
NM_026252 cytoplasmic polyadenylation element binding protein 4 1.364 0.030 
NM_001163741 RIKEN cDNA 1110021J02 gene 1.361 0.032 
NM_025554 polymerase (RNA) II (DNA directed) polypeptide E 1.358 0.008 
NM_144954 peptidylprolyl isomerase (cyclophilin)-like 2 1.352 0.016 
NM_027373 actin filament associated protein 1 1.344 0.001 
NM_145619 poly (ADP-ribose) polymerase family, member 3 1.343 0.003 
NM_026130 signal recognition particle receptor ('docking protein') 1.341 0.013 
NM_178367 DEAH (Asp-Glu-Ala-His) box polypeptide 33 1.341 0.038 
NM_145215 abhydrolase domain containing 11 1.339 0.024 
NM_172276 splicing factor, arginine/serine-rich 8 1.338 0.011 
NM_025783 vacuolar protein sorting 24 (yeast); predicted gene 7464 1.332 0.041 
NP_001104536 FK506 binding protein 8 1.326 0.011 
NM_153783 polyamine oxidase (exo-N4-amino) 1.322 0.003 
NM_001164663 hypothetical protein LOC639171; RIKEN cDNA 9830001H06 gene; 
similar to C34E11.3 
1.321 0.001 
NM_175153 RIKEN cDNA 2010321M09 gene 1.314 0.026 
NM_009825 serine (or cysteine) peptidase inhibitor, clade H, member 1 1.303 0.006 
NM_146239 PCTAIRE-motif protein kinase 2 1.302 0.049 
NM_007840 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5; predicted gene 12183 1.300 0.047 
NM_153412 pleckstrin homology-like domain, family B, member 2 1.284 0.002 
NM_018774 polyhomeotic-like 2 (Drosophila) 1.280 0.042 
NM_023403 mesoderm development candidate 2 1.272 0.018 
NM_001163622 prolyl endopeptidase-like 1.266 0.003 
NM_145553 predicted gene 7527; family with sequence similarity 76, member 
A 
1.262 0.037 
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NM_018888 ubiquinol-cytochrome c reductase complex chaperone, CBP3 
homolog (yeast) 
1.257 0.004 
NM_029365 mediator of RNA polymerase II transcription, subunit 25 homolog 
(yeast) 
1.250 0.006 
NM_153559 quiescin Q6 sulfhydryl oxidase 2 1.237 0.012 
NM_028017 N-ethylmaleimide sensitive fusion protein attachment protein 
gamma 
1.233 0.029 
NM_021412 matrix metallopeptidase 19 1.218 0.028 
NM_177592 transmembrane protein 164 1.214 0.013 
NM_019975 2-hydroxyacyl-CoA lyase 1 1.213 0.019 
NM_033320 glucuronyl C5-epimerase 1.208 0.029 
NM_172259 myosin, light polypeptide 6B 1.208 0.016 
NM_198160 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily c, member 2 
1.207 0.038 
NM_011521 syndecan 4 1.207 0.028 
NM_001033136 family with sequence similarity 82, member A2 1.202 0.020 
NM_019966 malonyl-CoA decarboxylase -1.202 0.035 
NM_028276 UTP14, U3 small nucleolar ribonucleoprotein, homolog A (yeast) -1.204 0.044 
NM_146200 eukaryotic translation initiation factor 3, subunit C; similar to 
Eukaryotic translation initiation factor 3, subunit 8 
-1.205 0.050 
NM_010442 heme oxygenase (decycling) 1 -1.206 0.020 
NM_017379 tubulin, alpha 8 -1.209 0.025 
XP_003085306 Polyadenylate-binding protein 1-like 2 -1.211 0.012 
NM_138745 methylenetetrahydrofolate dehydrogenase (NADP+ dependent), 
methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate 
synthase 
-1.212 0.027 
NM_170669 predicted gene 13048; predicted gene 11968; predicted gene 
13253; predicted gene 14166; predicted gene 10196; similar to 
ribosomal protein S15a; predicted gene 5623; ribosomal protein 
S15A; similar to hCG1994130; predicted gene 7263 
-1.214 0.031 
NM_011654 predicted gene 3756; tubulin, alpha 1B; predicted gene 5620; 
similar to alpha-tubulin isotype M-alpha-2; predicted gene 14150; 
predicted gene 3226 
-1.216 0.042 
NM_011291 predicted gene 4754; ribosomal protein L7; predicted gene 12174; 
LOC100049084; predicted gene 6543; predicted gene 7059; 
predicted gene 4734 
-1.223 0.015 
NM_023060 eukaryotic elongation factor, selenocysteine-tRNA-specific -1.227 0.021 
NM_018829 adaptor-related protein complex 3, mu 1 subunit; similar to 
Adapter-related protein complex 3 mu 1 subunit (Mu-adaptin 3A) 
(AP-3 adapter complex mu3A subunit) 
-1.239 0.021 
NP_705782 aldehyde dehydrogenase 18 family, member A1 -1.244 0.019 
NM_025380 eukaryotic translation elongation factor 1 epsilon 1 -1.256 0.036 
NM_019808 PDZ and LIM domain 5 -1.257 0.024 
NM_026545 proteasome (prosome, macropain) 26S subunit, non-ATPase, 8 -1.262 0.037 
NM_172735 zinc finger, C3HC type 1 -1.267 0.038 
NM_146217 alanyl-tRNA synthetase -1.268 0.014 
NM_013507 eukaryotic translation initiation factor 4, gamma 2 -1.280 0.046 
NM_134137 leucyl-tRNA synthetase -1.283 0.036 
NM_013742 cysteinyl-tRNA synthetase -1.299 0.010 
NM_011975 predicted gene 14439; predicted gene 8213; predicted gene 
13981; predicted gene 8451; predicted gene 6378; predicted gene 
-1.315 0.001 
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8667; predicted gene 4923; predicted gene 5908; ribosomal 
protein L27a; predicted gene 14044; predicted gene 7536; 
predicted gene 144 
NM_145546 general transcription factor IIB -1.318 0.009 
NM_009082 similar to ribosomal protein; predicted gene 6344; predicted gene 
11449; predicted gene 13841; predicted gene 8210; hypothetical 
protein LOC675793; ribosomal protein L29; predicted gene 12704; 
predicted gene 7252; predicted gene 8965; predicted gene 13213 
-1.318 0.002 
NM_023525 carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, 
and dihydroorotase 
-1.320 0.025 
NM_013454 ATP-binding cassette, sub-family A (ABC1), member 1 -1.321 0.040 
NM_028636 mannosidase, alpha, class 2C, member 1 -1.321 0.029 
NM_198007 activating signal cointegrator 1 complex subunit 3 -1.324 0.023 
NM_053181 pyridoxal-dependent decarboxylase domain containing 1 -1.329 0.009 
NM_023372 similar to ribosomal protein L38; predicted gene 13020; ribosomal 
protein L38; predicted gene 4991; karyopherin (importin) alpha 2; 
predicted gene 9028; predicted gene 8129; predicted gene 7123; 
predicted gene 5832; predicted gene 10184; predicted gene 73 
-1.330 0.040 
NM_028032 protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), 
alpha isoform 
-1.347 0.011 
NM_021514 phosphofructokinase, muscle -1.350 0.006 
NP_001135450 TPX2, microtubule-associated protein homolog (Xenopus laevis) -1.352 0.037 
NM_080638 major vault protein -1.360 0.006 
NM_133973 component of oligomeric golgi complex 4 -1.368 0.027 
NM_026969 Sec31 homolog A (S. cerevisiae) -1.370 0.043 
NM_009391 RAS-like, family 2, locus 9; RAN, member RAS oncogene family; 
similar to RAN, member RAS oncogene family 
-1.379 0.019 
NM_019581 GTP binding protein 2 -1.386 0.011 
NM_008388 eukaryotic translation initiation factor 3, subunit E -1.393 0.010 
NM_011889 septin 3 -1.395 0.014 
NM_028390 anillin, actin binding protein -1.402 0.012 
NM_033074 threonyl-tRNA synthetase -1.406 0.004 
NM_027815 RIKEN cDNA 9030624J02 gene -1.408 0.007 
NM_016905 galactokinase 1 -1.409 0.025 
NM_153058 microtubule-associated protein, RP/EB family, member 2 -1.409 0.046 
NM_028427 transmembrane protein 192 -1.409 0.043 
NM_025494 ATPase, H+ transporting, lysosomal V1 subunit C1 -1.409 0.006 
NM_011874 proteasome (prosome, macropain) 26S subunit, ATPase, 4 -1.421 0.004 
NM_001045489 milk fat globule-EGF factor 8 protein -1.422 0.021 
NM_001080929 cerebellar degeneration-related protein 2-like -1.431 0.021 
NM_133900 phosphoserine phosphatase -1.435 0.009 
NM_011484 signal transducing adaptor molecule (SH3 domain and ITAM motif) 
1 
-1.444 0.032 
NP_001165617 aminoacyl tRNA synthetase complex-interacting multifunctional 
protein 2 
-1.455 0.048 
NM_012003 COP9 (constitutive photomorphogenic) homolog, subunit 7a 
(Arabidopsis thaliana) 
-1.458 0.001 
NP_955769 Protein FAM63A -1.458 0.030 
NM_008033 farnesyltransferase, CAAX box, alpha; similar to farnesyltransferase 
alpha subunit 
-1.468 0.001 
NM_007386 aconitase 1 -1.470 0.019 
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NM_010123 eukaryotic translation initiation factor 3, subunit A -1.485 0.002 
NM_024281 ribosome binding protein 1 -1.488 0.015 
NM_018799 eukaryotic translation initiation factor 3, subunit I -1.498 0.012 
NM_010212 four and a half LIM domains 2 -1.509 0.010 
NM_025344 eukaryotic translation initiation factor 3, subunit F -1.509 0.030 
NM_031248 roadblock domain containing 3 -1.516 0.003 
NM_025536 COMM domain containing 5 -1.524 0.006 
NM_028633 similar to UCH37-interacting protein 1; HAUS augmin-like complex, 
subunit 7 
-1.533 0.018 
NM_054102 influenza virus NS1A binding protein -1.535 0.024 
NM_001038589 ubiquitin specific peptidase 14 -1.540 0.019 
NM_001033293 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 -1.541 0.003 
NM_001128601 5, 10-methenyltetrahydrofolate synthetase; predicted gene 2372; 
predicted gene 2382 
-1.543 0.041 
NM_023912 SCY1-like 1 (S. cerevisiae) -1.544 0.004 
NM_027188 SET and MYND domain containing 3 -1.548 0.011 
NP_001192260 Microtubule-associated protein 4 -1.549 0.026 
NM_053273 tweety homolog 2 (Drosophila); similar to tweety homolog 2 -1.555 0.007 
NM_021473 aldo-keto reductase family 1, member A4 (aldehyde reductase) -1.572 0.009 
NM_024433 methylthioadenosine phosphorylase -1.576 0.013 
NM_145507 aspartyl-tRNA synthetase -1.578 0.013 
NM_011369 Shc SH2-domain binding protein 1 -1.586 0.022 
NM_010239 ferritin heavy chain 1 -1.586 0.017 
NM_207670 GRIP1 associated protein 1 -1.592 0.034 
NM_021888 queuine tRNA-ribosyltransferase 1 -1.600 0.003 
NM_011125 phospholipid transfer protein -1.605 0.021 
NM_138603 coiled-coil domain containing 22 -1.613 0.017 
NM_007408 adipose differentiation related protein -1.622 0.020 
NM_183021 thyroid adenoma associated -1.636 0.032 
NP_058665 myeloid-associated differentiation marker -1.642 0.005 
NP_001107603 protein phosphatase 4, regulatory subunit 1 -1.674 0.007 
NM_181348 RIKEN cDNA A230083H22 gene -1.707 0.005 
NM_011777 zyxin -1.718 0.031 
NM_026825 leucine rich repeat containing 16A -1.753 0.007 
 
 
Table 2-E: Differentially regulated CHO K1 proteins determined in samples corresponding to 
culture using spent media from CHO DP-12 cells prepared using media maintained at pH 7.2. 
RefSeq 
Annotation 
Description Fold 
Change 
P-
Value 
NM_029576 RAB1B, member RAS oncogene family 1.750 0.001 
NM_198645 coiled-coil domain containing 58 1.721 0.005 
NM_015782 predicted gene 8655; predicted gene 5145; predicted gene 8587; 
small nuclear ribonucleoprotein polypeptide A; predicted gene 
5161 
1.682 0.014 
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NM_010442 heme oxygenase (decycling) 1 1.670 0.006 
NM_001033534 layilin 1.633 0.020 
NM_145073 histone cluster 1, H3i; histone cluster 1, H3h; histone cluster 1, 
H3g; predicted gene 12260; histone cluster 1, H3a 
1.606 0.002 
NM_001136075 numb gene homolog (Drosophila) 1.604 0.046 
NM_025562 fission 1 (mitochondrial outer membrane) homolog (yeast) 1.558 0.001 
NM_010756 similar to mafG; v-maf musculoaponeurotic fibrosarcoma 
oncogene family, protein G (avian) 
1.557 0.016 
NM_133804 transmembrane protein 132A 1.554 0.033 
NM_024166 coiled-coil-helix-coiled-coil-helix domain containing 2; predicted 
gene 13202; similar to coiled-coil-helix-coiled-coil-helix domain 
containing 2; predicted gene 12350 
1.533 0.044 
NM_025740 coiled-coil domain containing 104 1.519 0.014 
NM_007639 CD1d1 antigen; CD1d2 antigen 1.516 0.048 
NM_008416 Jun-B oncogene 1.516 0.042 
NM_008097 glutaryl-Coenzyme A dehydrogenase 1.495 0.004 
NM_010288 gap junction protein, alpha 1 1.483 0.002 
NM_027430 brain protein 44; similar to brain protein 44; predicted gene 3982 1.478 0.014 
NM_022310 heat shock protein 5 1.457 0.014 
NM_053115 acyl-Coenzyme A oxidase 2, branched chain 1.413 0.009 
NM_144800 metastasis suppressor 1 1.409 0.020 
NM_139001 chondroitin sulfate proteoglycan 4 1.400 0.026 
NM_010046 diacylglycerol O-acyltransferase 1 1.391 0.007 
NM_178112 integrator complex subunit 8 1.389 0.037 
NM_029437 cytoskeleton associated protein 5 1.388 0.012 
NM_016786 ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast) 1.363 0.001 
NM_007830 diazepam binding inhibitor 1.356 0.026 
NM_010655 similar to ribosomal protein L38; predicted gene 13020; 
ribosomal protein L38; predicted gene 4991; karyopherin 
(importin) alpha 2; predicted gene 9028; predicted gene 8129; 
predicted gene 7123; predicted gene 5832; predicted gene 
10184; predicted gene 73 
1.336 0.011 
NP_080965 mitochondrial ubiquitin ligase activator of NFKB 1 1.331 0.015 
NM_010485 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu 
antigen R) 
1.323 0.024 
NM_026573 reproductive homeobox 3B; UPF3 regulator of nonsense 
transcripts homolog B (yeast); reproductive homeobox 1; NFKB 
activating protein 
1.320 0.013 
NM_025833 BAI1-associated protein 2-like 1 1.317 0.025 
NM_026009 coiled-coil domain containing 47 1.307 0.013 
NM_175318 SPT2, Suppressor of Ty, domain containing 1 (S. cerevisiae) 1.303 0.001 
NM_028876 transmembrane emp24 protein transport domain containing 5; 
similar to Transmembrane emp24 protein transport domain 
containing 5 
1.300 0.006 
NM_007451 solute carrier family 25 (mitochondrial carrier, adenine 
nucleotide translocator), member 5; similar to ADP/ATP 
translocase 2 (Adenine nucleotide translocator 2) (ANT 2) 
(ADP,ATP carrier protein 2) (Solute carrier family 25 member 5); 
predicted gene 5529; 
1.287 0.027 
NM_027307 golgi membrane protein 1 1.285 0.002 
NM_019734 N-acylsphingosine amidohydrolase 1 1.283 0.005 
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NM_178772 arylacetamide deacetylase-like 1 1.283 0.005 
NM_024452 leucine zipper protein 1 1.278 0.024 
NM_010875 neural cell adhesion molecule 1 1.275 0.049 
NM_001037166 predicted gene 4925 1.274 0.018 
NM_172471 inter-alpha (globulin) inhibitor H5 1.273 0.019 
NM_025994 similar to EF hand domain containing 2; EF hand domain 
containing 2 
1.269 0.003 
NM_026184 ERO1-like beta (S. cerevisiae) 1.269 0.017 
NM_013771 YME1-like 1 (S. cerevisiae) 1.258 0.027 
NM_001082961 small nuclear ribonucleoprotein N; SNRPN upstream reading 
frame; predicted gene 5802; similar to SNRPN upstream reading 
frame protein 
1.258 0.018 
NM_145605 kelch domain containing 4 1.251 0.008 
NM_026487 ATPase family, AAA domain containing 1 1.246 0.034 
NM_020000 mediator of RNA polymerase II transcription, subunit 8 homolog 
(yeast) 
1.242 0.031 
NP_083142 WD repeat domain 33 1.234 0.013 
NM_010833 moesin 1.231 0.014 
NM_175229 serine/arginine repetitive matrix 2; similar to Serine/arginine 
repetitive matrix protein 2; similar to retinitis pigmentosa GTPase 
regulator 
1.228 0.009 
NM_145706 nucleoporin 43 1.222 0.006 
NM_023053 twisted gastrulation homolog 1 (Drosophila) 1.220 0.039 
NM_021895 actinin alpha 4 1.208 0.001 
NM_009101 Harvey rat sarcoma oncogene, subgroup R 1.208 0.005 
NM_001033375 RIKEN cDNA A230046K03 gene -1.208 0.007 
NM_001038589 ubiquitin specific peptidase 14 -1.218 0.016 
NM_009097 ribosomal protein S6 kinase polypeptide 1 -1.218 0.032 
NM_019703 phosphofructokinase, platelet -1.219 0.011 
NM_172712 ubiquitin-like modifier activating enzyme 6 -1.219 0.050 
NP_001157290 protein phosphatase 1, regulatory subunit 10 -1.225 0.026 
NM_145925 pituitary tumor-transforming 1 interacting protein -1.233 0.016 
NM_008950 protease (prosome, macropain) 26S subunit, ATPase 5 -1.237 0.025 
NM_152801 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 -1.239 0.038 
NM_011029 predicted gene 9323; predicted gene 7516; ribosomal protein SA 
pseudogene; predicted gene 9819; predicted gene 6339; 
predicted gene 9083; ribosomal protein SA; predicted gene 
13374; predicted gene 12595; similar to laminin receptor 1 
(ribosomal protein SA 
-1.252 0.041 
NM_178616 predicted gene 14048; proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 11 
-1.253 0.043 
NM_008017 structural maintenance of chromosomes 2 -1.261 0.046 
NM_019564 HtrA serine peptidase 1 -1.269 0.001 
NM_001033300 guanine monphosphate synthetase; predicted gene 7282 -1.273 0.007 
NM_009457 ubiquitin-like modifier activating enzyme 1 -1.287 0.002 
NM_133823 methylmalonic aciduria (cobalamin deficiency) type A -1.288 0.017 
NM_175115 IKAROS family zinc finger 5 -1.292 0.028 
NM_153116 GTP-binding protein 10 (putative); predicted gene 6877 -1.303 0.031 
NM_009439 proteasome (prosome, macropain) 26S subunit, non-ATPase, 3 -1.314 0.020 
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NM_008567 minichromosome maintenance deficient 6 (MIS5 homolog, S. 
pombe) (S. cerevisiae) 
-1.314 0.015 
NM_080554 proteasome (prosome, macropain) 26S subunit, non-ATPase, 5 -1.317 0.048 
NM_009462 ubiquitin specific peptidase 10 -1.335 0.006 
NM_017380 septin 9 -1.337 0.007 
NM_023248 Shwachman-Bodian-Diamond syndrome homolog (human) -1.341 0.002 
NM_025382 transmembrane protein 57 -1.342 0.016 
NM_133786 structural maintenance of chromosomes 4 -1.344 0.006 
NM_025706 TBC1 domain family, member 15 -1.348 0.002 
NM_009794 calpain 2 -1.352 0.021 
NM_030678 glycogen synthase 1, muscle -1.352 0.030 
NM_008481 laminin, alpha 2 -1.355 0.048 
NM_175126 zinc finger, CCHC domain containing 3 -1.358 0.037 
NM_019771 destrin -1.368 0.015 
NM_138584 spastic paraplegia 21 homolog (human); similar to spastic 
paraplegia 21 homolog 
-1.369 0.038 
NM_021523 HECT, UBA and WWE domain containing 1 -1.372 0.017 
NM_146093 UBX domain protein 1 -1.380 0.012 
NM_023871 predicted gene, EG625349; predicted gene 5789; predicted gene 
7085; predicted gene 5708; predicted gene 6847; SET 
translocation; cDNA sequence BC085271; predicted gene 7239; 
similar to protein phosphatase 2A inhibitor-2 I-2PP2A; predicted 
gene 9531 
-1.383 0.015 
NM_177364 SH3 and PX domains 2B -1.405 0.003 
NM_173379 leprecan-like 1 -1.406 0.010 
NM_018859 aldo-keto reductase family 1, member E1 -1.408 0.000 
NM_009120 SAR1 gene homolog A (S. cerevisiae) -1.421 0.019 
NM_010220 FK506 binding protein 5 -1.423 0.005 
NM_001033191 ARD1 homolog B (S. cerevisiae) -1.429 0.009 
NM_026277 NIN1/RPN12 binding protein 1 homolog (S. cerevisiae) -1.430 0.040 
NM_145564 F-box protein 21 -1.435 0.023 
NM_008708 N-myristoyltransferase 2 -1.438 0.042 
NM_007388 acid phosphatase 5, tartrate resistant -1.441 0.038 
NM_026969 Sec31 homolog A (S. cerevisiae) -1.448 0.028 
NM_015765 heat shock protein 14 -1.466 0.002 
NM_025864 transmembrane protein 206 -1.478 0.029 
NM_010239 ferritin heavy chain 1 -1.486 0.007 
NM_001077687 LPS-responsive beige-like anchor -1.489 0.018 
NM_013472 annexin A6 -1.491 0.010 
NM_146041 GDP-mannose 4, 6-dehydratase -1.492 0.003 
NM_001166024 ADP-ribosylation factor GTPase activating protein 2 -1.496 0.024 
NM_029005 mixed lineage kinase domain-like -1.511 0.041 
NM_016710 predicted gene 11914; nucleosome binding protein 1 -1.526 0.004 
NM_029839 TruB pseudouridine (psi) synthase homolog 1 (E. coli) -1.543 0.002 
NM_145836 similar to polyglutamine-containing protein; RIKEN cDNA 
6430527G18 gene 
-1.549 0.022 
NM_028152 MMS19 (MET18 S. cerevisiae) -1.562 0.014 
NM_001045528 FK506 binding protein 15 -1.596 0.009 
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NP_733469 copine I -1.596 0.030 
NM_178726 protein phosphatase 1 (formerly 2C)-like -1.602 0.018 
NM_021354 hypothetical protein LOC674305; predicted gene 8918; 
developmentally regulated GTP binding protein 2 
-1.623 0.001 
NM_001164559 TRM1 tRNA methyltransferase 1 homolog (S. cerevisiae) -1.669 0.028 
NM_025692 ubiquitin-like modifier activating enzyme 5 -1.689 0.025 
 
 
Table 2-F: Differentially regulated CHO K1 proteins determined in samples corresponding to 
culture using spent media from CHO DP-12 cells prepared using media maintained at pH 6.8. 
RefSeq 
Annotation 
Description Fold 
Change 
p-
value 
NM_010708 lectin, galactose binding, soluble 9 1.663 0.027 
NM_138589 ubiquitin family domain containing 1 1.650 0.048 
NM_133775 interleukin 33 1.648 0.006 
NM_001081218 host cell factor C2 1.648 0.008 
NM_025740 coiled-coil domain containing 104 1.589 0.038 
NM_009242 secreted acidic cysteine rich glycoprotein; similar to Secreted 
acidic cysteine rich glycoprotein 
1.520 0.027 
NM_133804 transmembrane protein 132A 1.512 0.041 
NM_011127 paired related homeobox 1 1.485 0.002 
NM_013558 heat shock protein 1B; heat shock protein 1A; heat shock protein 
1-like 
1.465 0.007 
NM_023232 diablo homolog (Drosophila) 1.458 0.028 
NM_001033534 layilin 1.456 0.039 
NM_011961 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 1.443 0.003 
NM_009811 caspase 6 1.406 0.036 
NM_177068 olfactomedin-like 2B 1.392 0.028 
NM_010302 guanine nucleotide binding protein, alpha 12; similar to Guanine 
nucleotide-binding protein alpha-12 subunit (G alpha-12) 
1.390 0.006 
NP_080965 mitochondrial ubiquitin ligase activator of NFKB 1 1.386 0.001 
NM_031185 A kinase (PRKA) anchor protein (gravin) 12 1.371 0.037 
NM_027373 actin filament associated protein 1 1.307 0.026 
NM_026267 NECAP endocytosis associated 1 1.296 0.027 
NM_011862 protein kinase C and casein kinase substrate in neurons 2 1.295 0.045 
NM_015782 predicted gene 8655; predicted gene 5145; predicted gene 8587; 
small nuclear ribonucleoprotein polypeptide A; predicted gene 
5161 
1.292 0.005 
NM_016706 RIKEN cDNA 2210409E12 gene; coilin 1.288 0.019 
NM_026184 ERO1-like beta (S. cerevisiae) 1.282 0.003 
NM_007803 cortactin; predicted gene 8786 1.277 0.036 
NM_026623 nudix (nucleoside diphosphate linked moiety X)-type motif 21 1.259 0.026 
NM_010288 gap junction protein, alpha 1 1.256 0.034 
NM_021493 RIKEN cDNA 4933428G20 gene 1.216 0.039 
NM_207625 acyl-CoA synthetase long-chain family member 4 1.209 0.012 
NP_001156986 exostoses (multiple)-like 2 1.201 0.023 
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NM_134037 ATP citrate lyase -1.205 0.008 
NM_008388 eukaryotic translation initiation factor 3, subunit E -1.231 0.014 
NP_001159610 armadillo repeat containing 8 -1.238 0.045 
NM_008017 structural maintenance of chromosomes 2 -1.242 0.037 
NM_008788 procollagen C-endopeptidase enhancer protein -1.256 0.017 
NM_027375 GRIP and coiled-coil domain containing 2 -1.311 0.014 
NM_183016 CDC42 binding protein kinase beta -1.315 0.003 
XP_483949 predicted gene 6807; predicted gene 6136; predicted gene 6883; 
predicted gene 5428; similar to ribosomal protein L6; predicted 
gene 5247; ribosomal protein L6 
-1.333 0.038 
NM_001004436 wings apart-like homolog (Drosophila) -1.337 0.014 
NM_017380 septin 9 -1.338 0.002 
NP_705782 aldehyde dehydrogenase 18 family, member A1 -1.339 0.036 
NM_133786 structural maintenance of chromosomes 4 -1.342 0.007 
NM_001081122 centrosomal protein 63 -1.346 0.020 
NM_001015507 Vpr (HIV-1) binding protein -1.347 0.017 
NM_015765 heat shock protein 14 -1.353 0.025 
NM_001033231 cDNA sequence BC003940 -1.417 0.031 
NM_012053 ribosomal protein L8; similar to 60S ribosomal protein L8 -1.427 0.001 
NM_011125 phospholipid transfer protein -1.436 0.050 
NM_001037166 predicted gene 4925 -1.453 0.038 
NM_008605 matrix metallopeptidase 12 -1.466 0.005 
NM_177884 expressed sequence AW146020 -1.508 0.035 
NM_021354 hypothetical protein LOC674305; predicted gene 8918; 
developmentally regulated GTP binding protein 2 
-1.536 0.003 
NM_009120 SAR1 gene homolog A (S. cerevisiae) -1.538 0.033 
NM_145925 pituitary tumor-transforming 1 interacting protein -1.541 0.020 
NM_175294 nuclear casein kinase and cyclin-dependent kinase substrate 1 -1.548 0.001 
NM_026539 chromodomain helicase DNA binding protein 1-like -1.582 0.042 
NM_145836 similar to polyglutamine-containing protein; RIKEN cDNA 
6430527G18 gene 
-1.685 0.014 
NM_138315 microtubule associated monoxygenase, calponin and LIM domain 
containing 1 
-1.726 0.044 
 
 
